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Major depressive disorder is marked by high rates of relapse and recurrence. Research
has suggested that formerly depressed individuals exhibit dysphoric mood or dysfunctional
beliefs that are similar to currently depressed individuals while in a dysphoric, but not euthymic,
mood and these changes prospectively predict relapse and recurrence over time. While there is
still disagreement as to whether dysfunctional thinking or dysphoric mood characterizes remitted
depression, these changes appear to be mood state dependent, or undetectable until activated by
sadness. These findings have led to the hypothesis that cardiovascular functioning may also be
mood state dependent in remitted depression; however, this has not yet been adequately assessed.
The few studies (Bylsma et al., 2015; Rottenberg et al., 2005b; Yaroslavsky et al., 2013, 2014)
that have investigated cardiovascular reactivity in response to sadness in formerly depressed
individuals have methodological issues. No studies have examined a wide range of
cardiovascular measures to assess cardiovascular reactivity to and recovery from a sad mood in
an exclusively formerly depressed sample.
The proposed study aimed to characterize cognitive, mood, and cardiovascular reactivity
to and recovery from a sad mood in individuals with a history of depression compared to healthy,
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never depressed individuals. Participants (N = 132) included formerly depressed and healthy
control individuals. Following screening, participants completed self-report measures of
depressive and anxiety symptoms and a structured clinical interview. Eligible participants were
randomly assigned to an experimental paradigm condition. During the experimental paradigm,
participants were connected to psychophysiological equipment, participated in a sad or neutral
music and autobiographical recall mood induction, and completed self-report measures of
dysfunctional thoughts and dysphoric mood pre- and post-mood induction. Results suggested
that mood, rather than cognitive, reactivity in response to a transient sad mood is present in
formerly depressed individuals. Additionally, results suggested that reduced heart period
recovery, rather than reactivity, following the induction of a transient sad mood is present in
formerly depressed individuals. Results indicated that formerly depressed individuals exhibit
increased sadness and impaired heart period recovery in response to a transient sad mood, which
may be potentially malleable risk factors for depressive relapse and recurrence.
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CHAPTER 1
INTRODUCTION
Major Depressive Disorder (MDD), characterized by prolonged depressed mood and/or
lack of interest or pleasure, is a serious and debilitating mental illness. Prevalence and incidence
rates obtained from large scale epidemiological studies have indicated that MDD is a commonly
occurring disorder. Various psychosocial factors that have been associated with MDD include
gender, age, race, ethnicity, national origin, and socioeconomic status. The course of MDD is
marked by high rates of relapse and recurrence. Consequently, it is often considered a chronic
disorder that typically recurs over time. While psychological and medical comorbidities
commonly co-occur with MDD, the disorder itself is independently associated with elevated
levels of functional impairment, disability, and death. The direct and indirect problems
associated with MDD pose a significant health and economic burden for the individuals suffering
with the disorder and society.
Diagnostic Criteria
According to the Diagnostic and Statistical Manual – Fifth Edition (DSM-5; American
Psychological Association (APAA), 2013), MDD is characterized by persistent depressed mood
and/or diminished interest or pleasure in previously enjoyed activities. These symptoms can be
based on the subjective experience reported by the individual or objective presentation observed
by others. In addition to these cardinal symptoms, an individual must endorse four or more of the
following disturbances in appetite, weight, sleep, psychomotor activity, energy level, selfconceptualization, cognitive ability, and suicidality. There is significant heterogeneity in
symptom presentation, such as increases or decreases in appetite, weight, sleep, and psychomotor
activity. Individuals with MDD often report persistent reductions in energy level despite
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adequate rest, negative self-concept (e.g., worthlessness or inappropriate guilt), and impaired
cognitive abilities (e.g., difficulty thinking or making decisions). In addition, a spectrum of
suicidal thoughts and behaviors can occur, including recurrent thoughts of death or dying and
suicidal ideations, plans, or attempts. A clinical diagnosis of depression requires that symptoms
are present most of the day, nearly every day for two weeks or longer and result in marked
impairment at school, work, or home or in social situations. In addition, these symptoms must be
attributable to depression and cannot be better explained by a medical condition, substance use,
or other psychiatric condition.
Recovery from a major depressive episode is classified as partial or full remission
(APAA, 2013). MDD in partial remission is defined as the absence of depressive symptoms for
less than two months or the presence of depressive symptoms that cause marked impairment but
do not meet the diagnostic threshold. MDD in full remission is defined as either the absence of
any depressive symptoms for at least two months or the presence of one or two depressive
symptoms that are mild in severity.
The diagnostic criteria for MDD allows for significant heterogeneity of symptoms.
Researchers have criticized the architects of the DSM-5 for its reliance on a symptom-based,
categorical approach, limited use of biological correlates, and inclusion of contradictory
symptomology within a single diagnosis (e.g., increase or decrease in appetite; Casey et al.,
2013). While the DSM-5 provides researchers and clinicians with the nomenclature necessary for
communication, the field is currently exploring alternative classification systems such as the
Research Domain Criteria (RDoC; Insel et al., 2010).
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Occurrence
MDD is one of the most commonly occurring mental disorders (National Institute of
Mental Health (NIMH), 2017). The occurrence of MDD within the general population has been
assessed by large epidemiological studies using two different measurement methods: prevalence
and incidence.
Prevalence
Prevalence is defined as the proportion of the population who have a condition during a
specific period of time. The majority of studies report point prevalence rates obtained within a
12-month period or within an individual’s lifetime. Several large-scale epidemiological studies
using the DSM – Fourth Edition (DSM-IV; APAA, 2000) diagnostic criteria have obtained a
range of prevalence rates of MDD depending on the sample and methodology used.
Eaton, Kalaydjian, Scharfstein, Mezuk, and Ding (2007) reported the lowest 12-month
prevalence rate of 2.70% among two cohorts using the Diagnostic Interview Schedule (DIS).
Hasin, Goodwin, Stinson, and Grant (2005) found a 12-month prevalence rate of 5.30% and a
lifetime prevalence rate of 13.20% using the Alcohol Use Disorder and Associated Disabilities
Interview Schedule – DSM-IV Version (AUDADIS-IV). The majority of studies have used the
Composite International Diagnostic Interview (CIDI) to diagnose depression, which have
obtained higher prevalence rates of MDD. Kessler and colleagues (2003) attained a 12-month
prevalence rate of 6.60% and a lifetime prevalence rate of 16.20%. Similarly, Kessler and
colleagues (2005) found a lifetime prevalence rate of 16.60%. González, Tarraf, Whitfield, and
Vega (2010) obtained a 12-month prevalence rate of 8.10% and a lifetime prevalence rate of
18.60%. Finally, Kessler and colleagues (2010) reported the highest 12-month prevalence rate of
8.30% and lifetime prevalence rate of 19.20%. Together, these epidemiological studies suggest
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that the prevalence rate for MDD ranges between 2.70% and 8.30% during a 12-month period
and 13.20% to 19.20% across an individual’s lifespan.
Incidence
Incidence is defined as the number of new cases of a condition within a certain time
period. The majority of studies report person-time incidence rates, which is defined as the
number of new cases that occur within the amount of time that the sample of participants were at
risk for developing the disease of interest. While prevalence rates are more commonly reported
in the literature, they are influenced by the chronicity of a disorder (Palsson, Östling, & Skoog,
2001). MDD is characterized as a chronic disorder in a subset of individuals (Monroe, Anderson,
& Harkness, in press; Richards, 2011); therefore, it is important to also assess the incidence rate
for MDD. Several large-scale epidemiological studies using the DSM-IV diagnostic criteria have
obtained a range of incidence rates of MDD depending on the measurement formula and
methodology used.
Eaton and colleagues (2007) reported the lowest incidence rate of 1.90 per 1,000 person
years using the DIS. Murphy, Laird, Monson, Sobol, and Leighton (2000) found similar
incidence rates for two cohorts using the DePression and AnXiety (DPAX) interview. Incidence
rates ranged from 4.50 per 1,000 person years for the cohort recruited from 1950 to 1970 to 3.70
per 1,000 person years for the cohort recruited from 1970 to 1992. Grant and colleagues (2009)
obtained the highest incidence rate of 1.51 per 100 person years, which is equal to 15.10 per
1,000 person years, using the AUDADIS-IV. Together, these epidemiological studies suggest
that the incident rate for MDD ranges between 1.90 and 15.10 per 1,000 person years.
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Gender
One of the strongest predictors for the occurrence of MDD is gender. Epidemiological
studies conducted in the United States have consistently shown that women report increased
prevalence and incidence rates of MDD. Kessler and colleagues (2003) reported that the
prevalence rate of MDD was elevated in women during a 12-month period (OR = 1.40, CI =
1.10, 1.80, p < .05) and over the course of their lifetime (OR = 1.70, CI = 1.50, 2.00, p < .05)
using the CIDI. Hasin and colleagues (2005) replicated these results using the AUDADIS-IV,
showing that the prevalence rate of MDD was two times higher in women over the course of
their lifetime (OR = 2.00, CI = 1.80, 2.40). Eaton and colleagues (2007) obtained even more
staggering results with the DIS, finding that the prevalence rate of MDD was over three times
higher in women during a 12-month period (OR = 3.80, CI = 2.60, 5.60). In addition, the authors
reported that the incidence rate of MDD was over two times higher in women during a 12-month
period (OR = 2.60, CI = 1.50, 4.10). Similarly, Grant and colleagues (2009) found that women
reported an elevated incidence rate of MDD (OR = 1.00) compared to men (OR = .50, CI = .37,
.76) on the AUDADIS-IV.
These results have been replicated by epidemiological studies conducted in countries
around the world, suggesting that increased rates of depression in women occurs cross-culturally.
Kuehner (2003) completed a systematic review of epidemiological studies that assessed the
prevalence of depression worldwide using various structured clinical interviews. Results
indicated that the prevalence rates for depressive disorders were significantly higher in women
compared to men, with a sex ratio of 1.70:1.00 for current prevalence and 2.10:1.00 for lifetime
prevalence. These results held true for studies conducted outside of the United States, which
obtained a sex ratio of 2.00:1.00 for both current and lifetime prevalence. Additional large-scale
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studies have been conducted to specifically assess gender differences in depression. Seedat and
colleagues (2009) obtained lifetime rates of MDD for individuals residing in 15 countries using
the CIDI. Results revealed that the lifetime prevalence rate for MDD was significantly higher in
women compared to men (OR = 1.90, CI = 1.80, 2.00). Together, these studies suggest that the
prevalence and incidence of MDD is generally two times higher in women compared to men
(Nolen-Hoeksema, 2001).
Several factors have been proposed to explain the elevated rates of MDD observed in
women. First, it is possible that differences in depression are an artifact of diagnostic or
methodological problems. Diagnostic issues include differences in the endorsement or
experience of depressive symptoms among men and women. Research has shown that women
are more likely to endorse more depressive symptoms than men, even though the two sexes
experience similar levels of impairment (Piccinelli & Wilkinson, 2000). In addition, it has been
suggested that there may be symptomatic differences between the sexes; women may be more
likely to experience stereotypical depressive symptoms like sadness and men may be more likely
to experience atypical depressive symptoms like irritability. Consequently, the diagnostic criteria
for MDD has been criticized as overemphasizing the depressive symptoms that are typically
experienced by females (Kuehner, 2003). Methodological issues include failure to account for
differences in the course of the disorder or treatment seeking behaviors among men and women.
Some research has suggested that females may be more likely to experience a singular depressive
episode, which would account for difference in point prevalence rates but not lifetime prevalence
rates (Piccinelli & Wilkinson, 2000). In addition, research has documented the differences in
treatment seeking behaviors across the sexes, which may explain why women are more likely to
be identified as having depression. Service utilization studies have shown that women are more
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likely than men to seek medical and psychological treatment (Piccinelli & Wilkinson, 2000)
while studies conducted in community and primary care settings have estimated that the
prevalence of MDD is roughly equal across the sexes (Kuehner, 2003). The literature has
identified some diagnostic or methodological issues that may account for the gender difference
in depression.
Second, biological factors specific to women have been associated with increased
vulnerability to developing depression. While differences in the heritability of depression have
not be identified, genetic differences may make women more vulnerable to developing
internalizing disorders (Kuehner, 2003). Sex hormones, such as estrogen, may directly or
indirectly impact mood. Research has shown that changes in sex hormones are associated with
changes in mood during puberty, postpartum, and premenstrual periods (Grigoriadis &
Robinson, 2007; Kuehner, 2003). In addition, sex hormones influence the activity of regulatory
mechanisms in the brain including neurotransmitters and components of the endocrine system
such as the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-thyroid axes
(Grigoriadis & Robinson, 2007; Kuehner, 2003).
Third, it has been proposed that psychosocial factors specific to women increase
vulnerability to depression. Women possess less social status and power in society compared to
men, which increases the likelihood for experiencing stressful life events such as sexual abuse
and assault, trauma, and victimization (Grigoriadis & Robinson, 2007; Nolen-Hoeksema, 2001).
In addition, society has subscribed certain social roles and expectations to women, which can
lead to significant emotional distress due to personal, educational, professional, and financial
limitations that may result in reduced freedom and autonomy (Kuehner, 2003; Piccinelli &
Wilkinson, 2000).
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Fourth, it has been proposed that psychological factors commonly observed in women
may increase their vulnerability to depression. Differences in coping style appear to exist among
men and women. Females tend to cope with stress using maladaptive strategies such as
rumination, or internally dwelling on problems, while males tend to use more adaptive and active
strategies such as distraction. Research has shown that rumination negatively impacts mood and
problem solving strategies and plays a significant role in the development of depression (NolenHoeksema, 2001). Additionally, some sex differences in self-perception have been identified.
Women tend to report lower self-esteem, self-confidence, and perceived control compared to
men, which may contribute to feelings of hopelessness and helplessness that are associated with
depression (Grigoriadis & Robinson, 2007; Kuehner, 2003; Piccinelli & Wilkinson, 2000).
Finally, the presence of previous mental health problems in women during adolescence
have been associated with increased vulnerability to depression across the lifespan. Research has
shown that women are at an increased risk for developing anxiety and depression earlier in life
compared to men (Piccinelli & Wilkinson, 2000). Early exposure to anxiety or depression is
thought to make women more vulnerable to experiencing multiple depressive episodes over the
course of their lifetime. This theory is based on the findings that the course of depression is
typically chronic and anxiety increases risk for the occurrence of depressive episode in the future
(Kuehner, 2003).
Age
As reviewed by Haigh, Bogucki, Sigmon, and Blazer (2018a), it has long been assumed
that older age is related to an increased occurrence of MDD. This commonly held belief is likely
due to the challenges typically associated with aging (e.g., changes in interpersonal relationships
and reduced independence, financial stability, and physical and cognitive capacity), which can
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result in significant emotional distress. However, the literature has consistently indicated that
older adults are significantly less likely to experience MDD compared to their younger
counterparts.
Large scale epidemiological and community-based studies have shown that younger
adults report higher prevalence and incidence rates of MDD compared to older adults. Kessler
and colleagues (2003) compared the prevalence of MDD across age groups using the CIDI.
Participants 60 years or older reported significantly lower point (OR = 1.00, χ2 = 42.3, p < .05)
and lifetime (OR = 1.00, χ2 = 53.5, p < .05) prevalence rates of MDD compared to younger
participants. 12-month prevalence rates were significantly higher for participants age 18 to 29
(OR = 3.00, CI = 2.00, 4.40, p < .05) and 30 to 44 (OR = 1.80, CI = 1.10, 2.90, p < .05) while
lifetime prevalence rates were significantly higher for participants age 18 to 29 (OR = 1.70, CI =
1.40, 2.20, p < .05), 30 to 44 (OR = 2.20, CI = 1.80, 2.80, p < .05), and 45 to 59 (OR = 2.00, CI =
1.60, 2.60, p < .05).
Kessler and colleagues (2005) replicated this result using the same structured interview,
finding a statistically significant difference for the lifetime prevalence rate of MDD in
participants age 18 to 29 (15.40%), 30 to 44 (19.80%), 45 to 59 (18.80%), and 60 or older
(10.60%; χ2 = 49.90, p < .05). Eaton and colleagues (2007) compared incidence rates of MDD
among middle age and older adults using the DIS. Younger participants age 30 to 44 (3.20%)
and 45 to 64 (1.90%) reported elevated incidence rates of MDD compared to participants 65
years or older (0.00%). Grant and colleagues (2009) examined differences in the incidence of
MDD across a wider age range with the AUDADIS-IV. Compared to participants 55 years or
older (OR = 1.00), incidence rates for MDD were significantly higher in participants age 20 to 29
(OR = 2.00, CI = 1.19, 3.41, p < .01) and 30 to 54 (OR = 1.70, CI = 1.22, 2.47, p < .01).
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Kessler and colleagues (2010) specifically assessed age-related differences in MDD using
the CIDI. Results indicated that there was a statistically significant difference in the prevalence
of MDD assessed across age groups. For the 30-day prevalence rate, participants in the 18 to 34
and 35 to 49-year age groups (3.70%) reported the highest rates while participants in the over 65
years age group reported the lowest rates (1.00%; χ2 = 46.9, p < .05). For the 12-month
prevalence rate, participants in the 18 to 34-year age group (10.40%) reported the higher rates
while participants in the over 65 years age group reported the lowest rates (2.60%, χ2 = 103.50, p
< .05). For the lifetime prevalence rate, participants in the 35 to 49-year age group (22.70%)
reported the higher rates while participants in the over 65 years age group reported the lowest
rates (9.80%, χ2 = 70.40, p < .05). Together, these studies suggest that younger adults are at the
highest risk for experiencing MDD. While the rates of MDD reported by middle age adults are
typically lower than young adults, they are still elevated compared to elderly population.
Multiple factors have been proposed to explain why the rate of MDD differs across the
lifespan. First, it is possible that recruitment and methodological issues account for the low rates
of depression reported by older adults. Recruitment issues include premature death, failure to
account for the elderly population that resides in assisted living or nursing home facilities, and
diminished interest in participating in research. Methodological issues include recall bias and
failure to endorse the presence of mental illness due to stigma and social desirability. However,
there is limited evidence supporting these recruitment and methodological issues, which suggests
that MDD does occur at different rates across the lifespan (as reviewed by Kessler et al., 2010).
Second, psychological factors specific to older adults may be protective against depression later
in life. Research has indicated that older adults report an increase in positive affect and wellbeing and a decrease in negative affect, which is theorized to be due to enhanced emotion
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regulation abilities or a normalization of adverse events that occur during this phase of life (as
reviewed by Haigh et al., 2018a). Therefore, it is possible that older adults are better able to cope
with stressful life events, which are a causal risk factor for depression (Kendler, Karkowski, &
Prescott, 1999), than their younger counterparts.
Race, Ethnicity, and National Origin
Race, ethnicity, and national origin impact the occurrence of MDD. Large scale
epidemiological and community-based studies have identified some differences in the prevalence
rates among racial and ethnic groups. Kessler and colleagues (2003) found that African
American individuals reported the lowest lifetime prevalence rate of MDD (OR = .60, CI = .50,
.80, p < .05) on the CIDI compared to individuals who identified as Hispanic, Caucasian, or
other (OR = 1.00-1.20, CI = .80, 1.50). No significant differences in 12-month prevalence rates
were identified between groups. Hasin and colleagues (2005) found that compared to Caucasian
participants, Native American participants reported significantly higher lifetime prevalence rate
of MDD (OR = 1.50, CI = 1.10, 2.10) while African American, Asian or Pacific Islander, and
Hispanic participants reported a significantly lower lifetime prevalence rate of MDD (OR = .60.70, CI = .40, .90) on the AUDADIS-IV. Williams and colleagues (2007) found that Caucasian
participants reporting significantly higher lifetime prevalence rates of MDD (17.90%, p < .001)
on the CIDI compared to African American (10.40%) and Caribbean Black (12.90%)
participants. Similar to Kessler and colleagues (2003), no significant differences in 12-month
prevalence rates reported on the CIDI were identified between groups.
Other studies have used the CIDI to examine the impact of other race-related variables,
such as membership to a particular ethnic group and country of national origin. Alegría and
colleagues (2007) examined differences in prevalence rates for among Latino individuals living
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in the United States. Findings suggested that there were some group differences; participants of
Mexican descent were significant less likely to experience any depressive disorder during their
lifetime (OR = .57-.69, CI = .34, .99, p < .05) compared to Puerto Rican participants. However,
this relationship was not found for 12-month prevalence rates. Alegría and colleagues (2008)
investigated differences in prevalence rates among Latino and non-Latino individuals living in
the United States. Findings indicated that non-Latino Caucasian participants had significantly
higher lifetime prevalence rates for MDD (22.10%, p < .001) compared to all Latino participants
(15.20%). Lifetime prevalence rates did not significantly differ among Latino subgroups (p =
.65). Immigration status also had an impact on both groups, with participants born in the United
States reporting significantly higher lifetime prevalence rates for both Latino (p < .001) and nonLatino (p < .008) groups. González and colleagues (2010) reported differences in prevalence
rates for MDD based on ethnic group and immigration status. Results indicated that ethnic
groups reported differences in both 12-month (χ2 = 33.70, p < .001) and lifetime (χ2 = 4.60, p <
.001) prevalence rates for MDD, with Puerto Rican participants reporting the highest rates and
Filipino, Vietnamese, and Chinese participants reporting the lowest rates. In addition,
participants who were born in the United States reported higher 12-month (χ2 = 28.20, p < .001)
and lifetime (χ2 = 87.30, p < .001) prevalence rates of MDD compared to foreign born
participants.
Together, these studies suggest that Caucasian individuals are significantly more likely to
experience MDD over the course of their lifetime than individuals from diverse racial or ethnic
backgrounds, with the exception of Native American individuals. In addition, it appears that
individuals born in the United States are at higher risk for developing MDD than foreign born
individuals who immigrate from their country of origin.
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Several factors have been proposed to explain the elevated rates of MDD observed in
Caucasian individuals. First, it is possible that the low rates of depression in racial and ethnic
minorities is attributable to cultural bias. The diagnostic system (i.e., DSM) used to assess the
presence of mental disorders has been criticized for failing to adequately represent minority
groups, which is likely to impact the assessment and diagnosis of mental illness (as reviewed by
Kress, Eriksen, Rayle, & Ford, 2005). In addition, the clinicians who implement the diagnostic
system may be culturally biased. Multicultural competence is a requirement of ethical practice;
clinicians must assess a client’s cultural identify to obtain an accurate formulation of a client’s
psychological, emotional, and behavioral functioning (as reviewed by Kress et al., 2005).
However, it is possible that clinicians who have inadequate cultural training may exhibit a bias
when assessing and diagnosing mental illness in culturally diverse clients. Second, the low rates
of depression in racial and ethnic minorities may be due to cultural differences in the experience
of depression, which has an impact on symptom reporting, treatment seeking behavior, and the
therapeutic relationship (Kleinman, 2004). Finally, some race-related variables (e.g., ethnicity,
national origin, acculturation status, etc.) are often overlooked by large epidemiology or
community-based studies (Alegría et al., 2008; Williams et al., 2007). Additional research on the
influence of these cultural factors on depression is warranted.
Socioeconomic Status
Socioeconomic status is defined as a combination of educational achievement and
income level. Research has identified an association between socioeconomic status and
depression. Cross-sectional studies have generally shown that individuals of low socioeconomic
status report elevated levels of depressive symptoms compared to individuals of middle or high
socioeconomic status (as reviewed by Gallo & Matthews, 2003). Longitudinal studies have
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generally shown that low socioeconomic status prospectively predicts an increased risk for the
development of MDD over time (as reviewed by Everson, Maty, Lynch, & Kaplan, 2002; Gallo
& Matthews, 2003; Muntaner, Eaton, Miech, & O’Campo, 2004). Of note, some longitudinal
studies that have used a specific epidemiological sample (i.e., Epidemiologic Catchment Area
Study) or dichotomous variables to classify socioeconomic status have failed to find this
association, suggesting that these null findings could be due to methodological differences across
studies (see Gallo & Matthews, 2003 for review of discrepant results). Together, these results
suggest that compared to individuals of higher socioeconomic status, individuals of lower
socioeconomic status are generally at higher risk for experiencing depressive symptoms and a
clinically-significant depressive episode over the course of their lifetime.
Building on this body of work, Lorant and colleagues (2003) conducted a meta-analysis
of 51 articles to quantify the relationship between socioeconomic status and depression.
Depression was assessed via self-report or structured clinical interviews, such that the final
sample was comprised of individuals with clinical and non-clinical depression. Results indicated
that the individuals of lower socioeconomic status reported higher prevalence (OR = 1.81, CI =
1.57, 2.10, p < .001) and incidence (OR = 1.24, CI = 1.04, 1.48, p < .004) rates of MDD
compared to individuals of higher socioeconomic status. In addition, individuals of lower
socioeconomic status were significantly more likely to experience persistent MDD (OR = 2.06,
CI = 1.39, 3.05, p < .001). A dose dependent relationship between socioeconomic factors and
depression appeared to exist. Increases in education and income were associated with decreases
in the likelihood of depression, which suggests that there is a linear relationship between these
variables. Of note, some of the studies utilized self-report measures to assess depressive
symptoms rather than diagnostic measures, which limits the generalizability of results to clinical
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samples. Overall, this body of research indicates that individuals of lower socioeconomic status
are at higher risk for experiencing depressive symptoms and depression compared to individuals
of higher socioeconomic status.
Multiple factors have been proposed to explain the elevated rates of MDD observed in
individuals of lower socioeconomic status. First, it has been suggested that individuals of lower
socioeconomic status are exposed to more stressful life events or have less resources to combat
stressful life events. More specifically, these individuals may exhibit more maladaptive coping
strategies and diminished perception of personal abilities, mastery, and control in response to
stressful life events (Lorant et al., 2003). Second, it has been proposed that individuals of lower
socioeconomic status experience significantly more strain due to larger societal factors. For
example, these individuals are treated more negatively due to societal views and values
associated with economic standing and public policy (Lorant et al., 2003). Therefore, it is
possible that individual or societal factors or an interaction between these factors contribute to
the relationship between socioeconomic status and depression.
Comorbidity
Psychological Comorbidity
MDD is marked by elevated rates of psychological comorbidities. Multiple large-scale
epidemiological studies have calculated rates of disorders comorbid with MDD. Kessler and
colleagues (2003) found that MDD was associated with elevated rates of comorbid psychological
conditions on the CIDI. The majority of participants (64.00%) who endorsed experiencing MDD
over the past 12 months also endorsed the presence of a comorbid psychological disorder, which
included an anxiety (57.50%), impulse control (16.60%), or substance use (8.50%) disorder. An
even higher percentage of participants (72.10%) who endorsed experiencing MDD over the
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course of their lifetime also endorsed the presence of a comorbid psychological disorder, which
included an anxiety (59.20%), impulse control (30.00%), or substance use (24.00%) disorder.
The onset of MDD was generally proceeded by another psychological disorder, with MDD
occurring first in a relatively small portion of participants (12.60% for 12-month prevalence,
12.30% for lifetime prevalence). Kessler and colleagues (2010) replicated these results using the
same diagnostic measure. Anxiety (64.20%) and other mood (37.20%) disorders were the most
common comorbid conditions while impulse control (14.70%) and substance use (10.70%)
disorders were less likely, but still frequently reported within the sample. Results indicated that
the majority of participants (75.80%) endorsed the presence of at least one comorbid
psychological condition, with participants reporting one (25.60%), two (17.60%), or three or
more (32.60%) comorbidities.
Hasin and colleagues (2005) examined a more expansive list of comorbid psychological
conditions using the AUDADIS-IV. Participants who endorsed MDD during the past 12 months
reported elevated rates of personality disorders (37.90%), anxiety disorders (36.10%), and
nicotine dependence (26.00%). Of note, these participants reported relatively low rates of alcohol
(14.10%) and drug (4.60%) use disorders. A different pattern of comorbidity emerged for
participants who endorsed MDD at some point during their lifetime, including elevated rates of
anxiety disorders (41.40%), alcohol use disorders (40.30%), personality disorders (30.80%),
nicotine dependence (30.00%), and drug use disorders (17.20%). The authors concluded that
individuals who endorse MDD over a 12-month period or their lifetime are highly likely to also
endorse the presence of a comorbid condition during the same time span.
The literature has clearly shown that MDD is associated with elevated rates of
psychological comorbidity. Across studies, anxiety disorders are the most prevalent class of
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comorbid conditions. Personality, mood, impulse control, and substance use disorders also
commonly co-occur with MDD.
Medical Comorbidity
MDD has been associated with an elevated risk for chronic medical conditions, such as
asthma, arthritis, cardiovascular disorder (CVD), cancer, and diabetes (as reviewed by Chapman,
Perry, & Strine, 2005). Epidemiological studies have provided additional evidence for the
association between depression and medical conditions. Kessler and colleagues (2010) found that
individuals who endorsed MDD on the CIDI over a 12-month period were highly likely to also
endorse the presence of a comorbid medical condition during the same time span. Various types
of musculoskeletal (48.20%), respiratory (43.50%), pain (41.30%), and cardiovascular (24.20%)
disorders were commonly reported by individuals who have recently suffered from depression.
Results indicated that the majority of participants (79.80%) endorsed the presence of at least one
medical comorbidity, with participants reporting one (22.30%), two (21.10%), or three or more
(36.40%) comorbidities.
These results have been replicated by large scale studies conducted around the world.
Moussavi and colleagues (2007) assessed the association between MDD and medical conditions
in a culturally diverse sample. Participants from 60 countries were assessed for the presence of
chronic medical conditions based on reports of MDD using the CIDI. Prevalence rates for
chronic medical conditions were relatively low, with rates ranging as high as 4.50% for angina
and as low as 2.00% for diabetes. There was a strong association between depression and chronic
medical conditions; participants with diabetes (9.30%), arthritis (10.70%), angina (15.00%), and
asthma (15.00%) also reported experiencing comorbid depression. The rates of depression were
even higher in participants who reported more than one chronic medical illness (23.00%), which
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was significantly different from healthy participants free from such conditions (3.20%, p < .001).
In addition, participants with chronic medical conditions and comorbid depression reported
significantly lower health scores than non-depressant participants with one or more chronic
medical conditions (p < .0001). Together, these results suggest that depression commonly cooccurs with comorbid medical conditions and has an additive negative impact on physical health.
The literature has indicated that depression is also associated with elevated rates of
mortality. Depressed individuals are significantly more likely to die by suicide than the general
population. Research has consistently shown that suicidal thoughts and behaviors are
significantly more common in depressed individuals. Depressed individuals are about 20 times
more likely to attempt and commit suicide compared to individuals who have never been
depressed (as reviewed by Lépine & Briley, 2011). In addition, the presence of certain comorbid
medical conditions in depressed individuals has been associated with an increased risk of death.
More specifically, research has shown that individuals with CVD and comorbid depression or
depressive symptoms are significantly more likely to die from cardiovascular-related causes than
their non-depressed counterparts (as reviewed by Lépine & Briley, 2011). These results indicate
that depression has a significant and negative impact on an individual’s life trajectory.
As outlined by Katon (2003), there are several potential reasons for the relationship
between depression and medical conditions. First, it is possible that depression is a risk factor for
certain medical conditions. Depression is associated with negative health behaviors (e.g.,
inactivity and obesity) that may contribute to the development of medical conditions.
Longitudinal studies that have found that depression prospectively predicts the risk for some
medical conditions, such as diabetes and CVD, have provided some support for this hypothesis.
Second, depression may result from the experience of developing a potentially life-threatening
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medical condition. This experience can result in functional impairment, reduced quality of life,
and feelings of helplessness, hopelessness, and stress, potentially leading to the development of
depression. Third, depression may be the result of a medication prescribed to treat the medical
condition. Depression is a known side effect for certain medications. However, depression has
also been reported as a nonspecific side effect that is not due to the pharmacological mechanism
of action (Barsky, Saintfort, Rogers, & Borus, 2002). Finally, it is possible that the medical
condition causes physiological changes that leads to the development of depression. The
potential mechanisms of change may be directly or indirectly related to the medical condition;
direct effects include changes to the brain structure or function while indirect effects include
changes in physiological systems (e.g., inflammation and cytokines) that has down-stream
effects on the brain.
Individual and Societal Impact
Individual Impact
MDD is associated with significant cost to the individual and society. Individuals with
MDD struggle with maladaptive thoughts, feelings, and behaviors that negatively impact
multiple aspects of their lives. In addition, these individuals experience elevated functional
impairment and reduced quality of life that make it more difficult to function within the
confounds of society. Functional impairment is defined as diminished ability to perform
everyday tasks. Backenstrass and colleagues (2006) assessed the impact of depression on
different areas of functioning. Participants who reported minimal depressive symptoms (n = 56)
or depressive symptoms consistent with major (n = 28) or minor (n = 38) depression on the
Patient Health Questionnaire – 9 (PHQ-9) were compared to healthy control participants (n =
491). Results indicated that participants who reported symptoms consistent with MDD endorsed
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experiencing significantly more days of minor impairment and missing daily activities or work
due to illness compared to participants with subclinical depressive symptoms or healthy control
participants (p < .001), suggesting that functional impairment is significantly worse in
individuals with clinically significant symptoms. These results indicate that depression has a
significant and negative impact on an individual’s ability to function within everyday activities
across multiple settings.
Quality of life is defined as diminished well-being due to disability in different aspects of
functioning, including physical and emotional health, professional and economic standing,
interpersonal relationships, and life satisfaction. Rapaport, Clary, Fayyad, and Endicott (2005)
assessed differences in quality of life using a large sample of participants with MDD (n = 242)
recruited from 11 multisite trials. Quality of life was assessed using the Quality of Life
Enjoyment and Satisfaction Questionnaire. Results indicated that participants with MDD
endorsed lower quality of life ratings for all categories compared to healthy control participants
from the community (n = 67). The majority of participants with MDD (63.00%) reported
clinically severe impairments in quality of life relative to healthy control participants (1.70%).
Impairments were even more pronounced in chronic or double depression (i.e., MDD and
dysthymia), with 85.00% of participants reporting clinically severe impairments in quality of
life. These results indicate that depression has a significant and negative impact on an
individual’s ability to engage in positive and pleasurable activities.
Societal Impact
Overall, the literature suggests that depression has a negative impact on an individual’s
functional ability and quality of life. These impairments result in a significant burden that makes
it difficult for depressed individuals to engage in typical aspects of daily life. Consequently,
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depression is associated with increased disability rates and decreased workplace productivity
(Lépine & Briley, 2011). Over the past several decades, the burden of depression has steadily
risen. As outlined by Whitaker (2015), the disability rate rose from one in every 468 Americans
in 1955 to one in every 184 Americans in 1987. This trend has continued to grow exponentially,
with the disability rate reaching one in every 70 Americans in 2013. This finding does not appear
to be confined to the United States, with other Western countries reporting similar increases in
disability rates. According to Mathers, Fat, and Boerma (2008), MDD is currently the leading
cause of disability and second leading cause of disease burden around the world. The negative
impact of MDD is projected to significantly increase relative to other disorders over the next
decade. Predictions have indicated that MDD will become the leading cause of disease burden by
the year 2030. These projections have significant implications for an individual’s ability to
function within the confounds of society.
The complications directly and indirectly associated with MDD are extremely costly to
society. The economic burden associated with MDD has risen in recent years. According to
Greenberg, Fournier, Sisitsky, Pike, and Kessler (2015), the estimated cost of MDD has
increased from $173.50 billion in 2005 to $210.50 billion in 2010. The rise in estimated cost was
attributable to increases direct (i.e., medical and pharmaceutical treatment expenses) and indirect
(i.e., suicide, work, and comorbidity related expenses) costs associated with depression or
comorbid psychological and medical conditions. The literature has clearly shown that MDD
represents a significant burden on individuals suffering from the disorder and society at-large.
Course
The course of MDD is characterized by different stages that occur within different phases
of the disorder (Figure 1). As outlined by Bockting, Hollon, Jarrett, Kuyken, and Dobson (2015),

21

definitions for the stages of depression that occur within the phases of treatment have been
proposed. The goal of the acute phase of treatment is to generate a treatment response, which is
defined as a reduction in the severity of depressive symptoms (e.g., typically a 50.00% reduction
compared to baseline). Over time, depressive symptoms begin to remit. The transition from the
acute phase to the continuation phase of depression is marked by remission, which is defined as
the absence of depressive symptoms for a period of time (e.g., typically two months) when an
individual is considered to be generally well. Remission can be categorized as partial, unstable,
or stable. Partial and unstable remission are characterized by the consistent (i.e., partial) or
inconsistent (i.e., unstable) presence of some residual depressive symptom. During the
continuation phase, depressive symptoms may increase to clinically significant levels. This
phenomenon is characterized as relapse, which is defined as the reemergence of a depressive
episode while an episode of depression is in remission. Alternatively, the transition from the
continuation phase to the maintenance phase of depression is marked by recovery, which is
defined as defined as the end of a depressive episode after a period of time (e.g., typically six to
12 months) when an individual is considered to no longer be depressed. During the maintenance
phase, depressive symptoms may increase to clinically significant levels. This phenomenon is
characterized as recurrence, which is defined as the experience of a new depressive episode after
recovery from an episode. While these phases of depression are typically conceptualized within
the stages of treatment, they can occur naturalistically without the influence of treatment.
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Figure 1. Diagram of the Stages of Depression from Bockting et al. (2015)

The literature has consistently shown that MDD is marked by high rates of relapse and
recurrence. Hardeveld, Spijker, De Graaf, Nolen, and Beekman (2010) conducted a systematic
review of nine naturalistic studies that assessed the recurrence in MDD using a structured
diagnostic interview. Prevalence rates for recurrence ranged from 21.00% to 40.00% within the
first year, 42.00% to 75.00% within a five-year span, 67.00% within a 10-year span, and 35.00%
to 85.00% within a 15-year span, indicating that recurrence is a commonly occurring
phenomenon. These results have been replicated by multiple studies conducted over the past
decade.
Poutanen and colleagues (2007) assessed the trajectory of depression in a sample of
Finnish outpatients. Participants recruited from primary (n = 62) and psychiatric (n = 84) care
settings were diagnosed with mild or severe depression using the Present State Examination
interview. Depression status was re-assessed at a seven-year follow-up using the CIDI – Short
Form. Results indicated that participants with mild and severe depression recruited from both
settings showed elevated rates of depression during the follow-up period. Depression was present
in 42.40% of participants with severe MDD and 48.30% of participants with mild MDD
recruited from primary care settings. Similarly, depression was present in 61.50% of participants
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with severe MDD and 68.50% of participants with mild MDD recruited from psychiatric care
settings. While this study provides important information about the chronicity of depression
across different healthcare settings, it does not decipher between relapse and recurrence rates.
Hardeveld, Spijker, De Graaf, Nolen, and Beekman (2013) assessed the recurrence of
MDD in the Netherlands Mental Health Survey and Incidence Study (NEMESIS), a large
community-based study of Dutch adults. Participants with a history of depression (n = 687)
retrospectively reported the timing of their last depressive episode on the CIDI. Participants were
longitudinally followed and depressive status was assessed after one and three years. The use of
retrospective and longitudinal assessments enabled the calculation of cumulative recurrence
rates, which spanned 20 years time. Results indicated that 19.70% of participants experienced a
recurrent episode of depression during the follow-up period. Cumulative recurrence rates ranged
from 2.50% at one year, 4.50% at two years, 13.20% at five years, 23.20% at 10 years, and
42.00% at 20 years, suggesting that the probability of recurrence of MDD increased as more time
passed.
ten Doesschate, Bockting, Koeter, and Schene (2010) extended these findings by
assessing the relapse and recurrence of MDD following treatment. Participants with a history of
depression (n = 172) participated in a clinical trial of cognitive therapy (CT) or treatment as
usual (TAU) for depression. Participants were assessed for depression at baseline and three, 12,
24, 36, and 66 months posttreatment using the Structured Clinical Interview for DSM-IV (SCIDI). Results indicated that across treatment conditions, the majority of participants (79.00%)
experienced a relapse or recurrence of MDD over the 5.50-year follow-up period. While the
authors did not specifically distinguish between relapse and recurrence, the results suggest that
both phenomena commonly occur in individuals with a history of depression.
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Johansson, Lundh, and Bjärehed (2013) replicated these results in a sample of Swedish
outpatients who had successfully completed treatment. Participants with a history of depression
(n = 51) who were in remission from MDD after exposure to psychotherapy or pharmacotherapy
were recruited. Depression status was assessed at baseline and 12-month follow-up using the
SCID-I. Results indicated that the majority of participants (61.00%) experienced a re-emergence
of depression during the 12-month follow-up period, with no significant differences across
groups based on the type of treatment modality. Recurrence (77.00%) was more common among
these participants than relapse (23.00%), indicating that typically participants recovered from
MDD posttreatment before experiencing a new depressive episode.
Together, these studies indicate that individuals with MDD experience high rates of
relapse and recurrence. There is significant variability for the estimated occurrence of relapse
and recurrence, with rates ranging from 2.50% to 85.00% over a period of one to 20 years. The
majority of research has combined the terms relapse and recurrence, making it difficult to
identify specific prevalence rate ranges for each term.
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CHAPTER 2
SAD MOOD REACTIVITY AND VULNERABILITY TO DEPRESSION
Research clearly suggests that MDD is marked by high rates of relapse and recurrence
and is typically viewed as a chronic mental illness (Richards, 2011). Most recent research
estimates that half of individuals who experience a major depressive episode will experience a
recurrence during their lifetime, with a subset of those individuals experiencing a relapsingremitting trajectory marked by multiple episodes of depression (Monroe et al., in press).
Vulnerability Factors
Vulnerability to depressive relapse and recurrence likely reflects a complex interaction of
biological, psychological, and environmental factors. Burcusa and Iacono (2007) completed a
review of the literature to identify vulnerability factors for relapse and recurrence, which can be
classified in different categories. Demographic vulnerability factors include female gender, lower
socioeconomic status, and single relationship status. Clinical vulnerability factors include a
higher number of previous depressive episodes, higher severity of first depressive episode, and
the presence of comorbid pathology, especially other mood disorders. Familial vulnerability
factors include a family history of psychopathology, especially depression or other mood
disorders. Psychological vulnerability factors include negative cognitions and high levels of
neuroticism. Psychosocial vulnerability factors include poor social support and exposure to
stressful life events during childhood and adulthood. Recent studies on the prevalence of relapse
and recurrence of depression have identified many of the same vulnerability factors, providing
additional evidence for their predictive validity (Harveveld et al., 2010, 2013; Johansson et al.,
2015; ten Doesschate et al., 2010).
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Unfortunately, the majority of vulnerability factors that have been identified are not
amenable to modification (e.g. female gender, multiple depressive episodes, stressful life events,
etc.), which makes it difficult for medical and mental healthcare providers to prevent or intervene
during the depressogenic cycle. Additional research is needed to identify and target malleable
vulnerability factors that are related to increased risk for future episodes of depression. Two
potentially malleable vulnerability factors that have been identified in the literature include
cognitive and mood reactivity in response to a sad mood. The following section will review the
theoretical models, experimental methodology, and empirical evidence related to cognitive and
mood reactivity.
Cognitive Reactivity
Theoretical Models
Cognitive theories of depression propose that dysfunctional patterns of thinking represent
a cognitive vulnerability that contributes to the etiology, maintenance, and reoccurrence of
depression (Beck, 1967; Lau, Segal, & Williams, 2004; Scher, Ingram, & Segal, 2005). Indeed, a
large body of empirical evidence has shown that currently, but not formerly, depressed
individuals endorse elevated rates of dysfunctional thoughts (as reviewed by Teasdale, 1999).
Interestingly, formerly depressed individuals remain at increased risk for depressive relapse or
recurrence, despite no longer exhibiting cognitive vulnerability to depression while in a euthymic
mood state. Several theoretical models have been proposed to account for differences in
cognitive patterns observed between currently and formerly depressed individuals. In particular,
the differential activation hypothesis and mood state dependent hypothesis have extended the
cognitive model of depression originally proposed by Beck (1967) and suggest that maladaptive
cognitions are dependent on an individual’s current mood state.
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The differential activation hypothesis. The differential activation hypothesis by
Teasdale (1988) suggests that depression results in a myriad of cognitive changes that continue
to persist after recovery from depression. Maladaptive cognitive patterns, including
dysfunctional thinking and biased information processing, are activated by dysphoric mood.
Over time, these cognitive patterns become associated with depressed mood and are
hypothesized to maintain depressive symptoms in individuals with current MDD. According to
this hypothesis, dysphoric mood can reactivate biased information processing and related
cognitive patterns (e.g., dysfunctional beliefs) among individuals who have recovered from
depression. In other words, whether dysfunctional thinking is activated among a formerly
depressed individual depends on their current mood state. Formerly depressed individuals who
are currently euthymic have low levels of dysfunctional thinking that resembles never depressed
individuals. In contrast, formerly depressed individuals in a dysphoric mood state experience an
increase in dysfunctional thinking similar to currently depressed individuals. The resurgence of
maladaptive cognitive patterns during a dysphoric mood for formerly depressed individuals is
hypothesized to increase the likelihood that an otherwise transient negative mood will develop
into a depressive episode. Overall, this hypothesis proposes a cyclical relationship in which
depressed mood leads to the activation of biased informational processing and dysfunctional
thinking patterns that serve to maintain or initiate a depressed mood or depressive episode.
The differential activation hypothesis by Teasdale (1988) argues that maladaptive
cognitive patterns are activated by dysphoric mood and perpetuate depressed mood. According
to this theory, the maladaptive cognitive patterns associated with depression include a wide range
of cognitive processes (e.g., biased attention, memory, and dysfunctional thinking patterns; as
reviewed by Lau et al., 2004) that occur in individuals with both current or remitted MDD. A
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similar theory, the mood state dependent hypothesis by Miranda and Persons (1988), focuses on
a narrower range of maladaptive cognitive processes (i.e., dysfunctional beliefs only).
The mood state dependent hypothesis. The mood state dependent hypothesis by
Miranda and Persons (1988) attempts to account for the differential patterns of dysfunctional
thinking observed in currently and formerly depressed individuals. Previous research has shown
that currently, but not formerly, depressed individuals endorse elevated levels of dysfunctional
thinking. It was hypothesized that dysfunctional thinking is mood state dependent in formerly
depressed individuals. Specifically, cognitive vulnerability in an individual with a history of
depression is not explicitly present during a euthymic mood state but is evident when an
individual is in a dysphoric mood state. According to this hypothesis, formerly depressed
individuals exhibit cognitive reactivity, or a significant increase in dysfunctional thinking after
exposure to a dysphoric mood. It is theorized that individuals with remitted MDD maintain latent
cognitive vulnerabilities that are activated by a sad mood. Once activated, these patterns of
dysfunctional thoughts are thought to increase risk for a subsequent depressive episode in
individuals who have a history of depression.
The depression literature has examined the tenants of the differential activation and mood
state dependent hypotheses. In the following sections, the experimental methodology used to
investigate these theoretical models as well as the empirical evidence for these theoretical
models is reviewed.
Mood Induction Procedures
Mood induction procedures induce a specific, transient mood state within an
experimental setting, which enables researchers to investigate the cognitive, affective, and
physiological factors that put an individual at risk for experiencing prolonged, maladaptive mood
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states that are characteristic of psychopathology. Martin (1990) systematically reviewed the
range of mood induction procedures that have been used in experimental psychology. While 14
different types of mood induction procedures have been empirically validated in the literature,
this review will focus on music plus autobiographical recall procedure, which is most commonly
used approach within the depression literature. During a music plus autobiographical recall mood
induction, individuals listen to a piece of emotionally-valenced music and are instructed to recall
an emotionally-valenced autobiographical memory to induce a particular mood. Research on
negative affect would typically ask participants to think about a specific time in their life when
they experienced sadness (i.e., autobiographical recall mood induction) while listening to a sad
piece of non-lyrical music played at a slower rate (i.e., music mood induction).
Martin (1990) acknowledged that while there is not a universally accepted procedure for
inducing transient mood states, the depression literature has identified the music plus
autobiographical recall mood induction as an effective method for inducing a sad mood state.
The sad music plus autobiographical recall mood induction has been compared to multiple selfreport, behavioral, and performance-based measures. Overall, the sad music plus
autobiographical recall mood induction has been shown to instate a transient despondent mood
that is equivalent to an intermediate level of clinical depression in more than 75.00% of
participants. In addition, the sad music plus autobiographical recall mood induction has been
shown to induce a mood state that most closely resembles the cognitive, somatic, and emotional
aspects of depression without the presence of residual anxiety. Of note, the transient mood state
only persists for a few minutes, which indicates that these mood induction procedures are not
only effective, but ethical. Overall, the sad music plus autobiographical recall mood induction
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procedure has been empirically validated as a reliable and valid method for eliciting a sad mood
within an experimental setting.
Empirical Evidence
Theoretical models have suggested that increases in maladaptive cognitive patterns in
response to sadness contribute to the recurrence and maintenance of depression. Studies have
assessed the presence of cognitive reactivity and its potential role as a predictor of relapse and
recurrence. Cognitive reactivity is defined as the change in underlying negative cognitions in
response to a sad mood induction. Cognitive reactivity is typically measured using the
Dysfunctional Attitudes Scale (DAS), which is used to compare the change in dysfunctional
beliefs assessed pre- and post-mood induction.
The differential activation and mood state dependent hypotheses have been investigated
by a large body of literature. Studies have employed a variety of empirically-validated sad mood
induction procedures to examine cognitive reactivity in participants with remitted MDD as these
experimental procedures have been shown to transiently create the cognitive, somatic, and
emotional experiences of depression in euthymic individuals. The majority of studies have used a
combination of music and autobiographical recall to create a mild, transient sad mood (Fresco,
Heimberg, Abramowtiz, & Bertram, 2006; Gemar, Segal, Sagrati, & Kennedy, 2001; Jarrett et
al., 2012; Kuyken et al., 2010; Lau, Haigh, Christensen, Segal, & Taube-Schiff, 2012; Pfeiffer,
Brockmeyer, Zimmermann, & Backenstrass, 2015; Segal, Gemar, & Williams, 1999; Segal et al.,
2006; Van der Does, 2002, 2005). Though, some studies have used other empirically-supported
techniques such as a combination of sad-valence music and self-statements (e.g., “I’m
discouraged and unhappy about myself”; Dykman, 1997), a sad-valence film (i.e., clip of a son
dealing with his father’s death from The Champ; Brosse, Craighead, & Craighead, 1999;
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Miranda, Gross, Persons, & Hahn, 1998), or a naturally occurring negative mood state (Miranda,
Persons, & Byers, 1990; Roberts & Kassel, 1996).
In general, cross-sectional studies have shown that participants with remitted MDD report
a significantly greater increase in dysfunctional attitudes following a negative mood state or after
exposure to a sad mood induction compared to healthy control participants (Gemar et al., 2001;
Lau et al., 2012; Miranda et al., 1990, 1998; Roberts & Kassel, 1996; Van der Does, 2002).
However, some studies failed to find this association, with formerly depressed and never
depressed participants reporting similar levels of dysfunctional attitudes following a negative
mood state or after exposure to a sad mood induction (Brosse et al., 1999; Dykman, 1999; Fresco
et al., 2006; Pfeiffer et al., 2015; Van der Does, 2005). Together, these results provide mixed
evidence for the hypothesis that individuals with remitted MDD exhibit significantly more
dysfunctional attitudes while in a dysphoric mood than their never depressed counterparts.
Longitudinal studies have investigated cognitive reactivity as a risk factor for relapse and
recurrence of MDD. Segal and colleagues (1999) examined differences in cognitive reactivity
between participants with remitted MDD who were successfully treated with cognitivebehavioral therapy (CBT; n = 25) or antidepressant medications (n = 29). At baseline,
participants completed a sad mood music and autobiographical recall mood induction. One to
five years later, participants were assessed for recurrence using the SCID-I. Results indicated
that at baseline, formerly depressed participants treated with antidepressant medications reported
a significantly greater increase in dysfunctional attitudes post-mood induction compared to those
treated with CBT (R2 = .09, p < .05). In addition, formerly depressed participants who reported
an increase in cognitive reactivity post-mood induction were significantly more likely to
experience a relapse during follow-up (χ2 = 4.64, p < 001). Results suggested that cognitive
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reactivity may be a risk factor for subsequent relapse and proposed that CBT may be an
efficacious treatment method for decreasing an individual’s dysfunctional attitudes.
In a follow up study, Segal and colleagues (2006) sought to replicate the finding that the
type of treatment for depression has an impact on subsequent cognitive reactivity. Participants
with current MDD were recruited and randomly assigned to a treatment condition, including
CBT (n = 88) or antidepressant medication (n = 56). After successful achieving remission from
MDD, participants completed a sad mood music and autobiographical recall induction. 18months later, participants were assessed for recurrence using the Longitudinal Interval FollowUp Evaluation interview and Hamilton Depression Rating Scale (HDRS). Results indicated that
formerly depressed participants who reported a significantly greater increase in dysfunctional
attitudes following the mood induction were at greater risk for experiencing a relapse during the
follow-up period (χ12 = 7.12, p < .05). Contrary to the Segal and colleagues (1999) findings, there
was no significant difference in cognitive reactivity between treatment groups (χ12 = .256, p >
.05), casting doubt on the hypothesis that CBT leads to a change in underlying dysfunctional
beliefs. However, this study does provide additional support for the finding that the presence of
cognitive reactivity predicts the recurrence of another depressive episode in participants with
remitted MDD.
Kuyken and colleagues (2010) aimed to extend previous findings to a different type of
psychotherapy: mindfulness-based cognitive therapy (MBCT). Participants in partial or full
remission from recurrent MDD (i.e., three or more lifetime episodes of depression) were
recruited and randomly assigned to a treatment condition, including MBCT plus discontinuation
of antidepressant medication (n = 43) or maintenance of antidepressant medication (n = 37).
After successful achieving remission from MDD, participants completed a sad mood music and
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autobiographical recall induction. Fifteen months later, participants were assessed for recurrence
using the SCID-I and depressive symptoms using the HDRS. Results indicated that formerly
depressed participants who received MBCT reported a significantly greater increase in
dysfunctional attitudes following the mood induction compared to formerly depressed
participants who received antidepressant medication (d = .47, p < .05). While formerly depressed
participants treated with antidepressant medications who reported increases in dysfunctional
attitudes following the mood induction were at greater risk for elevated depressive symptoms
and relapse during the follow-up period, this relationship was not found for participants who
received MBCT (χ12 = .01, p = .91). This study provides additional support for the finding that
the presence of cognitive reactivity predicts relapse in participants with remitted MDD and
proposed that MCBT may be protect against future episodes of depression.
Jarrett and colleagues (2012) investigated the impact of cognitive reactivity on relapse
and recurrence in formerly depressed participants who were at high risk for experiencing another
depressive episode. Participants with recurrent MDD and elevated depressive symptomology (n
= 523) who previously responded to CT were recruited and randomly assigned to an 8-month
continuation treatment condition, including CT, antidepressant medication, or placebo. Before
beginning continuation treatment, participants completed a sad mood music and autobiographical
recall mood induction. Participants were assessed for relapse using the SCID-I and HRSD eight,
20, and 32-months after the start of continuation treatment. Contrary to previous research, there
was no significant increase in dysfunctional attitudes following the mood induction (p = .76).
While these results are not in line with the differential activation or mood state dependent
hypotheses, are in line with previous research that has shown that participants who have received
CBT exhibit less cognitive reactivity than participants who were treated with pharmacotherapy
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(Segal et al., 1999). Additional analyses identified a relationship between unprimed
dysfunctional attitudes and relapse of depression over time; formerly depressed participants in all
conditions who endorsed higher dysfunctional attitudes pre-mood induction were at a greater risk
for relapse at 20 (χ2 = 3.93, p < .05) and 32 (χ2 = 4.49, p < .05) months, regardless of
posttreatment depressive symptom severity. Overall, this study suggests that the presence of
dysfunctional attitudes during a euthymic, rather than dysphoric, mood state has negative
implications for sustained remission in MDD.
The literature has found some support for the differential activation and mood state
dependent hypotheses. Cross-sectional studies have generally suggested that individuals who
have recovered from depression exhibit cognitive reactivity in response to a negative mood state
or sad mood induction compared to individuals without a history of depression. In addition,
longitudinal studies have shown that formerly depressed individuals who exhibit cognitive
reactivity while euthymic or dysphoric have higher rates of relapse and recurrence over time.
However, there are inconsistencies in this literature base. As a result, researchers have examined
other forms of reactivity that may explain elevated rates of relapse and recurrence. In the
following section, research examining mood reactivity in response to sadness will be reviewed.
Mood Reactivity
Theoretical Models
Some etiological theories of depression have focused on the experience of negative
emotions, proposing that depressed individuals exhibit abnormal patterns of mood reactivity, or a
significant change in mood state after exposure to a dysphoric mood. The cardinal symptoms of
depression include sad, low mood and loss of interest or pleasure in activities that were
previously enjoyable (APAA, 2013). In this sense, depression is a disorder marked by low levels
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of positive mood as well as high levels of negative mood (Rottenberg, Gross, & Gotlib, 2005b).
Indeed, research has indicated that individuals with current MDD report fewer positive emotions
and exhibit fewer positive responses to pleasurable stimuli. While depressed individuals have
conventionally been thought to express more negative emotions, the empirical evidence is mixed.
Some research has shown that individuals with current MDD exhibit greater responsivity to
negative stimuli while other studies have found the opposite (Rottenberg, Gross, & Gotlib,
2005b). Theoretical models that have been proposed to explain these empirical findings include
the positive attenuation, the negative potentiation, and the emotion context insensitivity
hypotheses.
The positive attenuation hypothesis. The positive attenuation hypothesis proposes that
currently depressed individuals exhibit a blunted emotional response to positively-valenced
emotional stimuli. This hypothesis is primarily based on clinical observations of depression; the
disorder is associated with symptoms related to reduced emotional (e.g., loss of interest),
behavioral (e.g., psychomotor retardation), and physiological (e.g., reduced appetite, weight, and
energy level) engagement that is adaptive and life sustaining (Rottenberg et al., 2005b). The
literature has generally provided empirical support for the positive attenuation hypothesis. A
meta-analysis by Bylsma, Morris, and Rottenberg (2007) found that positive emotional reactivity
was lower for self-report (p < .0001, d = -.70) and behavioral (p < .001, d = -.45) measures in
depressed participants compared to healthy control participants. Fewer studies have examined
positive emotional reactivity using physiological methodology, resulting in similar results across
depressed and never depressed participants (p = .29, d = -.15).
The negative potentiation hypothesis. The negative potentiation hypothesis proposes
that currently depressed individuals exhibit an exaggerated emotional response to negatively-
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valenced emotional stimuli. This hypothesis is also based on clinical observations of depression;
the disorder is associated with symptoms related to negative mood states (e.g., depressed mood)
and is often characterized by negative-valence behavioral reactions (e.g., crying and withdrawal;
Rottenberg et al., 2005b). It has been theorized that negative mood states result in a cascade of
cognitive changes that perpetuate depressogenic responsivity. As previously reviewed, the
cognitive model of depression states that negative mood activates maladaptive cognitive patterns
that lead to biased informational processing, dysfunctional thinking, and depressogenic behaviors
(Beck, 1967). The cyclical relationship between depressogenic thoughts, feelings, and behaviors
is hypothesized to initiate and maintain depression. The findings for the negative potentiation
hypothesis have been inconsistent. For example, studies have found that currently depressed
individual exhibit increased or decreased physiological reactivity to negatively-valenced stimuli
(as reviewed by Rottenberg et al., 2005b). In addition, meta-analysis by Bylsma and colleagues
(2007) found that negative emotional reactivity was lower for self-report (p < .0001, d = -.36)
and physiological (p < .05, d = -.22) measures in depressed participants compared to healthy
control participants. Results were less clear for negative emotional reactivity assessed by
behavioral measures, resulting in non-significant differences between depressed and never
depressed participants (p = .54, d = -.05). In general, the literature refutes the negative
potentiation hypothesis and suggest that depressed individuals tend to exhibit blunted, rather than
exaggerated, reactivity to negatively-valenced emotional stimuli.
The emotion context insensitivity hypothesis. The emotional context insensitivity
hypothesis by Rottenberg and Gotlib (2004) builds upon the empirical findings related to the
positive attenuation and negative potentiation hypotheses in proposing that depressed individuals
exhibit blunted emotional reactivity in response to both positively and negatively-valenced
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stimuli. The theory provides an evolutionary explanation to the emotional, behavioral, and
physiological reactions observed in depressed individuals. It is theorized that depressed
individuals disengage from positive and negative stimuli in their environment to protect
themselves from potential danger. As a result, depressed individuals exhibit blunted emotional,
behavioral, and physiological reactions in response to both positive and negative stimuli that are
normative and idiographic in nature. This pattern of responsivity is not appropriate in relation to
the environmental demands and results in a less adaptive response that is theorized to perpetuate
depressive symptoms or lead to recurrence of depression.
While it was initially hypothesized that this pattern of responsivity would be observed in
individuals with a history of depression, early empirical evidence (i.e., Rottenberg et al., 2005b)
suggested that emotional, behavioral, and physiological reactivity is mood state dependent in
formerly depressed individuals. Therefore, individuals who have a history of depression will
exhibit blunted responsivity while in a dysphoric mood, but not during a euthymic mood. This
pattern of responsivity is hypothesized to serve as a risk factor for experiencing a subsequent
depressive episode. The depression literature assessing reactivity to sad mood induction
procedures has primarily examined the emotion context insensitivity hypothesis. In the following
section, empirical evidence supporting and refuting this theoretical model will be reviewed.
Mood Induction Procedures
Studies have typically obtained multiple measures of mood to assess how emotions
changes in response to mood induction procedures. Within the cognitive reactivity literature,
changes in mood have been employed as a manipulation check to ensure that the sad mood
induction was in fact inducing a transient, dysphoric mood in participants. The aforementioned
studies all found that formerly depressed and healthy controls participants endorsed an increase
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in self-reported sad mood on the Visual Analogue Scale (VAS). Of the studies that examined
group differences among formerly depressed and never depressed participants, none found
significant variations in the degree of sadness endorsed by the two groups after exposure to the
sad mood induction procedures (Brosse et al., 1999; Dykman, 1997; Fresco et al., 2006; Gemar
et al., 2001; Lau et al., 2012; Miranda & Persons, 1988; Miranda et al., 1998; Segal et al., 2006;
Solomon et al., 1998; Van der Does, 2002, 2005). These findings suggest that formerly
depressed and healthy control participants show similar levels of mood reactivity in response to a
sad mood induction.
Empirical Evidence
Given that some studies have failed to show cognitive reactivity to sadness in individuals
with remitted depression, researchers examined other potential predictors of relapse and
recurrence. Recent findings suggest that there may be a difference in mood reactivity among
participants with remitted MDD. Mood reactivity is defined as the change in mood state in
response to a sad mood induction. Mood reactivity is typically measured using the VAS, which
compares an individual’s mood state (i.e., happy, sad, depressed, etc.) pre- and post-mood
induction
Before formally proposing the emotion context insensitivity hypothesis, Rottenberg,
Kasch, Gross, and Gotlib (2002) investigated mood reactivity in currently depressed individuals.
Depression was assessed using the SCID-I. Participants included individuals with current MDD
(n = 72) and healthy control participants without a history of Axis I disorders (n = 33).
Experimental procedures included a neutral film, two negative (i.e., sad and fear) films presented
in a counterbalanced order and separated by an arithmetic task, and an amusing film. Self-report
measures about emotional experiences were collected at baseline and after each emotional film.
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Results indicated that participants with current MDD reported more sadness in response to the
neutral (R2 = 25.11, p < .001) and amusing (R2 = 8.25, p < .01) films, but not the sad (R2 = 1.19, p
> .10) or fear (R2 = 2.05, p > .10) films, compared to healthy control participants. In addition,
participants with current MDD reported less amusement (R2 = 4.91, p < .05) in response to the
amusing film, but group differences were not statistically significant (p > .05). This study
provided empirical evidence for the successive theory that currently depressed individuals
exhibit inappropriate and insensitive mood reactivity to emotionally-valenced stimuli.
Rottenberg, Gross, and Gotlib (2005b) sought to extend these results to formerly
depressed individuals. Depression was assessed using the SCID-I. Participants were individuals
with current MDD (n = 19), remitted MDD (n = 22), and healthy control participants without a
history of Axis I disorders (n = 26). Experimental tasks included normative and idiographic sad,
happy, and neutral valenced films and imagery tasks (i.e., participants were instructed to create a
visual picture in their mind of the previously watched film) presented in a counterbalanced order.
Each film and imagery task were preceded by a one-minute resting baseline and followed by a
one-minute filler task to reduce carry over effects. Results indicated that participants with current
MDD reported similar levels of sadness (p > .10) and less happiness (p < .001) across all stimuli
compared to the two other groups, suggesting that these participants did not respond to the
emotional valence of the stimuli appropriately. Participants with current MDD who reported
higher levels of sadness and lower levels of happiness in response to idiographic stimuli were
more likely to have been depressed for a longer period of time. Participants with remitted MDD
reported emotional (i.e., happy, amused, sad, and anxious) responses that were similar to healthy
control participants (p < .001), indicating that both groups reported appropriate emotional
reactions to emotionally-valenced stimuli. This led the authors to hypothesize that the emotion
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context insensitivity hypothesis is mood state dependent, much like the previously reviewed
cognitive vulnerabilities.
The literature has used sad mood induction procedures to investigate the applicability of
the emotion context insensitivity hypothesis to formerly depressed individuals. Lethbridge and
Allen (2008) examined if cognitive or mood reactivity predicted recurrence in participants with
remitted MDD (n = 52). Depression was assessed with the SCID-I. At baseline, participants
completed a sad mood music and autobiographical recall mood induction. Cognitive reactivity
was assessed using the DAS while mood reactivity was assessed using the VAS. One year later,
participants were assessed for recurrence using the SCID-I and reported stressful life events
using the Stressful Life Events Questionnaire. In line with the cognitive reactivity literature,
results showed that participants with remitted MDD reported significant decreases in happiness (t
= 3.66-7.90, p < .01) and increases in sadness (t = -6.34--4.60, p < .01) on the VAS as well as
significant increases in dysfunctional thinking (t = -43.83, p < .01) on the DAS post-mood
induction. Mood reactivity on the happy scale of the VAS (i.e., decrease in happiness in response
to the sad mood induction) and self-reported life stress was predictive of relapse. Formerly
depressed participants who reported less decrease in happiness on the VAS or more life stress
was significantly more likely to relapse at one-year follow-up. Mood reactivity on the depressed
scale of the VAS (i.e., increase in depression in response to the sad mood induction) and
cognitive reactivity on the DAS were both not predictive of relapse.
While these results suggest that blunted mood reactivity, rather than cognitive reactivity,
in response to sadness predicts the recurrence of a new depressive episode in formerly depressed
individuals, these findings are limited by methodological issues. First, the literature consistently
uses a sad, rather than depressed, scale on the VAS. It is possible that participants with remitted
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MDD reported less increase of negative mood on the depressed scale of the VAS than the sad
scale of the VAS. These participants have experienced what a depressive episode is like, so they
may be less likely to endorse a mood state of “depressed” when encountered with a transient, sad
mood. Second, studies (i.e., van Rijsbergen et al., 2013) have hypothesized that it may be
necessary to assess cognitive reactivity at multiple time points to examine its impact of MDD
relapse and recurrence. This study conducted the sad mood music and autobiographical recall
mood induction at a single time point, rather than at baseline and follow-up. Therefore, results
from this study may have differed based on the methodological procedures that were employed.
van Rijsbergen and colleagues (2013) examined whether changes in cognitive or mood
reactivity predicted relapse in participants with remitted MDD after treatment. Participants with
remitted MDD were recruited and randomly assigned to a relapse prevention condition,
including preventive CBT and TAU (n = 84) or TAU alone (n = 88). Participants completed the
sad music and autobiographical recall mood induction at baseline and posttreatment. Cognitive
reactivity was assessed using the DAS while mood reactivity was assessed using the VAS.
Participants were assessed for relapse using the SCID-I at three, 12, 24, 36, and 66 months
follow-up. Results showed that participants in all conditions who endorsed higher DAS scores
before the mood induction were at a greater risk for relapse (χ2 = 12.29, p < .001), indicating that
unprimed dysfunctional attitudes predicted relapse 5.50 years later. However, pre (χ2 = 1.14, p =
.29) and posttreatment (χ2 = 2.10, p = .15) cognitive reactivity was not predictive of relapse.
While this finding is contradictory to some of the literature (i.e., Kuyken et al., 2010; Segal et al.,
1999, 2006), it is in line with the results obtained by Jarrett and colleagues (2012).
van Rijsbergen and colleagues (2013) also found that participants in all conditions who
endorsed exhibited mood reactivity were at greater risk for relapse, indicating that mood
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reactivity predicted relapse 5.50 years later. Of note, this relationship was only found for mood
reactivity assessed posttreatment (χ2 = 8.29, p = .004), but not pretreatment (χ2 = .06, p = .81).
Given that previous research has suggested that CBT reduces dysfunctional beliefs (Kuyken et
al., 2012; Segal et al., 1999), exploratory analyses were conducted to see if there was a change in
cognitive and mood reactivity before and after participation in the CBT relapse prevention
condition. Results revealed that an increase in cognitive (χ2 = 6.77, p = .01) and mood (χ2 = 6.85,
p = .01) reactivity posttreatment was predictive of relapse over the 5.50-year follow-up period.
This perplexing finding lead the authors to suggest that cognitive reactivity may need to be
assessed at multiple time points over the course of treatment in order to detect its true effect of
relapse. Overall, these results suggest that mood reactivity predicts relapse over time but does not
discount the role of cognitive reactivity in relapse prediction.
A growing body of research has supported the emotion context insensitivity hypothesis,
indicating that currently depressed individuals exhibit blunted emotional, behavioral, and
physiological reactivity in response to both negatively and positively-valenced stimuli (Bylsma
et al., 2007; Rottenberg & Hindash, 2015). However, the applicability of the emotion context
insensitivity hypothesis to formerly depressed individuals is less clear. A very limited literature
base has suggested that blunted (i.e., Lethbridge & Allen, 2008) or exaggerated (i.e., van
Rijsbergen et al., 2013) mood reactivity is predictive of another depressive episode. While these
findings are important, they have not completely discounted the role that cognitive reactivity
may play. In addition, cross-sectional research has not found differences in mood reactivity
among formerly depressed and never depressed participants (Brosse et al., 1999; Dykman, 1997;
Fresco et al., 2006; Gemar et al., 2001; Lau et al., 2012; Miranda & Persons, 1988; Miranda et
al., 1998; Solomon et al., 1998; Van der Does, 2002, 2005), which suggests that mood reactivity
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may not be measured properly by single session studies. Additional research is needed to
examine whether formerly depressed individuals exhibit cognitive or mood reactivity in response
to sadness and whether either form of reactivity contributes to relapse and recurrence of MDD.
Multiple mechanisms have been proposed to account for vulnerability to depressive
relapse. While some risk factors are trait dependent (e.g., age of onset, severity of the first
episode, number of symptoms, etc.; Burcusa & Iacono, 2007), theoretical models and empirical
evidence has suggested that some risk factors may be state dependent. Cross-sectional research
has shown that individuals with remitted MDD endorsed more dysfunctional thoughts (Gemar et
al., 2001; Lau et al., 2012; Miranda et al., 1990, 1998; Roberts & Kassel, 1996) in response to a
sad mood induction. Longitudinal research has suggested that individuals with remitted MDD
who report elevated cognitive (Kuyken et al., 2010; Segal et al., 1999, 2006) or blunted (i.e.,
Lethbridge & Allen, 2008) or exaggerated (i.e., van Rijsbergen et al., 2013) mood reactivity in
response to sadness are more likely to experience another depressive episode over time. While
there is currently disagreement in the literature about whether cognitive or mood reactivity are
markers of vulnerability for relapse in remitted MDD, there is clear support for the notion that
such vulnerabilities are mood state dependent in remitted depression.
One way to advance our understanding of the relationship between reactivity to negative
affect and vulnerability to depression is to move beyond self-report and examine cardiovascular
reactivity in response to sadness. The next section will provide an overview of the physiological
systems and psychophysiological markers related to cardiovascular functioning. Several
theoretical models, and empirical evidence related to cardiovascular functioning, and negative
affect including depression will be reviewed.
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CHAPTER 3
CARDIOVASCULAR SYSTEM
The human body is composed of numerous systems that regulate bodily functions,
maintain homeostasis, and enable an individual to respond to environmental stimuli. Multiple
systems and organs play a role in the regulation of the cardiovascular system. The components
that are most relevant to the cardiovascular system includes the nervous system and the heart.
The Nervous System
As outlined by Porges (1992), the nervous system is the executory structure responsible
for communicating information from the brain and spinal cord via the central nervous system to
the rest of the body via the peripheral nervous system. The peripheral nervous system is further
branched into the somatic nervous system and the autonomic nervous system (ANS). The ANS is
made up of two distinct systems: the sympathetic nervous system (SNS) and the parasympathetic
nervous system (PNS). The SNS is responsible for preparing and mobilizing the body to react to
external stimuli presented within the environment, commonly referred to as the fight or flight
response. The PNS is responsible for demobilizing the body and returning it to baseline
functioning, also known as the relaxation and restoration response. The SNS and the PNS enable
the coordination of bodily reactions in response to internal and external stimuli through
contradictory, but complementary functions. The PNS is mainly responsible for maintaining
homeostasis, or dynamic regulation of the internal organs to preserve or restore equilibrium,
while the SNS is mainly responsible for reacting to stress, or an interruption in homeostasis.
While both branches of the ANS play an important role in cardiovascular functioning,
psychological research primarily focuses on the activity of the PNS. Focus on the PNS is due to
the fact that many of the cardiovascular measures are primarily under parasympathetic control
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(i.e., heart rate (HR); Grossman & Taylor, 2007) or are thought to reflect parasympathetic
control (i.e., respiratory sinus arrhythmia (RSA); Allen, Chambers, & Towers, 2007).
The Heart
The heart is a muscular organ located within the chest cavity that pumps blood
throughout the body. The ANS is fundamental to cardiovascular functioning. The heart is
connected to the ANS via the vagus nerve, one of the 12 cranial nerves that branch out from the
brain to the body. The vagus nerve innervates the sinoatrial (SA) node and is responsible for
determining the rate at which the heart beats; the SNS accelerates the heart while the PNS
decelerates the heart (Porges, 1992).
The major structural components of the heart (Figure 2) include the chambers, valves,
and nodes. As detailed by Katz (2010), the heart consists of four chambers, the left atrium, right
atrium, left ventricle, and right ventricle, and two classes of valves, the atrioventricular (AV)
valves and semilunar valves. The AV valves, including the tricuspid valve on the right side of the
heart and the bicuspid valve on the left side of the heart, separate the atria from the ventricles.
The semilunar valves, including the pulmonary valve on the right side of the heart and the aortic
valve on the left side of the heart, separate the ventricles from the pulmonary artery or aorta. The
heart contains two clusters of cells that control electrical impulses in the heart, the SA and the
AV nodes. The SA node, located in the right atrium of the heart, is innervated by the vagus nerve
and generates the electrical impulses that cause the contraction of the atrial muscles. The AV
node, located in the center of the heart between the atria and ventricles, receives the electrical
impulses from the SA node then regulates and transports the electrical impulses to the ventricles,
which causes the contraction of the ventricular muscles. The heart contains two separate systems
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of pumps on the left and right side that work in concert with one another. Similar processes occur
within each side of the heart during the cardiac cycle.
Figure 2. Diagram of the Heart (n.d.)

The Cardiovascular System
The cardiovascular system is a complex structure that consists of the heart and
vasculature that extends throughout the entire body. The cardiovascular system regulates the
circulation of blood within the body, which follows a sequence of steps outlined by Berntson,
Quigley, and Lozano (2007). Deoxygenated blood travels through veins from the organs and
extremities to the heart. Deoxygenated blood enters the right atrium via the superior and inferior
vena cava, passing through the tricuspid valve into the right ventricle. Deoxygenated blood then
passes through the pulmonary valve into the pulmonary artery, which is connected to the lungs.
Blood is circulated through capillaries in the lungs, enabling the absorption of oxygen and
release of carbon dioxide. Oxygenated blood enters the left atrium via the lungs and pulmonary
vein, passing through the mitral valve into the left ventricle. Oxygenated blood then passes
through the aortic valve into the aorta. Oxygenated blood travels through arteries to the organs
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and extremities. Oxygenated blood is transported throughout the entire body via the vasculature
and circulated through the capillaries in the trunk and extremities, enabling the release of oxygen
and absorption of carbon dioxide. This sequence of steps occurs continuously, enabling the
circulation of blood throughout the body.
The Cardiac Cycle
The cardiac cycle (Figure 3) represents the mechanical and electrical activity of the
cardiovascular system that occurs during a single heartbeat. The cardiac cycle, as outlined by
Berntson and colleagues (2007), includes two distinct phases: systole and diastole. Systole
represents the contraction of the heart while diastole represents the relaxation of the heart.
During the diastole phase, the heart is relaxed and the AV valves are open. The atria and
ventricles fill with blood, resulting in an increase in the volume of blood in the ventricles.
Depolarization of the SA node occurs in the right atrium and passes through the atrial muscle,
which is represented on an electrocardiogram (ECG) as the P wave. Depolarization of the SA
node causes the atrial muscles to contract. Pressure in the atria and ventricles increases, which
causes the remainder of blood to flow into the ventricles. Depolarization of the AV node occurs
in the center of the heart near the tricuspid valve and causes the ventricle muscles to contract,
which leads to the closure of the AV valves. Together, this is represented on an ECG as the QRS
complex. This marks the end of the diastole phase and the beginning of the systole phase. During
the systole phase, pressure in the ventricles increases. The increase in ventricular pressure
compared to pulmonary and aortic pressure leads to the opening of the semilunar valves. Blood
is ejected through the pulmonary artery and aorta and the semilunar valves close. Pressure in the
ventricles decreases, resulting in the repolarization of the ventricles, which is represented on an
ECG as the T wave. This marks the end of the systole phase and the beginning of the next
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cardiac cycle. This sequence of steps occurs continually in the heart so that blood can be pumped
throughout the body.
Figure 3. Diagram of the Cardiac Cycle from Berntson et al. (2007)

Cardiovascular Markers
There are multiple cardiovascular markers that can be used to measure cardiovascular
functioning. The cardiovascular measures of interest relevant for this overview include HR, heart
period (HP), heart rate variability (HRV), RSA, cardiac output (CO), and pre-ejection period
(PEP), which are obtained through ECG or a combination of ECG and impedance cardiography
(ICG) as described below.
ECG
ECG (Figure 4) is a noninvasive technique for measuring the electrical activity of the
heart. ECG is obtained through the application of noninvasive electrode sensors placed on the
chest only or chest, legs, and arms. ECG measures the rate at which the heart beats as well as
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certain electrical events that occur during the cardiac cycle (e.g., atrial and ventricular
depolarization or ventricular repolarization). The ECG waveform is a visual representation of the
electrical activity occurring in the heart, including the P wave, QRS complex, and T wave. The P
wave represents atrial depolarization. The QRS complex represents ventricular depolarization.
The T wave represents ventricular repolarization. In addition, the ECG waveform provides
information on the speed of HR as well as the speed, magnitude, and direction of electrical
events (Katz, 2010).
Figure 4. ECG Waveform from Liang, Zhang, Tan, & Li (2014)

HP and HR. HP is defined as the amount of time between heart beats measured in
millisecond. For this investigation, HP will be used instead of HR, which is defined as the
number of beats produced by the heart per minute. While HP and HR are reciprocal
measurements of cardiovascular functioning, they are not linearly related and can generate
discrepant results when there are significant differences across participants or changes within
participants. Accordingly, research has indicated that HP should be used when changes in
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cardiovascular functioning are thought to be attributed to autonomic effects or differ significantly
due to experimental tasks or group membership (Berntson et al., 2007).
ECG is used to assess HP, which is calculated by determining the interbeat interval (IBI)
between successive R spikes on the ECG in milliseconds. Research has suggested that higher HP
during experimental procedures that require attention indicates that an individual is attending to
the stimuli that are presented in the environment. HP has been used in the literature as an index
of arousal, task involvement, and mental load and effort (Jorna, 1992).
ICG
Similar to ECG, ICG (Figure 5) is a noninvasive technique for measuring the electrical
activity of the heart. ICG can be obtained through the application of noninvasive electrode
sensors placed on the chest and back. ICG measures changes in blood flow and vascular
contraction throughout the chest cavity via resistance to electrical signal. ICG must be used in
concert with ECG, as the ECG waveforms are used as a reference for the timing of the cardiac
cycle (Berntson et al., 2007). The ICG waveform is a visual representation of electrical and
mechanical events that occur in the heart, including the B, C, X, Y, and O points. The B point
represents the opening of the aortic valve while the X point represents the closing of the aortic
valve. The C point marks the peak of blood flow through the aorta. The Y point signifies the
closing of the pulmonary valve. The O point indicates the closing of the mitral valve. In addition,
the ICG waveform provides information on the speed of mechanical events that occur in the
heart, volume of blood pumped through the heart, and amount of resistance exerted on the blood
vessels (Berntson et al., 2007).
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Figure 5. ICG Waveform from Critchley (2013)

HRV. HRV is defined as the beat-to-beat variability in HR and can be assessed using a
combination of ECG and ICG. HRV can be determined via the time domain method, which
calculates the IBI between successive R spikes on the ECG based on time. Standard Deviation of
the Normal-to-Normal (SDNN) examines the IBI across a specific period (e.g., 24 hours), which
provides a more comprehensive representation of variability with HRV (Carney et al., 2000).
Root Mean Square Successive Difference (RMSSD) examines the IBI during a short time span,
which provides a better representation of short-term changes in HRV (Carney et al., 2000). HRV
can also be assessed via the frequency domain method, which calculates the IBI between
successive R spikes on the ECG within certain frequencies. High frequency HRV (HF-HRV)
examines the IBI within the high frequency band (.15-.40 Hertz), which takes respiration into
account and approximates the amount of control the PNS exerts over the heart (Berntson et al.,
1997, 2007). Changes in respiration impact HF-HRV as HR naturally accelerates during
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inhalation and decelerates during exhalation. Consequently, HF-HRV represents vagal
modulation, rather than vagal tone (Shaffer & Ginsberg, 2017). Low frequency HRV (LF-HRV)
examines the IBI within the low frequency band (.05-.15 Hertz), which is thought to be impacted
by both sympathetic and parasympathetic rhythms (Berntson et al., 1997, 2007).
Several less commonly used measures of HRV measures rely on the frequency domain
method. For example, the LF/HF ratio is thought to approximate the degree of sympovagal
balance (Vaccarino et al., 2008), but a significant body of evidence contradicts this hypothesis
(Billman, 2013). Total power HRV (TP-HRV) assesses the IBI within the entire frequency band
(< .40 Hertz), very low frequency HRV (VLF-HRV) assesses the IBI within a lower frequency
band than LF-HRV (.0033-.039 Hertz), and ultra-low frequency HRV (ULF-HRV) assesses the
IBI within the lowest frequency band (< .003 Hertz; Berntson et al., 1997; Vaccarino et al.,
2008). While these measures are thought to be representative of both sympathetic and
parasympathetic rhythms, they are not well characterized due to their limited use (Berntson et al.,
1997, 2007).
RSA. RSA is defined as the beat-to-beat variability in HR during the respiration cycle. A
combination of ECG and ICG can be used to assess RSA, which is calculated using the
frequency domain method. The frequency domain method converts HP from time-domain to
frequency-domain then calculates the IBI between successive R spikes on the ECG within the
high frequency band (.15-.40 Hertz; Allen et al., 2007). Research has suggested that higher RSA
is generally desirable as it indicates that an individual can flexibly respond to environmental
stimuli (Berntson et al., 2007).
RSA sampled within the high frequency band is theorized to reflect the influence of the
PNS on HR via the vagus nerve, which affects HR acceleration and deceleration during
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respiration (Berntson et al., 1997, 2007). Greater parasympathetic input is thought to result in
more acceleration of cardiac activity during respiration and more deceleration of cardiac activity
after expiration, resulting in variable intervals between the heartbeats. Consequently, RSA has
been used in the literature as an index of cardiac vagal control, which approximates the amount
of control the PNS exerts over the heart (Grossman & Taylor, 2007). RSA is equivalent to the
cardiac measure of high-frequency heart rate variability (HF-HRV) and the two terms are often
used interchangeably in the literature (Allen et al., 2007).
CO. CO is defined as the volume of blood pumped by the heart per minute. CO is not
only influenced by the rate at which the heart beats, but changes in the contractility, preload, and
afterload of the cardiovascular muscles (Vincent, 2008). A combination of ECG and ICG are
used to assess CO, which is calculated by multiplying HR and stroke volume (SV; CO = HR X
SV), or volume of blood pumped through each ventricle per minute. Changes in CO is primarily
controlled by HR as SV remains consistent across time. CO has been used in the literature to
represent the efficiency of the heart. Research has suggested that higher CO indicates that the
heart is functioning in an efficient manner (Berntson et al, 2007).
PEP. PEP is defined as the amount of contractile force produced by the heart. CO is
influenced by changes in the contractility of the cardiovascular muscles (van Lien, Schutte,
Meijer, & de Geus, 2013). PEP is calculated by determining the amount of time between the Q
wave on an ECG, which represents the beginning of ventricular depolarization, and B on an ICG,
which represents the opening of the aortic valve and beginning of ejection.
PEP is hypothesized to reflect the influence of the SNS on the heart (Berntson et al.,
2007; van Lien et al., 2013). Research has suggested that higher PEP during experimental
procedures that involve stress-based tasks indicates greater sympathetic control over the heart
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and is associated with negative physiological responses (e.g., increase in cortisol and
Hypothalamic-Pituitary-Adrenal (HPA) axis activation; as reviewed by Uchino, Smith, HoltLunstad, Campo, & Reblin, 2007). Consequently, PEP has been used in the literature as an index
of sympathetic cardiac control, which approximates the amount of control the SNS exerts over
the heart (Berntson et al., 2007).
In summary, the ANS is made up of two distinct systems that serve contradictory, but
complementary, purposes: the SNS and the PNS. The SNS, or fight or flight response, is
responsible for preparing and mobilizing the body to react to external stimuli presented within
the environment. The PNS, or relaxation and restoration response, is responsible for
demobilizing the body and returning it to baseline functioning. The heart is connected to the
ANS via the vagus nerve, which connect the brain and the body. Consequently, the ANS is
fundamental to and influential on cardiovascular functioning.
There are multiple cardiovascular markers that can be used to quantify cardiovascular
functioning. The cardiovascular measures that were assessed in this investigation include HP,
RSA, CO, and RSA, which are obtained through ECG or a combination of ECG and ICG. Each
cardiovascular marker has been used as an index of physiological functioning. Higher HP during
experimental tasks that involve attention is believed to be adaptive, as it is thought to represent
arousal, task involvement, and mental load and effort. Higher RSA is hypothesized to be
adaptive and has been used index of cardiac vagal control, which approximates the amount of
control the PNS exerts over the heart. Higher CO is thought to be adaptive, as it has been used to
represent the efficiency of the heart. Finally, lower PEP during experimental tasks that induce
stress is hypothesized to be adaptive and has been used index of cardiac vagal control, which
approximates the amount of control the SNS exerts over the heart.
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Theoretical Models
Several theoretical models have been proposed to account for individual differences in
cardiovascular functioning. Generally, these theories characterize patterns of cardiovascular
functioning as adaptive or maladaptive. Relevant theoretical models include the polyvagal
theory, biopsychosocial model of challenge and threat, and hawk-dove model.
The polyvagal theory. The polyvagal theory by Porges (1995) focuses on the impact of
the ANS on physiological, psychological, and behavioral processes. The ANS contains two
opposing systems: the sympathetic-adrenal system and the vagus system. The sympatheticadrenal system mobilizes the body through the activation of SNS activity. The vagus system is
further branched into two subsystems: the ventral vagal complex and the dorsal vagal complex.
The ventral vagal complex contains myelinated vagal pathways that demobilizes the body
through the inhibition of SNS activity, which is referred to as the vagal brake. The vagal brake
activates the vagus nerve to reduce HR and blood pressure (BP), which produces a calming,
restorative response that is adaptive (Porges, 2007). The dorsal vagal complex contains
unmyelinated vagal pathways that immobilize the body through the inhibition of SA node, which
is referred to as the dorsal vagal surge. The dorsal vagal surge also activates the vagus nerve to
reduce HR and BP but is significantly more suppressing as it results in a shutdown physical and
behavioral responsivity (Porges, 2001).
The polyvagal theory provides an evolutionary explanation to explicate the dynamic
relationship between physiological, psychological, and behavioral processes. Each physiological
state is characterized by a pattern of physical, psychological, and behavioral reactivity. More
specifically, the sympathetic-adrenal system results in active avoidance, which include
behavioral responses such as of fighting, escaping, or freezing. In addition, the sympathetic-
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adrenal system is characterized by vagal withdrawal, or reduced RSA during an attentiondemanding task compared to RSA at rest (Porges, 2007). The ventral vagal complex results in
social engagement, which includes facial expressions, vocalizations, eye contact, head
orientation, and other communicative behaviors. In addition, the ventral vagal complex is
characterized by vagal augmentation, or increased RSA during an attention-demanding task
compared to RSA at rest (Porges, 2007). The dorsal vagal complex results in behavioral
immobilization, which includes passive avoidance, dissociation, and collapse. Of note, a valid
cardiovascular index does not yet exist for the dorsal vagal complex as the system has less
impact on the rate at which the heart pumps (Chapleau & Sabharwal, 2015). The polyvagal
theory proposes that the underlying neurobiological structures are responsible for determining
physiological, psychological, and behavioral response.
The polyvagal theory has been applied to the study of depression. Depression is a
disorder characterized by maladaptive patterns of social, emotional, and behavioral responding.
More specifically, research has shown that participants with current MDD exhibit deficits in
social engagement (e.g., withdrawal from and impairment in social relationships) as well as
emotional (e.g., flat affect) and behavioral (e.g., reduced startle response) inflexibility
(Rottenberg, 2007b). Research has also identified some cardiovascular differences in depressed
individuals that are in line with the polyvagal theory. Participants with current (Rottenberg,
Wilhelm, Gross, & Gotlib, 2003) MDD show blunted RSA reactivity when crying in response to
a sad film. In addition, depressed participants who exhibit this maladaptive pattern of
cardiovascular reactivity report lower rates of recovery over time (Rottenberg, Salomon, Gross,
& Gotlib, 2005a; Panaite et al., 2016). Empirical investigations of the polyvagal theory have
found that infants and children who exhibit blunted RSA in response to socially-engaging, stress-
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inducing, or attention-demanding tasks show maladaptive patterns of social, emotional, and
behavioral responding (e.g., DiPietro, Porges, & Uhly, 1992; Huffman et al., 1998; Porges,
Doussard-Roosevelt, Portales, & Greenspan, 1996; Stifter & Corey, 2001; Stifter & Fox, 1990).
Together, these studies suggest that the polyvagal theory can inform our understanding of
cardiovascular reactivity in response to sadness in depressed populations.
The biopsychosocial model of challenge and threat. The biopsychosocial model of
challenge and threat by Blascovich and Tomaka (1996) proposes a physiological basis for
psychological states experienced in response to stressors. The model is typically examined
within a goal-relevant situation, which can include motivated performance situations that require
attention and cognition or passive situations that are attention demanding, but not cognitively
draining. The goal-relevant situation leads to physiological and emotional responses, which are
influenced by a combination of biological, physiological, cognitive, and interpersonal factors.
The perception of goal-relevant situations is impacted by two components of cognitive appraisal:
primary and secondary appraisal. Primary appraisal is defined as the amount of demands
required by situation while secondary appraisal is defined as the amount of personal resources
one has within a situation. Primary and secondary appraisals influence how an individual
perceives a goal-relevant situation. When an individual perceives that he or she has the personal
resources necessary to surmount the situational demands, the situation is viewed as a challenge.
Conversely, when an individual perceives that he or she does not have the personal resources to
meet the situational demands, the situation is viewed as a threat.
As outlined by Mendes, Major, McCoy, and Blascovich (2008), challenge and threat
responses are theorized to result in differential patterns of performance and emotional and
cardiovascular reactivity. Challenge results in an increase in performance on goal-relevant tasks,
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which is associated with approach toward the task. Emotional reactions associated with
challenge include positively-valenced emotions such as confidence and pride as well as
externalized negatively-valenced emotions such as anger. The pattern of cardiovascular
reactivity associated with challenge includes increased HR, CO, and vasoconstriction (VC) and
decreased total peripheral resistance (TPR). Contrariwise, threat is associated with a decrease in
performance on goal-relevant tasks, which is associated with avoidance of, vigilance towards, or
feelings of defeat related to the task. Emotional reactions associated with threat include
internalized negatively-valenced emotions such as shame and anxiety. The pattern of
cardiovascular reactivity associated with threat includes increased HR, VC, and TPR and no
change in CO. The biopsychosocial model of challenge and threat proposes that the perception of
a situation influences physiological, psychological, and behavioral responsivity.
The biopsychosocial model of challenge and threat has been examined in relation to
depression. Research has shown that participants with current MDD exhibit lower HR, HRV,
RSA, and CO (Bylsma, Salomon, Taylor-Cliff, Morris, & Rottenberg, 2014; Salomon, Clift,
Karlsdóttir, & Rottenberg, 2009; Salomon, Bylsma, White, Panaite, & Rottenberg, 2013) when
exposed to stressors. While these findings are not in line with the patterns of cardiovascular
reactivity hypothesized by the biopsychosocial model of challenge and threat, they do suggest an
atypical pattern of cardiovascular reactivity in response to stress among currently depressed
individuals.
The biopsychosocial model of challenge and threat has been explored in depressed
populations within the context of stress, but not sadness. It is possible that individuals with
current and remitted MDD show similar cardiovascular responses in stressful and sad contexts as
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individuals may perceive that they have low personal resources in both types of high-demands
situations.
The hawk-dove model. The hawk-dove model by Smith (1982) provides an evolutionary
account of behavioral and physiological differences in response to stress. The model focuses on
the concepts of allostasis, or the process of attaining homeostasis through the regulation of
internal processes in response to external stressors, and allostatic load, or the impact of allostatic
regulation on the body. The model proposes two architypes that represent an individual’s typical
response to allostasis: “hawks” and “doves” (Korte, Koolhaas, Wingfield, & McEwen, 2005).
Individuals who are categorized as hawks exhibit aggressive, intrepid behavior. Their typical
behavioral response is to either react or run away, which results in limited behavioral flexibility.
Conversely, individuals who are categorized as doves exhibit non-aggressive, vigilant behavior.
Their typical behavioral response is to freeze or hide, which results in high levels of behavioral
flexibility. The behavioral patterns across groups are hypothesized to reflect differences in
underlying physiology (Korte et al., 2005). More specifically, hawks show elevated sympathetic
reactivity and reduced parasympathetic reactivity while doves show elevated parasympathetic
reactivity and reduced sympathetic reactivity. These differences in autonomic reactivity are
thought to result in varied cardiovascular responsivity, with hawks exhibiting increased
sympathetic activity as indexed by lower HRV and doves exhibited increased parasympathetic
activity as indexed by higher HRV (Korte et al., 2005).
The hawk-dove model has been extended to the study of depression. As reviewed by
Korte and colleagues (2005), allostatic load appears to have distinct effects on individuals
categorized as “hawks” or “doves.” Hawks have been found to have higher rates of coronary
heart disease and atherosclerosis due to elevated testosterone and BP and dominance of

60

sympathetic activity. Dominance of the sympathetic activity also impacts the immune system;
reduced activity of the HPA axis leads to a hyper-immune state characterized by excessive
inflammation and autoimmune responsivity. This physiological pathway is thought to contribute
to the higher rates of atypical depression in hawks, which is characterized by increased appetite,
weight gain, sleep, and social withdrawal. Doves more commonly show bradyarrhythmia, or an
abnormal heart rhythm, due to dominance of parasympathetic activity. In addition, doves have
been found to have higher rates of hypertension and atherosclerosis because of a cascade of
physiological events; increased levels of cortisol lead to an increase in fat deposits, which results
in elevated sympathetic activity. Neural differences in doves are thought to increase activity of
the HPA axis and sympathetic system, contributing to the higher rates of melancholic depression,
which is characterized by decreased appetite, weight, and sleep and increased feelings of
helplessness, worthlessness, anxiety, and arousal. The hawk-dove model proposes that
differences in physiological reactions may account for the presence of certain subtypes of
depression observed in research and clinical settings.
Multiple theoretical models have been proposed to provide a link between behavioral,
psychological, and physiological responding. These theoretical models have been extended to the
study of depression, providing a theoretical explanation for the maladaptive patterns of
cardiovascular responding that have been observed in depressed populations. Together, these
theoretical and empirical works suggest that cardiovascular functioning is related to depression
and can advance our understanding risk of relapse and recurrence. The following section will
review research on cardiovascular functioning and reactivity in current and remitted major
depressive disorder.
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Cardiovascular Functioning in Depression
Current Major Depressive Disorder
The association between MDD and CVD is likely bidirectional, with depression
contributing to the development of CVD and CVD related to increased risk of MDD (Lippi,
Montagnana, Favaloro, & Franchini, 2009). A large body of work indicates that depressive
symptoms and disorders are associated with an increased risk for CVD (see Haigh, Bogucki,
Dearborn, Robbins, & Elias, 2018b for a review). Systematic reviews and meta-analysis have
concluded that depressive symptoms or a clinical diagnosis of depression predict the
development of coronary heart disease (Gan et al., 2014; Nicholson, Kuper, & Hemingway,
2006; Ruglies, 2002; Wulsin & Singal, 2003; Van der Kooy et al., 2007), myocardial infarction,
stroke, and other forms of CVD (Van der Kooy et al., 2007). While evidence from these metaanalyses and systematic reviews are striking, there are significant
methodological flaws (e.g., failure to exclude for CVD at baseline, publication bias, impartial
adjustments, possibility of reverse causality; Nicholson et al., 2006) that temper the
interpretations that can be made about the impact that depression has on the development of
CVD.
Research suggests that cardiovascular events and CVD are associated with increased
depressive symptomology and diagnosis. Cross-sectional studies have shown that a large
proportion of individuals with CVD report elevated rates of depressive symptoms (11.0050.00%) or meet the diagnostic criteria for MDD (26.00%; Brown, Barton, & Lambert, 2009).
Longitudinal studies have shown that individuals with CVD who have comorbid depression
report poorer adherence to medical interventions, reduced quality of life, and increased
occurrence of subsequent cardiovascular events and mortality (Brown et al., 2009).
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While the literature has established that a relationship exists between depression and
CVD, the nature of this relationship remains unclear. Cardiovascular functioning has been
explored as a potential mechanism of action due to its association with physical and
psychological functioning (Rottenberg, 2007b). With respect to depression, various naturalistic
and experimental paradigms have been used to assess how different psychological states impact
cardiovascular functioning. The following section will review the literature base that examines
cardiovascular functioning at rest and in response to stress and sadness in individuals who are
currently depressed.
Cardiovascular functioning at rest. Cardiovascular functioning at rest is an important
indicator of cardiovascular health. Cardiovascular functioning has been assessed through balance
of the ANS (Thayer & Lane, 2009). Autonomic balance is evident when equipoise exists
between the SNS and the PNS while autonomic imbalance is present when the SNS is overactive
and the PSN is underactive. Previous research has found that autonomic imbalance, as indexed
by higher HR, lower HRV and RSA, and slower HR recovery, is associated with increased risk
of functional impairment, morbidity, and mortality (Phillips, Ginty, & Hughes, 2013; Thayer &
Lane, 2009).
A large body of literature has investigated cardiovascular functioning in adults with
current MDD at rest, which has employed a variety of activities (e.g., lay down, sit quietly, sleep,
engage in daily activities, or complete a breathing task). Rottenberg (2007b) conducted a metaanalysis of 13 articles that compared RSA at rest in clinically depressed and healthy control
participants. Results found lower resting RSA in currently depressed participants with (p < .001,
d = .28) and without (p < .001, d = .33) a history of CVD compared to healthy control
participants. While it is important to assess cardiovascular functioning in depressed individuals
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with and without cardiovascular problems, the presence of CVD may be a confound and
therefore should be controlled or excluded for when examining the relationship between
depression and cardiovascular health (Kemp et al., 2010).
Building on the work of Rottenberg (2007b), Kemp and colleagues (2010) conducted a
similar meta-analysis of 18 articles that compared multiple measures of HRV at rest in clinically
depressed and healthy control participants. Importantly, none of the participants included in these
analyses had a history of CVD. Results indicated that participants with current MDD showed
lower resting time frequency HRV (p = .01, d = -.29), long-term HRV (p = .03, d = -.46), and
HF-HRV (p = .03, d = -.21) and higher LF/HF ratio (p = .01, d = 066) compared to healthy
control participants. In addition, current depressive symptom severity was negatively associated
with HRV (p < .001, d = -.13), suggesting that more severe depressive symptoms were
associated with lower resting HRV. Together, these meta-analyses provide evidence for the
small, but significant association between depression and lower resting RSA and HRV measures.
This area of inquiry is important as cardiovascular abnormalities have been previously shown to
contribute to the relationship between depression and CVD (as reviewed by Rottenberg, 2007b).
Recent studies published after the aforementioned meta-analyses have found similar
results in currently depressed participants without a history of CVD. Kikuchi and colleagues
(2009) showed that participants with current MDD showed lower LF-HRV, but not HF-HRV,
while laying down after a 20-minute resting period compared to participants with panic disorder
(t = 2.54, p = .02) and healthy control participants (t = 2.47, p = .02). It was hypothesized that
cardiovascular differences reflect lower baroreflex sensitivity, implicated in the regulation of BP.
Kemp, Quintana, Felmingham, Matthews, and Jelinek (2012) found that compared to healthy
control participants, participants with current MDD exhibited significantly lower HRV on all
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measures (R2 = 2.99, η2p = .19, p = .001). Specifically, participants with current MDD showed
lower LF/HF ratio (R2 = 7.71, p = .01, d = .42) and HF-HRV (R2 = 7.71, p = .01, d = -.46) while
seated compared to healthy control participants. In addition, subgroup differences were found for
the current MDD group based on the presence of comorbid anxiety; participants with comorbid
generalized anxiety disorder had significantly higher LF/HF (p = .03, d = .94) and lower HFHRV (p = .01, d = .85) compared to participants without any comorbidities.
Chang and colleagues (2012) found that participants with current MDD showed
significantly lower HRV variance, LF-HRV, HF-HRV (p’s < .001), and LF/HF ratio (p = .061)
while laying down after a 20-minute resting period compared to healthy control participants. In
addition, subgroup differences existed in the current MDD group based on the presence of
suicidal ideation. Participants with MDD and suicidal ideations had significantly lower HRV
variance (p = .04) and HF-HRV (p = .01) compared to MDD participants without suicidal
ideation. While all studies identified some differences in HRV among currently depressed
participants, the specific cardiovascular abnormalities differed. This could be due to differences
in samples (i.e., subsamples with comorbidities) or recording procedures (i.e., laying versus
sitting, use of a pre-recording resting period). Overall, these studies provide additional support
for the association between depression and poorer resting cardiovascular functioning and suggest
that psychiatric comorbidity and suicidality may negatively impact cardiovascular functioning
further.
In summary, depression appears to be associated with poorer cardiovascular functioning
at rest compared to healthy control participants. More specifically, individuals with current MDD
generally show lower resting RSA and HRV. This line of research is important as it is possible
that these cardiovascular abnormalities contribute to the relationship between depression and
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CVD. To more fully understand the relationship between depression and cardiovascular
functioning, research has explored cardiovascular reactivity to emotionally-inducing stimuli (i.e.,
stress and sadness). The following section will review research on cardiovascular reactivity to
stress among individuals who are currently depressed.
Cardiovascular reactivity in response to stress. Research suggests that the link
between depression and CVD might be attributed to excessive cardiovascular reactivity in
response to stress. Kibler and Ma (2004) conducted a meta-analysis to examine the strength of
the relationship between depressive symptoms and cardiovascular reactivity to experimental
stressors (e.g., mental arithmetic, Stroop, startle, cold pressor, mirror tracing, anger recall, verbal
challenge, and caregiving story). Eleven empirical studies that primarily focused on the impact
of stress on HR and BP were statistically examined. Results indicated that there was a moderate
relationship between depressive symptoms and HR reactivity to stress (d = .37) and a weaker
relationship between depressive symptoms and systolic (d = .13) and diastolic (d = .17) BP
reactivity to stress. In addition, the effect size for HR and diastolic BP were significantly larger
in samples that included participants with CVD compared to samples with participants free from
cardiovascular problems (p’s < .05). Of note, most studies utilized self-report measures to assess
depressive symptoms rather than diagnostic measures, which limits the generalizability of results
to clinical samples. While this study does not inform the directionality of the relationship
between depression and CVD, the results suggest that depressive symptoms are related to
cardiovascular reactivity in response to stress.
Additional research has been conducted on cardiovascular reactivity in response to
experimental stress inductions in current MDD. Studies have employed a variety of empiricallyvalidated stress inductions that are physically (e.g., handgrip and mirror tracing tasks; Nugent et
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al., 2011; Rottenberg et al., 2007a; Salomon et al., 2009), cognitively (e.g., mental arithmetic and
N-back tasks; Ehrenthal et al., 2010; Liang, Lee, Chen, & Chang, 2015; Nugent et al., 2011),
emotionally (e.g., anger recall task; Ehrenthal et al., 2010), or socially (e.g., speech task; Panaite
et al., 2016; Rottenberg et al., 2007a; Salomon et al., 2009) stressful in nature. Importantly all
studies excluded for the presence of CVD. In general, studies showed that participants with
current MDD exhibited lower cardiovascular reactivity as measured by HR, HRV, RSA, and CO
in response to most stress induction tasks compared to healthy control participants (i.e.,
Ehrenthal et al., 2010; Liang et al., 2015; Nugent et al. 2011; Rottenberg et al., 2007a; Salomon
et al., 2009; with the exception of Panaite et al., 2016). In addition, one study showed that
participants with current MDD exhibited less HR recovery following the speech and mirror
tracing tasks relative to healthy control participants (p’s < .05; Salomon et al., 2009). Together,
these results suggest that individuals with current MDD exhibit a less adaptive pattern of
cardiovascular reactivity when faced with stress.
There is a growing body of evidence to suggest that depression is associated with
maladaptive cardiovascular reactivity in response to stress. More specifically, individuals with
current MDD generally show lower HR, HRV, RSA, and CO when exposed to stressful
experimental tasks. Given that MDD is characterized by depressed mood, negative affect, and
apathy, research has explored cardiovascular reactivity in response to sadness. In the following
section, research examining cardiovascular reactivity in response to sadness in individuals who
are currently depressed will be reviewed.
Cardiovascular reactivity in response to sadness. Research has investigated if the link
between depression and CVD may be attributed to maladaptive cardiovascular reactivity in
response to a sad mood (Table 1). This line of inquiry investigates if experimentally-induced
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sadness has a significant impact of the cardiovascular functioning of individuals who are already
experiencing a low, depressogenic mood.
Some studies have found differences in cardiovascular reactivity in response to sadvalenced stimuli among currently depressed participants. Rottenberg and colleagues (2003)
examined cardiovascular reactivity in response to a sad film. Contrary to the studies on
cardiovascular functioning at rest, no differences in RSA existed between women with current
MDD and healthy control women at baseline. While RSA significantly increased for healthy
control women who cried in response to the sad film (R2 = 12.65, p < .005, ε = .739), there was
no change in RSA among women with current MDD who cried (R2 = 2.64, p > .05, ε = .967).
Jin, Steding, and Webb (2015) also found that there were no differences in HR and RSA
between currently depressed and healthy control participants during baseline. While watching
sad and amusing films, HR decreased significantly more in healthy control participants
compared to participants with current MDD (p < .05, η2p = .83). This pattern of responding was
not observed for RSA, suggesting that depressed individuals showed blunted cardiovascular
reactivity for some, but not all, cardiovascular markers. Together, these studies suggest that
cardiovascular functioning does not differ between depressed and non-depressed individuals at
rest; however, differences emerge when exposed to sad stimuli.
Rottenberg and colleagues (2005a) showed that RSA reactivity in response to the sad
mood induction predicted recovery from MDD. Specifically, currently depressed participants
who exhibited vagal withdrawal (i.e., decrease in RSA from baseline) to the sad film had
significantly higher rates of remission at 6-months follow-up (p < .05). Of note, this relationship
was not found for the fear and amusing films. This study provides preliminary support for the
notion that participants with current MDD show differential responsivity to sad stimuli, but not
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other negatively-valenced stimuli (i.e., fear). Panaite and colleagues (2016) replicated the work
of Rottenberg and colleagues (2005a). Currently depressed participants who exhibited reduced
vagal withdrawal in response to a sad film had significantly higher depressive symptoms at 30weeks follow-up (b = 5.18, p = .002). This relationship was not found for fear or amusing films
(p’s > .05). Together, these studies suggest that individuals with current MDD who exhibit
blunted reactivity in response to sad-valenced stimuli are more likely to report elevated
depressive symptoms and less likely to experience remission of depression over time.
In contrast, other studies have failed to find differences in cardiovascular reactivity in
response to a sad mood induction among currently depressed participants. Rottenberg and
colleagues (2005b) compared participants with current and remitted MDD to those without a
history of Axis I disorders. The three groups did not show differences in HR in response to
happy, neutral, and sad films that were previously experimentally validated or idiographic in
nature (p’s > .10). Of note, participants with current and remitted MDD exhibited a nonstatistically significant increase in HR during all the experimental tasks. Tsai, Pole, Levenson,
and Muñoz (2003) compared Latino women with current MDD to those without a history of
Axis I disorders. Results indicated that current MDD and healthy control participants who
watched sad and amusing films did not differ in terms of cardiac IBI (p > .05).
While methodological procedures were generally consistent across studies, Tsai and
colleagues (2003) did use a different diagnostic assessment and sad mood induction procedure.
The samples recruited and cardiovascular measures assessed also differed across studies, with
some studies examining a restricted range of participants (e.g., Tsai et al. (2003) only included
Latino participants) and cardiovascular markers (e.g., Rottenberg et al. (2005b) only examined
HR). In addition, four studies did not assess or exclude for the presence of CVD (i.e., Rottenberg

69

et al., 2003, 2005a, 2005b; Tsai et al., 2003), which could potentially confound and cause
discrepancies in the cardiovascular results. These methodological problems could have
contributed to the differences observed across studies.
There is some evidence to suggest that depression is associated with maladaptive
cardiovascular reactivity in response to sadness. Specifically, individuals with current MDD
generally show blunted HR and RSA reactivity when exposed to sad mood induction procedures.
However, results have not been consistent across the literature, with some studies failing to
replicate these patterns of cardiovascular reactivity and showing an opposite trend of
cardiovascular reactivity (i.e., Rottenberg et al., 2005b; Tsai et al., 2003).
Remitted Major Depressive Disorder
As previously detailed, MDD is characterized by high rates of relapse and recurrence.
The chronic nature of the disorder suggests that a large proportion of individuals with a history
of depression will experience another depressive episode over the course of their lifetime.
Therefore, research is needed to identify risk factors for relapse and recurrence in euthymic
individuals with a history of depression. Two prominent classes of risk factors include cognitive
and mood vulnerabilities. The literature has suggested that cognitive and mood vulnerabilities
that are present in currently depressed individuals remain latent in formerly depressed
individuals until they are activated by dysphoric mood.
This body of evidence proposes that the differential activation and mood state dependent
hypotheses may extend to other areas, such as cardiovascular functioning. It is plausible that the
maladaptive patterns of cardiovascular reactivity observed in currently depressed individuals
may also be mood state dependent. It would follow that individuals with a history of depression
would show cardiovascular abnormalities in response to emotion-provoking stimuli such as
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stress and sadness, but not while they were euthymic. To test this hypothesis, research has
examined cardiovascular functioning at rest as well as cardiovascular reactivity in response to
stress and sadness in adults and adolescents with remitted MDD; however, cardiovascular
functioning among individuals with a history of depression has not been investigated to the same
extent as current depression. The available research that examines cardiovascular functioning in
adults and adolescents with remitted MDD is reviewed below.
Cardiovascular functioning at rest. Some studies have investigated cardiovascular
functioning in adults with remitted MDD at rest or during the completion of daily life activities.
Chang and colleagues (2013) examined HRV at rest among formerly depressed participants with
or without a history of suicide ideation. Participants were free from CVD and other medical
conditions (e.g., diabetes, hypertension, etc.) that could impact the recording of physiological
responses. Depression was diagnosed using the Modified Schedule for Affective Disorders and
Schizophrenia – Lifetime Version (SADSL) and the HDRS. Participants with remitted MDD
were classified as having (n = 237) or not having (n = 233) a history of suicidal ideation during a
past depressive episode. In addition to exploring cardiovascular differences based on a history of
suicidality, participants with remitted MDD were compared to healthy controls (n = 462) without
a history of MDD or suicidal ideation. HRV was assessed for five minutes while participants
relaxed following a 20-minute baseline period. Results showed that participants with remitted
MDD who endorsed a history of suicidal ideations have significantly lower HRV variance (p =
.001), HF-HRV (p = .01), and LF-HRV (p = .004) than participants with remitted MDD without
a history of suicidality and healthy control participants. No differences were identified between
remitted MDD participants without a history of suicidality and healthy control participants (p’s >
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.05). Overall, these findings suggest that some differences in cardiovascular functioning exist at
rest in participants with remitted MDD, but only among those with a history of suicidal ideation.
Vaccarino and colleagues (2008) evaluated HRV among a sample of twins with current
or remitted MDD. Participants were free from CVD when initially evaluated in 1990; however,
only coronary heart disease, myocardial infarction, and angina pectoris was assessed at the time
of the current investigation. The DIS was originally used to diagnose current and past MDD. A
total of 288 twins contributed psychophysiological data, which included participants with current
(n = 7) and remitted (n = 61) MDD that were collapsed into a single group. History of MDD was
re-confirmed by the SCID-I. HRV was recorded over the course of 24-hours and timing of daily
life activities were matched across participants. While TP-HRV, ULF-HRV, VLF-HRV, and LFHRV was significantly lower (p’s < .05) in twins with current or remitted MDD, this relationship
did not hold when additional variables (e.g., lifestyle factors, comorbid medical, and psychiatric
conditions) were entered into the model. Several methodological flaws (e.g., poor screening for
CVD and combined sample of current and remitted MDD participants), temper the finding that
history of depression is not associated with lower HRV while at rest and during activities of daily
living.
As reviewed, there does not appear to be significant differences in cardiovascular
functioning at rest among individuals with remitted MDD. These findings are in line with the
differential activation and mood state dependent hypotheses, which suggests that vulnerability to
depression (e.g. maladaptive patterns of cardiovascular functioning) is only observable when
formerly depressed individuals are faced with an emotional challenge. Therefore, it is possible
that maladaptive patterns of cardiovascular reactivity observed in currently depressed
participants will be present in formerly depressed participants exposed to stress. In the following
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section, research examining cardiovascular functioning in response to stress in remitted MDD
will be reviewed.
Cardiovascular reactivity in response to stress. A portion of the literature has
investigated cardiovascular functioning in adults with remitted MDD in response to experimental
stress inductions. Ahrens and colleagues (2008) examined HRV in adults with remitted MDD
during stressful and cognitively challenging tasks. All participants were free from major
ventricular or supraventricular arrhythmias and current medical conditions were endorsed as
stable; however, the presence of CVD was not comprehensively assessed, which could
potentially confound the cardiovascular results. Participants were women with remitted MDD (n
= 22) and healthy women without a history of affective disorders (n = 20). Experimental tasks
included completion of several stressful (i.e., speech and mental arithmetic) and cognitively
demanding (i.e., computer concentration) tasks. HR and HRV was collected continuously during
the experimental procedures. Three average HR measurements were computed during baseline,
completion of tasks, and recovery. Five average HRV measurements were computed during
baseline while supine and standing and during the speech, mental arithmetic, and computer
concentration tasks. Results did not reveal any significant differences in HR and HRV between
participants with remitted MDD and healthy control participants across the experimental
paradigm (p’s > .05). The authors theorized that the results might be due to the nature of the
stressful tasks, stating that more demanding tasks may elicit differences in cardiovascular
functioning across groups.
Salomon and colleagues (2013) used different methodological procedures to examine
cardiovascular reactivity in response to stress in adults with remitted MDD. Participants were
included if they did not endorse CVD and other medical conditions (e.g., head injury, substance
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abuse, etc.) or medications (e.g., antipsychotics, beta blockers, etc.) that could impact the
recording of physiological responses. Depression was assessed using the SCID-I. The sample
was comprised of participants with current MDD (n = 50) or remitted MDD (n = 25) and healthy
control participants without a history of Axis I disorders (n = 45). Participants watched a neutral
video during the baseline period, completed an active (i.e., speech preparation and delivery under
observation) and passive (i.e., forehead cold pressor task) stressful task in counterbalanced order,
and watched a video during the recovery period. HR, PEP, and CO were collected continuously
during the experimental procedures. Six average measurements were computed for each
cardiovascular measure during baseline, the speech preparation, delivery, and recovery, and the
cold pressor task and recovery.
Results did not reveal any significant differences in cardiovascular reactivity among
currently or formerly depressed or healthy control groups during baseline (p’s > .05) and the
forehead cold pressor task (p’s > .29). Salomon and colleagues (2013) speculated that the null
findings might be because participants with current MDD only show reduced reactivity when
confronted with an active task (e.g., speech) that they perceive as insurmountable, which is in
line with the biopsychosocial model of challenge and threat. Differential patterns of
cardiovascular reactivity were observed during components of the speech task. During the
speech preparation, participants with current MDD showed significantly lower HR (R2 = 3.74, p
< .01, η2p = .10) and PEP (R2 = 4.32, p < .05, η2p = .08) reactivity compared to participants with
remitted MDD and healthy control participants. During the speech delivery, participants with
current MDD showed significantly lower HR (R2 = 8.14, p < .001, η2p = .14), CO (R2 = 4.68, p <
.05, η2p = .08), and PEP (R2 = 9.33, p < .001, η2p = .16) reactivity compared to participants with
remitted MDD and healthy control participants. Of note, participants with remitted MDD did not
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significantly differ from healthy control participants on any cardiovascular measure during the
speech preparation delivery, and recovery (p’s > .05). Overall, these findings provide preliminary
support for the notion that individuals with current MDD, but not remitted MDD, show a blunted
cardiovascular response to active stressful tasks.
In a follow up study, Bylsma and colleagues (2014) sought to replicate the finding that
adults with current but not remitted MDD exhibit blunted cardiovascular reactivity to active,
stress inducing tasks. All participants were free from CVD and other medical conditions or
medications that could impact the recording of physiological responses. The sample was
comprised of participants with current MDD (n = 51) or remitted MDD (n = 25) and healthy
controls without a history of Axis I disorders (n = 45). Experimental tasks included a baseline
video, paced breathing baseline, an active (i.e., speech preparation and delivery under
observation) and passive (i.e., forehead cold pressor task) stressful task in counterbalanced order,
and recovery video. RSA was collected continuously during the experimental procedures. Eight
average measurements were computed for RSA during baseline, the paced breathing task, the
speech instructions, preparation, delivery, and recovery, and the cold pressor task and recovery.
Results revealed that cardiovascular measures did not significantly differ between groups
during baseline and the forehead cold pressor task (p’s > .05). However, Bylsma and colleagues
(2014) did observe differential patterns of cardiovascular reactivity during the speech task.
During the speech preparation, delivery, and recovery, participants with current MDD showed
significantly lower RSA (p < .05) compared to participants with remitted MDD and healthy
control participants. However, this relationship was no longer significant when adjustments were
made for covariates (p > .42; i.e., sleep quality). In line with the previous study by Salomon and
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colleagues (2013), findings suggested that individuals with current MDD, but not remitted MDD,
exhibit a blunted cardiovascular response to active stressful tasks.
Wilson and colleagues (2016) examined cardiovascular reactivity in response to stress
among adults with a history of MDD with or without a prior suicide attempt. All participants
were free from CVD and other autonomic disorders (e.g., diabetes, Parkinson’s disease, etc.) that
could impact the recording of physiological responses. Participants were assessed for depression
using the SCID-I and history of suicide using the Columbia University Suicide History Form and
the Lethality Scale. Participants included women with remitted MDD with (n = 13) or without (n
= 22) a previous suicide attempt. Experimental procedures included a resting baseline and the
Trier Social Stress Task (TSST), a widely-used laboratory-based paradigm used to induce
moderate levels of social stress. HF-HRV was collected continuously during the experimental
procedures and averaged within each experimental phase. Results showed that HF-HRV did not
significantly differ between groups during baseline (p = .09). However, participants with a
history of suicide attempts showed significantly lower HF-HRV during the TSST (t = 5.4, p =
.03) compared to participants without a history of suicide attempts. Findings echo previous
studies on the impact of stress on cardiovascular functioning, suggesting that individuals with
remitted MDD who have attempted suicide exhibit blunted cardiovascular reactivity in response
to stressful tasks that are active.
While Wilson and colleagues (2016) found that adults with a history of depression show
lower HF-HRV in response to stress, this study focused on a subset of the remitted depressed
individuals (i.e., those with a history of suicide behavior) that is not representative or the entire
population. Instead, the majority of the literature has shown that adults with remitted MDD do
not exhibit a maladaptive pattern of cardiovascular reactivity when exposed to stressful stimuli
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(i.e., Ahrens et al., 2008; Salomon et al., 2013; Bylsma et al., 2014). It is possible that the
differential activation and mood state dependent hypotheses only apply to emotions that are
relevant to depression and that the maladaptive patterns of cardiovascular reactivity observed in
currently depressed participants will be present in formerly depressed participants who become
sad. In the following section, research examining cardiovascular reactivity in response to sadness
in a mixed sample of currently and formerly depressed participants will be reviewed.
Cardiovascular reactivity in response to sadness. Cardiovascular reactivity in response
to a sad mood induction is separately reviewed below for research using a mixed adult and
adolescent sample of current and remitted MDD participants as well as an adult sample of
remitted MDD participants.
Cardiovascular reactivity in response to sadness in a mixed adult sample of current
and remitted depression. A set of studies have examined cardiovascular reactivity in response to
a sad mood induction in a mixed sample of adults with current and remitted MDD (Table 1).
Yaroslavsky, Rottenberg, and Kovacs (2013) examined if RSA measured at rest and in response
to a sad mood could predict current depressive symptoms and history of depression. Participants
were adults with a history of MDD during adolescence (n = 113; 37.00% currently experiencing
a depressive episode) and healthy control participants without a history of Axis I disorders (n =
93). Depressive symptoms were assessed using the BDI and Follow-Up Depression Scale, a
clinician-rated scale for depressive symptom severity. Experimental tasks included a resting
baseline and film-based mood inductions for joy, fear, sadness, anger, and disgust that were
followed by resting periods. RSA was collected continuously during the experimental
procedures.
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Yaroslavsky and colleagues (2013) found that the combination of resting RSA and RSA
reactivity, but not resting RSA and RSA reactivity alone, predicted current depressive symptoms
and previous depression status. Participants who showed high resting RSA and RSA withdrawal
(i.e., decrease in cardiac vagal control) in response to the sad mood induction were more likely to
report lower depressive symptoms and less likely to have a history of depression (p’s < .05). In
contrast, the interaction between resting RSA and RSA augmentation (i.e., increase in cardiac
vagal control) in response to the sad mood induction was not significant (p = .97).
Study 1 by Yaroslavsky, Rottenberg, and Kovacs (2014) investigated whether RSA
measured at rest and in response to a sad mood could predict depressive history in a sample of
women with juvenile-onset depression. Participants were adult women with a history of MDD
during adolescence (n = 27; 48.00% currently experiencing a depressive episode) and healthy
women without a history of Axis I disorders (n = 43). Experimental tasks included a resting
baseline and film mood inductions for joy and sadness. RSA was collected continuously during
the experimental procedures. The focus of this study was solely on RSA during rest and RSA in
response to the sad mood induction; average RSA resting measurements were computed via
resting baseline while average RSA reactivity was computed during the sad mood induction.
In Study 1, Yaroslavsky and colleagues (2014) found that participants who showed an
abnormal pattern of RSA responding (i.e., high resting RSA and RSA augmentation or low
resting RSA and RSA withdrawal) were more likely to endorse a history (p < .05) or current
episode (p < .001) of depression. In addition, participants who showed a normal pattern of RSA
responding (i.e., high resting RSA and RSA withdrawal or low resting RSA and RSA
augmentation) were less likely to endorse a history or current episode of depression. These
findings replicate their previous findings (Yaroslavsky et al., 2013), and suggest that
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cardiovascular reactivity during a sad mood can be used to characterize the presence of current
or past depression.
The aforementioned studies (Yaroslavsky et al., 2013, 2014 Study 1) showed that the
interaction between RSA at rest and RSA reactivity was a significant predictor of depressive
history and symptoms in participants with current and remitted MDD. However, there are
significant methodological problems that limit the generalizability and validity of these findings.
First, a portion of the participants endorsed currently experiencing a depressive episode during
data collection, which resulted in a mixed sample consisting of both current and remitted MDD.
It is possible that the findings are only applicable to the currently depressed participants as
research has been shown that current MDD impacts cardiovascular functioning during a sad
mood induction (e.g., Jin et al., 2015; Rottenberg et al., 2003; Rottenberg et al., 2005a; Panaite et
al., 2016). Second, participants were not assessed for the presence of CVD. Previous research
has indicated that CVD may be a confound and therefore should be controlled or excluded for
when examining the relationship between depression and cardiovascular health (Kemp et al.,
2010). Finally, the studies utilized the same sample of participants who experienced a depressive
episode during adolescence. Of note, differences have been found between adolescent and adult
depression (Kaufman, Martin, King, & Charney, 2001). Consequently, the results may not
generalize to adult-onset depression. While the interaction between RSA at rest and RSA
reactivity is an intriguing line of inquiry, additional methodologically sound research is needed
to investigate if this pattern of cardiovascular reactivity truly characterizes remitted depression in
adults.
Cardiovascular reactivity in response to sadness in a mixed adolescent sample of
current and remitted depression. A set of studies examined cardiovascular reactivity in response
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to a sad mood induction in a mixed sample of adolescents with current and remitted MDD (Table
1). Study 2 by Yaroslavsky and colleagues (2014) investigated if RSA measured at rest and in
response to a sad mood could predict depressive history and symptoms in adolescents.
Participants and another informant completed the Interview Schedule for Children and
Adolescents: Diagnostic Version (ISCA-D), a semi-structured interview used to diagnose
depression and the Children’s Depression Inventory – Second Edition (CDI-2), a self-report form
to assess depressive symptoms. Participants included 147 Hungarian proband-sibling pairs in
which one sibling had a history of MDD during childhood (n = 132) and the other sibling also
had a history of MDD during childhood (n = 36) or no history of MDD (n = 111). Of note, the
authors did not provide detailed information about the sample and refer to previous studies for
more information. These studies focus on currently depressed adolescents (e.g., Baji et al., 2009;
Kiss et al., 2007; Tamás et al., 2007), suggesting that the sample of interest is not made up of
purely formerly depressed participants. Experimental tasks included a paced breathing task and
film-based sad mood induction. RSA was collected continuously during the experimental
procedures. Average RSA resting measurements were computed during the paced breathing task
while average RSA reactivity was computed by taking the difference between RSA during the
paced breathing task and the sad mood induction.
In Study 2, Yaroslavsky and colleagues (2014) showed that an abnormal pattern of RSA
at rest and in response to the sad mood induction (i.e., high resting RSA and RSA augmentation
or low resting RSA and RSA withdrawal) were present in proband-sibling pairs where both
children experienced depression (OR = 6.46, CI = 1.15, 36.47, p < .05), but not in probandsibling pairs where only the proband experienced depression. These results, which replicate the
finding from the first study reported in the manuscript (Yaroslavsky et al., 2014 Study 1), found
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an abnormal pattern of RSA responding in depressed adolescents that corresponded with the
abnormal pattern of RSA responding previously observed in adults.
Bylsma and colleagues (2015) examined cardiovascular responsivity to sadness and stress
in adolescents with remitted MDD. Participants and another informant completed the ISCA-D to
diagnose depression and the CDI-2 to assess depressive symptoms. Participants included
adolescents with a history of MDD during childhood (n = 216; 14.80% currently experiencing a
depressive episode) and healthy control participants without a history of Axis I disorders (n =
161). Experimental tasks included a neutral and sad film mood induction, unsolvable puzzle,
handgrip task, and forehead cold pressor task followed by resting periods. RSA, PEP, cardiac
autonomic balance (CAB), and cardiac autonomic regulation (CAR) was collected continuously
during the experimental procedures. CAB was calculated by subtracting RSA and PEP and is an
index of the balance between SNS and PNS activation while CAR was calculated by adding
RSA and PEP and is an index of activation of both the SNS and the PNS. Average RSA, PEP,
CAB, and CAR resting measurements were computed during the resting periods while average
RSA, PEP, CAB, and CAR reactivity was computed for each experimental task.
Bylsma and colleagues (2015) did not find differences in cardiovascular responding
between groups at baseline (p’s > .10); however, some group differences did emerge during the
experimental paradigm. Participants with a history of MDD exhibited a greater increase in CAB
during the unsolvable puzzle (p = .17) and handgrip tasks (p = .14), which is indicative of greater
SNS and PNS activation. Conversely, healthy control participants exhibited a greater decrease in
PEP (p = .001) and increase in CAR during the handgrip task (p = .03), which is indicative of
greater SNS responding and less SNS and PNS activation. Interestingly, no differences were
found between groups during the sad film mood induction (p’s > .05). While the authors attribute
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this finding to the potency of the experimental task, the sad film clip (i.e., The Champ) has been
empirically validated and widely used in the literature. Although these findings suggest that CAB
increases in remitted depressed participants in response to stress but not sadness, it is possible
that these results were due to the use of a mixed samples made up of participants with current
and remitted MDD.
The aforementioned studies (Bylsma et al., 2015 Yaroslavsky et al., 2014 Study 2)
showed that adolescents with current and remitted MDD exhibit an abnormal pattern of
cardiovascular reactivity (i.e., interaction between RSA at rest and RSA reactivity, CAB, and
CAR) in response to a sad mood compared to healthy control participants. However, these results
must be evaluated in light of their significant methodological flaws. First, the studies used a
mixed sample of current and remitted MDD participants, which could limit the generalizability
of these findings to currently depressed rather than formerly depressed participants. Second, the
medical screening procedures employed by these studies were insufficient. While participants
were assessed for major medical disorders, they were not specifically evaluated for CVD.
Previous research has suggested that the presence of CVD may be a confound and therefore
should be controlled or excluded for when examining the relationship between depression and
cardiovascular health (Kemp et al., 2010). Additional methodologically sound research is needed
to investigate if an abnormal pattern of cardiovascular reactivity in response to sadness is
consistently observed in adolescents with remitted depression. It should also be noted that
differences have been found between adolescent and adult depression (Kaufman et al., 2001).
Consequently, results from these studies may not generalize to adult samples.
Cardiovascular reactivity in response to sadness in an adult sample of remitted
depression. Only one study has investigated cardiovascular functioning in adults with remitted

82

MDD in response to an experimentally-induced sad mood (Table 1). Rottenberg and colleagues
(2005b) examined HR reactivity in response to a sad mood in adults with remitted MDD.
Participants were free from medical conditions (e.g., head injury, substance abuse, etc.) that
could impact the recording of physiological responses; however, CVD was not assessed, which
could potentially confound the cardiovascular results. Depression was assessed using the SCID-I
and included individuals with current MDD (n = 19) or remitted MDD (n = 22) and healthy
controls without a history of Axis I disorders (n = 26). During the experimental paradigm,
participants were instructed to watch sad, happy, and neutral valenced films presented in a
counterbalanced order then imagine the scene in their mind. Each film and imagery task were
preceded by a one-minute resting baseline and followed by a one-minute filler task to reduce
carry over effects. HR was collected continuously during the experimental procedures and
average measurements were computed. Results revealed that HR did not significantly differ
across group, emotional valence, or stimulus type (p > .10). These findings provide preliminary
support that cardiovascular reactivity does not differ based on depression status in the face of
various emotional experiences.
The current literature examining cardiovascular reactivity in response to sadness for
formerly depressed individuals is extremely limited. Rottenberg and colleagues (2005b) did not
identify a significant difference in HR reactivity in response to sadness between participants with
remitted MDD to healthy control participants. It is possible that a single cardiovascular marker is
insufficient to characterize the pattern of cardiovascular reactivity in response to a sad mood
induction. As explained by the theoretical models, a cascade of complex physiological processes
is implicated in cardiovascular functioning. As such, it may be necessary to examine multiple
measures of cardiovascular reactivity that are thought to index various aspects of the ANS in
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order to truly characterize how individuals with remitted MDD react to a sad mood induction.
Additional research is needed to empirically test this hypothesis.
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Table 1. Previous Research on Cardiovascular Reactivity to Sadness in Current and Remitted Depression by Sample
CD in Adult Samples
Diagnostic Experimental Cardiovascular CVD
Interview Tasks
Measures
Assessed
SCID-I
Sad, fear, and RSA
Yes
happy films

Study

Sample

Panaite et
al. (2016)

CD = 49
RD = 24
HC = 45

Jin et al.
(2015)

CD = 25
HC = 25

SCID-I

Sad and
amusing
films

HR, RSA

Yes

Rottenberg
et al. (2003)

CD = 25♀
HC = 31♀

SCID-I

Sad and
neutral films

RSA

No

Rottenberg
et al.
(2005a)
Tsai et al.
(2003)

CD = 55

SCID-I

Sad, fear,
RSA
No
and amusing
films
CD = 12♀
PRIMESad,
Cardiac IBI
No
HC = 10♀
MD
amusing, and
neutral films
Combined CD/RD in Adult Samples
Study
Sample
Diagnostic Experimental Cardiovascular CVD
Interview Tasks
Measures
Assessed
Yaroslavsky CD/RD = 113 SCID-I
Sad, anger,
RSA
No
et al. (2013) HC = 93
disgust, fear,
and joy films
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Findings
↓ RSA withdrawal during sad film
predicted ↑ MDD symptoms at follow-up
in CD
• No other predictive results for other films
• ↓ HR decrease during sad and amusing
films in CD than HC
• No other group differences during
baseline or other films
• ↑ RSA after sad film in HC who cried
during sad film
• No ΔRSA after sad film in CD who cried
during sad film
• RSA withdrawal to sad film predicted
recovery from MDD at follow-up
• No other predictive results for other films
• No group differences in cardiac IBI
during baseline or films
•

Findings
Typical resting RSA X ΔRSA during sad
film predicted HC status
• No other results for sad or other films
•

Table 1 Continued
Yaroslavsky CD/RD = 27♀ SCID-I
et al. (2014) HC = 43♀
Study 1

Sad and joy
films

RSA

No

Atypical resting RSA X ΔRSA during sad
film predicted CD/RD status
• Typical resting RSA X ΔRSA during sad
film not predictive of CD/RD status
• No other predictive results for other film
•

Combined CD/RD in Adolescent Samples
Study
Sample
Diagnostic Experimental Cardiovascular CVD
Findings
Interview Tasks
Measures
Assessed
Yaroslavsky Proband:
ISCA-D
Sad film
RSA
No
• Atypical resting RSA X ΔRSA during sad
et al. (2014) CD/RD = 132
film observed in CD/RD proband/sibling
Study 2
Siblings:
pairs
CD/RD = 36
• No other group differences for sad film
HC = 111
Bylsma et
Proband:
ISCA-D
Sad and
RSA, PEP,
No
• No group differences in RSA, PEP, CAB,
al. (2015)
CD/RD = 216
neutral film
CAB, CAR
or CAR during baseline or films
HC = 161
RD in Adult Samples
Study
Sample
Diagnostic Experimental Cardiovascular CVD
Findings
Measure
Tasks
Measures
Assessed
Rottenberg et CD = 19
SCID-I
Sad, happy,
HR
No
• No group differences in HR during
al. (2005b)
RD = 22
and neutral
baseline, films, or imagery tasks
HC = 26
films and
imagery tasks
Note. CD = current major depressive disorder; CD/RD = mixed sample of current and remitted major depressive disorder; RD =
remitted major depressive disorder; HC = healthy control; SCID-I = Structured Clinical Interview for the DSM-IV; PRIME-MD =
Primary Care Evaluation of Mental Disorders; ISCA-D = Interview Schedule for Children and Adolescents: Diagnostic Version; HR =
heart rate; HRV = heart rate variability; RSA = respiratory sinus arrhythmia; IBI = interbeat interval; CAB = cardiac autonomic
balance; CAR = cardiac autonomic regulation; ↓ = decrease; ↑ = increase; Δ = change; ♀ = women only.
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CHAPTER 4
OVERVIEW AND STATEMENT PURPOSE
MDD is a serious, debilitating, and commonly occurring mental illness characterized by
pronounced negative mood and/or lack of interest or pleasure (APA A, 2013; Kessler et al., 2003).
MDD is associated with negative psychological, medical, and economic outcomes. Research has
found that individuals with MDD report high rates of morbidity, mortality, and functional
impairment, which results in increased disability and decreased workplace productivity (Lépine
& Briley, 2011). Consequently, MDD is currently the leading cause of disability and second
leading cause of disease burden around the world (Mathers et al., 2008). The direct and indirect
expenses associated with MDD are estimated to cost the United States $210.50 billion yearly
(Greenberg et al., 2015). Clearly, MDD is associated with significant burden at the individual
and societal level.
While research has typically focused on the acute aspect of depression, MDD is typically
understood as a chronic illness due to high rates of relapse and recurrence (Richards, 2011).
Results of a seminal study conducted by the NIMH found that within a 15-year period, up to
50.00% of individuals with MDD will experience a relapse, or reemergence of a depressive
episode before MDD has remitted, and up to 85.00% will experience a recurrence, or experience
of a new depressive episode after MDD has remitted (Mueller et al., 1999). This finding has been
replicated throughout the literature over the past decade. Research has shown that the rate of
relapse or recurrence in individuals with a history of MDD ranges from 2.50% to 77.00% over
periods of time ranging from one to 20 years (Hardeveld et al., 2010, 2013; Johansson et al.,
2015; Nöbbelin, Bogren, Mattisson, & Brådvik, 2018; Poutanen et al., 2007; ten Doesschate et
al., 2010).
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Vulnerability to depressive relapse and recurrence is likely multiply determined and due
to a complex interaction of biological, psychological, and environmental factors (Burcusa &
Iacono, 2007). Researchers have identified various clinical, demographic, familial,
psychological, and psychosocial factors that may make an individual more susceptible to
experiencing another depressive episode (Burcusa & Iacono, 2007; Harveveld et al., 2010, 2013;
Johansson et al., 2015; ten Doesschate et al., 2010). The majority of these vulnerability factors
are stable, unchangeable traits. More research is needed to identify malleable vulnerability
factors that can be specifically targeted during treatment or following treatment for relapse
prevention to reduce the occurrence of future episodes of depression.
Cognitive theories of depression have theorized that dysfunctional thinking patterns
contribute to the occurrence, maintenance, and reoccurrence of depression. Research has
indicated that currently depressed individuals endorse higher rates of dysfunctional thoughts;
however, individuals who have recovered from depression report patterns of thoughts that are
similar to never depressed individuals (as reviewed by Teasdale, 1999). These findings suggest
that cognitive vulnerability to depression (i.e. dysfunctional thoughts) are no longer present after
recovery from depression, despite the fact that individuals with a history of depression remain at
high risk for relapse or recurrence. Research aimed to account for these discrepant findings has
focused on individual differences in how one responds to a transient, sad mood. Specifically,
research has sought to understand how individuals with a history of MDD respond to the
experience of sadness in between depressive episodes.
The differential activation hypothesis by Teasdale (1988) and mood state dependent
hypothesis by Miranda and Persons (1988) similarly hypothesized that cognitive vulnerabilities
to depression remain latent in formerly depressed individuals until activated by a dysphoric
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mood. In accordance with these theories, researchers have hypothesized that individuals who
have recovered from depression exhibit maladaptive cognitions and affective states during a
dysphoric mood, but not a euthymic mood. Empirical evidence has generally supported these
theories, and found that compared to healthy control participants, those with remitted MDD
report significant increases in dysfunctional beliefs (i.e., cognitive reactivity; Kuyken et al.,
2010; Segal et al., 1999, 2006) or dysphoric mood (i.e., mood reactivity; Lethbridge & Allen,
2008; van Rijsbergen et al., 2013) in response to an experimentally-induced sad mood and
prospectively predict relapse of depression over time. While there is still disagreement in the
literature whether dysfunctional thinking patterns or dysphoric mood states characterize remitted
MDD, cognitive and mood reactivity in response to sadness have been proposed as two potential
pathways of vulnerability to relapse and recurrence for formerly depressed individuals.
Examination of cardiovascular functioning in response to negative affect may advance
our understanding of the relationship between reactivity to sad mood and vulnerability to
depressive relapse and recurrence. A large body of research has highlighted the important role of
cardiovascular functioning in MDD. Depression and depressive symptoms are associated with an
increased risk of CVD (Gan et al., 2014; Nicholson et al., 2006; Ruglies, 2002; Wulsin & Singal,
2003; Van der Kooy et al., 2007) and cardiovascular events. Similarly, CVD is associated with
increased rates of depression and depressive symptoms (Brown et al., 2009). This relationship
has led researchers to examine cardiovascular differences that can explain the susceptibility to
CVD in this population. Maladaptive patterns of cardiovascular functioning have been identified
in currently depressed individuals. Compared to non-depressed counterparts, individuals with
current MDD show lower RSA and HRV while at rest (Chang et al., 2012; Kemp et al., 2010,
2012; Kikuchi et al., 2009; Rottenberg, 2007b), lower HR, HRV, RSA, and CO in response to
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stress (Ehrenthal et al., 2010; Liang et al., 2015; Nugent et al. 2011; Rottenberg et al., 2007a;
Salomon et al., 2009), and blunted HR and RSA in response to sadness (Jin et al., 2015; Panaite
et al., 2016; Rottenberg et al., 2003, 2005a). Research on cardiovascular reactivity in response to
sadness is mixed, with some studies failing to replicate these patterns of cardiovascular reactivity
and showing an opposite trend of cardiovascular reactivity (i.e., Rottenberg et al., 2005b; Tsai et
al., 2003).
In general, the cardiovascular abnormalities that have been identified in currently
depressed individuals do not appear to be present in formerly depressed individuals. Formerly
depressed and healthy control participants do not differ in cardiovascular functioning at rest
(HRV; Chang et al., 2013; Vaccarino et al., 2008) or cardiovascular reactivity in response to
stress (HR, HRV, RSA, CO, and PEP; Ahrens et al., 2008; Bylsma et al., 2014; Salomon et al.,
2013). Thus far, it appears that the cardiovascular functioning of remitted depressed participants
generally resembles that of healthy control participants. These findings led researchers to
hypothesize that cardiovascular abnormalities may be mood-state dependent much like the
cognitive and mood vulnerabilities that have been identified in remitted depression.
Cardiovascular reactivity is operationalized as the change in an individual’s
cardiovascular functioning in response to a sad mood induction. The literature on cardiovascular
reactivity in response to sadness among formerly depressed individuals is limited to one study
that recruited a sample of adults with remitted depression. Rottenberg and colleagues (2005b)
failed to find cardiovascular differences among individuals with a history of depression; there
were no significant differences in HR reactivity in response to a sad mood induction when
comparing remitted depressed and healthy control participants. While other researchers have
attempted to study this topic, interpretation of findings have been limited by serious
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methodological flaws. Bylsma and colleagues (2015) did not identify any significant differences
in RSA and PEP reactivity in response to a sad mood induction when comparing remitted
depressed and healthy control adolescents. Conversely, Yaroslavsky and colleagues (2013, 2014
Study 2) found that a combined group of currently and formerly depressed adults and adolescents
exhibited an abnormal pattern of RSA responding (i.e., high resting RSA and RSA augmentation
or low resting RSA and RSA withdrawal during sad mood induction) compared to healthy
control participants.
While some of these abovementioned studies point to differences in cardiovascular
reactivity among formerly depressed individuals, there are significant concerns about the quality
and generalizability of these studies due to multiple methodological issues. First, most of the
literature has relied upon a mixed sample of participants who were currently or formerly
depressed (Bylsma et al., 2015; Yaroslavsky et al., 2013, 2014 Studies 1 and 2; with the
exception of Rottenberg et al., 2005b). The cardiovascular differences that were identified in
these studies may be attributable to the inclusion of currently depressed participants or the
presence of subclinical depressive symptom rather than remitted depression. As a result, only
one study (i.e., Rottenberg et al., 2005b) has truly investigated cardiovascular reactivity in
response to sadness in remitted depression.
Second, none of the abovementioned studies explicitly assessed for the presence of CVD
(Bylsma et al., 2015; Rottenberg et al., 2005b; Yaroslavsky et al., 2013, 2014 Studies 1 and 2).
Previous research has indicated that the presence of CVD may be a confound and therefore
should be controlled for or be an exclusion criterion when examining the relationship between
depression and cardiovascular health (Kemp et al., 2010). Therefore, it is possible that these
results are attributable to underlying cardiovascular illness rather than remitted depression.
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Additionally, it is possible that failure to find significant differences between groups is due to
differences in cardiovascular status rather than psychological variables.
Third, most of the literature has examined a very limited range of cardiovascular measures
(i.e., HR or RSA only; Rottenberg et al., 2005b; Yaroslavsky et al., 2013, 2014 Studies 1 and 2;
with the exception of Bylsma et al., 2015). The use of a singular cardiovascular measure may be
insufficient to characterize the complex pattern of cardiovascular reactivity, as different
measures are thought to index different components of the regulatory systems (e.g., SNS versus
PNS) that influence cardiovascular functioning. It may be necessary to examine multiple
measures of cardiovascular reactivity that are thought to index various aspects of the ANS to
truly characterize how individuals with remitted MDD react to a sad mood induction. Indeed,
several theoretical models (i.e., the biopsychosocial model of challenge and threat by Blascovich
and Tomaka (1996) and hawk-dove model by Smith (1982)), propose a complex pattern of
cardiovascular or physiological reactivity in response to stress. Consequently, analyses must be
conducted for those cardiovascular markers (e.g., CO and PEP) that have not been examined
among individuals with remitted depression.
Fourth, none of the relevant studies investigated cardiovascular recovery (Bylsma et al.,
2015; Rottenberg et al., 2005b; Yaroslavsky et al., 2013, 2014 Studies 1 and 2). Cardiovascular
recovery is operationalized as the amount of time that it takes for an individual’s cardiovascular
functioning to return to baseline levels following a sad mood induction. Cardiovascular recovery
provides an estimate of how long the physiological changes attributable to an emotionallyvalenced stimulus persist after the stimulus has been removed. It has been suggested that the
study of cardiovascular recovery has significant clinical utility. More specifically, cardiovascular
recovery can identify factors that contribute to the development of psychopathology and
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physiological dysfunction and disease (Linden, Earle, Gerin, & Christenfeld, 1997; Haynes,
Gannon, Orimoto, O’Brien, & Brandt, 1991). Cardiovascular recovery following the induction of
a transient mood state may be especially important as research has shown that individuals take a
longer amount of time to habituate to emotional distress compared to stress (Linden et al., 1997).
Given the hypothesis that the relationship between depression and CVD is due to long-standing
cardiovascular abnormalities, it is necessary to investigate the role of cardiovascular recovery as
a potential dormant mechanism of vulnerability to MDD that is activated by a dysphoric mood.
Fifth, a large portion of the literature has failed to compare cardiovascular reactivity in
response to both sad and neutral mood inductions (Yaroslavsky et al., 2013, 2014 Studies 1 and
2; with the exceptions of Bylsma et al., 2015 and Rottenberg et al., 2005b). The differential
activation hypothesis by Teasdale (1988) and mood state dependent hypothesis by Miranda and
Persons (1988) theorize that formerly depressed individuals only exhibit vulnerabilities to
depression when in a dysphoric mood. Based on these hypotheses, it is expected that formerly
depressed participants would react in a maladaptive manner to the sad mood induction but not
the neutral mood induction. Therefore, the comparison of reactivity to sad and neutral mood
inductions is necessary to empirically test these hypotheses.
Finally, a large portion of this literature has been conducted in formerly depressed
adolescents (Bylsma et al., 2015; Yaroslavsky et al., 2014 Study 2; with the exceptions of
Rottenberg et al., 2005b and Yaroslavsky et al., 2013, 2014 Study 1). Differences in adolescent
and adult depression have been identified. For example, depressed children and adolescents do
not show elevated basal cortisol levels, abnormal cortisol and prolactin secretion, and reduced
immunity cells like depressed adults (Kaufman et al., 2001), suggesting that physiological

93

correlates of depression may differ in the two age groups. As a result, these cardiovascular
findings may not generalize to adult-onset depression.
The proposed study aimed to examine the cognitive, mood, and cardiovascular correlates
in response to dysphoric mood among adults with a history of depression. The primary goal of
this study was to characterize cardiovascular reactivity to and recovery from a sad mood in
individuals with a history of MDD. To help clarify prior inconsistent results, the secondary goal
of this study was to examine cognitive and mood reactivity in individuals with a history of
MDD. This study will advance our understanding of potentially malleable vulnerability factors
associated with a history of depression.
This study overcame several methodological weaknesses associated with prior work.
First, while most of the literature has focused on a single cardiovascular measure, the current
study examined multiple cardiovascular measures to better characterize the pattern of
cardiovascular functioning in remitted depression. Second, the current study compared
cardiovascular reactivity to and recovery from sad and neutral mood induction. Prior work has
primarily focused on cardiovascular reactivity rather than recovery; however, it is possible that
cardiovascular recovery may increase vulnerability to depression as well as contribute to
cardiovascular abnormalities. Third, the current study recruited a sample of participants who
have fully recovered from depression and are free from CVD and other related medical illnesses.
Accordingly, results would not be attributable to current depression, residual depressive
symptoms, or medical comorbidities.
Research Hypotheses
This study examined cognitive, mood, and cardiovascular reactivity and cardiovascular
recovery in response to an experimentally-induced sad mood in remitted depression. Based on a
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review of the applicable theoretical models and existing literature, the following hypotheses were
proposed:
H1

Formerly depressed participants exposed to the sad mood induction would report
significantly higher levels of cognitive reactivity on the DAS post-mood induction than
formerly depressed participants exposed to the neutral mood induction and healthy
control participants exposed to the sad and neutral mood inductions.

H2

Formerly depressed and healthy control participants exposed to the sad mood induction
would report significantly higher levels of mood reactivity on the VAS post-mood
induction than formerly depressed and healthy control participants exposed to the neutral
mood inductions.

H3

Formerly depressed participants exposed to the sad mood induction would exhibit a
maladaptive pattern of cardiovascular reactivity (i.e., decreased HP, RSA, and CO and
increased PEP) during the mood induction compared to formerly depressed participants
exposed to the neutral mood induction and healthy control participants exposed to the sad
and neutral mood inductions.

H4

Formerly depressed participants exposed to the sad mood induction would exhibit
reduced cardiovascular recovery (i.e., decreased HP, RSA, and CO and increased PEP
compared to baseline) during the recovery film compared to formerly depressed
participants exposed to the neutral mood induction and healthy control participants
exposed to the sad and neutral mood inductions.
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CHAPTER 5
METHODS AND PROCEDURES
The following methods and procedures were employed. The University of Maine
Institutional Review Board (IRB) for the Protection of Human Subjects approved this study
(reference number: 2015-09-04, Investigating the Role of Attention and Elaboration in Relapse
to Depression), which is a large, ongoing study conducted by the Maine Mood Disorders Lab
(MMDL).
Participant Recruitment
Participants included 132 individuals between the ages of 18 to 60 years who were
currently undergraduate students enrolled at the University of Maine or individuals residing in
the surrounding community. Participants completed online and in-person screening procedures to
determine eligibility for the study. Participants that met inclusion and exclusion criteria were
invited to participate in the experimental paradigm. Power analysis using G*Power 3.1.9.2 (Faul,
Erdfelder, Lang, & Buchner, 2007), a statistical power calculation software, indicated that a
sample of 128 participants would result in an 80.00% chance of detecting a medium effect
between two groups (i.e., formerly depressed and healthy control participants) exposed to two
versions of the experimental paradigm (i.e., sad or neutral mood induction).
Undergraduate Participant Pool Recruitment
Participants included undergraduate students recruited from the University of Maine
Department of Psychology undergraduate participant pool. Recruitment was conducted through
announcements posted on the Sona Systems (2017), a participant management software.
Individuals recruited through the undergraduate participant pool initially completed electronic
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screening self-report measures (Appendix C) in Qualtrics (2017), an electronic data capturing
system, to determine eligibility for participating in session 1.
Participants recruited through the undergraduate pool were compensated for their
participation with research participation credits. Participants were awarded up to two research
participation credits for completing session 1 and one research participation credit for completing
session 2. Participants who did not complete all study procedures received a prorated rate of
research participation credits that reflected the amount of time that they spent in the laboratory
(Appendix F). If participants recruited through the undergraduate pool already earned sufficient
research participation credit, they were offered monetary compensation for their participation.
Participants were paid $30 for completing session 1 and $15 for completing session 2.
Participants who did not complete all study procedures received a prorated rate of payment that
reflected the amount of time that they spent in the laboratory.
Community Recruitment
Participants also included individuals recruited from the community surrounding the
University of Maine. Participants were recruited as part of a larger, ongoing study conducted by
the MMDL. Recruitment was conducted through electronic flyers (Appendix A) posted on online
announcement boards (i.e., University of Maine Announcements listserv, which was accessible
to faculty, staff, and students at the university), online classified advertisement and social media
websites (i.e., Craigslist and Facebook), and printed flyers placed in public areas within the
surrounding community (i.e., local business and restaurants). Individuals recruited from the
surrounding community completed electronic screening self-report measures (Appendix C) in
Qualtrics (2017) to determine eligibility for participating in session 1.
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Individuals recruited from the surrounding community were paid for their participation.
Participants were paid $30 for completing session 1 and $15 for completing session 2.
Participants who did not complete all study procedures received a prorated rate of payment that
reflected the amount of time that they spent in the laboratory (Appendix G).
Experimenters
The primary author, Olivia E. Bogucki, served as the primary experimenter for this study.
Study staff included clinical psychology graduate students and undergraduate research assistants
who have completed the Collaborative Institutional Training Initiative (CITI) online training
required by the IRB at the University of Maine. Clinical psychology graduate students scored
self-report measures during screening, completed diagnostic clinical interviews during session 1,
and determined eligibility during screening and session 1. Undergraduate research assistants
aided in participant recruitment (e.g., posted advertisements and flyers and contacted
participants), obtained informed consent and administered self-report measures during session 1
and 2, attached physiological sensors and monitored physiological recordings during session 2,
and conducted self-report and psychophysiological data cleaning. Undergraduate research
assistants were trained and supervised by clinical psychology graduate students. Clinical
psychology graduate students were supervised by the MMDL Director and Principal
Investigator, Emily A. P. Haigh, Ph.D.
Screening
Screening (Table 2) to determine eligibility for study session 1 participation was
completed remotely. Advertisements (Appendix A) and the Sona Systems (2017) directed
participants to complete an online survey hosted through Qualtrics (2017). Participants were
presented with an informed consent document (Appendix B). The informed consent document
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clearly stated that the purpose of this survey was to determine eligibility for the study. In
addition, the informed consent document highlighted that participation in the study was
voluntary and information obtained during the study would remain confidential. More
specifically, participants were informed that data would be stored via a secure server,
identification numbers would be assigned to de-identify their responses, and the subject key
matching participant names and identification numbers would be encrypted and saved on an
alternate computer. Despite these precautions, participants were made aware of potential risks
associated with the study (e.g., loss of privacy and potential for emotional discomfort) as well as
potential benefits (e.g., assistance in helping to better understand the study variables).
After electronically providing informed consent, participants were asked to provide their
contact and demographic information and complete self-report measures (Appendix C). Selfreport measures were presented in a standardized order and assessed current and past depressive
(i.e., Beck Depression Inventory – Second Edition (BDI-II) and Patient Health Questionnaire – 9
(PHQ-9)) and current anxiety (i.e., Beck Anxiety Inventory (BAI)) symptom severity as well as
language and visual abilities, learning disabilities, and current and past health conditions (i.e.,
General Health Screening (GHS)). Self-report measures were used to determine eligibility for
participation in session 1.
Following the completion of the self-report measures, participants received a referral list
(Appendix D). This referral list was presented as an information source, not something that must
be followed. Finally, participants were alerted that they would be contacted via email if they
were eligible to participate in the study.
Self-Report Measures
The following self-report measures were collected at screening.
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BDI-II. The BDI-II (Beck, Steer, & Brown, 1996a; Appendix C) was used to evaluate the
severity of current depressive symptoms. The BDI-II is a 21-item self-report measure that
assesses cognitive, affective, somatic, and vegetative symptoms of depression. Respondents rate
the severity of depressive symptoms experienced over the past two weeks on a scale from 0 to 3,
with 0 indicating the symptom is not present and 3 indicating that the symptom is present and
severe. Total scores range from 0 to 63, with higher scores indicating greater levels of depressive
symptom severity.
Research on the reliability of the BDI-II indicates excellent internal consistency (α = .91.94; Arnau, Meagher, Norris, & Bramson, 2001; Beck, Steer, Ball, & Ranieri, 1996b; Dozois,
Dobson, & Ahnberg, 1998; Osman et al., 1997a; Steer, Ball, Ranieri, & Beck, 1997) and
adequate test-retest reliability (Beck et al., 1996a). Research on the validity of the BDI-II
indicates adequate construct validity; convergent validity was evidenced by strong to moderate
correlations with other measures of depression and perceived mental health (Beck et al., 1996a;
Arnau et al., 2001; Dozois et al., 1998; Steer et al., 1997) while discriminant validity was
evidenced by low correlations with measures of social desirability (Osman et al., 1997a).
PHQ-9. The PHQ-9 (Kroenke, Spitzer, & Williams, 2001; Appendix C) was used to
evaluate the severity of past depressive symptoms. The PHQ-9 is a 9-item self-report measure
that assesses cognitive, affective, and vegetative symptoms of depression. Respondents rate the
severity of the worst depressive symptoms experienced over the course of their lifetime during
any two-week period on a scale from 0 to 3, with 0 indicating the symptom is not or rarely
present and 3 indicating that the symptom is present nearly every day. Total scores range from 0
to 27, with higher scores indicating greater levels of depressive symptom severity.
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Research on the reliability of the PHQ-9 indicates good internal consistency (α = .86-.89)
and adequate test-retest reliability (Kroenke et al., 2001). Research on the validity of PHQ-9
indicates adequate convergent validity with other measures of depression and psychological
distress (Martin, Rief, Klaiberg, & Braehler, 2006).
GHS. The GHS (Appendix C) was created by the MMDL to identify potential
confounding variables that other researchers have excluded for when examining
psychophysiological reactivity and recovery in remitted MDD (e.g., Bylsma et al., 2014; Chang
et al., 2013; Salomon et al., 2013; Wilson et al., 2016). The GHS is a 9-item self-report measure
that assesses language and visual abilities and learning disabilities that could significantly impair
an individual’s ability to understand the experimental paradigm as well as a range of current and
past health conditions that could impact the recording of physiological responses. Respondents
indicate the presence or absence of such conditions by selecting Yes or No to each question. In
addition, respondents are provided a free response textbox to report more detailed information.
BAI. The BAI (Beck & Steer, 1990; Appendix C) was used to evaluate the severity of
current anxiety symptoms. The BAI is a 21-item self-report measure that assesses cognitive,
affective, and somatic symptoms of anxiety. Respondents rate the severity of anxiety symptoms
experienced over the past two weeks on a scale from 0 to 3, with 0 indicating the symptom is not
present and 3 indicating that the symptom is present and severe. Total scores range from 0 to 63,
with higher scores indicating greater levels of anxiety symptom severity.
Research on the reliability of the BAI indicates excellent internal consistency (α = .90.92; Beck, Epstein, Brown, & Steer, 1988; Fydrich, Dowdall, & Chambless, 1992; Osman,
Barrios, Aukes, Osman, & Markway, 1993; Osman, Kopper, Barrios, Osman, & Wade, 1997b;
Steer & Ranieri, 1993) and adequate test-retest reliability (Beck et al., 1988; Fydrich et al.,
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1992). Research on the validity of the BAI indicates adequate construct validity; convergent
validity was evidenced by moderate correlations with other measures of anxiety while
discriminant validity was evidenced by low to moderate correlations with measures of depression
(Beck et al., 1988; Fydrich et al., 1992; Osman et al., 1997b; Steer & Ranieri, 1993).
Eligibility Criteria
The screening phase included general eligibility criteria that was created for all
participants and specific eligibility criteria that was created for formerly depressed and healthy
control participants. Participants who met general and specific eligibility criteria during
screening were sent an email (Appendix E) that included information on how to schedule session
1 using the Sona Systems (2017).
All participants. Participants were required to have been between 18 and 60 years of
age. The GHS was used to assess for a multitude of different physical and psychological
conditions. To ensure that participants were able to follow instructions associated with the
experimental paradigm, participants were deemed ineligible for the study if they did not speak
and read English fluently, were color blind, or had been diagnosed with a learning disability that
interferes with their ability to read or process visual information. To diminish the likelihood of
physical conditions known to impact the recording of physiological responses, participants were
deemed ineligible for the study if they had experienced head trauma resulting in a loss of
consciousness for over one hour, stroke, hemorrhage, brain tumors, medication-dependent
diabetes, cardiovascular disease, heart disease, hypertension, or medical conditions specific to
the central nervous system (i.e., epilepsy, transient ischemic attack, multiple sclerosis,
amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, and Huntington’s
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disease). Finally, participants were deemed ineligible for the study if they had undergone brain or
neural surgery or brain radiation treatment.
In addition to the GHS, eligibility for healthy control participants was assessed using the
BDI-II, PHQ-9, and BAI. The BDI-II was used to assess current depressive symptoms during the
past two weeks while the PHQ-9 was used to assess previous depressive symptoms across the
lifespan. The BAI was used to assess current anxiety symptoms during the past two weeks.
Formerly depressed participants. Formerly depressed participants were included in
session 1 if they obtained a score of less than 9 on the BDI-II, which is indicative of minimal
current depressive symptoms, and a score equal to or greater than 10 on the PHQ-9, which is
indicative of moderate to severe past depressive symptoms. Formerly depressed participants
were included in session 1 regardless of BAI scores as the presence of comorbid anxiety
disorders was permissible.
Healthy control participants. Healthy control participants were included in session 1 if
they obtained a score equal to or less than 8 on the BDI-II and PHQ-9, which is indicative of
minimal current and past depressive symptoms. Healthy control participants were ineligible for
session 1 if they obtained a score greater than 6 on the BAI. This exclusion criterion was
determined based on research examining the optimal cut score for various anxiety disorder
diagnoses (Leyfer, Ruberg, & Woodruff-Borden, 2006) and was intended to reduce the
likelihood that potential healthy control participants would ultimately be excluded after session 1
due to the presence of any major DSM-IV diagnosis.
Session 1
Session 1 (Table 2) took place in the MMDL space located in the Innovative Media,
Research, and Commercialization Center (IMRC) on the University of Maine campus.
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Participants were greeted by an undergraduate research assistant trained in the standardized study
procedures. The undergraduate research assistant introduced the study with the following
statement: “The purpose of the research is to learn about the emotional and physiological
responses related to sad mood.” The undergraduate research assistant reviewed the informed
consent document (Appendix H) with the participant, highlighting that participation in the study
was voluntary and information obtained during the study would remain confidential. More
specifically, participants were informed that data would be stored via a secure server,
identification numbers would be assigned to de-identify their responses, and the subject key
matching participant names and identification numbers would be encrypted and saved on an
alternate computer. Despite these precautions, participants were made aware of potential risks
associated with the study (e.g., loss of privacy and potential for emotional discomfort) as well as
potential benefits (e.g., assistance in helping to better understand the study variables). After the
undergraduate research assistant checked for comprehension and answered any questions,
informed consent was obtained from the participant.
Participants were asked to provide demographic information and complete self-report
measures (Appendix I) in Qualtrics (2017) on an electronic tablet. Self-report measures were
presented in a randomized order and assessed current depressive (i.e., BDI-II) and anxiety (i.e.,
State-Trait Anxiety Inventory – I & II (STAI-I & II)) symptoms. Self-report measures were used
as potential covariates. Following the completion of the self-report measures, clinical psychology
graduate students obtained the Treatment History self-report measure to identify past and current
therapeutic and psychopharmacological interventions. Current and past CBT and antidepressant
medication use were used as potential covariates. Clinical psychology graduate students then
conducted Structured Clinical Interview for DSM-IV-TR – Research Version (SCID-IV-RV) that
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had been adapted in accordance with the DSM-5 with participants to further determine eligibility
for participation in session 2. The clinical psychology graduate students recorded diagnoses that
the participant endorsed on paper, which were later transferred to a de-identified electronic
spreadsheet.
If a participant endorsed current suicidal ideation or intent, the clinical psychology
graduate student completed a suicide risk assessment (Appendix J) and consulted with a licensed
clinical psychologist affiliated with the University of Maine. If hospitalization was deemed
necessary, the clinical psychology graduate student encouraged the participant to voluntarily go
to the emergency department for an evaluation. The clinical psychology graduate student
accompanied the individual to the hospital by following the participant in their own vehicle. If
the participant declined to self-admit themselves to the emergency department and there was
imminent risk to the participants’ safety, the clinical psychology graduate student called law
enforcement to escort the participant to the emergency department.
Following the completion of the SCID-IV-RV, participants received a referral list to the
community counseling services as a potential resource (Appendix D). This referral list, which
was presented as an information source, and not something that must be followed, was presented
by a clinical psychology graduate student with the following statement: “This referral list is
provided for your information. If/when you would like counseling for distressing issues, these are
some of the available options in this area. The list includes a variety of resources, some of which
are low cost while others vary based on an hourly rate.”
The clinical psychology graduate student obtained height, weight, and waist and hip
circumference measurements. Height and weight measurements were used to calculate body
mass index (BMI). After all study procedures were completed, participants were thanked for
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their participation during session 1. Participants were compensated for their participation of
approximately two hours; participants recruited through the undergraduate participant pool were
awarded up to two research participation credits depending on the amount of time spent in the
laboratory while participants recruited from the surrounding community were awarded $30
payment.
Finally, clinical psychology graduate students determined eligibility for session 2 based
on the eligibility criteria. Eligible participants were invited to participate in session 2 with the
following statement: “Based on this interview it appears that you qualify to complete an
additional portion of this study that takes approximately one to two hours. This session will be
worth one to two credits. If you are interested, we’d request you avoid wearing a dress, overalls,
or a turtleneck shirt due to the physiological recordings we will be taking.” Clinical psychology
graduate students enrolled interested participants in session 2 using the Sona Systems (2017).
Ineligible participants were alerted that they are not eligible for the remainder of the study with
the following statement: “We are recruiting individuals who answer interview questions in a
very specific way, and according to your responses you do not qualify for session 2 at this time.
Thank you for your participation and we will be updating your Sona account with credits from
this session within the following month.”
Self-Report Measures
The following self-report measures were collected at session 1.
BDI-II. The BDI-II (Beck, Steer, & Brown, 1996a; Appendix C) was used to evaluate the
severity of current depressive symptoms at baseline.
STAI-I & II. The STAI-I & II (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983;
Appendix I) was used to evaluate the severity of current anxiety symptoms. The STAI-I & II
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contains two 20-item self-report measures that assesses cognitive, affective, and somatic
symptoms of both state and trait anxiety. Respondents rate the severity of anxiety symptoms
experienced at the moment for the state version and in general for the trait version from 1 to 4,
with 1 indicating the symptom is almost never present and 4 indicating that the symptom is
almost always present. Total scores for each version range from 20 to 80, with higher scores
indicating greater levels of state or trait anxiety symptom severity.
Research on the reliability of the STAI-I & II indicates good to excellent internal
consistency (α = .86-.95; Balsamo et al., 2016; Spielberger et al., 1993) and adequate test-retest
reliability (Spielberger et al., 1993). Research on the validity of the STAI-I & II indicates
adequate construct validity; convergent validity was evidenced by increased scores on the state
form during stressful situations while discriminant validity was evidenced by decreased scores
on the state form during relaxing situations (Spielberger, Gorsuch, & Luschene, 1970;
Spielberger, 1983, 1989). In addition, adequate concurrent validity with other measures of
similar affective states for the trait form has been found (Spielberger et al., 1970; Spielberger,
1989).
Interview Measures
The following interview measures were collected at session 1.
Treatment history. The Treatment History (Appendix C) self-report measure was
created by the MMDL to identify current and past therapeutic and psychopharmacological
interventions that other researchers have excluded for when examining cognitive, mood, and
psychophysiological reactivity and recovery in remitted MDD (e.g., Lethbridge & Allen, 2008;
Yaroslavsky et al., 2014 Studies 1 and 2). The Treatment History self-report measure is an 8item clinician-administered self-report measure that assesses current and past therapy and
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medication use for emotional or behavioral problems. Respondents are asked to indicate the
presence or absence of such conditions by answering Yes or No to each question. In addition,
respondents are asked report more detailed information about the types of therapy received (e.g.,
CBT) and medication prescribed (e.g., antidepressants).
SCID-IV-RV. The SCID-IV-RV (First, Gibbon, Spitzer, & Williams, 1995) was
administered by clinical psychology graduate students trained in administration and scoring by
the MMDL Director, Emily A. P. Haigh, Ph.D. The Director was available for supervision and
consultation when necessary. The SCID-IV-RV is a semi-structured clinical interview that
assesses current and past major DSM-IV clinical diagnoses based on the diagnostic criteria
outlined in the Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition – Text
Revision (DSM-IV-TR). The SCID-IV-RV had been adapted by the MMDL to be in accordance
with the DSM-5 diagnostic criteria. Clinical interviews were audio-recorded to conduct fidelity
checks and estimate inter-rater reliability.
Eligibility Criteria
Session 1 includes specific eligibility criteria for formerly depressed and healthy control
participants. Individuals who met specific eligibility criteria during session 1 were scheduled for
session 2.
Formerly depressed participants. Formerly depressed participants were included in the
remainder of the study if they met diagnostic criteria for a past episode of MDD according to
DSM-5 criteria (APAA, 2013). Participants were excluded from the remainder of the study if
they met diagnostic criteria for current MDD within the past month, current substance abuse
within the past 6 months, current or past substance dependence, bipolar disorder, psychotic
disorder, acute suicidal ideation, or mood episodes secondary to general medical conditions.
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Healthy control participants. Healthy control participants were included in the
remainder of the study if they were free from any current or past psychological disorder. Healthy
control participants were excluded from the remainder of the study if they met diagnostic criteria
for any current or past major DSM-5 diagnosis including mood, psychotic, substance use,
anxiety, or eating disorders.
Session 2
Session 2 (Table 2) took place in the MMDL space located in Corbett Hall on the
University of Maine campus. Participants were greeted by an undergraduate research assistant
trained in the standardized study procedures. The undergraduate research assistant provided an
overview of the study procedures with the following statement: “Thank you for returning for
session 2 of this study. We are interested in investigating the physiological effects of different
mood states, so today we will measure your physiological responses to a video and some audio
clips. There will also be some additional questionnaires for you to complete.” As part of the
informed consent procedure, the undergraduate research assistant reminded the participant that
their participation was entirely voluntary and that they could discontinue at any time without
penalty (Appendix K). After the undergraduate research assistant checked for comprehension
and answered any questions, informed consent was obtained from the participant.
Once in the physiological laboratory, participants answered questions about skin
sensitivity and allergies to electrode gel, medical tape, or Band-Aids. Participants were asked to
remove their jewelry and place it with other personal belongings (e.g., cell phones). Next,
participants were asked to wash their hands with glycerin-rich soap and prompted to use the
restroom, if necessary. Noninvasive electrode sensors were placed by a female undergraduate
research assistant referred to as the experimenter. Before placement of the electrode sensors,
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participants were briefed on electrode sensor placement and verbally alerted. While attaching
electrode sensors, the experimenter engaged the participants in conversation to help them feel
comfortable. Areas where electrode sensors were placed were cleaned with an abrasive alcohol
swab.
During electrode sensor placement, another undergraduate research assistant referred to
as the monitor examined the associated waveforms in Biolab 3.1, a physiological acquisition
software created by MindWare Technologies Ltd. (2009), to ensure that electrode sensors were
accurately placed. After the electrodes were correctly placed, the experimenter asked the
participant to sit in a comfortable chair in front of a computer screen with uncrossed legs for the
remainder of the study. The monitor selected the correct paradigm based on a predetermined
randomization table. The participant completed the experimental paradigm including; baseline
video, self-report measures, sad or neutral mood induction, self-report measures, recovery video,
and self-report measures while physiological responding was continuously recorded.
After completion of the experimental paradigm, the experimenter assisted the participant
in the removal of electrode sensors. The experimenter reviewed a debriefing form (Appendix M)
with the participant and answered any questions about the study. After all study procedures were
completed, participants were thanked for their participation during session 2. Participants were
compensated for their participation of approximately one hour; participants recruited through the
undergraduate participant pool were awarded one research participation credit while participants
recruited from the surrounding community were awarded $15 payment.
Experimental Paradigm
The experimental paradigm was presented using Experimenter’s Prime (E-Prime;
Experimenter’s Prime, 2015), an experimental research software suite. E-Prime (2015) enables
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the creation and presentation of experimental paradigms as well as the collection and
investigation of experimental data.
Baseline video. Participants completed a baseline period intended to allow physiological
responses to normalize following electrode placement. Participants were prompted by
instructions on the computer screen to put on over-ear headphones, sit still, and quietly watch a
10-minute neutrally valenced travel video about Alaska’s Denali National Park (Kolbeinsson,
2016). The video consisted of plants, animals, weather, and geographical scenes set to
instrumental music with minimal dialogue.
Self-report measures. Following the baseline period, participants were prompted by
instructions on the computer screen to complete the first set of self-report measures (Appendix
L) in Qualtrics (2017) on an electronic tablet. Self-report measures were presented in a
randomized order and assessed depression-related thoughts (i.e., Dysfunctional Attitudes Scale –
Short Form I (DAS-SF I)) and feelings (i.e., VAS and Positive and Negative Affect Schedule –
Expanded Form (PANAS-X)).
Mood induction. Following the first set of self-report measures, participants were
prompted by instructions on the computer screen to complete the sad or neutral mood induction.
Prior to the sad mood induction, participants completed a 40-word sad (e.g., doomed, crying,
hurt, etc.) or neutral (e.g., note, dial, zoom, etc.) emotional Stroop task that was part of a larger,
ongoing study conducted by the MMDL. Words appeared individually on the computer screen,
printed in red, green, yellow, or blue and participants were instructed to select the matching color
key on the keyboard (i.e., f for red, g for green, h for yellow, and j for blue). Before each word is
presented, a fixation cross (i.e., +) appeared on the screen for 700 milliseconds to help
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participants focus their attention. Participants were collapsed into two groups based on mood
induction condition (i.e., sad or neutral).
Sad mood induction. The sad mood induction methodology used a combination of music
and autobiographical recall to create a mild, transient sad mood. This method has been
empirically validated by previous research (e.g., Martin, 1990; Segal et al., 1999, 2006).
Participants listened to a digitally re-mastered, half-speed, non-lyrical 7:38-minute piece of
classical music entitled “Russia under the Mongolian Yoke” by Prokofiev. Simultaneously,
participants were prompted to recall a time in their lives when they felt sad with the following
statement: “During this task, you will listen to a 7-minute piece of classical music on the
computer. Please listen to the music and think about a specific time or situation when you felt
depressed and/or low. If you find that your mind wanders, please go back to thinking about the
specific time or situation when you felt depressed and/or low.” This text remained on the
computer screen for the entire neutral mood induction.
Neutral mood induction. The neutral mood induction methodology used a combination
of music and autobiographical recall to serve as a control condition. This mood induction method
has been empirically validated by previous research, which showed that it does not result in a
significant change in mood (e.g., Green, Sedikides, Saltzberg, Wood, & Forzano, 2003; Wood,
Saltzberg, & Goldsamt, 1990). Participants listened to a digitally re-mastered, half-speed, nonlyrical 7:38-minute selection of classical music (i.e., Waltzes No. 11 in G flat, Op. 70, No. 1 and
No. 12 in F minor, and Op. 70, No. 2 by Chopin). Simultaneously, participants were prompted to
recall an uneventful day in their life that was neither especially happy nor sad with the following
statement: “During this task, you will listen to a 7-minute piece of classical music on the
computer. Please listen to the music and think about a specific but unemotional day in detail.
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For example, this could be a typical day at school or work when everything followed your typical
routine. If you find that your mind wanders, please go back to thinking about the specific but
unemotional day.” This text remained on the computer screen for the entire neutral mood
induction.
Self-report measures. Following the mood induction, participants were prompted by
instructions on the computer screen to complete a second set of self-report measures (Appendix
L) in Qualtrics (2017) on an electronic tablet. Self-report measures were presented in a
randomized order and assessed depression-related thoughts (i.e., Dysfunctional Attitudes Scale –
Short Form II (DAS-SF II)) and feelings (i.e., VAS, PANAS-X).
Recovery video. Following the second set of self-report measures, participants
completed a recovery period intended to evaluate the amount of time that it took for
physiological responses to return to baseline levels. Participants were instructed on the computer
screen to sit quietly while watching a different 10-minute neutral travel video about Alaska’s
Last Frontier. The video consisted of plants, animals, weather, and geographical scenes set to
instrumental music with minimal dialogue. This recovery procedure was selected to increase
similarity to the baseline procedure. In addition, this recovery procedure, which was passive yet
attentionally demanding, was selected in lieu of a silent recovery to reduce the potential impact
of cognitive processes (e.g., rumination) on recovery and minimize feelings of sadness before
participants leave the laboratory (Linden et al., 1997).
Self-Report Measures
The following self-report measures were collected at session 2.
DAS-SF I & II. The DAS-SF I & II (Beevers, Strong, Meyer, & Pilkonis, 2007;
Appendix L), an abbreviated version of the original Dysfunctional Attitudes Scale – Forms A
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and B (DAS; Weissman & Beck, 1978), was used to evaluate changes in dysfunctional beliefs
about oneself before and after the mood induction. The DAS-SF I & II are each 9-item selfreport measures that assess an individual’s beliefs about his or her self. Respondents rate their
beliefs experienced most of the time on a scale of 1 to 4, with 1 indicating that they totally agree
with the statement and 4 indicating that they totally disagree with the statement. Total scores
range from 9 to 36, with lower scores indicating greater levels of the dysfunctional beliefs. Two
versions of the DAS-SF have been created to reduce test-retest effects. Qualtrics (2017) does not
allow the randomization of self-report measures across a multi-block experimental paradigm, so
the DAS-SF I & II were presented in a fixed order; the DAS-SF I was always be presented
before the mood induction while the DAS-SF II was always be presented after the mood
induction.
Research on the reliability of the DAS-SF I & II indicates good internal consistency (ɑ =
.83-.94) and adequate test-retest reliability (Beevers et al., 2007). Research on the validity of
DAS-SF I & II indicates adequate convergent validity as evidenced by moderate correlations
with other measures of dysfunctional attitudes and adequate predictive validity as evidenced by
significant prediction of posttreatment depressive symptom severity scores by pretreatment DAS
I & II scores (Beevers et al., 2007). In addition, Beevers and colleagues (2007) found that there
were no significant differences in residualized change scores for the DAS-A, DAS I, and DAS II
(p’s = .79-.93, d’s = .00-.01) and the residualized change scores for the DAS-A, DAS I, and DAS
II were very strongly correlated (r’s = .84-.91), suggesting that the long and short forms of the
DAS perform similarly.
VAS. The VAS (Appendix L) was used to evaluate subjective changes in mood before
and after the mood induction. Respondents rate their current level of sadness on a scale of 0 to
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100, with 0 indicating lower levels of sadness and 100 indicating higher levels of sadness. Total
scores range from 0 to 100, with higher scores indicating greater levels of sadness. Participants
were presented with a 100-millimeter line on an electronic tablet anchored by “not at all” at 0
and “extremely” at 100.
The VAS has been empirically validated by previous research. Studies have shown that
the VAS is sensitive to change in emotion and stress states when standardized measures cannot
be obtained due to time or experimental constraints (Cella & Perry, 1986). Change in sadness
served as a manipulation check for sad and neutral mood inductions to ensure that they produced
their intended moods. Research on the reliability of the VAS indicates adequate test-retest
reliability (Cella & Perry, 1986; Folstein & Luria, 1973). Research on the validity of VAS
indicates adequate concurrent validity with other measures of similar affective states (Cella &
Perry, 1986; Folstein & Luria, 1973; Little & McPhail, 1973; Davies, Burrows, & Poynton,
1975).
PANAS-X. The PANAS-X (Watson & Clark, 1994; Appendix L), an expanded version
of the original Positive and Negative Affect Schedule (PANAS; Watson et al., 1988), was used
to evaluate changes in mood before and after the mood induction. The PANAS-X is a 60-item
self-report measure that assess affect, including two general dimension scales (i.e., negative
(PANAS-X N) and positive affect (PANAS-X P)), four basic negative emotional scales (i.e., fear
(PANAS-X F), guilt (PANAS-X G), hostility (PANAS-X H), and sadness (PANAS-X S)), three
basic positive emotional scales (i.e., joviality, self-assurance, and attentiveness), and four other
affective states (i.e., shyness, fatigue, serenity, and surprise). Respondents rate the extent to
which they are experiencing 60 affective adjectives on a Likert scale from 1 to 5, with 1
indicating that they have not or very slightly experienced the affective state and 3 indicating that
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they have experienced the experienced the affective state extremely. Total scores for the general
dimension scales are calculated by summing the 10 affective adjectives that comprise each scale
and range from 10 to 50, with higher scores indicating greater levels of the respective affect.
Total scores for specific affective state scales are calculated by summing the five (i.e., sadness)
or six (i.e., fear, guilt, and hostility) affective adjectives that comprise each scale and range from
5 to 25 (i.e., sadness) or 6 to 30 (i.e., fear, guilt, and hostility), with higher scores indicating
greater levels of the respective affect. Given this investigation’s focus on negative emotionality,
the negative and positive affect general dimension scales and basic negative emotional scales
(i.e., fear, guilt, hostility, and sadness) were used.
Research on the reliability of the PANAS-X indicates excellent to good internal
consistency (ɑ = .83-.90) for the general dimension scales and excellent to acceptable internal
consistency (ɑ = .76-.93) for the specific affective state scales as well as adequate test-retest
reliability (Watson & Clark, 1994). Research on the validity of PANAS-X indicates adequate
construct validity; convergent validity was evidenced by strong correlations with other measures
of similar affective states while discriminant validity was evidenced by moderate correlations
with other measures of dissimilar affective states (Watson & Clark, 1994; Watson & Clark,
1997).
Cardiovascular Measures
Physiological responding was recorded throughout the entire experimental paradigm. The
physiological recordings of interest were cardiovascular measures derived from ECG and ICG.
In addition, as part of a larger ongoing study, two electrode sensors filled with isotonic electrode
paste were placed on the heal of the participants’ non-dominant hand to collect Galvanic Skin
Response (GSR).
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ECG. Five Galvanic Skin Conductance (GSC) electrode sensors were filled with
electrode gel and placed on the participants’ chest to measure the electrical activity of the heart
and collect data that was used to calculate HP and RSA. MindWare Technologies Ltd. (2009)
hardware and Biolab 3.1 analysis software set to collect ECG data falling within -5 and 5 volts
with a sampling rate of 1,000 hertz were utilized in conjunction with the five GSC electrode
sensors located on the participants’ right collarbone, bottom left rib, bottom right rib, jugular
notch, and sternum (Figure 6).
ICG. Two GSC electrode sensors were filled with electrode gel and placed on the
participants’ chest and back to measure the electrical activity of the heart and collect data that
was used to calculate RSA, CO, and PEP. MindWare Technologies Ltd. (2009) hardware and
Biolab 3.1 analysis software set to collect ICG data falling at a sampling rate of 1,000 Hertz and
calibrated at .10 volts per one-ohm change for Z0 and 1.00 volts per ohms per second for dZ/dt
were utilized in conjunction with the two GSC electrode sensors located on the participants’ midback and upper-back parallel within 1.50 inches of the jugular notch and sternum sensors (Figure
6).
Figure 6. Sensor Placement from MindWare Technologies Ltd. (2009)

Note. Session 2 electrode placement for physiological data collection. Brown, white, and black
circles represent GSC electrodes for ECG. Red circles represent GSC electrodes for ICG. Green
circles represent GSR electrodes for GSR.
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Table 2. Study Procedure Chart
Time

Task Category

Task Description

Contact and demographic information
GHS: language and visual abilities, current and past health conditions
Self-report
Screening
BDI-II: current depressive symptoms
measures
PHQ-9: past depressive symptoms
BAI: current anxiety symptoms
Demographic information: age, sex, race, ethnicity, marital status, and education level
Self-report
BDI-II: current depressive symptoms
measures
STAI-I & II: current anxiety symptoms
Session 1
Physical measure BMI
Treatment History: current and past CBT and antidepressant use
Interview
SCID-IV-RV: psychiatric diagnoses
Baseline
ECG and ICG recording while viewing 10-minute clip of Alaska Denali Park Video
DAS-SF I: dysfunctional beliefs at baseline (i.e., baseline cognitions)
Self-report
VAS: dysphoric mood at baseline (i.e., baseline mood)
measures
PANAS-X: dysphoric mood at baseline (i.e., baseline mood)
ECG and ICG recording while listening to 7:38-minute piece of sad/neutral music and recalling
Mood induction
Session 2
sad/neutral autobiographical memory
DAS-SF II: dysfunctional beliefs post-mood induction (i.e., cognitive reactivity to mood induction)
Self-report
VAS: dysphoric mood post-mood induction (i.e., mood reactivity to mood induction)
measures
PANAS-X: dysphoric mood post-mood induction (i.e., mood reactivity to mood induction)
Recovery
ECG and ICG recording while viewing 10-minute clip of Alaska Wilderness Video
Debriefing
Provide and review debriefing form
Note. GHS = General Health Screen; BDI-II = Beck Depression Inventory – Second Edition; PHQ-9 = Patient Health Questionnaire –
9; BAI = Beck Anxiety Inventory; STAI-I & II = State-Trait Anxiety Inventory – I & II; BMI = body mass index; SCID-IV-RV =
Structured Clinical Interview for DSM-IV-TR – Research Version; ECG = electrocardiogram; ICG = impedance cardiography; DAS I
= Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional Attitudes Scale – Short Form II; VAS = Visual Analogue
Scale; PANAS-X = Positive and Negative Affect Scale – Expanded Form.
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CHAPTER 6
ANALYSES AND HYPOTHESIZED RESULTS
All analyses were conducted using IBM SPSS Statistics Version 25.0 (IBM Corporation,
2017).
Preliminary Analyses
Data Cleaning and Calculation
The following procedures were used to clean demographic, self-report, cognitive, mood,
and cardiovascular data and calculate change scores for cognitive, mood, and cardiovascular data
before analyses were conducted. All data were manually inspected for potential univariate
outliers, defined as z-scores exceeding ± 3.00 (Daszykowski, Kaczmarek, Heyden, & Walczak,
2007). Winsorizing, a data transformation procedure that retains outliers by adjusting extreme
values to the next most non-outlier extreme value, was utilized if necessary. Winsorization is an
alternative to deleting outliers that reduces the skew of the distribution while preserving the
general pattern of variability (Field, 2009). Outlier data were winsorized to address extreme
values at the group by condition level. Outliers for cognitive, mood, and cardiovascular data was
addressed differently depending on the type of analyses conducted. For analyses conducted using
difference scores, outliers for pre- and post-mood induction data were not winsorized as
participants’ data points were dependent upon one another and would impact the validity of the
difference scores. For analyses conducted using residualized change scores or repeated measures,
outliers for pre- and post-mood induction data were winsorized as participants’ data points were
aggregated and therefore, would not impact the validity of the residualized change scores and
pre- and post-mood induction data points.
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Of note, this study drew from two distinct literature bases (i.e., cognitive and mood
literature and cardiovascular literature) that use different techniques to calculate change scores.
Over the years, there has been a fierce debate in the literature about the use of change scores (see
Cronbach & Furby, 1970 for the argument against the use of change scores and Zimmerman &
Williams, 1982a, 1982b for rebuttals). Today, the literature has generally come to the consensus
that the difference score and residualized change score methods for calculating change scores are
reliable and valid methods for assessing reactivity (Castro-Schilo & Grimm, 2018; Dimitrov &
Rumrill, 2003; Linden et al., 1997; Llabre et al., 1991). To represent the conventions of each
literature base, two different data calculation techniques for change scores were used: difference
scores, which are typically used in the cardiovascular literature, and residualized change scores,
which are typically used in the cognitive and mood literature.
Demographic information. Demographic information collected during session 2 (i.e.,
age, sex, race, ethnicity, marital status, education level, current and past CBT and antidepressant
use, and BMI) were manually inspected for potential univariate outliers.
Self-report measures. Self-report measures collected during session 2 (i.e., BDI-II,
STAI-I & II) were manually inspected for potential univariate outliers.
Cognitive measures. Cognitive measures collected during session 2 (i.e., DAS-SF I & II)
were manually inspected for potential univariate outliers.
Difference scores for cognitive reactivity were calculated for the DAS by subtracting
post-mood induction scores and pre-mood induction scores (i.e., DASPOST – DASPRE). These
values were used in the subsequent analyses to represent cognitive (i.e., DASDS) reactivity to the
mood induction procedures. Previous research has shown difference scores are reliable measures
of self-reported reactivity with the exception of cases in which pretest and post test scores have
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equal variance and equal reliability (Dimitrov & Rumrill, 2003), which was not hypothesized for
this study.
Simple linear regression for cognitive reactivity were used to create residualized change
scores for the pre- and post-mood induction DAS. These values were used in the subsequent
analyses to represent cognitive (i.e., Z RESDAS) reactivity to the mood induction procedures. This
technique has been used in studies investigating similar hypotheses and employing similar
methodological procedures in an effort to make variability of pre-mood induction DAS scores
independent from variability of post-mood induction DAS scores (Segal et al., 2006; Van
Rijsbergen et al., 2013). Previous research has shown that while residualized change scores are
reliable measures of self-reported reactivity and results in less error than difference scores when
pre-test score variance is greater than posttest score variance (Dimitrov & Rumrill, 2003), which
could have been the pattern of responding observed during this study. Of note, the use of
residualized change scores can lead to an overly conservative test for self-reported reactivity
(Dimitrov & Rumrill, 2003).
Mood measures. Mood measures collected during session 2 (i.e., VAS, and PANAS-X
N, P, F, G, H, and S) were manually inspected for potential univariate outliers.
Difference scores for mood reactivity were calculated for the VAS and PANAS-X N, P,
F, G, H, and S by subtracting post-mood induction scores and pre-mood induction scores (i.e.,
VASPOST –VASPRE, PANAS-X NPOST –PANAS-X NPRE, PANAS-X PPOST –PANAS-X PPRE,
PANAS-X FPOST –PANAS-X FPRE, PANAS-X GPOST –PANAS-X GPRE, PANAS-X HPOST –
PANAS-X HPRE, and PANAS-X SPOST –PANAS-X SPRE). These values were used in the
subsequent analyses to represent mood (i.e., VASDS) reactivity to the mood induction
procedures. In addition, these values were used in the subsequent analyses as a manipulation
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check for the mood induction procedures to ensure that a sad mood was induced (i.e., VASDS)
and to assess if emotions other than sadness were induced (i.e., PANAS-X NDS, PANAS-X PDS,
PANAS-X FDS, PANAS-X GDS, PANAS-X HDS, and PANAS-X SDS). Previous research has
shown difference scores are reliable measures of self-reported reactivity with the exception of
cases in which pretest and post test scores have equal variance and equal reliability (Dimitrov &
Rumrill, 2003), which was not hypothesized for this study.
Simple linear regression for cognitive and mood reactivity were used to create
residualized change scores for the pre- and post-mood induction VAS and PANAS-X N, P, F, G,
H, and S. These values were used in the subsequent analyses to represent mood (i.e., ZRESVAS)
reactivity to the mood induction procedures. In addition, these values were used in the
subsequent analyses as a manipulation check for the mood induction procedures to ensure that a
sad mood was induced (i.e., ZRESVAS) and to assess if emotions other than sadness were induced
(i.e., ZRESPANAS-X N, ZRESPANAS-X P, ZRESPANAS-X F, ZRESPANAS-X G, ZRESPANAS-X
H, and ZRESPANAS-X S). This technique has been used in studies investigating similar
hypotheses and employing similar methodological procedures in an effort to make variability of
pre-mood induction VAS scores independent from variability of post-mood induction VAS
scores (Segal et al., 2006; Van Rijsbergen et al., 2013). Previous research has shown that while
residualized change scores are reliable measures of self-reported reactivity and results in less
error than difference scores when pre-test score variance is greater than posttest score variance
(Dimitrov & Rumrill, 2003), which could have been the pattern of responding observed during
this study. Of note, the use of residualized change scores can lead to an overly conservative test
for self-reported reactivity (Dimitrov & Rumrill, 2003).
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Cardiovascular measures. Multiple cardiovascular measures were used in this
investigation including HP, RSA, CO, and PEP. Cardiovascular measures were calculated from
ECG and ICG data. ECG and ICG data were collected with Mindware hardware and Biolab 3.1
(MindWare Technologies Ltd., 2009) acquisition software. ECG data fell within -5 and 5 volts
with a sampling rate of 1,000 Hertz. The following calculation methods were used to compute
ECG measures: entire for calculation method and Z0 for respiration signal to use. ICG data was
sampled at a rate of 1,000 Hertz. Z0 was calibrated at .10 volts per one-ohm change while dZ/dt
was calibrated at 1.00 volts per ohms per second. The following calculation methods were used
to compute ICG measures: minimum value K to R interval for the ECG Q point (K = 35), the
Framingham method for LVET windowing (LVET minimum = 300, LVET maximum = 600),
the percentage of dZ/dt time + C (percent dZ/dt peak = 55.00%, C = 4; Lozano et al., 2008) for
the ICG B point, the kubieck formula for SV, and measured for dZ/dt source. ECG and ICG data
were ensemble averaged using 60 second epochs.
Specialized Biolab software modules (MindWare Technologies Ltd., 2009) were utilized
to clean and calculate HP, RSA, CO, and PEP data. All data was visually screened and manually
cleaned for artifacts before calculations are computed. HP and RSA were derived using
Mindware’s HRV Analysis 3.1.4 module. HP was calculated using the time series method to
determine the IBI between successive R spikes on the ECG in milliseconds. RSA was calculated
using the frequency domain method to determine the IBI between successive R spikes on the
ECG within the high frequency band derived from a Fast Fourier Transform, which fell within
.15 and .40 Hertz. In addition, the Z0 measure obtained via ICG was used to account for the
impact of respiration rate on RSA. CO and PEP was derived using Mindware’s Impedance
Analysis 3.1.4 module. CO was calculated by multiplying HR by SV. PEP was calculated by
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determining the time in milliseconds between the B point of dZ/dt from ICG and the Q point
from ECG. Cardiovascular functioning at baseline, cardiovascular reactivity in response to the
mood induction, and cardiovascular recovery were calculated by taking an average of the last
two and five minutes of HP, RSA, CO, and PEP data for baseline (i.e., HPBL2/BL5, RSABL2/BL5,
COBL2/BL5, and PEPBL2/BL5) and recovery (i.e., HPRC2/RC5, RSARC2/RC5, CORC2/RC5, and PEPRC2/RC5)
and the first two and five minutes of HP, RSA, CO, and PEP data for the mood induction (i.e.,
HPMI2/MI5, RSAMI2/MI5, COMI2/MI5, and PEPMI2/MI5). Cardiovascular data collected during session 2
were manually inspected for potential univariate outliers.
Difference scores for cardiovascular reactivity were calculated for each cardiovascular
measure by subtracting the average obtained during the first two and five minutes of the mood
induction from the average obtained during the last two and five minutes of baseline (i.e.,
HPMI2/MI5 – HPBL2/BL5, RSAMI2/MI5 – RSABL2/BL5, COMI2/MI5 – COBL2/BL5, and PEPMI2/MI5 –
PEPBL2/BL5). These values were used in the subsequent analyses to represent cardiovascular
reactivity (i.e., HPDS2RA/DS5RA, RSADS2RA/DS5RA, CODS2RA/DS5RA, and PEPDS2RA/DS5RA) to the mood
induction procedures. In addition, difference scores for cardiovascular recovery were calculated
for each cardiovascular measure by subtracting the average obtained during the last two and five
minutes of recovery from the average obtained during the last two and five minutes of baseline
(i.e., HPRC2/RC5 – HPBL2/BL5, RSARC2/RC5 – RSABL2/BL5, CORC2/RC5 – COBL2/BL5, and PEPRC2/RC5 –
PEPBL2/BL5). These values were used in the subsequent analyses to represent cardiovascular
recovery (i.e., HPDS2RA/DS5RC, RSADS2RA/DS5RC, CODS2RA/DS5RC, and PEPDS2RA/DS5RC) from the
mood induction procedures. This technique has been used in studies investigating similar
hypotheses and employing similar methodological procedures to examine cardiovascular
reactivity and recovery (Salomone et al., 2013; Yaroslavsky et al., 2013). Previous research has
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shown that differences scores are reliable measures of psychophysiological reactivity across
multiple experimental sessions with the exception of cases in which pretest and post test scores
have equal variance and equal reliability (as reviewed by Llabre, Spitzer, Saab, Ironson, &
Schneiderman, 1991), which was not hypothesized for this study.
Simple linear regression for cardiovascular reactivity was used to create residualized
change scores. These values were used in the subsequent analyses to represent cardiovascular
reactivity (i.e., ZRES2/RES5HPRA, ZRES2/RES5RSARA, ZRES2/RES5CORA, and ZRES2/RES5PEPRA) to the
mood induction procedures. In addition, simple linear regression for cardiovascular recovery was
used to create residualized change scores. These values were used in the subsequent analyses to
represent cardiovascular recovery (i.e., ZRES2/RES5HPRC, ZRES2/RES5RSARC, ZRES2/RES5CORC, and
ZRES2/RES5PEPRC) from the mood induction procedures. Previous research has shown that that
residualized change scores are reliable measures of psychophysiological reactivity across
multiple experimental sessions and results in less error than difference scores when pre-test score
variance is greater than posttest score variance (as reviewed by Llabre et al., 1991), which could
have been the pattern of responding observed during this study.
Data Analysis
The following procedures were used to analyze demographic, cognitive, mood, and
cardiovascular data. All data were assessed for homogeneity of variance using Levene’s test.
Violation of homogeneity of variance (p < .05) indicates that the assumption underlying analyses
is not met. If homogeneity of variance was violated for independent samples t tests, results for
equal variances not assumed were reported. If homogeneity of variance was violated for oneway, factorial, or repeated measures analysis of variance (ANOVA), additional analyses were
conducted to assess whether violation of homogeneity of variance were driven by the inclusion
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of covariates. If homogeneity of variance was significant with covariates and not significant
without covariates, calculating the residual of the residualized change scores to assess normality
and transforming the residualized change scores to re-assess homogeneity of variance would not
have the intended effect. Instead, the planned analyses were conducted with the α level decreased
from .05 to .01.
There are multiple possibilities to remedy the violation this assumption which includes
using a non-parametric test, transforming the data to reduce skewness, or decreasing the α level
to reduce the likelihood of type II error (S. W. Ell, personal communication, February 9, 2016).
Multiple steps were explored in an attempt to remedy the violation of this assumption. First,
residuals of differences scores were calculated, and Kolmogorov-Smirnov’s and Shapiro-Wilk’s
tests of normality were conducted (Field, 2009). If Levene’s test for homogeneity of variance
continued to be significant, this indicated that the assumption underlying ANOVA was still not
met. Second, residualized change scores were transformed using the reciprocal transformation
(1/XiR). Of note, residualized change scores were reversed before conducting this transformation
to preserve order (XiR = XHIGHEST – Xi). This transformation method was selected as the
cognitive, mood, and cardiovascular data contained negative values, which cannot be
transformed using log and square root transformations (Field, 2009). If Levene’s test for
homogeneity of variance continued to be significant, this indicated that the assumption
underlying ANOVA was still not met. Given that there are not non-parametric tests for
evaluating interactions (Grace-Martin, 2019a), the remaining option was to move forward with
the planned analyses and decreased the α level from .05 to .01.
Of note, this study drew from two distinct literature bases (i.e., cognitive and mood
literature and cardiovascular literature) that use different techniques to analyze data. As
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previously noted by researchers (e.g., Castro-Schilo & Grimm, 2018), there is not one correct
data analysis technique that can be used to test a study’s hypotheses when experimental
procedures (e.g., random assignment, use of experimental and control conditions) intended to
distribute variability and error across conditions are employed. The calls for a consensus on data
analysis techniques for reactivity and recovery have been left unanswered (Linden et al., 1997).
To represent the conventions of each literature base, two different data analysis techniques were
used: repeated measures ANOVAs, which are typically used in the cardiovascular literature, and
factorial ANOVAs, which are typically used in the cognitive and mood literature.
Demographic information. Descriptive statistics were used to summarize the sample.
Measures of central tendency and variability were used for continuous variables (i.e., age and
BMI) while frequency statistics were used for categorical variables (i.e., sex, race, ethnicity,
marital status, education level, and current and past CBT and antidepressant use). A series of
independent samples t-tests were used to assess significant group differences of continuous
variables (i.e., age and BMI) collected during session 1 (Table 3). In addition, a series of chisquare tests were used to assess significant group differences of categorical variables (i.e., sex,
race, ethnicity, education level, marital status, and current and past CBT and antidepressant use)
collected during session 1 (Table 3). These variables were considered as potential covariates in
subsequent analyses.
Self-report measures. A series of independent samples t-tests were used to assess
significant group differences of current depressive (i.e., BDI-II) and anxiety (i.e., STAI-I & II)
symptoms collected during session 1 (Table 3). These variables were considered as potential
covariates in subsequent analyses.
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Cognitive measures. A series of 2 (group: formerly depressed, healthy control) X 2
(condition: sad, neutral) factorial ANOVAs and a 2 (group: formerly depressed, healthy control)
X 2 (condition: sad, neutral) repeated measures ANOVA were conducted to examine changes in
dysfunctional beliefs on the DAS pre- and post-mood induction. Analyses were conducted using
difference scores (i.e., DASDS), residualized change scores (i.e., ZRESDAS), and pre- and postmood induction measures (i.e., DAS I and DAS II). These analyses were used to assess
significant differences in cognitive reactivity based on depressive history and mood induction
procedure. Planned comparisons were conducted using contrast analyses. It was expected that
formerly depressed participants exposed to the sad mood induction would report significantly
more dysfunctional beliefs compared to formerly depressed participants exposed to the neutral
mood induction and healthy control participants exposed to the sad and neutral mood inductions.
Mood measures. A series of one-way (condition: sad, neutral) ANOVAs and a one-way
(condition: sad, neutral) repeated measures ANOVA were conducted to examine changes in
sadness on the VAS pre- and post-mood induction. Analyses were conducted using difference
scores (i.e., VASDS), residualized change scores (i.e., ZRESVAS), and pre- and post-mood
induction measures (i.e., VASPRE and VASPOST). These analyses were used as a manipulation
check for the mood induction procedures to ensure that a sad mood was induced. Significant
differences between conditions was only expected post-mood induction. It was expected that
formerly depressed and healthy control participants exposed to the sad mood induction would
report significantly more dysphoric mood (> 10.00% change in mood state; Martin, 1990) after
the mood induction compared to formerly depressed and healthy control participants exposed to
the neutral mood induction.
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In addition, a series of one-way (condition: sad, neutral) ANOVAs and a one-way
(condition: sad, neutral) repeated measures ANOVA were conducted to assess changes in
multiple emotions on the negative and positive affect general dimension and fear, guilt, hostility,
and sadness basic negative emotional scales of the PANAS-X pre- and post-mood induction.
Analyses were conducted using difference scores (i.e., PANAS-X NDS, PANAS-X PDS, PANASX FDS, PANAS-X GDS, PANAS-X HDS, and PANAS-X SDS), residualized change scores (i.e.,
ZRESPANAS-X N, ZRESPANAS-X P, ZRESPANAS-X F, ZRESPANAS-X G, ZRESPANAS-X H,
and ZRESPANAS-X S), and pre- and post-mood induction measures (i.e., PANAS-X NPRE/POST,
PANAS-X PPRE/POST, PANAS-X FPRE/POST, PANAS-X GPRE/POST, PANAS-X HPRE/POST, and
PANAS-X SPRE/POST). These analyses were used as a manipulation check for the mood induction
procedures to assess if emotions other than sadness were induced. Significant differences
between conditions were only expected post-mood induction. It was expected that formerly
depressed and healthy control participants exposed to the sad mood induction would report a
significant increase in negative affect and a significant decrease in positive affect after the mood
induction compared to formerly depressed and healthy control participants exposed to the neutral
mood induction.
A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral)
factorial ANOVAs and a 2 (group: formerly depressed, healthy control) X 2 (condition: sad,
neutral) repeated measures ANOVA were conducted to examine changes in dysphoric mood on
the VAS pre- and post-mood induction. Analyses were conducted using difference scores (i.e.,
VASDS), residualized change scores (i.e., ZRESVAS), and pre- and post-mood induction measures
(i.e., VASPRE and VASPOST). These analyses were used to assess significant differences in mood
reactivity based on depressive history and mood induction procedure. Planned comparisons were
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conducted using contrast analyses. It was expected that formerly depressed and healthy control
participants exposed to the sad mood induction would report significantly more dysphoric mood
compared to formerly depressed and healthy control participants exposed to the neutral mood
induction.
Cardiovascular measures. A series of one-way ANOVAs were used to assess
significant group differences in cardiovascular functioning at baseline. Analyses were conducted
using an average of the last two and five minutes of HP, RSA, CO, and PEP during baseline
(e.g., HPBL2/BL5, RSABL2/BL5, COBL2/BL5, and PEPBL2/BL5). It was expected that formerly depressed
and healthy control participants would exhibit similar cardiovascular functioning for HP, RSA,
PEP, or CO during the baseline film.
A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral)
factorial ANOVAs and a 2 (group: formerly depressed, healthy control) X 2 (condition: sad,
neutral) repeated measures ANOVAs were used to assess significant group differences in
cardiovascular reactivity during the mood induction. Analyses were conducted using difference
scores (i.e., HPDS2RA/DS5RA, RSADS2RA/DS5RA, CODS2RA/DS5RA, and PEPDS2RA/DS5RA), residualized
change scores (i.e., ZRES2/RES5HPRA, ZRES2/RES5RSARA, ZRES2/RES5CORA, and ZRES2/RES5PEPRA),
and baseline and mood induction measures (i.e., HPBL2/BL5/MI2/MI5, RSABL2/BL5/MI2/MI5,
COBL2/BL5/MI2/MI5, and PEPBL2/BL5/MI2/MI5). Planned comparisons were conducted using contrast
analyses. It was expected that formerly depressed participants exposed to the sad mood induction
would exhibit decreased HP, RSA, and CO and increased PEP during the mood induction
compared to formerly depressed participants exposed to the neutral mood induction and healthy
control participants exposed to the sad and neutral mood inductions.
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A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral)
factorial ANOVAs and a 2 (group: formerly depressed, healthy control) X 2 (condition: sad,
neutral) repeated measures ANOVAs were used to assess significant group differences in
cardiovascular recovery after the mood induction. Analyses were conducted using difference
scores (i.e., HPDS2RC/DS5RC, RSADS2RC/DS5RC, CODS2RC/DS5RC, and PEPDS2RC/DS5RC), residualized
change scores (i.e., ZRES2/RES5HPRC, ZRES2/RES5RSARC, ZRES2/RES5CORC, and ZRES2/RES5PEPRC), and
baseline and recovery measures (i.e., HPBL2/BL5/RC2/RC5, RSABL2/BL5/RC2/RC5, COBL2/BL5/RC2/RC5, and
PEPBL2/BL5/RC2/RC5). Planned comparisons were conducted using contrast analyses. It was
expected that formerly depressed participants exposed to the sad mood induction would exhibit
reduced cardiovascular recovery during the recovery film compared to formerly depressed
participants exposed to the neutral mood induction and healthy control participants exposed to
the sad and neutral mood induction.
Hypothesis 1
Formerly depressed participants exposed to the sad mood induction would report
significantly higher levels of cognitive reactivity on the DAS post-mood induction than formerly
depressed participants exposed to the neutral mood induction and healthy control participants
exposed to the sad and neutral mood inductions. Cognitive reactivity was operationalized as
difference scores (i.e., DASDS) and residualized change scores (i.e., ZRESDAS) for the DAS
administered pre- and post-mood induction as well as pre- and post-mood induction measures
(i.e., DAS-SF I and DAS II). A series of 2 (group: formerly depressed, healthy control) X 2
(condition: sad, neutral) factorial ANOVAs using difference scores and residualized change
scores and a 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral) repeated
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measures ANOVA were used to assess the relationship between depression history, mood
manipulation, and cognitive reactivity.
Figure 7. Cognitive Reactivity Post-Mood Induction
36
32
28
24
20

DAS

16
12
8
4
0
-4

Formerly Depressed

Healthy Control

-8
-12
-16

Group
Sad Mood Induction

Neutral Mood Induction

Note. Lower DAS scores indicate cognitive reactivity post-mood induction.
Hypothesis 2
Formerly depressed and healthy control participants exposed to the sad mood induction
would report significantly higher levels of mood reactivity on the VAS post-mood induction than
formerly depressed and healthy control participants exposed to the neutral mood induction. No
significant differences in mood reactivity on the VAS post-mood induction were expected
between formerly depressed and healthy control participants exposed to the sad mood induction.
Mood reactivity was operationalized as difference scores (i.e., VASDS) and residualized change
scores (i.e., ZRESVAS) for the VAS administered pre- and post-mood induction as well as preand post-mood induction measures (i.e., VASPRE and VASPOST). A series of 2 (group: formerly
depressed, healthy control) X 2 (condition: sad, neutral) factorial ANOVAs using difference
scores and standardized change scores and a 2 (group: formerly depressed, healthy control) X 2
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(condition: sad, neutral) repeated measures ANOVA were used to assess the relationship
between depression history, mood manipulation, and mood reactivity.
Figure 8. Mood Reactivity Post-Mood Induction
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Note. Higher VAS scores indicate mood reactivity post-mood induction.
Hypothesis 3
Formerly depressed participants exposed to the sad mood induction would exhibit a
maladaptive pattern of cardiovascular reactivity (i.e., decreased HP, RSA, and CO and increased
PEP) during the mood induction compared to formerly depressed participants exposed to the
neutral mood induction and healthy control participants exposed to the sad and neutral mood
inductions. An average of the first five minutes of the mood induction was computed for HP,
RSA, PEP, and CO (i.e., HPMI2/MI5, RSAMI2/MI5, COMI2/MI5, and PEPMI2/MI5) and serve as a mood
induction measure. An average of the last five minutes of the mood induction was computed for
HP, RSA, PEP, and CO (i.e., HPBL2/BL5, RSABL2/BL5, COBL2/BL5, and PEPBL2/BL5) and serve as a
baseline measure. Cardiovascular reactivity was operationalized as the difference score for the
average of each cardiovascular measure (i.e., HPDS2RA/DS5RA, RSADS2RA/DS5RA, CODS2RA/DS5RA,
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and PEPDDS2RA/DS5RA) and residualized change scores for the average of each cardiovascular
measure (i.e., ZRES2/RES5HPRA, ZRES2/RES5RSARA, ZRES2/RES5CORA, and ZRES2/RES5PEPRA) assessed
during baseline and the mood induction (i.e., HPBL2/BL5/MI2/MI5, RSABL2/BL5/MI2/MI5,
COBL2/BL5/MI2/MI5, and PEPBL2/BL5/MI2/MI5). A series of 2 (group: formerly depressed, healthy
control) X 2 (condition: sad, neutral) factorial ANOVAs using difference scores and residualized
change scores and a 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral)
repeated measures ANOVA were used to assess the relationship between history of depression,
mood manipulation, and cardiovascular reactivity.
Figure 9. Cardiovascular Reactivity during Mood Induction

HP

RSA

1000

8
7.5

MRSA

MHP

950
900
850

7
6.5
6
5.5

800

5

Formerly Depressed

Healthy Control

Formerly Depressed

Group

CO

PEP

11

120

10.5

115

10

MPEP

MCO

Healthy Control

Group

9.5
9

110
105

8.5
8

100

Formerly Depressed

Healthy Control

Formerly Depressed

Group

■Sad Mood Induction

Healthy Control

Group

■Neutral Mood Induction

Note. Higher HP, RSA, and CO and lower PEP is considered to represent more adaptive
cardiovascular reactivity in response to the mood induction procedures.
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Hypothesis 4
Formerly depressed participants exposed to the sad mood induction would exhibit
reduced cardiovascular recovery (i.e., decreased HP, RSA, and CO and increased PEP compared
to baseline) during the recovery film compared to formerly depressed participants exposed to the
neutral mood induction and healthy control participants exposed to the sad and neutral mood
inductions. An average of the last five minutes of recovery was computed for HP, RSA, PEP,
and CO (e.g., HPRC2/RC5, RSARC2/RC5, CORC2/RC5, and PEPRC2/RC5) and serve as a recovery
measure. An average of the last five minutes of the mood induction was computed for HP, RSA,
PEP, and CO (i.e., HPBL2/BL5, RSABL2/BL5, COBL2/BL5, and PEPBL2/BL5) and serve as a baseline
measure. Cardiovascular recovery was operationalized as the difference score for the average of
each cardiovascular measure (i.e., HPDS2RC/DS5RC, RSADS2RC/DS5RC, CODS2RC/DS5RC, and
PEPDS2RC/DS5RC) and residualized change scores for the average of each cardiovascular measure
(i.e., ZRES2/RES5HPRC, ZRES2/RES5RSARC, ZRES2/RES5CORC, and ZRES2/RES5PEPRC) during the baseline
and the recovery period (i.e., HPBL2/BL5/RC2/RC5, RSABL2/BL5/RC2/RC5, COBL2/BL5/RC2/RC5, and
PEPBL2/BL5/RC2/RC5). A series of 2 (group: formerly depressed, healthy control) X 2 (condition:
sad, neutral) factorial ANOVAs using difference scores and residualized change scores and a 2
(group: formerly depressed, healthy control) X 2 (condition: sad, neutral) repeated measures
ANOVA were used to assess the relationship between history of depression, mood manipulation,
and cardiovascular recovery.
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Figure 10. Cardiovascular Recovery during Recovery Film
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Note. A return to baseline cardiovascular functioning is considered to represent more adaptive
cardiovascular recovery during the recovery period.
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Table 3. Study Procedure and Hypotheses Chart
Time

Screening

Session 1

Session 2

Task Category

Task Description
Contact and demographic information
GHS: language and visual abilities, current and past health conditions
Self-report
BDI-II: current depressive symptoms
measures
PHQ-9: past depressive symptoms
BAI: current anxiety symptoms
Demographic information: age, sex, race, ethnicity, marital status, and
education level
Self-report
measures
BDI-II: current depressive symptoms
STAI-I & II: current anxiety symptoms
Physical measure BMI: calculated via height and weight
Treatment History: current and past CBT and antidepressant use
Interview
SCID-IV-RV: psychiatric diagnoses
ECG and ICG recording while viewing 10-minute clip of Alaska Denali
Baseline
Park Video
DAS-SF I: dysfunctional beliefs at baseline
Self-report
VAS: dysphoric mood at baseline
measures
PANAS-X: dysphoric mood at baseline
ECG and ICG recording while listening to 7:38 minute piece of sad or
Mood induction
neutral music and recalling sad or neutral autobiographical memory
DAS-SF II: dysfunctional beliefs post MI (i.e., cognitive reactivity to MI)
Self-report
measures

VAS: dysphoric mood post MI (i.e., mood reactivity to MI)
PANAS-X: dysphoric mood post MI

Recovery
Debriefing

ECG and ICG recording while viewing 10-minute clip of Alaska
Wilderness Video
Provide and review debriefing form
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Purpose

Exclusion criteria

Potential covariates

Exclusion criteria
Baseline cardiovascular
functioning
Baseline cognitions
Baseline mood,
manipulation check
Cardiovascular
reactivity, H3
Post MI cognitions, H1
Post MI mood,
manipulation check, H2
Post MI mood,
manipulation check
Cardiovascular
recovery, H4
None

Note. GHS = General Health Screen; BDI-II = Beck Depression Inventory – Second Edition; PHQ-9 = Patient Health Questionnaire –
9; BAI = Beck Anxiety Inventory; STAI-I & II = State-Trait Anxiety Inventory – I & II; CBT = cognitive-behavioral therapy; BMI =
body mass index; SCID-IV-RV = Structured Clinical Interview for DSM-IV-TR – Research Version; ECG = electrocardiogram; ICG
= impedance cardiography; H = hypothesis; DAS I = Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional Attitudes
Scale – Short Form II; VAS = Visual Analogue Scale; PANAS-X = Positive and Negative Affect Scale – Expanded Form.
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CHAPTER 7
RESULTS
The purpose of this study was to characterize cognitive, mood, and cardiovascular
reactivity to and recovery from a sad mood induction in individuals with a history of depression
compared to healthy, never depressed individuals. A transient sad or neutral mood was
experimentally induced using an empirically validated music and autobiographical recall mood
induction. Self-report measures were used to test the study hypotheses regarding cognitive and
mood reactivity to the transient mood (i.e., Hypotheses 1 and 2). Cardiovascular measures were
used to test the study hypotheses regarding cardiovascular reactivity to and cardiovascular
recovery from the transient mood (i.e., Hypotheses 3 and 4).
Session 1
Demographic Information
Participants were recruited from the University of Maine psychology undergraduate
participant pool and the surrounding community. The distribution of participants by recruitment
source and group is presented in Table 4. While the majority of the final sample was drawn from
the undergraduate participant pool (n = 87, 65.90%), over a third of the sample was recruited
from the surrounding community (n = 45, 34.10%).
Table 4. Recruitment Source by Group
Group
Total (N = 132)
FD (n = 45)
Recruitment source
n
%
n
%
Participant pool
87
65.90
21
46.70
Community
45
34.10
24
53.30
Note. FD = formerly depressed; HC = healthy control.
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HC (n = 87)
n
%
66
75.90
21
24.10

Participants who met the eligibility criteria during screening were invited to participate in
session 1. 282 participants completed session 1. At session 1, 109 participants (38.65%) were
excluded, leaving 173 participants (61.35%) who were eligible to participate in session 2. Of
these participants, 59 participants met the inclusion criteria for the formerly depressed group and
114 participants met the inclusion criteria for the healthy control group. Between sessions 1 and
2, 41 participants (23.70%) were lost to follow-up. 132 participants (76.30%) completed session
2, with 45 participants in the formerly depressed group and 87 participants in the healthy control
group. A flow chart of participant recruitment visually depicts this information (Figure 11).
Figure 11. Flow Chart of Participant Recruitment
Screening
Session 1
N = 109 excluded

N = 282

Session 1 eligible for session 2
N = 173

nFD = 59

nHC = 114

N = 41 attrition

Session 2
N = 132

nFD = 45

nHC = 87

Note. FD = formerly depressed; HC = healthy control.
Following session 1, participants in the two groups were randomly assigned to the two
experimental conditions. The distribution of participants in the two experimental conditions by
group is presented in Table 5. Formerly depressed and healthy control participants were assigned
to the sad (n = 65) and neutral (n = 67) mood inductions roughly evenly, with slight differences
in the size of groups due to between-session attrition from sessions 1 and 2.
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Table 5. Condition by Group
Group
Total (N = 132)
FD (n = 45)
HC (n = 87)
Condition
n
%
n
%
n
%
SMI
65
49.20
21
46.70
44
50.60
NMI
67
50.80
24
53.30
43
49.40
Note. FD = formerly depressed; HC = healthy control; SMI = sad mood induction; NMI = neutral
mood induction.
Descriptive statistics. Participants demographic information that was considered as
potential covariates. Descriptive statistics for demographic information for the entire sample are
presented in Table 6 while means, standard deviations, p values, and effect sizes for
demographic information by group are presented in Tables 6 and 7. Participants in this study (N
= 132) were predominantly younger (M = 20.79, SD = 5.65), female (n = 81, 61.40%), Caucasian
(n = 115, 87.10%), never married (n = 121, 91.67%) college students (n = 114, 86.40%). These
results are consistent with the demographic make-up of the University of Maine and surrounding
community as Orono, Maine is a university town. Of note, the racial and ethnic make-up of the
study is consistent with the location as the state of Maine currently has the highest proportion of
Caucasian residents in the country at 94.70% (United States Census Bureau, 2017). A subset of
the sample included older (range = 18-60), college educated (n = 16, 12.90%) adults.
Participants’ BMI was on average, in the overweight range (M = 25.16, SD = 5.65), which is
consistent with recent estimates that 35.90% of Maine’s population falls within the overweight
range (Centers for Disease Control and Prevention, 2017). A low proportion of participants
reported current or previous mental health treatment (psychotherapy = 2.00-8.00%, psychotropic
medication = 7.00-12.00%).
Independent samples t-tests. Means, standard deviations, p values, and effect sizes for
demographic information by group are presented in Table 7. Independent samples t-tests were
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used to examine differences between groups for continuous variables (i.e., age and BMI).
Levene’s test for homogeneity of variance was significant for age (F(129) = 26.96, p < .001) but
not BMI (F(128) = .97, p = .33), indicating that this assumption underlying t-test was met for
BMI but not age. Consequently, results for equal variances not assumed are reported for age.
Formerly depressed participants were significantly older (t(49.01) = 2.27, p = .03, CI = .34, 5.62,
d = .47) than healthy control participants. There were no significant difference between groups
for BMI (t(128) = -.18, p = .86, CI = -2.28, 1.90, d = .03).
Chi-square tests. Means, standard deviations, p values, and effect sizes for demographic
information by group are presented in Table 7. Chi-square tests were used to examine differences
between the two groups for categorical variables (i.e., sex, race, ethnicity, education level,
marital status, and current and past CBT and antidepressant use). Unsurprisingly, formerly
depressed participants reported significantly more past CBT use (χ2(1) = 6.72, p = .04, w = .23)
and current (χ2(1) = 16.54, p < .001, w = .35) and past (χ2(1) = 21.78, p < .001, w = .41)
antidepressant use than healthy control participants. There were no significant difference
between groups for sex (χ2(1) = 3.33, p = .07, w = .16), race (χ2(3) = 2.44, p = .49, w = .14),
Hispanic/Latino (χ2(1) = 3.18, p = .08, w = .16) or Franco-American (χ2(1) = .06, p = .80, w =
.02) ethnicity, marital status (χ2(2) = 5.18, p = .08, w = .20), education level (χ2(5) = 5.67, p =
.34, w = .21), and current CBT use (χ2(1) = 4.82, p = .09, w = .19). Treatment history data was
not collected for 16 formerly depressed and 40 healthy control participants. Due to the large
amount of missing data, current and past CBT and antidepressant use were removed from further
analyses.
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Table 6. Descriptive Statistics for Demographic Information
Measure
M
Age, years
20.79
2
BMI, kg/m
25.16
Note. BMI = body mass index.

SD
5.65
5.65

Sample range
18-60
16.14-47.76

Table 7. Means, Standard Deviations, P Values, and Effect Sizes for Demographic Information
by Group

Variable
Age, years
BMI, kg/m2
Variable
Sex
Male
Female
Race
Caucasian
African American
Asian American
Multiple races
Ethnicity
Hispanic/Latino
Franco-American
Marital status
Married
Never married
Divorced
Education level
High school
1 year of college
2+ years of college
Associates degree
Bachelor’s degree
Doctoral degree
Treatment history
Past CBT
Current CBT
Past RX
Current RX

Total (N = 132)
M
SD
20.79 5.65
25.16 5.65
n
%

Group
FD (n = 45)
HC (n = 87)
M
SD
M
SD
22.77 8.43
19.79 3.11
25.04 5.73
25.22 5.64
n
%
n
%

50
81

12
32

37.90
61.40

26.70
71.10

38
49

d
.47
.03
w
.16

.49

.14

.08
.80
.08

.16
.02
.20

.34

.21

.04
.09
< .001
< .001

.23
.19
.41
.35

43.70
56.30

115
4
4
7

87.10
3.00
3.00
5.30

41
0
1
2

91.10
N/A
2.20
4.40

74
4
3
5

85.10
4.60
3.40
5.70

6
10

4.50
7.60

0
3

N/A
6.70

6
7

6.90
8.00

8
121
2

6.10
91.70
1.50

4
38
2

8.90
84.40
4.40

4
83
0

4.60
95.40
N/A

57
30
27
1
9
7

43.20
22.70
20.50
.80
6.80
5.30

15
9
12
0
5
3

33.30
20.00
26.70
N/A
11.10
6.70

42
21
15
1
4
4

48.30
24.10
17.20
1.10
4.60
4.60

8
2
12
7

6.10
1.50
9.10
5.30

6
2
11
7

13.30
4.40
24.40
15.60

2
0
1
0

2.30
N/A
1.10
N/A

143

p
.03
.86
p
.07

Note. FD = formerly depressed; HC = healthy control; BMI = body mass index; CBT = cognitive
behavioral therapy; RX = antidepressant medication; One FD participant elected not to provide
any demographic data and one HC participant elected not to provide race data. Treatment history
data was not collected for 16 FD and 40 HC participants. Consequently, percentages for some
category do not add up to 100.00%.
Self-Report Measures
During session 1, participants completed two self-report measures that were considered
as potential covariates. The BDI-II (Beck et al., 1996a; Appendix C) was used to evaluate the
severity of current depressive symptoms. Respondents rated the severity of depressive symptoms
experienced over the past two weeks on a scale from 0 to 3, with 0 indicating the symptom is not
present and 3 indicating that the symptom is present and severe. Total scores ranged from 0 to
63, with higher scores indicating greater levels of depressive symptom severity. The STAI-I & II
(Spielberger et al., 1983; Appendix I) was used to assesses cognitive, affective, and somatic
symptoms of both state and trait anxiety. Respondents rated the severity of anxiety symptoms
experienced at the moment for the state version and in general for the trait version from 1 to 4,
with 1 indicating the symptom is almost never present and 4 indicating that the symptom is
almost always present. Total scores for each version ranged from 20 to 80, with higher scores
indicating greater levels of state or trait anxiety symptom severity. Outlier data for the STAI-II (n
= 1) was winsorized to address extreme values. No outlier data was present for the BDI-II or
STAI-I.
Descriptive statistics. Descriptive statistics for session 1 self-report measures are
presented in Table 8. The BDI-II demonstrated good internal consistency (α = .89) and the STAII demonstrated acceptable internal consistency (α = .71) in this study sample (Tavakol &
Dennick, 2011). Cronbach’s alpha indicated that the STAI-II was not a reliable measure of state
anxiety symptoms (α = .40). Consequently, the measure was removed from further analyses
(Tavakol & Dennick, 2011).
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Table 8. Descriptive Statistics for Session 1 Self-Report Measures
Measure
M
SD
Sample range
Sample α
BDI-II
5.50
6.28
0-35
.89
STAI-I
45.35
5.67
32-64
.71
STAI-II
44.90
4.08
36-55
.40
Note. BDI-II = Beck Depression Inventory – Second Edition; STAI-I = State-Trait Anxiety
Inventory – I; STAI-II = State-Trait Anxiety Inventory – II.
Independent samples t-tests. Means, standard deviations, p values, and effect sizes for
session 1 self-report measures by group are presented in Table 9. Independent samples t-tests
were used to examine differences between groups for current depressive (i.e., BDI-II) and state
anxiety (i.e., STAI-I) symptoms. Levene’s test for homogeneity of variance was significant for
the BDI-II (F(125) = 24.92, p < .001) and STAI-I (F(121) = 5.05, p = .03), indicating that this
assumption underlying t-test was not met. Consequently, results for equal variances not assumed
are reported for the BDI-II and STAI-I. Formerly depressed participants reported significantly
higher levels of current depressive symptoms on the BDI-II (t(49.77) = 5.08, p < .001, CI = 3.98,
9.19, d = 1.06) than healthy control participants. There were no significant difference between
groups for current state anxiety symptoms on the STAI-I (t(60.73) = -1.01, p = .32, CI = -3.63,
1.19, d = .20).
Table 9. Means, Standard Deviations, P Values, and Effect Sizes for Session 1 Self-Report
Measures by Group
Group
Total (N = 127)
FD (n = 42)
HC (n = 85)
Measure
M
SD
M
SD
M
SD
p
d
BDI-II
5.50
6.28
9.91
7.99
3.32
3.68
< .001 1.06
Total (N = 123)
FD (n = 40)
HC (n = 83)
Measure
M
SD
M
SD
M
SD
p
d
STAI-I
45.35
5.67
44.53
6.77
45.74
5.06
.32
.20
Note. FD = formerly depressed; HC = healthy control; BDI-II = Beck Depression Inventory –
Second Edition; STAI-I = State-Trait Anxiety Inventory – I.
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Session 2
Cognitive Measures
During session 2, participants completed two versions of one self-report measure that was
used to assess cognitive reactivity to the mood induction (i.e., Hypothesis 1). The DAS-SF I & II
(Beevers et al., 2007; Appendix L) was used to evaluate changes in dysfunctional beliefs about
oneself before and after the mood induction. Respondents rated their beliefs experienced most of
the time on a scale of 1 to 4, with 1 indicating that they totally agreed with the statement and 4
indicating that they totally disagreed with the statement. Total scores ranged from 9 to 36, with
lower scores indicating greater levels of the dysfunctional beliefs. Cognitive reactivity was
operationalized as difference scores (i.e., DAS DS) and residualized change scores (i.e., ZRESDAS)
for the DAS administered pre- and post-mood induction as well as pre- and post-mood induction
measures (i.e., DAS I and DAS II). No outlier data was present for the DAS-SF I, DAS-SF II,
and DASDS.
Descriptive statistics. Descriptive statistics for session 2 cognitive measures are
presented in Table 10. The DAS-SF I & II demonstrated acceptable internal consistency (α = .79.80) in this study sample (Tavakol & Dennick, 2011). The difference (i.e., DS) and residualized
change (i.e., ZRES/ZRES) scores are calculated measures. Consequently, Cronbach’s alpha could
not be calculated.
Table 10. Descriptive Statistics for Session 2 Cognitive Measures
Measure
M
SD
Sample range
Sample α
DAS-SF I
27.67
3.87
19-36
.80
DAS-SF II
27.03
3.96
16-36
.79
DASDS
-.64
2.87
-8-8
ZRESDAS
.00
1.00
-2.51-2.95
Note. DAS I = Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional Attitudes
Scale – Short Form II; DS = difference score; ZRES = residualized change scores.
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Hypothesis 1
A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral)
factorial ANOVAs using difference scores and residualized change scores and a 2 (group:
formerly depressed, healthy control) X 2 (condition: sad, neutral) repeated measures ANOVA
were used to test the hypothesis that formerly depressed participants exposed to the sad mood
induction would report significantly more dysfunctional beliefs on the DAS post-mood induction
than formerly depressed participants exposed to the neutral mood induction and healthy control
participants exposed to the sad and neutral mood inductions. Means, standard deviations, p
values, and effect sizes for session 2 cognitive measures by group are presented in Table 11
while means, standard deviations, p values, and effect sizes for session 2 cognitive measures by
group and condition are presented in Table 12. Planned comparisons were conducted using
contrast analyses. Means, standard deviations, and p values for session 2 cognitive measures for
planned comparisons are presented in Table 13.
DAS. Analyses conducted using the DAS are reviewed below.
2 X 2 factorial ANOVA – difference score. None of the covariates that were under
consideration were significantly associated with cognitive reactivity (all p’s > .05) and were
dropped from the final model. Levene’s test for homogeneity of variance was not significant
(F(3,122) = .43, p = .73), indicating that this assumption underlying ANOVA was met. Neither
the main effects of group (F(1,122) = 1.27, p = .26, η2 = .01) or condition (F(1,122) = .23, p =
.63, η2 = .002) nor the group by condition interaction (F(1,122) = 1.81, p = .18, η2 = .02) were
significant, indicating that there was no significant difference in cognitive reactivity on the DAS
post-mood induction between groups or conditions or the group by condition interaction when
using difference scores. Contrast analyses revealed that there was no significant difference in
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cognitive reactivity on the DAS post-mood induction (t(122) = -1.51, pL = .23, pQ = .18, pC =
.94) when comparing formerly depressed participants exposed to the sad mood induction to
formerly depressed participants exposed to the neutral mood induction and healthy control
participants exposed to the sad and neutral mood inductions.
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were
under consideration were significantly associated with cognitive reactivity (all p’s > .05) and
were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(3,122) = .68, p = .57), indicating that this assumption underlying ANOVA was
met. Formerly depressed participants reported significantly higher levels of dysfunctional beliefs
on the DAS post-mood induction (F(1,122) = 5.11, p = .03, η2 = .04) than healthy control
participants. Neither the main effect of condition (F(1,122) = .14, p = .71, η2 = .001) nor the
group by condition interaction (F(1,122) = 1.02, p = .31, η2 = .008) were significant, indicating
that there was no significant difference in cognitive reactivity on the DAS post-mood induction
between mood induction conditions or the group by condition interaction when using
residualized change scores. Using contrast analyses, formerly depressed participants exposed to
the sad mood induction reported significantly higher levels of dysfunctional beliefs on the DAS
post-mood induction (t(122) = -1.86, pL = .03, pQ = .31, pC = .49) compared to healthy control
participants exposed to the sad mood induction and formerly depressed and healthy control
participants exposed to the neutral mood induction.
2 X 2 repeated measures ANOVA. Current depressive (p < .001) and state anxiety (p =
.03) symptoms were significantly associated with cognitive reactivity and were included in the
final model. The remaining covariates that were under consideration were not significantly
associated with cognitive reactivity (all p’s > .05) and were dropped from the final model.
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Levene’s test for homogeneity of variance was not significant (DAS-SF I: F(3,111) = .14, p =
.93; DAS-SF II: F(3,111) = .04, p = .99), indicating that this assumption underlying ANOVA
was met. Neither the main effects of group (F(1,109) = .67, p = .42, η2 = .006) or condition
(F(1,109) = .03, p = .87, η2 < .001) nor the group by condition interaction (F(1,109) = .79, p =
.38, η2 = .007) were significant, indicating that there was no significant difference in cognitive
reactivity on the DAS post-mood induction between groups or conditions or the group by
condition interaction when using repeated measures. Contrast analyses revealed that there was no
significant difference in cognitive reactivity on the DAS post-mood induction (F(1,111) = .01, p
= .92) when comparing formerly depressed participants exposed to the sad mood induction to
formerly depressed participants exposed to the neutral mood induction and healthy control
participants exposed to the sad and neutral mood inductions.
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the DAS analyses. Results
indicated that the current model had a power of .36 for the difference score, .17 for the
residualized change score, and .13 for the repeated measures. Results suggested that given the
current study’s sample size, α level, and observed effect size, there was a 13 to 36% chance of
detecting an effect depending on which analytic technique was used.
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et
al., 2007) to determine the minimum effect size needed to obtain significant results for the DAS
analyses. Results indicated that the required effect size was f = .25 for the factorial ANOVAs and
f = .28 for the repeated measures ANOVA. Results suggested that given the current study’s
sample size and α level, at least a medium effect size was required to obtain significant results if
a power of .80 was achieved.
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Table 11. Means, Standard Deviations, P Values, and Effect Sizes for Session 2 Cognitive
Measures by Group
Group
FD (n = 43)
HC (n = 83)
M
SD
M
SD
26.23
3.87
28.40
3.68
25.27
3.59
27.95
3.84
-1.02
2.94
-.45
2.83
-.27
.97
.14
.99

Total (N = 126)
Measure
M
SD
p
η2
DAS-SF I
27.67
3.87
DAS-SF II
27.03
3.96
DASDS
-.64
2.87
.26
.01
ZRESDAS
.00
1.00
.03
.04
DASRM
.42
.006
Note. FD = formerly depressed; HC = healthy control; DAS I = Dysfunctional Attitudes Scale –
Short Form I; DAS II = Dysfunctional Attitudes Scale – Short Form II; DS = difference score;
ZRES = residualized change scores; RM = repeated measures.
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Table 12. Means, Standard Deviations, P Values, and Effect Sizes for Session 2 Cognitive Measures by Group and Condition

Total (N = 126)
M
SD
27.67
3.87
27.03
3.96
-.64
2.87
.00
1.00

Group and Condition
FD/SMI (n = 20) FD/NMI (n = 23) HC/SMI (n = 42)
M
SD
M
SD
M
SD
26.85
4.02
25.70
3.75
28.00
3.50
25.30
3.50
25.25
3.75
27.95
3.81
-1.55
2.54
-.57
3.23
-.21
2.78
-.41
.82
-.15
1.10
.20
.98

HC/NMI (n = 41)
Measure
M
SD
p
η2
DAS-SF I
28.79
3.85
DAS-SF II
27.95
3.92
DASDS
-.68
2.89
.18
.02
ZRESDAS
.08
1.00
.31
.008
DASRM
.38
.007
Note. The difference between pre- and post-mood induction measures may not precisely equal the difference score as outlier data was
addressed differently depending on the type of analyses conducted; FD = formerly depressed; HC = healthy control; SMI = sad mood
induction; NMI = neutral mood induction; DAS I = Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional Attitudes
Scale – Short Form II; DS = difference score; ZRES = residualized change scores; RM = repeated measures.

Table 13. Means, Standard Deviations, and P Values for Session 2 Cognitive Measures for Planned Comparisons
Group and Condition
Total (N = 126)
FD/SMI (n = 20)
FD/NMI, HC/SMI,
HC/NMI (n = 106)
Measure
M
SD
M
SD
M
SD
pL
pQ
pC
DAS-SF I
27.67
3.87
26.85
4.02
27.83
3.84
DAS-SF II
27.03
3.96
25.30
3.50
27.35
3.97
DASDS
-.64
2.87
-1.55
2.54
-.47
2.90
.23
.18
.94
ZRESDAS
.00
1.00
-.41
.82
.08
1.01
.03
.31
.49
DASRM
.92
Note. FD = formerly depressed; HC = healthy control; SMI = sad mood induction; NMI = neutral mood induction;
= linear; Q = quadratic; C = cubic; DAS I = Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional
Attitudes Scale – Short Form II; DS = difference score; ZRES = residualized change scores; RM = repeated measures.

151

L

Mood Measures
During session 2, participants completed one self-report measure twice that was used to
assess mood reactivity to the mood induction (i.e., Hypothesis 2) and served as a manipulation
check for the mood induction procedures to assess if feelings of sadness were induced. The VAS
(Appendix L) was used to evaluate subjective changes in mood before and after the mood
induction. Respondents rated their current level of sadness on a scale of 0 to 100, with 0
indicating lower levels of sadness and 100 indicating higher levels of sadness. Total scores
ranged from 0 to 100, with higher scores indicating greater levels of sadness. Mood reactivity
was operationalized as difference scores (i.e., VAS DS) and residualized change scores (i.e.,
ZRESVAS) for the VAS administered pre- and post-mood induction as well as pre- and postmood induction measures (i.e., VASPRE and VASPOST).
In addition, participants completed one self-report measure twice that was used as a
manipulation check for the mood induction procedures to assess if emotions other than sadness
were induced. The PANAS-X (Watson & Clark, 1994; Appendix L) was used to evaluate
changes in mood before and after the mood induction. Respondents rated the extent to which
they were experiencing 60 affective adjectives on a Likert scale from 1 to 5, with 1 indicating
that were not or very slightly experiencing the affective state and 3 indicating that they were
experiencing the affective state extremely. Total scores for the general dimension scale (i.e.,
negative and positive affect) were calculated by summing the 10 affective adjectives that
comprise each scale and ranged from 0 to 10, with higher scores indicating greater levels of the
respective affect. Total scores for specific affective state scales (i.e., fear, guilt, hostility, and
sadness) were calculated by summing the three to eight affective adjectives that comprise each
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scale and ranged from 0 to 4, 5, 6, or 8, with higher scores indicating greater levels of the
respective affect.
Outlier data for the VASDS (n = 7), PANAS-X NDS (n = 1), PANAS-X PDS (n = 4),
PANAS-X FDS (n = 1), PANAS-X GDS (n = 24), PANAS-X HDS (n = 6), and PANAS-X SDS (n =
3) were winsorized to address extreme values. Outlier data for the VASPRE (n = 3), PANAS-X
NPRE (n = 4), PANAS-X NPOST (n = 2), PANAS-X FPRE (n = 4), PANAS-X FPOST (n = 2),
PANAS-X GPRE (n = 6), PANAS-X GPOST (n = 2), PANAS-X HPRE (n = 2), PANAS-X HPOST (n
= 2), PANAS-X SPRE (n = 1) were winsorized to address extreme values. In addition, outlier data
for the ZRESVAS (n = 5), ZRESPANAS-X N (n = 2), ZRESPANAS-X P (n = 4), ZRESPANAS-X F
(n = 1), ZRESPANAS-X G (n = 27), ZRESPANAS-X H (n = 1), and ZRESPANAS-X P (n = 4) were
winsorized to address extreme values. No outlier data was present for the VASPOST, PANAS-X
PPRE, PANAS-X PPOST, or PANAS-X SPOST.
Descriptive statistics. Descriptive statistics for session 2 mood measures are presented in
Table 14. The pre- (i.e., PRE) and post- (i.e., POST) mood induction scores are single item
measures. Consequently, Cronbach’s alpha could not be calculated. The difference (i.e., DS) and
residualized change (i.e., ZRES) scores are calculated measures. Consequently, Cronbach’s alpha
could not be calculated. All of the general dimension and basic negative emotion scales of the
PANAS-X demonstrated good (α = .84-.90) or excellent (α = .91-.93) internal consistency in this
study sample.
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Table 14. Descriptive Statistics for Session 2 Mood Measures
Measure
M
SD
Sample range
Sample α
VASPRE
8.67
13.29
0-63
VASPOST
24.99
26.22
0-93
VASDS
15.61
24.33
-17-93
ZRESVAS
-.14
.89
-1.30-3.05
PANAS-X NPRE
14.80
5.62
10-41
.90
PANAS-X NPOST
15.35
5.58
10-42
.89
PANAS-X NDS
.47
2.33
-6-9
ZRESPANAS-X N
-.05
.75
-1.95-4.33
PANAS-X PPRE
29.82
6.42
12-43
.85
PANAS-X PPOST
27.66
7.55
10-46
.90
PANAS-X PDS
-2.14
3.36
-14-7
ZRESPANAS-X P
.14
.91
-4.18-4.76
PANAS-X FPRE
8.96
3.81
6-26
.89
PANAS-X FPOST
8.94
3.79
6-22
.90
PANAS-X FDS
-.06
1.58
-5-6
ZRESPANAS-X F
.02
.85
-2.81-3.83
PANAS-X GPRE
7.91
3.32
6-23
.91
PANAS-X GPOST
8.27
3.62
6-25
.93
PANAS-X GDS
.24
1.36
-3-8
ZRESPANAS-X G
-.15
.36
-1.98-4.70
PANAS-X HPRE
8.46
3.19
6-27
.86
PANAS-X HPOST
8.66
3.27
6-30
.84
PANAS-X HDS
.14
1.79
-4-8
ZRESPANAS-X H
-.12
.73
-1.59-6.98
PANAS-X SPRE
7.80
3.39
5-25
.89
PANAS-X SPOST
8.06
3.51
5-25
.90
PANAS-X SDS
.20
1.83
-4-9
ZRESPANAS-X S
-10
.80
-1.76-4.87
Note. The difference between pre- and post-mood induction measures may not precisely equal
the difference score as outlier data was addressed differently depending on the type of analyses
conducted; VAS = Visual Analogue Scale; PRE = pre-mood induction; POST = post-mood
induction; DS = difference score; ZRES = residualized change scores; PANAS-X = Positive and
Negative Affect Scale – Expanded Form; N = negative affect general dimension scale; P =
positive affect general dimension scale; F = fear basic negative emotional scale; H = hostility
basic negative emotional scale; G = guilt basic negative emotional scale; S = sadness basic
negative emotional scale.
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Manipulation Check
A series of one-way (condition: sad, neutral) ANOVAs using difference scores and
residualized change scores and a one-way (condition: sad, neutral) repeated measures ANOVA
were used as a manipulation check for the mood induction procedures to ensure that a sad mood
was induced. The manipulation was conducted using both the VAS and the PANAS-X negative
and positive affect general dimension and fear, guilt, hostility, and sadness basic negative
emotional scales.
Descriptive statistics. Descriptive statistics for session 2 measures used for the
manipulation check are included in Table 14. Means, standard deviations, p values, and effect
sizes for the VAS and PANAS-X negative and positive affect general dimension and fear, guilt,
hostility, and sadness basic negative emotional scales by condition are presented in Table 15.
VAS. Analyses conducted using the VAS are reviewed below.
One-way ANOVA – difference score. Sex (p = .02) was significantly associated with the
VAS and was included in the final model. The remaining covariates that were under
consideration were not significantly associated with the VAS (all p’s > .05) and were dropped
from the final model. Levene’s test for homogeneity of variance was significant (F(1,120) =
47.46, p < .001), indicating that this assumption underlying ANOVA was not met. Of note, this
did not appear to be driven by the inclusion of the covariate. Without the covariate, Levene’s test
for homogeneity of variance was significant (F(1,121) = 55.62, p < .001).
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of differences scores were calculated and
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
difference scores were normally distributed for the formerly depressed participants exposed to
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the sad mood induction condition (Kolmogorov-Smirnov: D(17) = .15, p = .20; Shapiro-Wilk:
D(17) = .95, p = .38). However, residuals of difference scores were not normally distributed for
the remaining groups and conditions (all p’s < .05). Second, difference scores were transformed
using the reciprocal transformation. Levene’s test for homogeneity of variance continued to be
significant (F(1,121) = 23.84, p < .001), indicating that this assumption underlying ANOVA was
still not met. Consequently, the one-way ANOVA was conducted with the α level decreased
from .05 to .01. Participants exposed to the sad mood induction reported significantly higher
levels of sadness on the VAS post-mood induction (F(1,119) = 44.68, p < .001, η2 = .27) than
participants exposed to the neutral mood induction when using difference scores.
One-way ANOVA – residualized change score. Sex (p = .02) was significantly
associated with the VAS and was included in the final model. The remaining covariates that were
under consideration were not significantly associated with the VAS (all p’s > .05) and were
dropped from the final model. Levene’s test for homogeneity of variance was significant
(F(1,120) = 50.61, p < .001), indicating that this assumption underlying ANOVA was not met.
Of note, this did not appear to be driven by the inclusion of the covariate. Without the covariate,
Levene’s test for homogeneity of variance was significant (F(1,121) = 49.74, p < .001).
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of residualized change scores were calculated
and Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
residualized change scores were normally distributed for the formerly depressed participants
exposed to the sad mood induction (Kolmogorov-Smirnov: D(17) = .15, p = .20; Shapiro-Wilk:
D(17) = .95, p = .38). However, residuals of residualized change scores were not normally
distributed for the remaining groups and conditions (all p’s < .05). Second, residualized change
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scores were transformed using the reciprocal transformation. Levene’s test for homogeneity of
variance continued to be significant (F(1,121) = 24.68, p < .001), indicating that this assumption
underlying ANOVA was still not met. Consequently, the one-way ANOVA was conducted with
the α level decreased from .05 to .01. Participants exposed to the sad mood induction reported
significantly higher levels of sadness on the VAS post-mood induction (F(1,119) = 48.36, p <
.001, η2 = .29) than participants exposed to the neutral mood induction when using residualized
change scores.
One-way repeated measures ANOVA. Sex (p = .04) and current depressive symptoms (p
= .008) were significantly associated with the VAS and were included in the final model. The
remaining covariates that were under consideration were not significantly associated with the
VAS (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity of
variance was not significant for the pre-mood induction measure (VASPRE : F(1,116) = 2.92, p =
.09) but was significant for the post-mood induction measure (VASPOST: F(1,116) = 47.84, p <
.001), indicating that this assumption underlying ANOVA was not met. Of note, this did not
appear to be driven by the inclusion of the covariates. Without the covariates, Levene’s test for
homogeneity of variance was not significant for the pre-mood induction measure (VASPRE :
F(1,121) = 1.54, p = .22) but was significant for the post-mood induction measure (VASPOST:
F(1,121) = 38.95, p < .001).
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. Residuals could not be calculated as there was only one measure
for each calculation. The pre- and post-mood induction measures were transformed using the
reciprocal transformation. Levene’s test for homogeneity of variance was not significant for the
pre-mood induction measure (VASPRE : F(1,121) = .005, p = .95) but continued to be significant
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for the post-mood induction measure (VASPOST: F(1,121) = 4.34, p = .04), indicating that this
assumption underlying ANOVA was still not met. Consequently, the one-way ANOVA was
conducted with the α level decreased from .05 to .01. Participants exposed to the sad mood
induction reported significantly higher levels of sadness on the VAS post-mood induction
(F(1,114) = 25.80, p < .001, η2 = .19) than participants exposed to the neutral mood induction
when using repeated measures.
PANAS-X N. Analyses conducted using the PANAS-X negative affect general
dimension scale are reviewed below.
One-way ANOVA – difference score. None of the covariates that were under
consideration were significantly associated with negative affect on the PANAS-X (all p’s > .05)
and were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(1,118) = 3.07, p = .08), indicating that this assumption underlying ANOVA was
met. The main effect of condition (F(1,118) = 2.37, p = .13, η2 = .02) was not significant,
indicating that there was no significant difference in reporting of negative affect on the PANASX between mood induction conditions when using difference scores.
One-way ANOVA – residualized change score. Current depressive symptoms (p = .002)
were significantly associated with negative affect on the PANAS-X and were included in the
final model. The remaining covariates that were under consideration were not significantly
associated with negative affect on the PANAS-X (all p’s > .05) and were dropped from the final
model. Levene’s test for homogeneity of variance was significant (F(1,113) = 8.04, p = .005),
indicating that this assumption underlying ANOVA was not met. Of note, this did not appear to
be driven by the inclusion of the covariate. Without the covariate, Levene’s test for homogeneity
of variance was significant (F(1,118) = 6.44, p = .01).
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In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of differences scores were calculated and
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
difference scores were normally distributed for the formerly depressed participants exposed to
the sad (Kolmogorov-Smirnov: D(23) = .15, p = .20; Shapiro-Wilk: D(23) = .93, p = .11) and
neutral (Kolmogorov-Smirnov: D(17) = .20, p = .07; Shapiro-Wilk: D(17) = .91, p = .09) mood
inductions. However, residuals of difference scores were not normally distributed for the
remaining groups and conditions (p’s < .05). Second, difference scores were transformed using
the reciprocal transformation. Levene’s test for homogeneity of variance continued to be
significant (F(1,118) = 10.35, p = .002), indicating that this assumption underlying ANOVA was
still not met. Consequently, the one-way ANOVA was conducted with the α level decreased
from .05 to .01. With the adjusted p value, the main effect of condition (F(1,112) = 5.35, p = .02,
η2 = .05) was not significant, indicating that there was no significant difference in reporting of
negative affect on the PANAS-X between mood induction conditions when using residualized
change scores.
One-way repeated measures ANOVA. Current depressive symptoms (p < .001) were
significantly associated with negative affect on the PANAS-X and were included in the final
model. The remaining covariates that were under consideration were not significantly associated
with negative affect on the PANAS-X (all p’s > .05) and were dropped from the final model.
Levene’s test for homogeneity of variance was not significant (PANAS-X NPRE: F(1,113) = .52,
p = .47; PANAS-X NPOST: F(1,113) = .06, p = .80), indicating that this assumption underlying
ANOVA was met. The main effect of condition (F(1,112) = .55, p = .46, η2 = .005) was not
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significant, indicating that there was no significant difference in reporting of negative affect on
the PANAS-X between mood induction conditions when using repeated measures.
PANAS-X P. Analyses conducted using the PANAS-X positive affect general dimension
scale are reviewed below.
One-way ANOVA – difference score. BMI (p = .04) and current depressive symptoms (p
= .004) were significantly associated with positive affect on the PANAS-X and were included in
the final model. The remaining covariates that were under consideration were not significantly
associated with positive affect on the PANAS-X (all p’s > .05) and were dropped from the final
model. Levene’s test for homogeneity of variance was not significant (F(1,116) = 3.26, p = .07),
indicating that this assumption underlying ANOVA was met. The main effect of condition
(F(1,114) = 3.59, p = .06, η2 = .03) was not significant, indicating that there was no significant
difference in reporting of positive affect on the PANAS-X between mood induction conditions
when using difference scores.
One-way ANOVA – residualized change score. BMI (p = .04) and current depressive
symptoms (p = .0014) were significantly associated with positive affect on the PANAS-X and
were included in the final model. The remaining covariates that were under consideration were
not significantly associated with positive affect on the PANAS-X (all p’s > .05) and were
dropped from the final model. Levene’s test for homogeneity of variance was significant
(F(1,116) = 3.89, p = .05), indicating that this assumption underlying ANOVA was not met. Of
note, this appeared to be driven by the inclusion of the covariates. Without the covariates,
Levene’s test for homogeneity of variance was not significant (F(1,121) = 2.65, p = .11).
Consequently, calculating the residual of the residualized change scores to assess normality and
transforming the residualized change scores to re-assess homogeneity of variance would not have
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the intended effect. Instead, the one-way ANOVA was conducted with the α level decreased
from .05 to .01. The main effect of condition (F(1,114) = 3.77, p = .06, η2 = .03) was not
significant, indicating that there was no significant difference in reporting of positive affect on
the PANAS-X between mood induction conditions when using residualized change scores.
One-way repeated measures ANOVA. Current state anxiety symptoms (p < .001) were
significantly associated with positive affect on the PANAS-X and were included in the final
model. The remaining covariates that were under consideration were not significantly associated
with positive affect on the PANAS-X (all p’s > .05) and were dropped from the final model.
Levene’s test for homogeneity of variance was not significant (PANAS-X PPRE: F(1,113) = .44,
p = .51; PANAS-X PPOST: F(1,113) = 1.85, p = .18), indicating that this assumption underlying
ANOVA was met. The main effect of condition (F(1,112) = .78, p = .38, η2 = .007) was not
significant, indicating that there was no significant difference in reporting of positive affect on
the PANAS-X between mood induction conditions when using repeated measures.
PANAS-X F. Analyses conducted using the PANAS-X fear negative basic emotional
scale are reviewed below.
One-way ANOVA – difference score. None of the covariates that were under
consideration were significantly associated with fear on the PANAS-X (all p’s > .05) and were
dropped from the final model. Levene’s test for homogeneity of variance was not significant
(F(1,121) = .10, p = .76), indicating that this assumption underlying ANOVA was met. The main
effect of condition (F(1,121) = .003, p = .96, η2 < .001) was not significant, indicating that there
was no significant difference in reporting of fear on the PANAS-X between mood induction
conditions when using difference scores.
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One-way ANOVA – residualized change score. None of the covariates that were under
consideration were significantly associated with fear on the PANAS-X (all p’s > .05) and were
dropped from the final model. Levene’s test for homogeneity of variance was not significant
(F(1,121) = 1.08, p = .30), indicating that this assumption underlying ANOVA was met. The
main effect of condition (F(1,121) = .02, p = .89, η2 < .001) was not significant, indicating that
there was no significant difference in reporting of fear on the PANAS-X between mood
induction conditions when using residualized change scores.
One-way repeated measures ANOVA. Current depressive symptoms (p < .001) were
significantly associated with fear on the PANAS-X and were included in the final model. The
remaining covariates that were under consideration were not significantly associated with fear on
the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test for
homogeneity of variance was not significant (PANAS-X FPRE: F(1,116) = 1.70, p = .20;
PANAS-X FPOST: F(1,116) = .12, p = .73), indicating that this assumption underlying ANOVA
was met. The main effect of condition (F(1,115) = .08, p = .78, η2 = .001) was not significant,
indicating that there was no significant difference in reporting of fear on the PANAS-X between
mood induction conditions when using repeated measures.
PANAS-X G. Analyses conducted using the PANAS-X guilt negative basic emotional
scale are reviewed below.
One-way ANOVA – difference score. Current depressive symptoms (p < .001) were
significantly associated with guilt on the PANAS-X and were included in the final model. The
remaining covariates that were under consideration were not significantly associated with guilt
on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test for
homogeneity of variance was not significant (F(1,116) = .66, p = .42), indicating that this
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assumption underlying ANOVA was met. Participants exposed to the sad mood induction
reported significantly higher levels of guilt on the PANAS-X post-mood induction (F(1,115) =
9.72, p = .002, η2 = .08) than participants exposed to the neutral mood induction when using
difference scores.
One-way ANOVA – residualized change score. Current depressive symptoms (p < .001)
were significantly associated with guilt on the PANAS-X and were included in the final model.
The remaining covariates that were under consideration were not significantly associated with
guilt on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test for
homogeneity of variance was not significant (F(1,116) = 1.23, p = .27), indicating that this
assumption underlying ANOVA was met. Participants exposed to the sad mood induction
reported significantly higher levels of guilt on the PANAS-X post-mood induction (F(1,115) =
8.69, p = .004, η2 = .07) than participants exposed to the neutral mood induction when using
residualized change scores.
One-way repeated measures ANOVA. Current depressive symptoms (p < .001) were
significantly associated with guilt on the PANAS-X and were included in the final model. The
remaining covariates that were under consideration were not significantly associated with guilt
on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test for
homogeneity of variance was not significant (PANAS-X GPRE: F(1,116) = 1.32, p = .25;
PANAS-X GPOST: F(1,116) = .02, p = .88), indicating that this assumption underlying ANOVA
was met. The main effect of condition (F(1,115) = .02, p = .90, η2 < .001) was not significant,
indicating that there was no significant difference in reporting of guilt on the PANAS-X between
mood induction conditions when using repeated measures.
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PANAS-X H. Analyses conducted using the PANAS-X hostility negative basic
emotional scale are reviewed below.
One-way ANOVA – difference score. Current state anxiety symptoms (p = .01) were
significantly associated with hostility on the PANAS-X and were included in the final model.
The remaining covariates that were under consideration were not significantly associated with
hostility on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test
for homogeneity of variance was significant (F(1,114) = 5.92, p = .02), indicating that this
assumption underlying ANOVA was not met. Of note, this did not appear to be driven by the
inclusion of the covariate. Without the covariate, Levene’s test for homogeneity of variance was
significant (F(1,123) = 5.48, p = .02).
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of differences scores were calculated and
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
difference scores were normally distributed for one measure of normality for the formerly
depressed participants exposed to the neutral mood induction (Shapiro-Wilk: D(23) = .93, p =
.12). However, residuals of difference scores were not normally distributed for the remaining
groups and conditions (p’s < .05). Second, difference scores were transformed using the
reciprocal transformation. Levene’s test for homogeneity of variance continued to be significant
(F(1,122) = 5.31, p = .02), indicating that this assumption underlying ANOVA was still not met.
Consequently, the one-way ANOVA was conducted with the α level decreased from .05 to .01.
The main effect of condition (F(1,113) = 2.99, p = .09, η2 = .03) was not significant, indicating
that there was no significant difference in reporting of hostility on the PANAS-X between mood
induction conditions when using difference scores.
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One-way ANOVA – residualized change score. Current depression (p = .004) and state
anxiety (p = .003) symptoms were significantly associated with hostility on the PANAS-X and
were included in the final model. The remaining covariates that were under consideration were
not significantly associated with hostility on the PANAS-X (all p’s > .05) and were dropped
from the final model. Levene’s test for homogeneity of variance was significant (F(1,111) =
3.85, p = .05), indicating that this assumption underlying ANOVA was not met. Of note, this did
not appear to be driven by the inclusion of the covariates. Without the covariates, Levene’s test
for homogeneity of variance was significant (F(1,123) = 3.80, p = .05).
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of differences scores were calculated and
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
residualized change scores were normally distributed for one measure of normality for the
formerly depressed participants exposed to the neutral mood induction (Shapiro-Wilk: D(23) =
.93, p = .12). However, residuals of residualized change scores were not normally distributed for
the remaining groups and conditions (p’s < .05). Second, residualized change scores were
transformed using the reciprocal transformation. Levene’s test for homogeneity of variance
continued to be significant (F(1,123) = 4.07, p = .05), indicating that this assumption underlying
ANOVA was still not met. Consequently, the one-way ANOVA was conducted with the α level
decreased from .05 to .01. The main effect of condition (F(1,109) = 2.32, p = .13, η2 = .02) was
not significant, indicating that there was no significant difference in reporting of hostility on the
PANAS-X between mood induction conditions when using residualized change scores.
One-way repeated measures ANOVA. BMI (p =.05) and current depression symptoms (p
< .001) were significantly associated with hostility on the PANAS-X and were included in the
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final model. The remaining covariates that were under consideration were not significantly
associated with hostility on the PANAS-X (all p’s > .05) and were dropped from the final model.
Levene’s test for homogeneity of variance was not significant (PANAS-X HPRE: F(1,118) = 3.14,
p = .08; PANAS-X HPOST: F(1,118) = 3.38, p = .07), indicating that this assumption underlying
ANOVA was met. The main effect of condition (F(1,116) = 1.22, p = .27, η2 = .01) was not
significant, indicating that there was no significant difference in reporting of hostility on the
PANAS-X between mood induction conditions when using repeated measures.
PANAS-X S. Analyses conducted using the PANAS-X sadness negative basic emotional
scale are reviewed below.
One-way ANOVA – difference score. Current depressive symptoms (p = .03) were
significantly associated with sadness on the PANAS-X and were included in the final model. The
remaining covariates that were under consideration were not significantly associated with
sadness on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test
for homogeneity of variance was significant (F(1,118) = 16.56, p < .001), indicating that this
assumption underlying ANOVA was not met. Of note, this did not appear to be driven by the
inclusion of the covariate. Without the covariate, Levene’s test for homogeneity of variance was
significant (F(1,123) = 11.42, p = .001).
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of differences scores were calculated and
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
difference scores were normally distributed for the formerly depressed participants exposed to
the neutral mood induction (Kolmogorov-Smirnov: D(23) = .14, p = .20; Shapiro-Wilk: D(23) =
.95, p = .30) and for one measure of normality for the formerly depressed participants exposed to

166

the sad mood induction (Kolmogorov-Smirnov: D(19) = .20, p = .06). However, residuals of
difference scores were not normally distributed for the remaining groups and conditions (all p’s
< .05). Second, difference scores were transformed using the reciprocal transformation. Levene’s
test for homogeneity of variance continued to be significant (F(1,123) = 14.33, p < .001),
indicating that this assumption underlying ANOVA was still not met. Consequently, the one-way
ANOVA was conducted with the α level decreased from .05 to .01. Participants exposed to the
sad mood induction reported significantly higher levels of sadness on the PANAS-X post-mood
induction (F(1,117) = 11.67, p = .001, η2 = .09) than participants exposed to the neutral mood
induction when using difference scores.
One-way ANOVA – residualized change score. Current depressive symptoms (p < .001)
were significantly associated with sadness on the PANAS-X and were included in the final
model. The remaining covariates that were under consideration were not significantly associated
with sadness on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s
test for homogeneity of variance was significant (F(1,118) = 20.67, p < .001), indicating that this
assumption underlying ANOVA was not met. Of note, this did not appear to be driven by the
inclusion of the covariate. Without the covariate, Levene’s test for homogeneity of variance was
significant (F(1,123) = 17.35, p < .001).
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of differences scores were calculated and
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
difference scores were normally distributed for the formerly depressed participants exposed to
the neutral mood induction (Kolmogorov-Smirnov: D(23) = .14, p = .20; Shapiro-Wilk: D(23) =
.95, p = .30) and for one measure of normality for the formerly depressed participants exposed to
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the sad mood induction (Kolmogorov-Smirnov: D(19) = .20, p = .06). However, residuals of
difference scores were not normally distributed for the remaining groups and conditions (all p’s
< .05). Second, residualized change scores were transformed using the reciprocal transformation.
Levene’s test for homogeneity of variance continued to be significant (F(1,123) = 11.89, p =
.001), indicating that this assumption underlying ANOVA was still not met. Consequently, the
one-way ANOVA was conducted with the α level decreased from .05 to .01. Participants
exposed to the sad mood induction reported significantly higher levels of sadness on the
PANAS-X post-mood induction (F(1,117) = 12.76, p = .001, η2 = .10) than participants exposed
to the neutral mood induction when using residualized change scores.
One-way repeated measures ANOVA. Current depressive symptoms (p < .001) were
significantly associated with sadness on the PANAS-X and were included in the final model. The
remaining covariates that were under consideration were not significantly associated with
sadness on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test
for homogeneity of variance was not significant (PANAS-X SPRE: F(1,118) = .12, p = .74;
PANAS-X SPOST: F(1,118) = .82, p = .37), indicating that this assumption underlying ANOVA
was met. The main effect of condition (F(1,117) = .13, p = .72, η2 = .001) was not significant,
indicating that there was no significant difference in reporting of sadness on the PANAS-X
between mood induction conditions when using repeated measures.
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Table 15. Means, Standard Deviations, P Values, and Effect Sizes for Measures Used for the
Manipulation Check by Condition

Measure
VASPRE
VASPOST
VASDS
ZRESVAS
VASRM
Measure
PANAS-X NPRE
PANAS-X NPOST
PANAS-X NDS
ZRESPANAS-X N
PANAS-X NRM
Measure
PANAS-X PPRE
PANAS-X PPOST
PANAS-X PDS
ZRESPANAS-X P
PANAS-X PRM
Measure
PANAS-X FPRE
PANAS-X FPOST
PANAS-X FDS
ZRESPANAS-X F
PANAS-X FRM
Measure
PANAS-X GPRE
PANAS-X GPOST
PANAS-X GDS
ZRESPANAS-X G
PANAS-X GRM

Total (N = 123)
M
SD
8.67
13.29
24.99
26.22
15.61
24.33
-.14
.89

Condition
SMI (n = 60)
NMI (n = 63)
M
SD
M
SD
9.05
14.90
8.30
11.64
38.18
28.23
12.22
16.00
28.33
27.25
3.49
12.32
.52
1.09
-.52
.52

Total (N = 120)
M
SD
14.80
5.62
15.35
5.58
.47
2.33
-.05
.75

SMI (n = 61)
M
SD
14.73
6.18
15.65
6.00
.79
2.63
.14
1.13

NMI (n = 59)
M
SD
14.87
5.03
15.05
5.16
.14
1.93
-.19
.71

Total (N = 123)
M
SD
29.82
6.42
27.66
7.55
-2.14
3.36
.14
.91

SMI (n = 62)
M
SD
29.52
6.46
26.84
7.93
-2.71
3.76
-.13
.95

NMI (n = 61)
M
SD
30.11
6.42
28.48
7.12
-1.56
2.81
.16
.68

Total (N = 123)
M
SD
8.96
3.81
8.94
3.79
-.06
1.58
.02
.85

SMI (n = 61)
M
SD
8.94
4.30
8.89
3.92
-.05
1.61
-.02
.91

NMI (n = 62)
M
SD
8.98
3.30
9.00
3.68
-.07
1.56
.003
1.02

Total (N = 123)
M
SD
7.91
3.32
8.27
3.62
.24
1.36
-.15
.36

SMI (n = 63)
M
SD
7.73
3.25
8.37
3.97
.55
1.65
.14
1.05

NMI (n = 60)
M
SD
8.08
3.40
8.18
3.24
-.09
.87
-.24
.51
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p

< .001
< .001
< .001

η2

.27
.29
.19

p

η2

.13
.02a
.46

.02
.05
.005

p

η2

.06
.12
.38

.03
.02
.007

p

η2

.96
.89
.78

< .001
< .001
.001

p

η2

.002
.004
.90

.08
.07
< .001

Table 15 Continued
Measure
PANAS-X HPRE
PANAS-X HPOST
PANAS-X HDS
ZRESPANAS-X H
PANAS-X HRM

Total (N = 125)
M
SD
8.46
3.19
8.66
3.27
.14
1.79
-.12
.73

SMI (n = 63)
M
SD
8.49
3.59
8.97
3.82
.43
2.15
.14
1.18

NMI (n = 62)
M
SD
8.42
2.77
8.34
2.57
-.15
1.29
-.15
.73

Total (N = 125)
M
SD
7.80
3.39
8.06
3.51
.20
1.83
-10
.80

SMI (n = 63)
M
SD
7.52
3.65
8.32
3.96
.71
2.18
.24
1.16

NMI (n = 62)
M
SD
8.08
3.12
7.79
3.00
-.32
1.18
-.28
.56

p

η2

.09
.13
.27

.03
.02
.01

Measure
p
η2
PANAS-X SPRE
PANAS-X SPOST
PANAS-X SDS
.001
.09
ZRESPANAS-X S
.001
.10
PANAS-X SRM
.72
.001
Note. SMI = sad mood induction; NMI = neutral mood induction; VAS = Visual Analogue
Scale; DS = difference score; ZRES = residualized change scores; PANAS-X = Positive and
Negative Affect Scale – Expanded Form; N = negative affect general dimension scale; a = not
significant due to adjusted p value; P = positive affect general dimension scale; F = fear basic
negative emotional scale; H = hostility basic negative emotional scale; G = guilt basic negative
emotional scale; S = sadness basic negative emotional scale; RM = repeated measures.
Hypothesis 2
A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral)
factorial ANOVAs using difference scores and residualized change scores and a 2 (group:
formerly depressed, healthy control) X 2 (condition: sad, neutral) repeated measures ANOVA
were used to test the hypothesis that formerly depressed and healthy control participants exposed
to the sad mood induction would report significantly more dysphoric mood on the VAS postmood induction than formerly depressed and healthy control participants exposed to the neutral
mood inductions. Means, standard deviations, p values, and effect sizes for session 2 mood
measures by group are presented in Table 16 while means, standard deviations, p values, and
effect sizes for session 2 mood measures by group and condition are presented in Table 17.
Planned comparisons were conducted using contrast analyses. Means, standard deviations, and p
values for session 2 mood measures for planned comparisons are presented in Table 18.
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VAS. Analyses conducted using the VAS are reviewed below.
2 X 2 factorial ANOVA – difference score. None of the covariates that were under
consideration were significantly associated with mood reactivity (all p’s > .05) and were dropped
from the final model. Levene’s test for homogeneity of variance was significant (F(3,119) =
17.15, p < .001), indicating that this assumption underlying ANOVA was not met.
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of differences scores were calculated and
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
difference scores were normally distributed for the formerly depressed participants exposed to
the sad mood induction (Kolmogorov-Smirnov: D(17) = .15, p = .20; Shapiro-Wilk: D(17) = .95,
p = .38). However, residuals of difference scores were not normally distributed for the remaining
groups and conditions (all p’s < .05). Second, difference scores were transformed using the
reciprocal transformation. Levene’s test for homogeneity of variance continued to be significant
(F(3,119) = 14.60, p < .001), indicating that this assumption was still not met. Consequently, the
one-way ANOVA was conducted with the α level decreased from .05 to .01.
Formerly depressed participants reported significantly higher levels of sadness on the
VAS post-mood induction (F(1,119) = 7.49, p = .007, η2 = .06) than healthy control participants.
In addition, participants exposed to the sad mood induction reported significantly higher levels of
sadness on the VAS post-mood induction (F(1,119) = 51.17, p < .001, η2 = .30) than participants
exposed to the neutral mood induction. The group by condition interaction was not significant
(F(1,119) = 3.20, p = .08, η2 = .03) when using difference scores. It is possible that this is due to
lack of power rather than lack of effect. Using contrast analyses that did not assume equal
variances, formerly depressed and healthy control participants exposed to the sad mood
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induction reported significantly higher levels of sadness on the VAS post-mood induction
(t(37.12) = 6.23, pL < .001, pQ = .08, pC < .001) compared to formerly depressed and healthy
control participants exposed to the neutral mood induction. In addition, formerly depressed
participants exposed to the sad mood induction reported significantly higher levels of sadness on
the VAS post-mood induction (t(18.16) = 4.14, pL < .001, pQ = .08, pC < .001) compared to
healthy control participants exposed to the sad mood induction and formerly depressed and
healthy control participants exposed to the neutral mood induction.
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were
under consideration were significantly associated with mood reactivity (all p’s > .05) and were
dropped from the final model. Levene’s test for homogeneity of variance was significant
(F(3,119) = 15.94, p < .001), indicating that this assumption underlying ANOVA was not met.
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of residualized change scores were calculated
and Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
residualized change scores were normally distributed for the formerly depressed participants
exposed to the sad mood induction (Kolmogorov-Smirnov: D(17) = .15, p = .20; Shapiro-Wilk:
D(17) = .95, p = .38). However, residuals of residualized change scores were not normally
distributed for the remaining groups and conditions (all p’s < .05). Second, residualized change
scores were transformed using the reciprocal transformation. Levene’s test for homogeneity of
variance continued to be significant (F(3,119) = 14.98, p < .001), indicating that this assumption
was still not met. Consequently, the factorial ANOVA was conducted with the α level decreased
from .05 to .01.
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Formerly depressed participants reported significantly higher levels of sadness on the
VAS post-mood induction (F(1,119) = 10.16, p = .002, η2 = .08) than healthy control
participants. In addition, participants exposed to the sad mood induction reported significantly
higher levels of sadness on the VAS post-mood induction (F(1,119) = 53.94, p < .001, η2 = .31)
than participants exposed to the neutral mood induction. The group by condition interaction was
not significant (F(1,119) = 2.18, p = .14, η2 = .02) when using residualized change scores. It is
possible that this is due to lack of power rather than lack of effect. Using contrast analyses that
did not assume equal variances, formerly depressed and healthy control participants exposed to
the sad mood induction reported significantly higher levels of sadness on the VAS post-mood
induction (t(38.07) = 6.54, pL < .001, pQ = .14, pC < .001) compared to formerly depressed and
healthy control participants exposed to the neutral mood induction. In addition, formerly
depressed participants exposed to the sad mood induction reported significantly higher levels of
sadness on the VAS post-mood induction (t(18.22) = 4.37, pL < .001, pQ = .14, pC < .001)
compared to healthy control participants exposed to the sad mood induction and formerly
depressed and healthy control participants exposed to the neutral mood induction.
2 X 2 repeated measures ANOVA. None of the covariates that were under consideration
were significantly associated with mood reactivity (all p’s > .05) and were dropped from the final
model. Levene’s test for homogeneity of variance was not significant for the pre-mood induction
measure (VASPRE : F(3,119) = 2.48, p = .06) but was significant for the post-mood induction
measure (VASPOST: F(3,119) = 12.07, p < .001), indicating that this assumption underlying
ANOVA was not met.
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. Residuals could not be calculated as there was only one measure
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for each calculation. The pre- and post-mood induction measures were transformed using the
reciprocal transformation. Levene’s test for homogeneity of variance continued to be significant
(VASPRE: F(3,119) = 2.97, p = .04; VASPOST: F(3,119) = 9.71, p < .001), indicating that this
assumption underlying ANOVA was still not met. Consequently, the factorial ANOVA was
conducted with the α level decreased from .05 to .01.
Formerly depressed participants reported significantly higher levels of sadness on the
VAS post-mood induction (F(1,119) = 11.95, p = .001, η2 = .09) than healthy control
participants. In addition, participants exposed to the sad mood induction reported significantly
higher levels of sadness on the VAS post-mood induction (F(1,119) = 23.60, p < .001, η2 = .17)
than participants exposed to the neutral mood induction. The group by condition interaction was
not significant (F(1,119) = .02, p = .90, η2 < .001) when using repeated measures. Using contrast
analyses that did not assume equal variances, formerly depressed and healthy control participants
exposed to the sad mood induction reported significantly higher levels of sadness on the VAS
post-mood induction (F(1,121) = 22.79, p < .001) compared to formerly depressed and healthy
control participants exposed to the neutral mood induction. In addition, formerly depressed
participants exposed to the sad mood induction reported significantly higher levels of sadness on
the VAS post-mood induction (F(1,121) = 14.58, p < .001) compared to healthy control
participants exposed to the sad mood induction and formerly depressed and healthy control
participants exposed to the neutral mood induction.
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the VAS analyses. Results
indicated that the current model had a power of .26 for the difference score, .16 for the
residualized change score, and .01 for the repeated measures. Results suggested that given the

174

current study’s sample size, α level, and observed effect size, there was a 1 to 26% chance of
detecting an effect depending on which analytic technique was used.
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et
al., 2007) to determine the minimum effect size needed to obtain significant results for the VAS
analyses. Results indicated that the required effect size was f = .31 for the factorial ANOVAs and
f = .30 for the repeated measures ANOVA. Results suggested that given the current study’s
sample size and α level, at least a medium effect size was required to obtain significant results if
a power of .80 was achieved.
Table 16. Means, Standard Deviations, P Values, and Effect Sizes for Session 2 Mood Measures
by Group

Total (N = 123)
M
SD
8.67
13.29
24.99 26.22
15.61 24.33
-.14
.89

Group
FD (n = 40)
HC (n = 83)
M
SD
M
SD
11.78 15.02 7.17
12.19
33.90 27.81 20.59 24.39
20.85 29.47 13.08 21.15
.25
1.15
-.14
.89

Measure
p
η2
VASPRE
VASPOST
VASDS
.007
.06
ZRESVAS
.002
.08
VASRM
.001
.09
Note. The difference between pre- and post-mood induction measures may not precisely equal
the difference score as outlier data was addressed differently depending on the type of analyses
conducted; FD = formerly depressed; HC = healthy control; VAS = Visual Analogue Scale; PRE =
pre-mood induction; POST = post-mood induction; DS = difference score; ZRES = residualized
change scores; RM = repeated measures.
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Table 17. Means, Standard Deviations, P Values, and Effect Sizes for Session 2 Mood Measures by Group and Condition

Total (N = 123)
M
SD
8.67
13.29
24.99
26.22
15.61
24.33
-.14
.89

Group and Condition
FD/SMI (n = 17) FD/NMI (n = 23) HC/SMI (n = 43)
M
SD
M
SD
M
SD
9.22
15.11
13.78
14.97
8.98
14.99
51.83
27.38
19.87
18.93
32.47
26.87
41.12
29.60
5.87
18.71
23.28
24.85
1.05
1.16
-.35
.71
.31
1.00

HC/NMI (n = 40)
Measure
M
SD
p
η2
VASPRE
5.22
7.94
VASPOST
7.83
12.28
VASDS
2.13
6.19
.08
.03
ZRESVAS
-.62
.34
.14
.02
VASRM
.90
< .001
Note. The difference between pre- and post-mood induction measures may not precisely equal the difference score as outlier data was
addressed differently depending on the type of analyses conducted; FD = formerly depressed; HC = healthy control; SMI = sad mood
induction; NMI = neutral mood induction; VAS = Visual Analogue Scale; PRE = pre-mood induction; POST = post-mood induction; DS =
difference score; ZRES = residualized change scores; RM = repeated measures.
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Table 18. Means, Standard Deviations, and P Values for Session 2 Mood Measures for Planned Comparisons

Total (N = 123)
Measure
VASPRE
VASPOST
VASDS
ZRESVAS
VASRM

M
8.67
24.99
15.61
-.14

SD
13.29
26.22
24.33
.89

Total (N = 123)

Group and Condition
FD+HC/SMI
FD+HC/NMI
(n = 60)
(n = 63)
M
SD
M
SD
9.05
14.90
8.30
11.64
38.18
28.23
12.22
16.00
28.33
27.25
3.49
12.32
.52
1.09
-.52
.52
FD/SMI (n = 17)

pL

pQ

pC

< .001
< .001
< .001

.08
.14

< .001
< .001

FD/NMI, HC/SMI,
HC/NMI (n = 106)
Measure
M
SD
M
SD
M
SD
pL
pQ
pC
VASPRE
8.67
13.29
9.22
15.11
8.57
13.04
VASPOST
24.99
26.22
51.83
27.38
20.43
23.23
VASDS
15.61
24.33
41.12
29.60
11.52
20.78
< .001 .08
< .001
ZRESVAS
-.14
.89
1.05
1.16
-.18
.85
< .001 .14
< .001
VASRM
< .001
Note. The difference between pre- and post-mood induction measures may not precisely equal the difference score
as outlier data was addressed differently depending on the type of analyses conducted; FD = formerly depressed; HC
= healthy control; SMI = sad mood induction; NMI = neutral mood induction; L = linear; Q = quadratic; C = cubic;
VAS = Visual Analogue Scale; PRE = pre-mood induction; POST = post-mood induction; DS = difference score; ZRES =
residualized change scores; RM = repeated measures.
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Cardiovascular Measures
During session 2, participants’ physiological responding was recorded to assess
cardiovascular reactivity to the mood induction (i.e., Hypothesis 3) and recovery from the mood
induction (i.e., Hypothesis 3). The physiological recordings of interest are cardiovascular
measures derived from ECG and ICG. ECG was used to collect data that was used to calculate
HP and RSA. MindWare Technologies Ltd. (2009) hardware and Biolab 3.1 analysis software
set to collect ECG data falling within -5 and 5 volts with a sampling rate of 1,000 hertz were
utilized in conjunction with the five GSC electrode sensors located on the participants’ right
collarbone, bottom left rib, bottom right rib, jugular notch, and sternum. ICG was used to collect
data that was used to calculate RSA, CO, and PEP. Of note, CO was dropped from analyses.
Typical values for resting CO range from 4 to 12 liters per minute (J. Schmidt, personal
communication, April 16, 209). Average CO values ranged from 1.62 to 365.73 during baseline,
1.49 to 390.58 during the mood induction, and 1.69 to 175.80 during recovery, indicating that
this cardiovascular measure was not accurate. It was determined that this issue was due to
inaccurate SV values. SV is not used to calculate HP, RSA, or PEP and therefore, these
cardiovascular measures were not affected. MindWare Technologies Ltd. (2009) hardware and
Biolab 3.1 analysis software set to collect ICG data falling at a sampling rate of 1,000 Hertz and
calibrated at .10 volts per one-ohm change for Z0 and 1.00 volts per ohms per second for dZ/dt
were utilized in conjunction with the two GSC electrode sensors located on the participants’ midback and upper-back parallel within 1.50 inches of the jugular notch and sternum sensors.
Cardiovascular functioning at baseline was calculated for each cardiovascular measure
using the average obtained during the last two and five minutes of baseline (i.e., HPBL2/BL5,
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RSABL2/BL5, COBL2/BL5, and PEPBL2/BL5). No outlier data was present for HPBL2, HPBL5, RSABL2,
RSABL5, PEPBL2, and PEPBL5.
Cardiovascular functioning for the mood induction was calculated for each
cardiovascular measure using the average obtained during the first two and five minutes of the
mood induction (i.e., HPMI2/5, RSAMI2/5, COMI2/5, and PEPMI2/5). No outlier data was present for
HPMI2, HPMI5, RSAMI2, RSAMI5, PEPMI2, and PEPMI5.
Cardiovascular functioning for recovery was calculated for each cardiovascular measure
using the average obtained during the last two and five minutes of recovery (i.e., HPRC2/5,
RSARC2/5, CORC2/5, and PEPRC2/5). Outlier data for the PEPRC2 (n = 1) were winsorized to address
extreme values. No outlier data was present for HPRC2, HPRC5, RSARC2, RSARC5, and PEP RC5.
Cardiovascular reactivity was operationalized as the difference score for the average of
each cardiovascular measure (i.e., HPDS2RA/DS5RA, RSADS2RA/DS5RA, CODS2RA/DS5RA, and
PEPDS2RA/DS5RA) and residualized change scores for the average of each cardiovascular measure
(i.e., ZRES2/RES5HPRA, ZRES2/RES5RSARA, ZRES2/RES5CORA, and ZRES2/RES5PEPRA) assessed during
baseline and the mood induction (i.e., HPBL2/BL5/MI2/MI5, RSABL2/BL5/MI2/MI5, COBL2/BL5/MI2/MI5, and
PEPBL2/BL5/MI2/MI5). Outlier data for the RSADS2RA (n = 1), RSADS5RA (n = 1), PEPDS2RA (n = 2),
and PEPDS5RA (n = 2) were winsorized to address extreme values. No outlier data was present for
HPDS2RA and HPDS5RA. In addition, outlier data for the ZRES2RSARA (n = 1), ZRES5RSARA (n = 1),
ZRES2PEPRA (n = 2), and ZRES5PEPRA (n = 2) were winsorized to address extreme values.
Cardiovascular recovery was operationalized as the difference score for the average of
each cardiovascular measure (i.e., HPDS2RC/DS5RC, RSADS2RC/DS5RC, CODS2RC/DS5RC, and
PEPDS2RC/DS5RC) and residualized change scores for the average of each cardiovascular measure
(i.e., ZRES2/RES5HPRC, ZRES2/RES5RSARC, ZRES2/RES5CORC, and ZRES2/RES5PEPRC) during the mood
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induction and the recovery period (i.e., HPBL2/BL5/RC2/RC5, RSABL2/BL5/RC2/RC5, COBL2/BL5/RC2/RC5,
and PEPBL2/BL5/RC2/RC5). Outlier data for the RSADS5RC (n = 3), PEPDS2RC (n = 4), and PEPDS5RC (n
= 2) were winsorized to address extreme values. No outlier data was present for HPDS2RA, and
HPDS5RA, and RSADS2RC. In addition, outlier data for the ZRES2HPRC (n = 1), ZRES5HPRC (n = 1),
and ZRES2PEPRC (n = 4) were winsorized to address extreme values
Descriptive statistics. Descriptive statistics for session 2 cardiovascular measures are
presented in Table 19. The baseline (i.e., BL2/BL5), mood induction (i.e., MI2/MI5), and recovery
(i.e., RC2/RC5) scores are single item measures. Consequently, Cronbach’s alpha could not be
calculated. The difference (i.e., DS) and residualized change (i.e., ZRES2/ZRES5) scores are
calculated measures. Consequently, Cronbach’s alpha could not be calculated.

180

Table 19. Descriptive Statistics for Session 2 Cardiovascular Measures
Measure
HPBL2
HPBL5
HPMI2
HPMI5
HPRC2
HPRC5
HPDS2RA
ZRES2HPRA
HPDS5RA
ZRES5HPRA
HPDS2RC
ZRES2HPRC
HPDS5RC
ZRES5HPRC
RSABL2
RSABL5
RSAMI2
RSAMI5
RSARC2
RSARC5
RSADS2RA
ZRES2RSARA
RSADS5RA
ZRES5RSARA
RSADS2RC
ZRES2RSARC
RSADS5RC
ZRES5RSARC
PEPBL2
PEPBL5
PEPMI2
PEPMI5
PEPRC2
PEPRC5
PEPDS2RA
ZRES2PEPRA
PEPDS5RA
ZRES5PEPRA
PEPDS2RC
ZRES2PEPRC
PEPDS5RC
ZRES5PEPRC

M
781.45
785.51
799.21
788.89
783.98
787.42
17.76
.00
3.38
.00
4.23
.07
3.70
.03
5.84
5.83
6.03
5.89
5.82
5.79
.24
.02
.11
.03
-.02
.00
-.05
.00
120.61
120.37
119.77
119.91
120.15
120.91
-.48
-.01
-.31
.04
.68
.09
.79
.00

SD
104.55
105.88
111.48
108.15
102.44
103.62
39.29
1.00
33.73
1.00
49.12
.78
37.99
.85
1.04
1.01
1.15
1.13
1.00
.93
.61
.73
.45
.58
.70
1.00
.43
1.00
11.90
11.68
12.74
13.04
14.33
12.24
4.19
.65
4.13
.64
5.06
.53
4.57
1.00
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Sample range
487.51-1,060.85
538.41-1,045.88
591.72-1,045.57
600.29-1,049.48
627.45-1,109.76
633.77-1,109.32
-79.84-159.61
-2.48-3.64
-91.22-126.04
-2.67-3.48
-97.39-236.03
-1.40-1.70
-104.38-189.20
-2.69-1.29
3.75-9.19
3.65-9.37
1.81-9.49
1.36-9.44
3.45-8.13
3.67-8.45
-1.22-1.97
-1.52-1.89
-.72-1.78
-1.02-1.38
-1.82-1.99
-2.99-2.65
-1.37-.96
-2.11-3.12
90-146.50
90-145.80
77.00-147.00
75.00-146.00
58.50-145.50
87.60-146.00
-10.50-9.00
-1.33-1.06
-18.80-10.40
-1.26-1.47
-17.00-15.50
-1.80-1.51
-16.00-11.00
-3.50-1.85

Note. The difference between baseline and mood induction or mood induction and recovery
measures may not precisely equal the difference score as outlier data was addressed differently
depending on the type of analyses conducted; HP = heart period at baseline; BL = baseline; MI =
mood induction; RC = recovery; 2 = average obtained during a two-minute interval; 5 = average
obtained during a five-minute interval; DS = difference score; RA = reactivity; ZRES = residualized
change scores; RSA = respiratory sinus arrhythmia; PEP = pre-ejection period.
Baseline Cardiovascular Functioning
A series of one-way ANOVAs were used to assess significant group differences in
cardiovascular functioning at baseline. It was expected that formerly depressed and healthy
control participants would exhibit similar cardiovascular functioning for HP, RSA, PEP, or CO
during baseline.
HP – two-minutes. Analyses conducted for baseline cardiovascular functioning using
two-minute averages of HP are reviewed below.
One-way ANOVA. Age (p = .01) and BMI (p = .04) were significantly associated with
baseline two-minute HP functioning and were included in the final model. The remaining
covariates that were under consideration were not significantly associated with two-minute HP
functioning (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity
of variance was not significant (F(1,90) = .04, p = .84), indicating that this assumption
underlying ANOVA was met. The main effect of group (F(1,88) = .80, p = .37, η2 = .009) was
not significant, indicating that there was no significant difference in baseline two-minute HP
functioning between groups when using univariate analysis.
HP – five-minutes. Analyses conducted for baseline cardiovascular functioning using
five-minute averages of HP are reviewed below.
One-way ANOVA. Age (p = .008) and BMI (p = .04) were significantly associated with
baseline five-minute HP functioning and were included in the final model. The remaining
covariates that were under consideration were not significantly associated with five-minute HP
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functioning (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity
of variance was not significant (F(1,90) = .03, p = .86), indicating that this assumption
underlying ANOVA was met. The main effect of group (F(1,88) = .80, p = .37, η2 = .009) was
not significant, indicating that there was no significant difference in baseline five-minute HP
functioning between groups when using univariate analysis.
RSA – two-minutes. Analyses conducted for baseline cardiovascular functioning using
two-minute averages of RSA are reviewed below.
One-way ANOVA. None of the covariates that were under consideration were
significantly associated with baseline two-minute RSA functioning (all p’s > .05) and were
dropped from the final model. Levene’s test for homogeneity of variance was not significant
(F(1,93) = .05, p = .82), indicating that this assumption underlying ANOVA was met. The main
effect of group (F(1,93) = .47, p = .50, η2 = .005) was not significant, indicating that there was no
significant difference in baseline two-minute RSA functioning between groups when using
univariate analysis.
RSA – five-minutes. Analyses conducted for baseline cardiovascular functioning using
five-minute averages of RSA are reviewed below.
One-way ANOVA. None of the covariates that were under consideration were
significantly associated with baseline five-minute RSA functioning (all p’s > .05) and were
dropped from the final model. Levene’s test for homogeneity of variance was not significant
(F(1,93) = .26, p = .61), indicating that this assumption underlying ANOVA was met. The main
effect of group (F(1,93) = .80, p = .38, η2 = .008) was not significant, indicating that there was no
significant difference in baseline five-minute RSA functioning between groups when using
univariate analysis.
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PEP – two-minutes. Analyses conducted for baseline cardiovascular functioning using
two-minute averages of PEP are reviewed below.
One-way ANOVA. Current state anxiety symptoms (p = .03) were significantly
associated with baseline two-minute PEP functioning and were included in the final model. The
remaining covariates that were under consideration were not significantly associated with twominute PEP functioning (all p’s > .05) and were dropped from the final model. Levene’s test for
homogeneity of variance was not significant (F(1,84) = .19, p = .66), indicating that this
assumption underlying ANOVA was met. The main effect of group (F(1,83) = 2.04, p = .16, η2 =
.02) was not significant, indicating that there was no significant difference in baseline twominute PEP functioning between groups when using univariate analysis.
PEP – five-minutes. Analyses conducted for baseline cardiovascular functioning using
five-minute averages of PEP are reviewed below.
One-way ANOVA. Current state anxiety symptoms (p = .01) were significantly
associated with baseline five-minute PEP functioning and were included in the final model. The
remaining covariates that were under consideration were not significantly associated with fiveminute PEP functioning (all p’s > .05) and were dropped from the final model. Levene’s test for
homogeneity of variance was not significant (F(1,84) = .06, p = .80), indicating that this
assumption underlying ANOVA was met. The main effect of group (F(1,83) = 1.60, p = .21, η2 =
.02) was not significant, indicating that there was no significant difference in baseline fiveminute PEP functioning between groups when using univariate analysis.
Hypothesis 3
A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral)
factorial ANOVAs using difference scores and residualized change scores and a series of 2
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(group: formerly depressed, healthy control) X 2 (condition: sad, neutral) repeated measures
ANOVAs were used to test the hypothesis that formerly depressed individuals exposed to the sad
mood induction would exhibit a maladaptive pattern of cardiovascular reactivity (i.e., decreased
HP, RSA, and CO and increased PEP) during the mood induction compared to formerly
depressed participants exposed to the neutral mood induction and healthy control participants
exposed to the sad and neutral mood inductions. Means, standard deviations, p values, and effect
sizes for session 2 cardiovascular measures by group are presented in Table 20 while means,
standard deviations, p values, and effect sizes for session 2 cardiovascular measures by group
and condition are presented in Table 21. Planned comparisons were conducted using contrast
analyses. Means, standard deviations, and p values for session 2 mood measures for planned
comparisons are presented in Table 22.
HP – two-minutes. Analyses conducted for cardiovascular reactivity using two-minute
averages of HP are reviewed below.
2 X 2 factorial ANOVA – difference score. None of the covariates that were under
consideration were significantly associated with two-minute HP reactivity (all p’s > .05) and
were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(3,92) = .94, p = .43), indicating that this assumption underlying ANOVA was met.
Neither the main effects of group (F(1,92) = 2.52, p = .12, η2 = .03) or condition (F(1,92) = 1.15,
p = .29, η2 = .01) nor the group by condition interaction (F(1,92) = .24, p = .62, η2 = .003) were
significant, indicating that there was no significant difference in two-minute HP reactivity
between groups or conditions or the group by condition interaction when using difference scores.
Contrast analyses revealed that there was no significant difference in two-minute HP reactivity
(t(92) = 1.62, pL = .06, pQ = .62, pC = .80) when comparing formerly depressed participants
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exposed to the sad mood induction to formerly depressed participants exposed to the neutral
mood induction and healthy control participants exposed to the sad and neutral mood inductions.
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were
under consideration were significantly associated with two-minute HP reactivity (all p’s > .05)
and were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(3,92) = .95, p = .42), indicating that this assumption underlying ANOVA was met.
Neither the main effects of group (F(1,92) = 2.51, p = .12, η2 = .03) or condition (F(1,92) = 1.14,
p = .29, η2 = .01) nor the group by condition interaction (F(1,92) = .25, p = .62, η2 = .003) were
significant, indicating that there was no significant difference in two-minute HP reactivity
between mood induction conditions or the group by condition interaction when using
residualized change scores. Contrast analyses revealed that there was no significant difference in
two-minute HP reactivity (t(92) = 1.62, pL = .07, pQ = .62, pC = .80) when comparing formerly
depressed participants exposed to the sad mood induction to formerly depressed participants
exposed to the neutral mood induction and healthy control participants exposed to the sad and
neutral mood inductions.
2 X 2 repeated measures ANOVA. Age (p = .01) and BMI (p = .02) were significantly
associated with two-minute HP reactivity and were included in the final model. The remaining
covariates that were under consideration were not significantly associated with two-minute HP
reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity
of variance was not significant (HPBL2: F(3,88) = 1.54, p = .21; HPMI2: F(3,88) = 2.00, p = .12),
indicating that this assumption underlying ANOVA was met. Neither the main effects of group
(F(1,86) = .07, p = .79, η2 = .001) or condition (F(1,86) = 1.78, p = .19, η2 = .02) nor the group
by condition interaction (F(1,86) = .61, p = .44, η2 = .007) were significant, indicating that there
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was no significant difference in two-minute HP reactivity between groups or conditions or the
group by condition interaction when using repeated measures. Contrast analyses revealed that
there was no significant difference in two-minute HP reactivity (F(1,88) = .54, p = .46) when
comparing formerly depressed participants exposed to the sad mood induction to formerly
depressed participants exposed to the neutral mood induction and healthy control participants
exposed to the sad and neutral mood inductions.
HP – five-minutes. Analyses conducted for cardiovascular reactivity using five-minute
averages of HP are reviewed below.
2 X 2 factorial ANOVA – difference score. Franco-American ethnicity (p = .002) was
significantly associated with five-minute HP reactivity and was included in the final model. The
remaining covariates that were under consideration were not significantly associated with fiveminute HP reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for
homogeneity of variance was not significant (F(3,91) = 1.60, p = .20), indicating that this
assumption underlying ANOVA was met. Formerly depressed participants exhibited
significantly higher levels of five-minute HP reactivity during the mood induction (F(1,90) =
4.13, p = .05, η2 = .04) than healthy control participants. Neither the main effect of condition
(F(1,90) = 2.10, p = .15, η2 = .02) nor the group by condition interaction (F(1,90) = 1.22, p = .27,
η2 = .01) were significant, indicating that there was no significant difference in five-minute HP
reactivity between mood induction conditions or the group by condition interaction when using
difference scores. Using contrast analyses, formerly depressed participants exposed to the sad
mood induction reported exhibited higher levels of five-minute HP reactivity during the mood
induction (F(3,90) = 2.18, p = .10) compared to healthy control participants exposed to the sad
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mood induction and formerly depressed and healthy control participants exposed to the neutral
mood induction.
2 X 2 factorial ANOVA – residualized change score. Franco-American ethnicity (p =
.002) was significantly associated with five-minute HP reactivity and was included in the final
model. The remaining covariates that were under consideration were not significantly associated
with five-minute HP reactivity (all p’s > .05) and were dropped from the final model. Levene’s
test for homogeneity of variance was not significant (F(3,91) = 1.41, p = .25), indicating that this
assumption underlying ANOVA was met. Formerly depressed participants exhibited
significantly higher levels of five-minute HP reactivity during the mood induction (F(1,90) =
4.49, p = .04, η2 = .05) than healthy control participants. Neither the main effect of condition
(F(1,90) = 2.20, p = .14, η2 = .02) nor the group by condition interaction (F(1,90) = 1.21, p = .27,
η2 = .01) were significant, indicating that there was no significant difference in five-minute HP
reactivity between mood induction conditions or the group by condition interaction when using
residualized change scores. Using contrast analyses, formerly depressed participants exposed to
the sad mood induction reported exhibited higher levels of five-minute HP reactivity during the
mood induction (F(3,90) = 2.32, p = .08) compared to healthy control participants exposed to the
sad mood induction and formerly depressed and healthy control participants exposed to the
neutral mood induction.
2 X 2 repeated measures ANOVA. Age (p = .01) and BMI (p = .03) were significantly
associated with five-minute HP reactivity and were included in the final model. The remaining
covariates that were under consideration were not significantly associated with five-minute HP
reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity
of variance was not significant (HPBL5: F(3,88) = 2.12, p = .10; HPMI5: F(3,88) = 2.19, p = .10),
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indicating that this assumption underlying ANOVA was met. Neither the main effects of group
(F(1,86) = .001, p = .97, η2 < .001) or condition (F(1,86) = 2.17, p = .14, η2 = .03) nor the group
by condition interaction (F(1,86) = 1.38, p = .24, η2 = .02) were significant, indicating that there
was no significant difference in five-minute HP reactivity between groups or conditions or the
group by condition interaction when using repeated measures. Contrast analyses revealed that
there was no significant difference in five-minute HP reactivity (F(1,88) = 1.29, p = .26) when
comparing formerly depressed participants exposed to the sad mood induction to formerly
depressed participants exposed to the neutral mood induction and healthy control participants
exposed to the sad and neutral mood inductions.
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the HP reactivity analyses. Of
note, analyses were only conducted using five-minute HP reactivity as this is a more stable
measure than of HP reactivity. Results indicated that the current model had a power of .16 for
the difference and residualized change scores and .19 for the repeated measures. Results
suggested that given the current study’s sample size, α level, and observed effect size, there was
a 16 to 19% chance of detecting an effect depending on which analytic technique was used.
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et
al., 2007) to determine the minimum effect size needed to obtain significant results for the HP
reactivity analyses. Of note, analyses were only conducted using five-minute HP reactivity as
this is a more stable measure than two-minute HP reactivity. Results indicated that the required
effect size was f = .29 for the factorial ANOVAs and f = .34 for the repeated measures ANOVA.
Results suggested that given the current study’s sample size and α level, at least a medium effect
size was required to obtain significant results if a power of .80 was achieved.
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RSA – two-minutes. Analyses conducted for cardiovascular reactivity using two-minute
averages of RSA are reviewed below.
2 X 2 factorial ANOVA – difference score. Education level (p = .01) was significantly
associated with two-minute RSA reactivity and was included in the final model. The remaining
covariates that were under consideration were not significantly associated with two-minute RSA
reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity
of variance was not significant (F(3,90) = .50, p = .69), indicating that this assumption
underlying ANOVA was met. Neither the main effects of group (F(1,89) = 2.49, p = .12, η2 =
.03) or condition (F(1,89) = .04, p = .85, η2 < .001) nor the group by condition interaction
(F(1,89) = .36, p = .55, η2 = .004) were significant, indicating that there was no significant
difference in two-minute RSA reactivity between groups or conditions or the group by condition
interaction when using difference scores. Contrast analyses revealed that there was no significant
difference in two-minute RSA reactivity (F(3,89) = 1.00, p = .40) when comparing formerly
depressed participants exposed to the sad mood induction to formerly depressed participants
exposed to the neutral mood induction and healthy control participants exposed to the sad and
neutral mood inductions.
2 X 2 factorial ANOVA – residualized change score. Sex (p = .04) and education level
(p = .01) were significantly associated with two-minute RSA reactivity and were included in the
final model. The remaining covariates that were under consideration were not significantly
associated with two-minute RSA reactivity (all p’s > .05) and were dropped from the final
model. Levene’s test for homogeneity of variance was not significant (F(3,90) = .13, p = .94),
indicating that this assumption underlying ANOVA was met. Neither the main effects of group
(F(1,88) = .46, p = .50, η2 = .005) or condition (F(1,88) = .24, p = .62, η2 = .003) nor the group
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by condition interaction (F(1,88) = .52, p = .47, η2 = .006) were significant, indicating that there
was no significant difference in two-minute RSA reactivity between groups or conditions or the
group by condition interaction when using residualized change scores. Contrast analyses
revealed that there was no significant difference in two-minute RSA reactivity (F(3,88) = .53, p
= .66) when comparing formerly depressed participants exposed to the sad mood induction to
formerly depressed participants exposed to the neutral mood induction and healthy control
participants exposed to the sad and neutral mood inductions.
2 X 2 repeated measures ANOVA. None of the covariates that were under consideration
were significantly associated with two-minute RSA reactivity (all p’s > .05) and were dropped
from the final model. Levene’s test for homogeneity of variance was not significant (RSABL2:
F(3,91) = .87, p = .46; RSAMI2: F(3,91) = .42, p = .74), indicating that this assumption
underlying ANOVA was met. Neither the main effects of group (F(1,91) = .35, p = .56, η2 =
.004) or condition (F(1,91) = .27, p = .61, η2 = .003) nor the group by condition interaction
(F(1,91) = 2.48, p = .12, η2 = .03) were significant, indicating that there was no significant
difference in two-minute RSA reactivity between groups or conditions or the group by condition
interaction when using repeated measures. Contrast analyses revealed that there was no
significant difference in two-minute RSA reactivity (F(1,93) = .73, p = .40) when comparing
formerly depressed participants exposed to the sad mood induction to formerly depressed
participants exposed to the neutral mood induction and healthy control participants exposed to
the sad and neutral mood inductions.
RSA – five-minutes. Analyses conducted for cardiovascular reactivity using five-minute
averages of RSA are reviewed below.
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2 X 2 factorial ANOVA – difference score. None of the covariates that were under
consideration were significantly associated with five-minute RSA reactivity (all p’s > .05) and
were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(3,91) = 1.38, p = .25), indicating that this assumption underlying ANOVA was
met. Neither the main effects of group (F(1,91) = 1.43, p = .23, η2 = .02) or condition (F(1,91) =
.83, p = .36, η2 = .009) nor the group by condition interaction (F(1,91) = .14, p = .71, η2 = .002)
were significant, indicating that there was no significant difference in five-minute RSA reactivity
between groups or conditions or the group by condition interaction when using difference scores.
Contrast analyses revealed that there was no significant difference in five-minute RSA reactivity
(t(91) = .89, pL = .15, pQ = .71, pC = .78) when comparing formerly depressed participants
exposed to the sad mood induction to formerly depressed participants exposed to the neutral
mood induction and healthy control participants exposed to the sad and neutral mood inductions.
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were
under consideration were significantly associated with five-minute RSA reactivity (all p’s > .05)
and were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(3,91) = 1.88, p = .14), indicating that this assumption underlying ANOVA was
met. Neither the main effects of group (F(1,91) = .87, p = .35, η2 = .009) or condition (F(1,91) =
1.19, p = .28, η2 = .01) nor the group by condition interaction (F(1,91) = .68, p = .41, η2 = .007)
were significant, indicating that there was no significant difference in five-minute RSA reactivity
between mood induction conditions or the group by condition interaction when using
residualized change scores. Contrast analyses revealed that there was no significant difference in
five-minute RSA reactivity (t(91) = .62 pL = .19, pQ = .41, pC = .58) when comparing formerly
depressed participants exposed to the sad mood induction to formerly depressed participants
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exposed to the neutral mood induction and healthy control participants exposed to the sad and
neutral mood inductions.
2 X 2 repeated measures ANOVA. None of the covariates that were under consideration
were significantly associated with five-minute RSA reactivity (all p’s > .05) and were dropped
from the final model. Levene’s test for homogeneity of variance was not significant (RSA BL5:
F(3,91) = 1.41, p = .24, RSAMI5: F(3,91) = .19, p = .90), indicating that this assumption
underlying ANOVA was met. Neither the main effects of group (F(1,91) = .14, p = .71, η2 =
.002) or condition (F(1,91) = .67, p = .41, η2 = .007) nor the group by condition interaction
(F(1,91) = 2.12, p = .15, η2 = .02) were significant, indicating that there was no significant
difference in five-minute RSA reactivity between groups or conditions or the group by condition
interaction when using repeated measures. Contrast analyses revealed that there was no
significant difference in five-minute RSA reactivity (F(1,93) = .28, p = .60) when comparing
formerly depressed participants exposed to the sad mood induction to formerly depressed
participants exposed to the neutral mood induction and healthy control participants exposed to
the sad and neutral mood inductions.
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the RSA reactivity analyses. Of
note, analyses were only conducted using five-minute RSA reactivity as this is a more stable
measure than two-minute RSA reactivity. Results indicated that the current model had a power
of .12 for the difference score, .13 for the residualized change score, and .20 for the repeated
measures. Results suggested that given the current study’s sample size, α level, and observed
effect size, there was a 12 to 20% chance of detecting an effect depending on which analytic
technique was used.
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Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et
al., 2007) to determine the minimum effect size needed to obtain significant results for the RSA
reactivity analyses. Of note, analyses were only conducted using five-minute RSA reactivity as
this is a more stable measure than two-minute RSA reactivity. Results indicated that the required
effect size was f = .29 for the factorial ANOVAs and f = .32 for the repeated measures ANOVA.
Results suggested that given the current study’s sample size and α level, at least a medium effect
size was required to obtain significant results if a power of .80 was achieved.
PEP – two-minutes. Analyses conducted for cardiovascular reactivity using two-minute
averages of PEP are reviewed below.
2 X 2 factorial ANOVA – difference score. Education level (p = .01) was significantly
associated with two-minute PEP reactivity and was included in the final model. The remaining
covariates that were under consideration were not significantly associated with cardiovascular
reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity
of variance was not significant (F(3,90) = 1.02, p = .39), indicating that this assumption
underlying ANOVA was met. Neither the main effects of group (F(1,89) = .005, p = .94, η2 <
.001) or condition (F(1,89) = .85, p = .36, η2 = .009) nor the group by condition interaction
(F(1,89) = .003, p = .96, η2 < .001) were significant, indicating that there was no significant
difference in two-minute PEP reactivity between groups or conditions or the group by condition
interaction when using difference scores. Contrast analyses revealed that there was no significant
difference in two-minute PEP reactivity (F(3,89) = .35, p = .79) when comparing formerly
depressed participants exposed to the sad mood induction to formerly depressed participants
exposed to the neutral mood induction and healthy control participants exposed to the sad and
neutral mood inductions.
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2 X 2 factorial ANOVA – residualized change score. Education level (p = .04) was
significantly associated with two-minute PEP reactivity and was included in the final model. The
remaining covariates that were under consideration were not significantly associated with twominute PEP reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for
homogeneity of variance was not significant (F(3,90) = .91, p = .44), indicating that this
assumption underlying ANOVA was met. Neither the main effects of group (F(1,89) = .004, p =
.95, η2 < .001) or condition (F(1,89) = .78, p = .38, η2 = .009) nor the group by condition
interaction (F(1,89) = .02, p = .89, η2 < .001) were significant, indicating that there was no
significant difference in two-minute PEP reactivity between mood induction conditions or the
group by condition interaction when using residualized change scores. Contrast analyses
revealed that there was no significant difference in two-minute PEP reactivity (F(3,89) = .35, p =
.79) when comparing formerly depressed participants exposed to the sad mood induction to
formerly depressed participants exposed to the neutral mood induction and healthy control
participants exposed to the sad and neutral mood inductions.
2 X 2 repeated measures ANOVA. Age (p = .05), race (p = .05), and current state anxiety
symptoms (p = .02) were significantly associated with two-minute PEP reactivity and were
included in the final model. The remaining covariates that were under consideration were not
significantly associated with two-minute PEP reactivity (all p’s > .05) and were dropped from
the final model. Levene’s test for homogeneity of variance was not significant (PEPBL2: F(3,80)
= .71, p = .55; PEPMI2: F(3,80) = .63, p = .60), indicating that this assumption underlying
ANOVA was met. Neither the main effects of group (F(1,77) = .21, p = .65, η2 = .003) or
condition (F(1,77) = .81, p = .37, η2 = .01) nor the group by condition interaction (F(1,77) = .29,
p = .59, η2 = .004) were significant, indicating that there was no significant difference in two-
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minute PEP reactivity between groups or conditions or the group by condition interaction when
using repeated measures. Contrast analyses revealed that there was no significant difference in
two-minute PEP reactivity (F(1,79) = .17, p = .68) when comparing formerly depressed
participants exposed to the sad mood induction to formerly depressed participants exposed to the
neutral mood induction and healthy control participants exposed to the sad and neutral mood
inductions.
PEP – five-minutes. Analyses conducted for cardiovascular reactivity using five-minute
averages of PEP are reviewed below.
2 X 2 factorial ANOVA – difference score. Race (p = .004) and education level (p =
.004) were significantly associated with five-minute PEP reactivity and were included in the final
model. The remaining covariates that were under consideration were not significantly associated
with five-minute PEP reactivity (all p’s > .05) and were dropped from the final model. Levene’s
test for homogeneity of variance was not significant (F(3,89) = .29, p = .83), indicating that this
assumption underlying ANOVA was met. Neither the main effects of group (F(1,87) = .03, p =
.86, η2 < .001) or condition (F(1,87) = .64, p = .43, η2 = .007) nor the group by condition
interaction (F(1,87) = .69, p = .41, η2 = .008) were significant, indicating that there was no
significant difference in five-minute PEP reactivity between groups or conditions or the group by
condition interaction when using difference scores. Contrast analyses revealed that there was no
significant difference in two-minute PEP reactivity (F(3,87) = .33, p = .80) when comparing
formerly depressed participants exposed to the sad mood induction to formerly depressed
participants exposed to the neutral mood induction and healthy control participants exposed to
the sad and neutral mood inductions.
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2 X 2 factorial ANOVA – residualized change score. Education level (p = .008) was
significantly associated with five-minute PEP reactivity and was included in the final model. The
remaining covariates that were under consideration were not significantly associated with fiveminute PEP reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for
homogeneity of variance was not significant (F(3,90) = .41, p = .75), indicating that this
assumption underlying ANOVA was met. Neither the main effects of group (F(1,89) = .05, p =
.82, η2 = .001) or condition (F(1,89) = .79, p = .38, η2 = .009) nor the group by condition
interaction (F(1,89) = .30, p = .59, η2 = .003) were significant, indicating that there was no
significant difference in five-minute PEP reactivity between mood induction conditions or the
group by condition interaction when using residualized change scores. Contrast analyses
revealed that there was no significant difference in five-minute PEP reactivity (F(3,89) = .30, p =
.82) when comparing formerly depressed participants exposed to the sad mood induction to
formerly depressed participants exposed to the neutral mood induction and healthy control
participants exposed to the sad and neutral mood inductions.
2 X 2 repeated measures ANOVA. Age (p = .04), race (p = .03), and current state anxiety
symptoms (p = .02) were significantly associated with five-minute PEP reactivity and were
included in the final model. The remaining covariates that were under consideration were not
significantly associated with five-minute PEP reactivity (all p’s > .05) and were dropped from
the final model. Levene’s test for homogeneity of variance was not significant (PEPBL5: F(3,80)
= .68, p = .57; PEPMI5: F(3,80) = .49, p = .69), indicating that this assumption underlying
ANOVA was met. Neither the main effects of group (F(1,77) = .18, p = .67, η2 = .002) or
condition (F(1,77) = .54, p = .46, η2 = .007) nor the group by condition interaction (F(1,77) =
.35, p = .56, η2 = .004) were significant, indicating that there was no significant difference in
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five-minute PEP reactivity between groups or conditions or the group by condition interaction
when using repeated measures. Contrast analyses revealed that there was no significant
difference in two-minute PEP reactivity (F(1,80) = .05, p = .83) when comparing formerly
depressed participants exposed to the sad mood induction to formerly depressed participants
exposed to the neutral mood induction and healthy control participants exposed to the sad and
neutral mood inductions.
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the PEP reactivity analyses. Of
note, analyses were only conducted using five-minute PEP reactivity as this is a more stable
measure than two-minute PEP reactivity. Results indicated that the current model had a power of
.14 for the difference score, .08 for the residualized change score, and .07 for the repeated
measures. Results suggested that given the current study’s sample size, α level, and observed
effect size, there was a 7 to 14% chance of detecting an effect depending on which analytic
technique was used.
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et
al., 2007) to determine the minimum effect size needed to obtain significant results for the PEP
reactivity analyses. Of note, analyses were only conducted using five-minute PEP reactivity as
this is a more stable measure than two-minute PEP reactivity. Results indicated that the required
effect size was f = .29 for the factorial ANOVAs and f = .34 for the repeated measures ANOVA.
Results suggested that given the current study’s sample size and α level, at least a medium effect
size was required to obtain significant results if a power of .80 was achieved.
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Hypothesis 4
A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral)
factorial ANOVAs using difference scores and residualized change scores and a series of 2
(group: formerly depressed, healthy control) X 2 (condition: sad, neutral) repeated measures
ANOVAs were used to test the hypothesis that formerly depressed individuals exposed to the sad
mood induction would exhibit reduced cardiovascular recovery (i.e., decreased HP, RSA, and
CO and increased PEP compared to baseline) during the recovery film compared to formerly
depressed participants exposed to the neutral mood induction and healthy control participants
exposed to the sad and neutral mood inductions. Means, standard deviations, p values, and effect
sizes for session 2 cardiovascular measures by group are presented in Table 20 while means,
standard deviations, p values, and effect sizes for session 2 cardiovascular measures by group
and condition are presented in Table 21. Planned comparisons were conducted using contrast
analyses. Means, standard deviations, and p values for session 2 mood measures for planned
comparisons are presented in Table 22.
HP – two-minutes. Analyses conducted for cardiovascular recovery using two-minute
averages of HP are reviewed below.
2 X 2 factorial ANOVA – difference score. None of the covariates that were under
consideration were significantly associated with two-minute HP recovery (all p’s > .05) and were
dropped from the final model. Levene’s test for homogeneity of variance was significant
(F(3,91) = 4.23, p = .008), indicating that this assumption underlying ANOVA was not met.
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of difference scores were calculated and
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
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difference scores were normally distributed for the healthy control group (Kolmogorov-Smirnov:
D(65) = .09, p = .20; Shapiro-Wilk: D(65) = .96, p = .06), formerly depressed participants
exposed to the neutral mood induction (Kolmogorov-Smirnov: D(15) = .13, p = .20; ShapiroWilk: D(15) = .95, p = .51), and healthy control participants exposed to the sad mood induction
(Kolmogorov-Smirnov: D(34) = .08, p = .20; Shapiro-Wilk: D(34) = .97, p = .52) and for one
measure of normality for the formerly depressed group (Kolmogorov-Smirnov: D(30) = .13, p =
.18), sad mood induction condition (Kolmogorov-Smirnov: D(49) = .11, p = .17), and formerly
depressed participants exposed to the sad mood induction (Kolmogorov-Smirnov: D(15) = .16, p
= .20). However, residuals of difference scores were not normally distributed for the remaining
groups and conditions (all p’s < .05). Second, difference scores were transformed using the
reciprocal transformation. Levene’s test for homogeneity of variance continued to be significant
(F(3,91) = 18.69, p < .001), indicating that this assumption underlying ANOVA was still not
met. Consequently, the factorial ANOVA was conducted with the α level decreased from .05 to
.01.
With the adjusted p value, neither the main effects of group (F(1,91) = 4.96, p = .03, η2 =
.05) or condition (F(1,91) = 4.09, p = .05, η2 = .04) nor the group by condition interaction
(F(1,91) = 5.55, p = .02, η2 = .06) were significant, indicating that there was no significant
difference in two-minute HP recovery between groups or conditions or the group by condition
interaction when using difference scores. For the main effects and interaction, it is possible that
this is due to lack of power rather than lack of effect. Using contrast analyses that did not assume
equal variances, formerly depressed participants exposed to the sad mood induction reported
exhibited higher levels of five-minute HP reactivity during the mood induction (t(15.26) = 1.31,
pL = .11, pQ = .04, pC = .53) compared to healthy control participants exposed to the sad mood
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induction and formerly depressed and healthy control participants exposed to the neutral mood
induction.
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were
under consideration were significantly associated with two-minute HP recovery (all p’s > .05)
and were dropped from the final model. Levene’s test for homogeneity of variance was
significant (F(3,91) = 7.08, p < .001), indicating that this assumption underlying ANOVA was
not met.
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of residualized change scores were calculated
and Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
residualized change scores were normally distributed for the healthy control group
(Kolmogorov-Smirnov: D(65) = .07, p = .20; Shapiro-Wilk: D(65) = .99, p = .92), neutral mood
induction condition (Kolmogorov-Smirnov: D(46) = .12, p = .10; Shapiro-Wilk: D(46) = .97, p =
.17), formerly depressed participants exposed to the neutral mood induction (KolmogorovSmirnov: D(15) = .13, p = .20; Shapiro-Wilk: D(15) = .95, p = .51), and healthy control
participants exposed to the sad mood induction (Kolmogorov-Smirnov: D(34) = .08, p = .20;
Shapiro-Wilk: D(34) = .97, p = .52) and for one measure of normality for the formerly depressed
group (Kolmogorov-Smirnov: D(30) = .13, p = .18), sad mood induction condition
(Kolmogorov-Smirnov: D(49) = .11, p = .17), formerly depressed participants exposed to the sad
mood induction (Kolmogorov-Smirnov: D(15) = .16, p = .20), and healthy control participants
exposed to the neutral mood induction (Shapiro-Wilk: D(31) = .94, p = .06). However, residuals
of difference scores were not normally distributed for the remaining groups and conditions (all
p’s < .05). Second, residualized change scores were transformed using the reciprocal
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transformation. Levene’s test for homogeneity of variance continued to be significant (F(1,91) =
19.58, p < .001), indicating that this assumption underlying ANOVA was still not met.
Consequently, the factorial ANOVA was conducted with the α level decreased from .05 to .01.
With the adjusted p value, neither the main effects of group (F(1,91) = 4.12, p = .05, η2 =
.04) or condition (F(1,91) = .16, p = .69, η2 = .002) nor the group by condition interaction
(F(1,91) = 4.58, p = .04, η2 = .05) were significant, indicating that there was no significant
difference in two-minute HP recovery between groups or conditions or the group by condition
interaction when using residualized change scores. For the main effects and interaction, it is
possible that this is due to lack of power rather than lack of effect. Using contrast analyses that
did not assume equal variances, formerly depressed participants exposed to the sad mood
induction reported exhibited higher levels of five-minute HP reactivity during the mood
induction (t(15.24) = 1.44, pL = .05, pQ = .04, pC = .58) compared to healthy control participants
exposed to the sad mood induction and formerly depressed and healthy control participants
exposed to the neutral mood induction.
2 X 2 repeated measures ANOVA. BMI (p = .05) was significantly associated with twominute HP recovery and was included in the final model. The remaining covariates that were
under consideration were not significantly associated with two-minute HP recovery (all p’s >
.05) and were dropped from the final model. Levene’s test for homogeneity of variance was not
significant for the mood induction measure (HPBL2: F(3,88) = .90, p = .45) but was significant
for the recovery measure (HPRC2: F(3,88) = 2.89, p = .04), indicating that this assumption
underlying ANOVA was not met. Of note, this appeared to be driven by the inclusion of the
covariate. Without the covariate, Levene’s test for homogeneity of variance was not significant
(HPBL2: F(3,91) = 1.02, p = .39; HPRC2: F(3,91) = 2.58, p = .06). Consequently, calculating the
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residual of the mood induction and recovery measures to assess normality or transforming the
mood induction and recovery measures to re-assess homogeneity of variance would not have the
intended effect. Instead, the factorial ANOVA was conducted with the α level decreased from
.05 to .01. Neither the main effects of group (F(1,87) = .05, p = .82, η2 = .001) or condition
(F(1,87) = 1.20, p = .28, η2 = .01) nor the group by condition interaction (F(1,87) = .87, p = .35,
η2 = .01) were significant, indicating that there was no significant difference in two-minute HP
recovery between groups or conditions or the group by condition interaction when using repeated
measures. Contrast analyses that did not assume equal variances revealed that there was no
significant difference in two-minute HP recovery (F(1,90) = .86, p = .36) when comparing
formerly depressed participants exposed to the sad mood induction to formerly depressed
participants exposed to the neutral mood induction and healthy control participants exposed to
the sad and neutral mood inductions.
HP – five-minutes. Analyses conducted for cardiovascular recovery using five-minute
averages of HP are reviewed below.
2 X 2 factorial ANOVA – difference score. None of the covariates that were under
consideration were significantly associated with five-minute HP recovery (all p’s > .05) and were
dropped from the final model. Levene’s test for homogeneity of variance was significant
(F(3,91) = 3.08, p = .03), indicating that this assumption underlying ANOVA was not met.
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of difference scores were calculated and
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
difference scores were normally distributed for the healthy control group (Kolmogorov-Smirnov:
D(65) = .06, p = .20; Shapiro-Wilk: D(65) = .97, p = .17), neutral mood induction condition
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(Kolmogorov-Smirnov: D(46) = .10, p = .20; Shapiro-Wilk: D(46) = .95, p = .06), formerly
depressed participants exposed to the sad (Kolmogorov-Smirnov: D(15) = .15, p = .20; ShapiroWilk: D(15) = .90, p = .09) and neutral (Kolmogorov-Smirnov: D(15) = .11, p = .20; ShapiroWilk: D(15) = .97, p = .91) mood inductions, and healthy control participants exposed to the sad
mood induction (Kolmogorov-Smirnov: D(34) = .11, p = .20; Shapiro-Wilk: D(34) = .96, p =
.22) and for one measure of normality for the formerly depressed group (Kolmogorov-Smirnov:
D(30) = .12, p = .20), sad mood induction condition (Kolmogorov-Smirnov: D(49) = .11, p =
.13), and healthy control participants exposed to the neutral mood induction (KolmogorovSmirnov: D(31) = .12, p = .20). However, residuals of difference scores were not normally
distributed for the remaining groups and conditions (all p’s < .05). Second, difference scores
were transformed using the reciprocal transformation. Levene’s test for homogeneity of variance
continued to be significant (F(3,91) = 7.19, p < .001), indicating that this assumption underlying
ANOVA was still not met. Consequently, the factorial ANOVA was conducted with the α level
decreased from .05 to .01.
Neither the main effects of group (F(1,91) = 3.55, p = .06, η2 = .04) or condition (F(1,91)
= .65, p = .42, η2 = .007) nor the group by condition interaction (F(1,91) = 3.66, p = .06, η2 = .04)
were significant, indicating that there was no significant difference in five-minute HP recovery
between groups or conditions or the group by condition interaction when using difference scores.
For the main effects and interaction, it is possible that this is due to lack of power rather than
lack of effect. Using contrast analyses that did not assume equal variances, formerly depressed
participants exposed to the sad mood induction reported exhibited higher levels of five-minute
HP reactivity during the mood induction (t(15.87) = 1.61, pL = .05, pQ = .06, pC = .90) compared
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to healthy control participants exposed to the sad mood induction and formerly depressed and
healthy control participants exposed to the neutral mood induction.
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were
under consideration were significantly associated with five-minute HP recovery (all p’s > .05)
and were dropped from the final model. Levene’s test for homogeneity of variance was
significant (F(3,91) = 6.92, p < .001), indicating that this assumption underlying ANOVA was
not met.
In line with the planned analyses, multiple steps were explored in an attempt to remedy
the violation of this assumption. First, residuals of difference scores were calculated and
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of
difference scores were normally distributed for the healthy control group (Kolmogorov-Smirnov:
D(65) = .07, p = .20; Shapiro-Wilk: D(65) = .97, p = .15), neutral mood induction condition
(Kolmogorov-Smirnov: D(46) = .09, p = .20; Shapiro-Wilk: D(46) = .98, p = .75), formerly
depressed participants exposed to the sad (Kolmogorov-Smirnov: D(15) = .15, p = .20; ShapiroWilk: D(15) = .90, p = .09) and neutral (Kolmogorov-Smirnov: D(15) = .11, p = .20; ShapiroWilk: D(15) = .97, p = .91) mood inductions, and healthy control participants exposed to the sad
(Kolmogorov-Smirnov: D(34) = .11, p = .20; Shapiro-Wilk: D(34) = .96, p = .22) and neutral
(Kolmogorov-Smirnov: D(31) = .10, p = .20; Shapiro-Wilk: D(31) = .98, p = .75) mood
induction and for one measure of normality for the formerly depressed group (KolmogorovSmirnov: D(30) = .12, p = .20) and sad mood induction condition (Kolmogorov-Smirnov: D(49)
= .11, p = .13). However, residuals of difference scores were not normally distributed for the
remaining groups and conditions (all p’s < .05). Second, difference scores were transformed
using the reciprocal transformation. Levene’s test for homogeneity of variance continued to be
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significant (F(3,91) = 13.14, p < .001), indicating that this assumption underlying ANOVA was
still not met. Consequently, the factorial ANOVA was conducted with the α level decreased from
.05 to .01.
With the adjusted p value, neither the main effects of group (F(1,91) = 4.91, p = .03, η2 =
.05) or condition (F(1,91) = 1.24, p = .27, η2 = .01) nor the group by condition interaction
(F(1,91) = 3.86, p = .05, η2 = .04) were significant, indicating that there was no significant
difference in five-minute HP recovery between groups or conditions or the group by condition
interaction when using residualized change scores. For the main effects and interaction, it is
possible that this is due to lack of power rather than lack of effect. Using contrast analyses that
did not assume equal variances, formerly depressed participants exposed to the sad mood
induction reported exhibited higher levels of five-minute HP reactivity during the mood
induction (t(15.88) = 1.79, pL = .02, pQ = .05, pC = 1.00) compared to healthy control participants
exposed to the sad mood induction and formerly depressed and healthy control participants
exposed to the neutral mood induction.
2 X 2 repeated measures ANOVA. BMI (p = .05) was significantly associated with fiveminute HP recovery and was included in the final model. The remaining covariates that were
under consideration were not significantly associated with five-minute HP recovery (all p’s >
.05) and were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (HPBL5: F(3,88) = 1.22, p = .31; HPRC5: F(3,88) = 2.23, p = .09), indicating that this
assumption underlying ANOVA was met. Neither the main effects of group (F(1,87) = .09, p =
.77, η2 = .001) or condition (F(1,87) = 1.71, p = .19, η2 = .02) nor the group by condition
interaction (F(1,87) = 1.27, p = .26, η2 = .01) were significant, indicating that there was no
significant difference in five-minute HP recovery between groups or conditions or the group by
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condition interaction when using repeated measures. Contrast analyses revealed that there was no
significant difference in five-minute HP recovery (F(1,90) = 1.36, p = .25) when comparing
formerly depressed participants exposed to the sad mood induction to formerly depressed
participants exposed to the neutral mood induction and healthy control participants exposed to
the sad and neutral mood inductions.
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the HP recovery analyses. Of note,
analyses were only conducted using five-minute HP recovery as this is a more stable measure
than two-minute HP recovery. Results indicated that the current model had a power of .27 for the
difference and residualized change scores and .11 for the repeated measures. Results suggested
that given the current study’s sample size, α level, and observed effect size, there was a 11 to
27% chance of detecting an effect depending on which analytic technique was used.
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et
al., 2007) to determine the minimum effect size needed to obtain significant results for the HP
recovery analyses. Of note, analyses were only conducted using five-minute HP recovery as this
is a more stable measure than two-minute HP recovery. Results indicated that the required effect
size was f = .36 for the factorial ANOVAs and f = .34 for the repeated measures ANOVA.
Results suggested that given the current study’s sample size and α level, at least a medium effect
size was required to obtain significant results if a power of .80 was achieved.
RSA – two-minutes. Analyses conducted for cardiovascular recovery using two-minute
averages of RSA are reviewed below.
2 X 2 factorial ANOVA – difference score. None of the covariates that were under
consideration were significantly associated with two-minute RSA recovery (all p’s > .05) and

207

were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(3,90) = 1.39, p = .25), indicating that this assumption underlying ANOVA was
met. Neither the main effects of group (F(1,90) = .02, p = .88, η2 < .001) or condition (F(1,90) =
.85, p = .36, η2 = .009) nor the group by condition interaction (F(1,90) = 2.17, p = .14, η2 = .02)
were significant, indicating that there was no significant difference in two-minute RSA recovery
between groups or conditions or the group by condition interaction when using difference scores.
Contrast analyses revealed that there was no significant difference in two-minute RSA recovery
(t(90) = 1.32, pL = .59, pQ = .14, pC = .45) when comparing formerly depressed participants
exposed to the sad mood induction to formerly depressed participants exposed to the neutral
mood induction and healthy control participants exposed to the sad and neutral mood inductions.
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were
under consideration were significantly associated with two-minute RSA recovery (all p’s > .05)
and were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(3,90) = 1.93, p = .13), indicating that this assumption underlying ANOVA was
met. Neither the main effects of group (F(1,90) = .06, p = .81, η2 = .001) or condition (F(1,90) =
1.08, p = .30, η2 = .01) nor the group by condition interaction (F(1,90) = 1.05, p = .31, η2 = .01)
were significant, indicating that there was no significant difference in two-minute RSA recovery
between groups or conditions or the group by condition interaction when using residualized
change scores. Contrast analyses revealed that there was no significant difference in two-minute
RSA recovery (t(90) = .94, pL = .81, pQ = .31, pC = .30) when comparing formerly depressed
participants exposed to the sad mood induction to formerly depressed participants exposed to the
neutral mood induction and healthy control participants exposed to the sad and neutral mood
inductions.

208

2 X 2 repeated measures ANOVA. None of the covariates that were under consideration
were significantly associated with two-minute RSA recovery (all p’s > .05) and were dropped
from the final model. Levene’s test for homogeneity of variance was not significant (RSABL2:
F(3,90) = 1.09, p = .36; RSARC2: F(3,90) = 2.54, p = .06), indicating that this assumption
underlying ANOVA was met. Neither the main effects of group (F(1,90) = .99, p = .32, η2 = .01)
or condition (F(1,90) = .20, p = .66, η2 = .002) nor the group by condition interaction (F(1,90) =
.90, p = .35, η2 = .01) were significant, indicating that there was no significant difference in twominute RSA recovery between groups or conditions or the group by condition interaction when
using repeated measures. Contrast analyses revealed that there was no significant difference in
two-minute RSA recovery (F(1,92) = .46, p = . 50) when comparing formerly depressed
participants exposed to the sad mood induction to formerly depressed participants exposed to the
neutral mood induction and healthy control participants exposed to the sad and neutral mood
inductions.
RSA – five-minutes. Analyses conducted for cardiovascular recovery using five-minute
averages of RSA are reviewed below.
2 X 2 factorial ANOVA – difference score. None of the covariates that were under
consideration were significantly associated with five-minute RSA recovery (all p’s > .05) and
were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(3,90) = 2.37, p = .08), indicating that this assumption underlying ANOVA was
met. Neither the main effects of group (F(1,90) = .06, p = .81, η2 = .001) or condition (F(1,90) =
.24, p = .63, η2 = .003) nor the group by condition interaction (F(1,90) = 1.86, p = .18, η2 = .02)
were significant, indicating that there was no significant difference in five-minute RSA recovery
between groups or conditions or the group by condition interaction when using difference scores.

209

Contrast analyses revealed that there was no significant difference in two-minute RSA recovery
(t(90) = 1.08, pL = .67, pQ = .18, pC = .74) when comparing formerly depressed participants
exposed to the sad mood induction to formerly depressed participants exposed to the neutral
mood induction and healthy control participants exposed to the sad and neutral mood inductions.
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were
under consideration were significantly associated with five-minute RSA recovery (all p’s > .05)
and were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(3,90) = 1.67, p = .18), indicating that this assumption underlying ANOVA was
met. Neither the main effects of group (F(1,90) = .001, p = .98, η2 < .001) or condition (F(1,90) =
.51, p = .48, η2 = .006) nor the group by condition interaction (F(1,90) = .88, p = .35, η2 = .01)
were significant, indicating that there was no significant difference in five-minute RSA recovery
between mood induction conditions or the group by condition interaction when using
residualized change scores. Contrast analyses revealed that there was no significant difference in
two-minute RSA recovery (t(90) = .88, pL = .73, pQ = .35, pC = .53) when comparing formerly
depressed participants exposed to the sad mood induction to formerly depressed participants
exposed to the neutral mood induction and healthy control participants exposed to the sad and
neutral mood inductions.
2 X 2 repeated measures ANOVA. None of the covariates that were under consideration
were significantly associated with five-minute RSA recovery (all p’s > .05) and were dropped
from the final model. Levene’s test for homogeneity of variance was not significant (RSA BL5:
F(3,90) = 1.44, p = .24; RSARC5: F(3,90) = .73, p = .54), indicating that this assumption
underlying ANOVA was met. Neither the main effects of group (F(1,90) = .45, p = .50, η2 =
.005) or condition (F(1,90) = .20, p = .66, η2 = .002) nor the group by condition interaction
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(F(1,90) = 1.05, p = .31, η2 = .01) were significant, indicating that there was no significant
difference in five-minute RSA recovery between groups or conditions or the group by condition
interaction when using repeated measures. Contrast analyses revealed that there was no
significant difference in two-minute RSA recovery (F(1,92) = .49, p = .49) when comparing
formerly depressed participants exposed to the sad mood induction to formerly depressed
participants exposed to the neutral mood induction and healthy control participants exposed to
the sad and neutral mood inductions.
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the RSA recovery analyses. Of
note, analyses were only conducted using five-minute RSA recovery as this is a more stable
measure than two-minute RSA recovery. Results indicated that the current model had a power of
.28 for the difference score, .16 for the residualized change score, and .11 for the repeated
measures. Results suggested that given the current study’s sample size, α level, and observed
effect size, there was a 11 to 28% chance of detecting an effect depending on which analytic
technique was used.
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et
al., 2007) to determine the minimum effect size needed to obtain significant results for the RSA
recovery analyses. Of note, analyses were only conducted using five-minute RSA recovery as
this is a more stable measure than two-minute RSA recovery. Results indicated that the required
effect size was f = .29 for the factorial ANOVAs and f = .34 for the repeated measures ANOVA.
Results suggested that given the current study’s sample size and α level, at least a medium effect
size was required to obtain significant results if a power of .80 was achieved.
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PEP – Two-Minute. Analyses conducted for cardiovascular recovery using two-minute
averages of PEP are reviewed below.
2 X 2 factorial ANOVA – difference score. None of the covariates that were under
consideration were significantly associated with two-minute PEP recovery (all p’s > .05) and
were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(3,90) = 1.83, p = .15), indicating that this assumption underlying ANOVA was
met. Neither the main effects of group (F(1,90) = .006, p = .94, η2 < .001) or condition (F(1,90) =
.15, p = .70, η2 = .002) nor the group by condition interaction (F(1,90) = .11, p = .75, η2 = .001)
were significant, indicating that there was no significant difference in two-minute PEP recovery
between groups or conditions or the group by condition interaction when using difference scores.
Contrast analyses revealed that there was no significant difference in two-minute PEP recovery
(t(90) = -.01, pL = .92, pQ = .75, pC = .71) when comparing formerly depressed participants
exposed to the sad mood induction to formerly depressed participants exposed to the neutral
mood induction and healthy control participants exposed to the sad and neutral mood inductions.
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were
under consideration were significantly associated with two-minute PEP recovery (all p’s > .05)
and were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(3,90) = 2.46, p = .07), indicating that this assumption underlying ANOVA was
met. Neither the main effects of group (F(1,90) = .03, p = .86, η2 < .001) or condition (F(1,90) =
.17, p = .68, η2 = .002) nor the group by condition interaction (F(1,90) = .04, p = .85, η2 < .001)
were significant, indicating that there was no significant difference in two-minute PEP recovery
between groups or conditions or the group by condition interaction when using residualized
change scores. Contrast analyses revealed that there was no significant difference in two-minute
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PEP recovery (t(90) = .03, pL = .98, pQ = .85, pC = .65) when comparing formerly depressed
participants exposed to the sad mood induction to formerly depressed participants exposed to the
neutral mood induction and healthy control participants exposed to the sad and neutral mood
inductions.
2 X 2 repeated measures ANOVA. Current state anxiety symptoms (p = .01) were
significantly associated with two-minute PEP recovery and were included in the final model. The
remaining covariates that were under consideration were not significantly associated with twominute PEP recovery (all p’s > .05) and were dropped from the final model. Levene’s test for
homogeneity of variance was not significant (PEPBL2: F(3,81) = .86, p = .47; PEPRC2: F(3,81) =
1.57, p = .20), indicating that this assumption underlying ANOVA was met. Neither the main
effects of group (F(1,80) = .08, p = .78, η2 = .001) or condition (F(1,80) = .43, p = .52, η2 = .005)
nor the group by condition interaction (F(1,80) = .33, p = .57, η2 = .004) were significant,
indicating that there was no significant difference in two-minute PEP recovery between groups
or conditions or the group by condition interaction when using repeated measures. Contrast
analyses revealed that there was no significant difference in two-minute PEP recovery (F(1,82) =
.03, p = .86) when comparing formerly depressed participants exposed to the sad mood induction
to formerly depressed participants exposed to the neutral mood induction and healthy control
participants exposed to the sad and neutral mood inductions.
PEP – Five-Minute. Analyses conducted for cardiovascular recovery using five-minute
averages of PEP are reviewed below.
2 X 2 factorial ANOVA – difference score. Hispanic/Latino ethnicity (p = .03) was
significantly associated with five-minute PEP recovery and was included in the final model. The
remaining covariates that were under consideration were not significantly associated with five-
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minute PEP recovery (all p’s > .05) and were dropped from the final model. Levene’s test for
homogeneity of variance was not significant (F(3,89) = 1.46, p = .23), indicating that this
assumption underlying ANOVA was met. Neither the main effects of group (F(1,88) = .65, p =
.42, η2 = .007) or condition (F(1,88) = .08, p = .78, η2 = .001) nor the group by condition
interaction (F(1,88) = .24, p = .62, η2 = .003) were significant, indicating that there was no
significant difference in five-minute PEP recovery between groups or conditions or the group by
condition interaction when using difference scores. Contrast analyses revealed that there was no
significant difference in two-minute PEP recovery (F(3,88) = .29, p = .83) when comparing
formerly depressed participants exposed to the sad mood induction to formerly depressed
participants exposed to the neutral mood induction and healthy control participants exposed to
the sad and neutral mood inductions.
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were
under consideration were significantly associated with five-minute PEP recovery (all p’s > .05)
and were dropped from the final model. Levene’s test for homogeneity of variance was not
significant (F(3,90) = 2.39, p = .07), indicating that this assumption underlying ANOVA was
met. Neither the main effects of group (F(1,90) = .79, p = .38, η2 = .009) or condition (F(1,90) =
.01, p = .94, η2 < .001) nor the group by condition interaction (F(1,90) = .22, p = .64, η2 = .002)
were significant, indicating that there was no significant difference in five-minute PEP recovery
between groups or conditions or the group by condition interaction when using residualized
change scores. Contrast analyses revealed that there was no significant difference in two-minute
PEP recovery (t(90) = -.26, pL = .41, pQ = .64, pC = .74) when comparing formerly depressed
participants exposed to the sad mood induction to formerly depressed participants exposed to the

214

neutral mood induction and healthy control participants exposed to the sad and neutral mood
inductions.
2 X 2 repeated measures ANOVA. Current state anxiety symptoms (p = .02) were
significantly associated with five-minute PEP recovery and were included in the final model. The
remaining covariates that were under consideration were not significantly associated with fiveminute PEP recovery (all p’s > .05) and were dropped from the final model. Levene’s test for
homogeneity of variance was not significant (PEPBL5: F(3,81) = .97, p = .41; PEPRC5: F(3,81) =
.57, p = .64), indicating that this assumption underlying ANOVA was met. Neither the main
effects of group (F(1,80) = .01, p = .91, η2 < .001) or condition (F(1,80) = .76, p = .39, η2 = .009)
nor the group by condition interaction (F(1,80) = .14, p = .71, η2 = .002) were significant,
indicating that there was no significant difference in five-minute PEP recovery between groups
or conditions or the group by condition interaction when using repeated measures. Contrast
analyses revealed that there was no significant difference in two-minute PEP recovery (F(1,82) =
.07, p = .79) when comparing formerly depressed participants exposed to the sad mood induction
to formerly depressed participants exposed to the neutral mood induction and healthy control
participants exposed to the sad and neutral mood inductions.
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the PEP recovery analyses. Of
note, analyses were only conducted using five-minute PEP recovery as this is a more stable
measure than two-minute PEP recovery. Results indicated that the current model had a power of
.08 for the difference score, .07 for the residualized change score, and .06 for the repeated
measures. Results suggested that given the current study’s sample size, α level, and observed
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effect size, there was a 6 to 8% chance of detecting an effect depending on which analytic
technique was used.
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et
al., 2007) to determine the minimum effect size needed to obtain significant results for the PEP
recovery analyses. Of note, analyses were only conducted using five-minute PEP recovery as this
is a more stable measure than two-minute PEP recovery. Results indicated that the required
effect size was f = .29 for the factorial ANOVAs and f = .34 for the repeated measures ANOVA.
Results suggested that given the current study’s sample size and α level, at least a medium effect
size was required to obtain significant results if a power of .80 was achieved.
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Table 20. Means, Standard Deviations, P Values, and Effect Sizes for Session 2 Cardiovascular
Measures by Group

Measure
HPBL2
HPBL5
HPMI2
HPMI5
Measure
HPRC2
HPRC5
Measure
HPDS2RA
ZRES2HPRA
HPDS5RA
ZRES5HPRA
HPRARM2
HPRARM5
Measure
HPDS2RC
ZRES2HPRC
HPDS5RC
ZRES5HPRC
HPRCRM2
HPRCRM5
Measure
RSABL2
RSABL5
RSAMI2
RSAMI5
Measure
RSARC2
RSARC5

Total (N = 96)
M
SD
781.45 104.55
785.51 105.88
799.21 111.48
788.89 108.15
Total (N = 95)
M
SD
783.98 102.44
787.42 103.62
Total (N = 96)
M
SD
17.76
39.29
.00
1.00
3.38
33.73
.00
1.00

Group
FD (n = 31)
HC (n = 65)
M
SD
M
SD
788.61 115.45 778.03 99.71
795.20 118.17 780.89 100.14
815.35 120.99 791.51 106.77
809.20 119.87 779.20 101.64
FD (n = 30)
HC (n = 65)
M
SD
M
SD
800.54 119.94 776.33 93.30
804.24 121.00 779.65 94.56
FD (n = 31)
HC (n = 65)
M
SD
M
SD
26.74
42.78 13.48
37.10
.24
1.09
-.10
.94
14.00
39.80 -1.69
29.43
.34
1.18
-.14
.88

Total (N = 95)
M
SD
4.23
49.12
.07
.78
3.70
37.99
.03
.85

FD (n = 30)
M
SD
17.09
62.74
.29
1.32
14.41
48.55
.31
1.32

HC (n = 65)
M
SD
-1.70
40.59
-.14
.75
-1.24
31.19
-.16
.74

Total (N = 95)
M
SD
5.84
1.04
5.83
1.01
6.03
1.15
5.89
1.13
Total (N = 94)
M
SD
5.82
1.00
5.79
.93

FD (n = 31)
M
SD
5.68
1.13
5.71
1.11
6.02
1.09
5.90
1.07
FD (n = 30)
M
SD
5.69
1.11
5.71
1.00

HC (n = 64)
M
SD
5.91
.99
5.89
.96
6.03
1.18
5.88
1.16
HC (n = 64)
M
SD
5.89
.95
5.83
.90
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p
.37
.37

η2
.009
.009

p

η2

p
.12
.12
.05
.04
.79
.97

η2
.03
.03
.04
.05
.001
< .001

p
.03b
.05b
.06
.03b
.82
.77

η2
.05
.04
.04
.05
.001
.001

p
.50
.38

η2
.005
.008

p

η2

Table 20 Continued
Measure
RSADS2RA
ZRES2RSARA
RSADS5RA
ZRES5RSARA
RSARARM2
RSARARM5
Measure
RSADS2RC
ZRES2RSARC
RSADS5RC
ZRES5RSARC
RSARCRM2
RSARCRM5
Measure
PEPBL2
PEPBL5
PEPMI2
PEPMI5
Measure
PEPRC2
PEPRC5
Measure
PEPDS2RA
ZRES2PEPRA
PEPDS5RA
ZRES5PEPRA
PEPRARM2
PEPRARM5
Measure
PEPDS2RC
ZRES2PEPRC
PEPDS5RC
ZRES5PEPRC
PEPRCRM2
PEPRCRM5

Total (N = 95)
M
SD
.24
.61
.02
.73
.11
.45
.03
.58

FD (n = 31)
M
SD
.34
.65
.13
.74
.19
.52
.15
.66

HC (n = 64)
M
SD
.20
.59
.02
.73
.07
.41
.03
.58

Total (N = 94)
M
SD
-.02
.70
.00
1.00
-.05
.43
.00
1.00

FD (n = 30)
M
SD
-.004
.79
-.03
1.12
-.04
.41
.005
.91

HC (n = 64)
M
SD
-.03
.66
.03
.94
-.06
.44
-.002
1.04

Total (N = 95)
M
SD
120.61 11.90
120.37 11.68
119.77 12.74
119.91 13.04
Total (N = 94)
M
SD
120.15 14.33
120.91 12.24
Total (N = 95)
M
SD
-.48
4.19
-.01
.65
-.31
4.13
.04
.64

FD (n = 31)
M
SD
121.05 11.10
120.70 11.13
120.73 11.01
121.15 11.41
FD (n = 30)
M
SD
119.43 15.34
120.51 10.72
FD (n = 31)
M
SD
-.32
4.24
.10
.76
.13
3.61
.11
.67

HC (n = 64)
M
SD
120.40 12.34
120.21 12.02
119.31 13.56
119.31 13.81
HC (n = 64)
M
SD
120.48 13.95
121.09 12.96
HC (n = 64)
M
SD
-.56
4.20
.05
.76
-.52
4.37
-.02
.81

Total (N = 94)
M
SD
.68
5.06
.09
.53
.79
4.57
.00
1.00

FD (n = 30)
M
SD
.60
3.41
.07
.39
.12
3.94
-.11
.73

HC (n = 64)
M
SD
.71
5.70
.09
.59
1.10
4.84
.05
.92
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p
.12
.50
.23
.35
.56
.70

η2
.03
.005
.02
.009
.004
.002

p
.88
.81
.81
.98
.32
.50

η2
< .001
.001
.001
< .001
.01
.005

p
.16
.21

η2
.02
.02

p

η2

p
.94
.95
.86
.82
.65
.67

η2
< .001
< .001
< .001
.001
.003
.002

p
.94
.86
.42
.38
.78
.91

η2
< .001
< .001
.007
.009
.001
< .001

Note. The difference between baseline and mood induction or mood induction and recovery
measures may not precisely equal the difference score as outlier data was addressed differently
depending on the type of analyses conducted; FD = formerly depressed; HC = healthy control;
HP = heart period at baseline; BL = baseline; MI = mood induction; RC = recovery; 2 = average
obtained during a two-minute interval; 5 = average obtained during a five-minute interval; DS =
difference score; RA = reactivity; ZRES = residualized change scores; RSA = respiratory sinus
arrhythmia; PEP = pre-ejection period; RM = repeated measures; b = only linear results are
presented as analyses were run with covariates.
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Table 21. Means, Standard Deviations, P Values, and Effect Sizes for Session 2 Cardiovascular Measures by Group and Condition

Measure
HPBL2
HPBL5
HPMI2
HPMI5
Measure
HPRC2
HPRC5
Measure
HPDS2RA
ZRES2HPRA
HPDS5RA
ZRES5HPRA
HPRARM2
HPRARM5
Measure
HPDS2RC
ZRES2HPRC
HPDS5RC
ZRES5HPRC
HPRCRM2
HPRCRM5

Group and Condition
Total (N = 96)
FD/SMI (n = 15) FD/NMI (n = 16) HC/SMI (n = 34)
M
SD
M
SD
M
SD
M
SD
781.45 104.55 787.33 131.66 789.82 102.36 784.73 87.35
785.51 105.88 798.91 134.77 791.72 104.65 785.17 87.23
799.21 111.48 820.97 129.38 810.08 116.58 800.55 98.33
788.89 108.15 823.91 130.36 795.40 111.60 784.78 91.44
Total (N = 95)
FD/SMI (n = 15) FD/NMI (n = 15) HC/SMI (n = 34)
M
SD
M
SD
M
SD
M
SD
783.98 102.44 816.44 135.64 784.64 104.21 773.14 83.03
787.42 103.62 824.47 133.33 784.01 108.06 779.60 85.45
Total (N = 96)
FD/SMI (n = 15) FD/NMI (n = 16) HC/SMI (n = 34)
M
SD
M
SD
M
SD
M
SD
17.76
39.29 33.64
52.14
20.27 32.09
15.83
38.57
.00
1.00
.42
1.33
.08
.81
-.04
.98
3.38
33.73 25.00
44.83
3.69
32.53
-.39
30.55
.00
1.00
.67
1.31
.03
.98
-.10
.91

HC/NMI (n = 31)
M
SD
770.69 112.74
776.20 113.92
781.59 116.15
773.08 112.99
HC/NMI (n = 31)
M
SD
779.83 104.71
779.71 105.08
HC/NMI (n = 31)
M
SD
10.90
35.87
-.16
.91
-3.12
28.57
-.19
.84

Total (N = 95)
M
SD
4.23
49.12
.07
.78
3.70
37.99
.03
.85

HC/NMI (n = 31)
M
SD
9.14
39.12
.05
.64
3.51
28.04
-.07
.55

FD/SMI (n = 15)
M
SD
29.11
81.49
.56
1.68
25.56
58.82
.63
1.56

FD/NMI (n = 15)
M
SD
5.07
34.67
.02
.79
3.26
34.00
-.01
.98
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HC/SMI (n = 34)
M
SD
-11.58 39.91
-.32
.80
-5.57
33.63
-.24
.89

p
.62
.62
.27
.27
.44
.24

η2
.003
.003
.01
.01
.007
.02

p
.02b
.04b
.06
.05b
.35
.26

η2
.06
.05
.04
.04
.01
.01

Table 21 Continued
Measure
RSABL2
RSABL5
RSAMI2
RSAMI5
Measure
RSARC2
RSARC5
Measure
RSADS2RA
ZRES2RSARA
RSADS5RA
ZRES5RSARA
RSARARM2
RSARARM5
Measure
RSADS2RC
ZRES2RSARC
RSADS5RC
ZRES5RSARC
RSARCRM2
RSARCRM5
Measure
PEPBL2
PEPBL5
PEPMI2
PEPMI5

Total (N = 95)
M
SD
5.83
1.04
5.83
1.01
6.03
1.15
5.89
1.13
Total (N = 94)
M
SD
5.82
1.00
5.79
.93
Total (N = 95)
M
SD
.24
.61
.02
.73
.11
.45
.03
.58

FD/SMI (n = 15)
M
SD
5.54
1.07
5.63
1.06
5.92
1.02
5.84
1.00
FD/SMI (n = 15)
M
SD
5.73
.86
5.70
.92
FD/SMI (n = 15)
M
SD
.37
.53
.14
.61
.22
.37
.17
.47

FD/NMI (n = 16)
M
SD
5.81
1.21
5.79
1.19
6.11
1.19
5.96
1.16
FD/NMI (n = 15)
M
SD
5.65
1.34
5.72
1.10
FD/NMI (n = 16)
M
SD
.30
.76
.13
.86
.17
.64
.14
.81

HC/SMI (n = 32)
M
SD
6.08
1.02
6.06
.97
6.32
1.04
6.20
1.04
HC/SMI (n = 32)
M
SD
6.01
.99
5.97
.94
HC/SMI (n = 32)
M
SD
.24
.61
.13
.71
.14
.40
.16
.57

HC/NMI (n = 32)
M
SD
5.74
.94
5.71
.93
5.75
1.25
5.56
1.21
HC/NMI (n = 32)
M
SD
5.76
.91
5.70
.86
HC/NMI (n = 32)
M
SD
.16
.57
-.09
.74
.01
.42
-.10
.57

Total (N = 94)
M
SD
-.02
.70
.00
1.00
-.05
.43
.00
1.00

FD/SMI (n = 15)
M
SD
.18
.74
.20
.94
.05
.35
.19
.79

FD/NMI (n = 15)
M
SD
-.19
.82
-.26
1.26
-.12
.46
-.18
1.00

HC/SMI (n = 32)
M
SD
-.07
.78
.03
1.10
-.10
.53
-.03
1.19

HC/NMI (n = 32)
M
SD
.02
.53
.03
.78
-.02
.34
.02
.88

Total (N = 95)
M
120.61
120.37
119.77
119.91

FD/SMI (n = 15)
SD
11.90
11.68
12.74
13.04

FD/NMI (n = 16)
M
118.97
118.99
118.73
119.29

HC/SMI (n = 32)
SD
11.36
11.06
10.52
10.98

HC/NMI (n = 32)
M
123.00
122.30
122.59
122.89
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p
.55
.47
.71
.41
.12
.15

η2
.004
.006
.002
.007
.03
.02

p
.14
.31
.18
.35
.35
.31

η2
.02
.01
.02
.01
.01
.01

Table 21 Continued
Measure
PEPRC2
PEPRC5
Measure
PEPDS2RA
ZRES2PEPRA
PEPDS5RA
ZRES5PEPRA
PEPRARM2
PEPRARM5

Total (N = 94)
M
SD
120.15 14.33
120.91 12.24
Total (N = 95)
M
SD
-.48
4.19
-.01
.65
-.31
4.13
.04
.64

FD/SMI (n = 15)
M
SD
120.47 10.68
120.12 10.35
FD/SMI (n = 15)
M
SD
-.23
4.69
.10
.83
.31
3.73
.15
.70

FD/NMI (n = 15)
M
SD
118.40 19.26
120.91 11.42
FD/NMI (n = 16)
M
SD
-.41
3.92
.09
.71
-.04
3.62
.07
.67

HC/SMI (n = 32)
M
SD
120.66 12.65
120.27 12.78
HC/SMI (n = 32)
M
SD
-.04
4.21
.15
.74
-.31
4.95
.03
.91

HC/NMI (n = 32)
M
SD
120.28 15.51
122.03 13.33
HC/NMI (n = 32)
M
SD
-1.13
4.19
-.06
.77
-.77
3.67
-.07
.70

Total (N = 94)
M
SD
.68
5.06
.09
.53
.79
4.57
.00
1.00

FD/SMI (n = 15)
M
SD
.63
3.64
.08
.37
.35
2.95
-.08
.54

FD/NMI (n = 15)
M
SD
.57
3.29
.06
.42
-.11
4.84
-.15
.89

HC/SMI (n = 32)
M
SD
1.09
4.54
.13
.43
.82
3.69
.003
.65

HC/NMI (n = 32)
M
SD
.28
6.84
.06
.74
1.41
5.93
.11
1.16

p
.96
.89
.41
.59
.59
.56

η2
< .001
< .001
.008
.003
.004
.004

Measure
p
η2
PEPDS2RC
.75
.001
ZRES2PEPRC
.85
< .001
PEPDS5RC
.62
.003
ZRES5PEPRC
.64
.002
PEPRARM2
.57
.004
PEPRARM5
.71
.002
Note. The difference between baseline and mood induction or mood induction and recovery measures may not precisely equal
the difference score as outlier data was addressed differently depending on the type of analyses conducted; FD = formerly
depressed; HC = healthy control; SMI = sad mood induction; NMI = neutral mood induction; HP = heart period at baseline; BL
= baseline; MI = mood induction; RC = recovery; 2 = average obtained during a two-minute interval; 5 = average obtained during
a five-minute interval; DS = difference score; RA = reactivity; ZRES = residualized change scores; RSA = respiratory sinus
arrhythmia; PEP = pre-ejection period; RM = repeated measures; b = only linear results are presented as analyses were run with
covariates.
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Table 22. Means, Standard Deviations, and P Values for Session 2 Cardiovascular Measures for Planned
Comparisons

Total (N = 96)
Measure
HPBL2
HPBL5
HPMI2
HPMI5

M
SD
781.45
104.55
785.51
105.88
799.21
111.48
788.89
108.15
Total (N = 95)

Measure
HPRC2
HPRC5

M
SD
783.98
102.44
787.42
103.62
Total (N = 96)

Measure
HPDS2RA
ZRES2HPRA
HPDS5RA
ZRES5HPRA
HPRARM2
HPRARM5

M
17.76
.00
3.38
.00

SD
39.29
1.00
33.73
1.00

Group and Condition
FD/SMI (n = 15)
FD/NMI, HC/SMI,
HC/NMI (n = 81)
M
SD
M
SD
787.33
131.66
780.36
99.70
798.91
134.77
783.03
100.47
820.97
129.38
795.18
108.28
823.91
130.36
782.40
103.16
FD/SMI (n = 15)
FD/NMI, HC/SMI,
HC/NMI (n = 80)
M
SD
M
SD
816.44
135.64
777.89
94.80
824.47
133.33
780.47
96.52
FD/SMI (n = 15)
FD/NMI, HC/SMI,
HC/NMI (n = 81)
M
SD
M
SD
33.64
52.14
14.82
36.08
.42
1.33
-.06
.92
25.00
44.83
-.63
29.93
.67
1.31
-.11
.89
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pL
.06
.07
.10b
.08b
.46
.26

pQ
.62
.62

pC
.80
.80

Table 22 Continued

Measure
HPDS2RC
ZRES2HPRC
HPDS5RC
ZRES5HPRC
HPRCRM2
HPRCRM5

Total (N = 95)

FD/SMI (n = 15)

M
4.23
.07
3.70
.03

M
29.11
.56
25.56
.63

SD
49.12
.78
37.99
.85

SD
81.49
1.68
58.82
1.56

Total (N = 95)

FD/SMI (n = 15)

Measure
RSABL2
RSABL5
RSAMI2
RSAMI5

M
SD
5.84
1.04
5.83
1.01
6.03
1.15
5.89
1.13
Total (N = 94)

M
SD
5.54
1.07
5.63
1.06
5.92
1.02
5.84
1.00
FD/SMI (n = 15)

Measure
RSARC2
RSARC5

M
SD
5.82
1.00
5.79
.93
Total (N = 95)

M
SD
5.73
.86
5.69
.92
FD/SMI (n = 15)

Measure
RSADS2RA
ZRES2RSARA
RSADS5RA
ZRES5RSARA
RSARARM2
RSARARM5

M
.24
.02
.11
.03

M
.37
.14
.22
.17

SD
.61
.73
.45
.58

SD
.53
.61
.37
.47

FD/NMI, HC/SMI,
HC/NMI (n = 80)
M
SD
-.43
39.43
-.11
.75
-.40
31.56
-.13
.79

FD/NMI, HC/SMI,
HC/NMI (n = 80)
M
SD
5.89
1.03
5.87
1.00
6.05
1.17
5.90
1.16
FD/NMI, HC/SMI,
HC/NMI (n = 79)
M
SD
5.84
1.03
5.81
.94
FD/NMI, HC/SMI,
HC/NMI (n = 80)
M
SD
.22
.62
.04
.75
.09
.46
.05
.63
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pL
.11
.05
.05
.02
.36
.25

pQ
.04
.04
.06
.05

pC
.53
.58
.90
1.00

pL
.40b
.66b
.15
.19
.40
.60

pQ

pC

.71
.41

.78
.58

Table 22 Continued

Measure
RSADS2RC
ZRES2RSARC
RSADS5RC
ZRES5RSARC
RSARCRM2
RSARCRM5

Total (N = 94)

FD/SMI (n = 15)

M
-.02
.00
-.05
.00

M
.18
.20
.05
.19

SD
.70
1.00
.43
1.00

SD
.74
.94
.35
.79

Total (N = 95)

FD/SMI (n = 15)

Measure
PEPBL2
PEPBL5
PEPMI2
PEPMI5

M
SD
120.61
11.90
120.37
11.68
119.77
12.74
119.91
13.04
Total (N = 94)

M
SD
118.97
11.37
118.99
11.06
118.73
10.52
119.29
10.98
FD/SMI (n = 15)

Measure
PEPRC2
PEPRC5

M
SD
120.15
14.33
120.91
12.24
Total (N = 95)

M
SD
120.47
10.68
120.12
10.35
FD/SMI (n = 15)

Measure
PEPDS2RA
ZRES2PEPRA
PEPDS5RA
ZRES5PEPRA
PEPRARM2
PEPRARM5

M
-.48
-.01
-.31
.04

M
-.23
.10
.31
.15

SD
4.19
.65
4.13
.64

SD
4.69
.83
3.73
.70

FD/NMI, HC/SMI,
HC/NMI (n = 79)
M
SD
-.06
.69
-.03
1.01
-.07
.44
-.04
1.03

FD/NMI, HC/SMI,
HC/NMI (n = 80)
M
SD
120.92
12.04
120.63
11.84
119.96
13.17
120.03
13.45
FD/NMI, HC/SMI,
HC/NMI (n = 79)
M
SD
120.09
14.98
121.06
12.62
FD/NMI, HC/SMI,
HC/NMI (n = 80)
M
SD
-.53
4.12
.06
.74
-.43
4.21
.001
.78
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pL
.59
.81
.67
.73
.50
.49

pQ
.14
.31
.18
.35

pC
.45
.30
.74
.53

pL
.79b
.79b
.80b
.82b
.68
.83

pQ

pC

Table 22 Continued
Total (N = 94)

FD/SMI (n = 15)

FD/NMI, HC/SMI,
HC/NMI (n = 79)
M
SD
.68
5.31
.09
.56
.87
4.83
.01
.91

Measure
M
SD
M
SD
pL
pQ
pC
PEPDS2RC
.68
5.06
.63
3.64
.92
.75
.71
ZRES2PEPRC
.09
.53
.08
.37
.98
.85
.65
PEPDS5RC
.79
4.57
.35
2.95
.83b
ZRES5PEPRC
.00
1.00
-.08
.54
.41
.64
.74
PEPRCRM2
.86
PEPRCRM5
.79
Note. The difference between baseline and mood induction or mood induction and recovery measures may not
precisely equal the difference score as outlier data was addressed differently depending on the type of analyses
conducted; FD = formerly depressed; HC = healthy control; SMI = sad mood induction; NMI = neutral mood
induction; L = linear; Q = quadratic; C = cubic; HP = heart period at baseline; BL = baseline; MI = mood induction; RC
= recovery; 2 = average obtained during a two-minute interval; 5 = average obtained during a five-minute interval; DS
= difference score; RA = reactivity; ZRES = residualized change scores; RSA = respiratory sinus arrhythmia; PEP =
pre-ejection period; RM = repeated measures; b = only linear results are presented as analyses were run with
covariates.
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Bivariate Correlations. Bivariate correlations were used to examine correlations for
cognitive, mood, and cardiovascular measures. Of note, only relevant variables were analyzed.
Only five-minute averages for cardiovascular measures are presented as they are more a reliable
measure of cardiovascular functioning than two-minute averages (S. K. McCoy, personal
communication, June 14, 2019). A correlation matrix for cognitive, mood, and cardiovascular
pre- and post-mood induction scores for the entire sample is presented in Table 23, correlation
matrices for cognitive, mood, and cardiovascular pre- and post-mood induction scores by group
are presented in Table 24, and correlation matrices for cognitive, mood, and cardiovascular preand post-mood induction scores by group and condition are presented in Table 25. Correlation
matrices for cognitive, mood, and cardiovascular change scores for the entire sample are
presented in Table 26, correlation matrices for cognitive, mood, and cardiovascular change
scores by group are presented in Table 27, and correlation matrices for cognitive, mood, and
cardiovascular change scores by group and condition are presented in Table 28.
Cognitive and mood measures. Bivariate correlations were used to investigate the
relationship between cognitive and mood measures pre- and post-mood induction. Correlations
between pre- and post-mood induction scores for the entire sample were examined. Pre- and
post-mood induction measures were positively correlated for the DAS-SF I & II, VASPRE and
VASPOST, PANAS-X NPRE and PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST,
PANAS-X GPRE and PANAS-X GPOST, and PANAS-X SPRE and PANAS-X SPOST (r = .36-.91, p
< .001 for all). These results suggest that pre- and post-mood induction scores for cognitive and
mood measures all correlate with one another as expected.
Correlations between pre- and post-mood induction, difference, and residualized change
scores for the entire sample were examined by measure. The DAS I was negatively correlated
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with the VASPRE, PANAS-X NPRE, PANAS-X NPOST, PANAS-X GPRE, PANAS-X GPOST,
PANAS-X SPRE, and PANAS-X SPOST (r = -.31--.47, p < .001 for all). The DAS II was positively
correlated with the PANAS-X PPOST (r = .27, p < .01) and negatively correlated with the
VASPRE, VASPOST, PANAS-X NPRE, PANAS-X NPOST, PANAS-X GPRE, PANAS-X GPOST,
PANAS-X SPRE, and PANAS-X SPOST (r = -.24--.46, p < .01-.001). Some of these correlations
were also obtained when using difference and residualized change scores. The DASDS and
ZRESDAS was positively correlated with the PANAS-X PDS and ZRESPANAS-X P (r = .26-.29, p
< .01-.001) and negatively correlated with the VASDS and ZRESVAS (r = -.20--.23, p < .05 for
all). Of note, the valences of these correlations are in the expected direction as lower scores on
the DAS are indicative of increased dysfunctional beliefs. Therefore, these results suggest that
increased dysfunctional thoughts pre- and post-mood induction were associated with increased
dysphoric mood, negative affect, guilt, and sadness pre- and post-mood induction while
increased dysfunctional thoughts post-mood induction were also associated with decreased
positive affect post-mood induction. In addition, these results indicate that increased
dysfunctional thoughts during the experimental paradigm was associated with increased
dysphoric mood and decreased positive affect post-mood induction.
The VASPRE was positively correlated with the PANAS-X NPRE, PANAS-X NPOST,
PANAS-X GPRE, PANAS-X GPOST, PANAS-X SPRE, and PANAS-X SPOST (r = .33-.41, p < .001
for all). The VASPOST was positively correlated with the PANAS-X NPOST and PANAS-X SPOST
(r = .22-.39, p < .05-.001) and negatively correlated with the PANAS-X PPOST (r = -.27, p < .01).
Correlations were also obtained between the VAS and PANAS-X subscales when using
difference and residualized change scores. The VASDS and ZRESVAS was positively correlated
with the PANAS-X NDS, GDS, and SDS and ZRESPANAS-X N, G, and S (r = .24-.52, p < .01-.001)
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and negatively correlated with the PANAS-X PDS and ZRESPANAS-X P (r = -.36--.38, p < .001
for all). These results suggest that increased dysphoric mood pre-mood induction was associated
with increased negative affect, guilt, and sadness pre- and post-mood induction while increased
dysphoric mood post-mood induction was associated with increased negative affect and sadness
and decreased positive affect post-mood induction. In addition, these results indicate that
increased dysphoric mood during the experimental paradigm was associated with increased
negative affect, guilt, and sadness and decreased positive affect post-mood induction.
The PANAS-X NPRE was positively correlated with the PANAS-X GPRE, PANAS-X
GPOST, PANAS-X SPRE, and PANAS-X SPOST (r =.67-.87, p < .001 for all). The PANAS-X NPOST
was positively correlated with the PANAS-X GPRE, PANAS-X GPOST, PANAS-X SPRE, and
PANAS-X SPOST (r =.73-.84, p < .001 for all). These correlations were also obtained when using
difference and residualized change scores. The PANAS-X NDS and ZRESPANAS-X N was
positively correlated with the PANAS-X GDS, ZRESPANAS-X G, PANAS-X SDS, and
ZRESPANAS-X S (r = .46-.64, p < .001 for all). These results suggest that increased negative
affect pre- and post-mood induction was associated with increased guilt and sadness pre- and
post-mood induction. In addition, these results indicate that increased negative affect during the
experimental paradigm was associated with increased guilt and sadness post-mood induction.
While the PANAS-X PPRE and PANAS-X PPOST were not associated with other pre- and
post-mood induction PANAS-X measures, significant correlations were present when using
difference and residualized change scores. The PANAS-X PDS was negatively correlated with the
PANAS-X SDS (r = -.38, p < .001) while the ZRESPANAS-X P was negatively correlated with the
ZRESPANAS-X G (r = -.40, p < .001). Generally, these results indicate that increased positive
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affect during the experimental paradigm was associated with decreased guilt and sadness postmood induction.
The PANAS-X GPRE and PANAS-X GPOST was positively correlated with the PANAS-X
SPRE and PANAS-X SPOST (r =.60-.70, p < .001 for all). These correlations were also obtained
when using difference and residualized change scores. The PANAS-X GDS and ZRESPANAS-X
G was positively correlated with the PANAS-X SDS and ZRESPANAS-X S (r = .48-.52, p < .001
for all). These results suggest that increased guilt pre- and post-mood induction was associated
with increased sadness pre- and post-mood induction. In addition, these results indicate that
increased guilt during the experimental paradigm was associated with increased sadness postmood induction.
Correlations between cognitive and mood pre- and post-mood induction, difference, and
residualized change scores were evaluated between groups. For formerly depressed participants,
most of the pre- and post-mood induction measures were positively correlated, including the
DAS-SF I & II, PANAS-X NPRE and PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST,
PANAS-X GPRE and PANAS-X GPOST, and PANAS-X SPRE and PANAS-X SPOST (r = .69-.90, p
< .001 for all). However, the VASPRE and VASPOST (r = .14, p > .05) were not significantly
correlated, suggesting that there was a significant difference in dysphoric mood pre- and postmood induction for formerly depressed participants. The DASDS and ZRESDAS were not
correlated with any of the mood or affect measures. The VASDS and ZRESVAS were positively
correlated with the PANAS-X NDS, GDS, and SDS and ZRESPANAS-X N, G, and S (r = .40-.56, p
< .05-.001) and negatively correlated with the PANAS-X PDS and ZRESPANAS-X P (r = -.52, p <
.001 for all). The PANAS-X NDS and ZRESPANAS-X N were positively correlated with the
PANAS-X GDS, ZRESPANAS-X G, PANAS-X SDS, and ZRESPANAS-X S (r = .56-.74, p < .001
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for all). The PANAS-X PDS and ZRESPANAS-X P were negatively correlated with the PANAS-X
SDS and ZRESPANAS-X G (r = -.49--.56, p < .001 for all). Finally, the PANAS-X GDS and
ZRESPANAS-X G were positively correlated with the PANAS-X SDS and ZRESPANAS-X S (r =
.60-.65, p < .001 for all). Overall, these correlations show a similar pattern to those previously
reported for the entire sample.
For healthy control participants, all pre- and post-mood induction measures were
positively correlated, including the DAS-SF I & II, VASPRE and VASPOST, PANAS-X NPRE and
PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST, PANAS-X GPRE and PANAS-X GPOST,
and PANAS-X SPRE and PANAS-X SPOST (r = .46-.91, p < .001 for all). Importantly, these results
suggest that there was no difference in dysphoric mood pre- and post-mood induction for healthy
control participants. The DASDS and ZRESDAS was positively correlated with the PANAS-X PDS
and ZRESPANAS-X P (r = .25-.28, p < .05 for all). The VASDS and ZRESVAS were positively
correlated with the PANAS-X SDS and ZRESPANAS-X G (r = .41-.50, p < .001 for all) and
negatively correlated with the PANAS-X PDS and ZRESPANAS-X P (r = -.29-.32, p < .01 for all).
The PANAS-X NDS and ZRESPANAS-X N were positively correlated with the PANAS-X GDS,
ZRESPANAS-X G, PANAS-X SDS, and ZRESPANAS-X S (r = .36-.48, p < .001 for all). The
PANAS-X PDS and ZRESPANAS-X P were negatively correlated with the PANAS-X SDS and
ZRESPANAS-X G (r = -.34--.37, p < .01-.001). Finally, the PANAS-X GDS and ZRESPANAS-X G
were positively correlated with the PANAS-X SDS and ZRESPANAS-X S (r = .29-.30, p < .01 for
all). Overall, these correlations show a similar pattern to those previously reported for the entire
sample.
Correlations between cognitive and mood pre- and post-mood induction, difference, and
residualized change scores were evaluated between groups and conditions. For formerly
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depressed participants exposed to the sad mood induction, most of the pre- and post-mood
induction measures were positively correlated, including the DAS-SF I & II, PANAS-X NPRE and
PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST, PANAS-X GPRE and PANAS-X GPOST,
and PANAS-X SPRE and PANAS-X SPOST (r = .77-.87, p < .001 for all). However, the VASPRE
and VASPOST (r = .16, p > .05) were not significantly correlated, suggesting that there was a
significant difference in dysphoric mood pre- and post-mood induction for formerly depressed
participants exposed to the sad mood induction. The DASDS was negatively correlated with the
VASDS (r = -.58, p < .05) while the ZRESDAS was not correlated with any of the mood or affect
measures. The VASDS and ZRESVAS were positively correlated with the PANAS-X NDS,
PANAS-X SDS, ZRESPANAS-X N, and ZRESPANAS-X G (r = .49-.57, p < .05 for all). The
PANAS-X NDS and ZRESPANAS-X N were positively correlated with the PANAS-X GDS,
ZRESPANAS-X G, PANAS-X SDS, and ZRESPANAS-X S (r = .52-.78, p < .05-.001). The
PANAS-X PDS and ZRESPANAS-X P were negatively correlated with the PANAS-X SDS and
ZRESPANAS-X G (r = -.57--.65, p < .01-.001). Finally, the PANAS-X GDS and ZRESPANAS-X G
were positively correlated with the PANAS-X SDS and ZRESPANAS-X S (r = .59-.65, p < .01 for
all). Overall, these correlations show a similar pattern to those previously reported for the entire
sample.
For formerly depressed participants exposed to the neutral mood induction, most of the
pre- and post-mood induction measures were positively correlated, including the DAS-SF I & II,
PANAS-X NPRE and PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST, PANAS-X GPRE
and PANAS-X GPOST, and PANAS-X SPRE and PANAS-X SPOST (r = .63-.95, p < .001 for all).
However, the VASPRE and VASPOST (r = .37, p > .05) were not significantly correlated,
suggesting that there was a significant difference in dysphoric mood pre- and post-mood
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induction for formerly depressed participants exposed to the neutral mood induction. Of note,
this correlation was stronger than the correlation for formerly depressed participants exposed to
the sad mood induction (r = .16, p > .05). The DASDS, ZRESDAS, VASDS, ZRESVAS, PANAS-X
PDS, ZRESPANAS-X P, PANAS-X GDS, and ZRESPANAS-X G were not correlated with any of
the mood or affect measures. The PANAS-X NDS and ZRESPANAS-X N were positively
correlated with the PANAS-X GDS, ZRESPANAS-X G, PANAS-X SDS, and ZRESPANAS-X S (r =
.62-.72, p < .01-.001). Overall, these correlations show a similar pattern to those previously
reported for the entire sample with the exception of some of the mood and affective measures.
For healthy control participants exposed to the sad mood induction, all pre- and postmood induction measures were positively correlated, including the DAS-SF I & II, VASPRE and
VASPOST, PANAS-X NPRE and PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST,
PANAS-X GPRE and PANAS-X GPOST, and PANAS-X SPRE and PANAS-X SPOST (r = .41-.92, p
< .01-.001). Importantly, these results suggest that there was no difference in dysphoric mood
pre- and post-mood induction for healthy control participants exposed to the sad mood induction.
The DASDS and ZRESDAS were not correlated with any of the mood or affect measures. The
VASDS and ZRESVAS were positively correlated with the PANAS-X SDS and ZRESPANAS-X G (r
= .40-.51, p < .01-.001). The PANAS-X NDS and ZRESPANAS-X N were positively correlated
with the PANAS-X GDS, ZRESPANAS-X G, PANAS-X SDS, and ZRESPANAS-X S (r = .42-.53, p
< .01-.001). The PANAS-X PDS and ZRESPANAS-X P were negatively correlated with the
PANAS-X SDS and ZRESPANAS-X G (r = -.40--.41, p < .01 for all). Finally, the PANAS-X GDS
and ZRESPANAS-X G were positively correlated with the PANAS-X SDS and ZRESPANAS-X S
(r = .34, p < .01 for all). Overall, these correlations show a similar pattern to those previously
reported for the entire sample.
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For healthy control participants exposed to the neutral mood induction, all pre- and postmood induction measures were positively correlated, including the DAS-SF I & II, VASPRE and
VASPOST, PANAS-X NPRE and PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST,
PANAS-X GPRE and PANAS-X GPOST, and PANAS-X SPRE and PANAS-X SPOST (r = .64-.94, p
< .001 for all). Importantly, these results suggest that there was no difference in dysphoric mood
pre- and post-mood induction for healthy control participants exposed to the neutral mood
induction. The ZRESDAS was positively correlated with ZRESPANAS-X P (r = .36, p < .05). The
ZRESPANAS-X N was positively correlated with the, ZRESPANAS-X G and ZRESPANAS-X S (r
= .39-.40, p < .05 for all). The DASDS, VASDS, ZRESVAS, PANAS-X NDS, PANAS-X PDS,
ZRESPANAS-X P, PANAS-X GDS, and ZRESPANAS-X G were not correlated with any of the
mood or affect measures. Overall, these correlations show a similar pattern to those previously
reported for the entire sample with the exception of some of the mood and affective measures.
Cardiovascular measures. Bivariate correlations were used to investigate the relationship
between cardiovascular measures pre- and post-mood induction. Correlations between pre- and
post-mood induction, difference, and residualized change scores for the entire sample were
examined. Five-minute HP during baseline, mood induction, and recovery were positively
correlated when using pre- and post-mood induction (r = .94-.96, p < .001 for all). Five-minute
HP reactivity and recovery were positively correlated when using difference and residualized
change scores (r = .59, p < .001 for all). Five-minute RSA during baseline, mood induction, and
recovery were positively correlated when using pre- and post-mood induction (r = .75-.90, p <
.001 for all). Five-minute RSA reactivity and recovery were positively correlated when using
difference and residualized change scores (r = .46-.47, p < .001 for all). Five-minute PEP during
baseline, mood induction, and recovery were positively correlated when using pre- and post-
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mood induction (r = .89-.91, p < .001 for all). Finally, five-minute PEP reactivity and recovery
were positively correlated when using difference and residualized change scores (r = .37-.45, p <
.001 for all). These results suggest that pre- and post-mood induction scores for cardiovascular
measures all correlate with one another as expected.
Correlations between cardiovascular pre- and post-mood induction, difference, and
residualized change scores were evaluated between groups. For formerly depressed participants,
five-minute HP during baseline, mood induction, and recovery were positively correlated when
using pre- and post-mood induction (r = .95-.97, p < .001 for all). Five-minute HP reactivity and
recovery were positively correlated when using difference and residualized change scores (r =
.54-.55, p < .05 for all). Five-minute RSA during baseline, mood induction, and recovery were
positively correlated when using pre- and post-mood induction (r = .89-.93, p < .001 for all).
Five-minute RSA reactivity and recovery were positively correlated when using difference and
residualized change scores (r = .48-.53, p < .01 for all). Five-minute PEP during baseline, mood
induction, and recovery were positively correlated when using pre- and post-mood induction (r =
.92-.96, p < .001 for all). Five-minute PEP reactivity and recovery were positively correlated
when using difference and residualized change scores (r = .59-.60, p < .05 for all). Overall, these
correlations show a similar pattern to those previously reported for the entire sample.
For healthy control participants, five-minute HP during baseline, mood induction, and
recovery were positively correlated when using pre- and post-mood induction (r = .94-.97, p <
.001 for all). Five-minute HP reactivity and recovery were positively correlated when using
difference and residualized change scores (r = .45-.48, p < .05 for all). Five-minute RSA during
baseline, mood induction, and recovery were positively correlated when using pre- and postmood induction (r = .69-.88, p < .001 for all). Five-minute RSA reactivity and recovery were
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positively correlated when using difference and residualized change scores (r = .46, p < .001 for
all). Five-minute PEP during baseline, mood induction, and recovery were positively correlated
when using pre- and post-mood induction (r = .96-.97, p < .001 for all). Five-minute PEP
reactivity and recovery were positively correlated when using difference and residualized change
scores (r = .39-.46, p < .05 for all). Overall, these correlations show a similar pattern to those
previously reported for the entire sample.
Correlations between cardiovascular pre- and post-mood induction, difference, and
residualized change scores were evaluated between groups and conditions. For formerly
depressed participants exposed to the sad mood induction, five-minute HP during baseline, mood
induction, and recovery were positively correlated when using pre- and post-mood induction (r =
.94-.98, p < .001 for all). Five-minute HP reactivity and recovery were not correlated when using
difference and residualized change scores. Five-minute RSA during baseline, mood induction,
and recovery were positively correlated when using pre- and post-mood induction (r = .94-.96, p
< .001 for all). Five-minute RSA reactivity and recovery were positively correlated when using
difference and residualized change scores (r = .65-.67, p < .01 for all). Five-minute PEP during
baseline, mood induction, and recovery were positively correlated when using pre- and postmood induction (r = .93-.95, p < .001 for all). Five-minute PEP reactivity and recovery were not
correlated when using difference and residualized change scores. Overall, these correlations
show a similar pattern to those previously reported for the entire sample with the exception of
some cardiovascular measures.
For formerly depressed participants exposed to the neutral mood induction, five-minute
HP during baseline, mood induction, and recovery were positively correlated when using preand post-mood induction (r = .93-.97, p < .001 for all). Five-minute HP reactivity and recovery
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were positively correlated when using difference and residualized change scores (r = .88-.89, p <
.05 for all). Five-minute RSA during baseline, mood induction, and recovery were positively
correlated when using pre- and post-mood induction (r = .85-.93, p < .001 for all). Five-minute
RSA reactivity and recovery were not correlated when using difference and residualized change
scores. Five-minute PEP during baseline, mood induction, and recovery were positively
correlated when using pre- and post-mood induction (r = .91-.98, p < .001 for all). Five-minute
PEP reactivity and recovery were not correlated when using difference and residualized change
scores. Overall, these correlations show a similar pattern to those previously reported for the
entire sample with the exception of some cardiovascular measures.
For healthy control participants exposed to the sad mood induction, five-minute HP
during baseline, mood induction, and recovery were positively correlated when using pre- and
post-mood induction (r = .92-.97, p < .001 for all). Five-minute HP reactivity and recovery were
positively correlated when using residualized change, but not difference, scores (r = .59, p < .01).
Five-minute RSA during baseline, mood induction, and recovery were positively correlated
when using pre- and post-mood induction (r = .85-.92, p < .001 for all). Five-minute RSA
reactivity and recovery were positively correlated when using difference and residualized change
scores (r = .49-.50, p < .01 for all). Five-minute PEP during baseline, mood induction, and
recovery were positively correlated when using pre- and post-mood induction (r = .96-.98, p <
.001 for all). Five-minute PEP reactivity and recovery were positively correlated when using
difference, but not residualized change, scores (r = .63, p < .05). Overall, these correlations show
a similar pattern to those previously reported for the entire sample with the exception of some
cardiovascular measures.
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For healthy control participants exposed to the neutral mood induction, five-minute HP
during baseline, mood induction, and recovery were positively correlated when using pre- and
post-mood induction (r = .95-.97, p < .001 for all). Five-minute HP reactivity and recovery were
not correlated when using difference and residualized change scores. Five-minute RSA during
baseline, mood induction, and recovery were positively correlated when using pre- and postmood induction (r = .47-.90, p < .01-.001). Five-minute RSA reactivity and recovery were
positively correlated when using difference and residualized change scores (r = .47-.48, p < .01
for all). Five-minute PEP during baseline, mood induction, and recovery were positively
correlated when using pre- and post-mood induction (r = .92-.97, p < .001 for all). Five-minute
PEP reactivity and recovery were not correlated when using difference and residualized change
scores. Overall, these correlations show a similar pattern to those previously reported for the
entire sample with the exception of some cardiovascular measures.
Cognitive, mood, and cardiovascular measures. Bivariate correlations were used to
investigate the relationship between cognitive, mood, and cardiovascular measures pre- and postmood induction. Correlations between pre- and post-mood induction, difference, and
residualized change scores for the entire sample were examined. The majority of the self-report
measures (with the exception of the PANAS-X PPRE, PANAS-X PPOST, and ZRESVAS) were not
significantly correlated with HP, RSA, or PEP.
Correlations between pre- and post-mood induction, difference, and residualized change
scores were evaluated between groups. For formerly depressed participants, the majority of the
self-report measures (with the exception of the VASPOST and PANAS-X NDS) were not
significantly correlated with HP, RSA, or PEP. For healthy control participants, the majority of
the self-report measures (with the exception of the PANAS-X PPRE, PANAS-X PPOST, VASDS,
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PANAS-X GDS, PANAS-X SDS, ZRESDAS, ZRESVAS, ZRESPANAS-X G, and ZRESPANAS-X S)
were not significantly correlated with HP, RSA, or PEP. Overall, these correlations show a
similar pattern to those previously reported for the entire sample with the exception of some
measures. However, one notable association was observed. The post-mood induction VAS was
negatively correlated with five-minute HP during baseline, mood induction, and recovery (r = .56--.57, p < .05 for all), suggesting that formerly depressed participants who experience an
increase in sadness post-mood induction exhibit decreased HP during baseline, mood induction,
and recovery. These correlations run counter to the trends found for Hypotheses 2, 3, and 4.
Consequently, additional analyses were conducted for the group and condition interaction, which
revealed that the relationship between the VASPOST and HP during baseline, mood induction, and
recovery was more robust in formerly depressed participants exposed to the neutral mood
induction (r = -.51--.62, p > .19 for all) than those exposed to the sad mood induction (r = -.31-.46, p > .19 for all).
Correlations between pre- and post-mood induction, difference, and residualized change
scores were evaluated between groups and conditions. For formerly depressed participants
exposed to the sad mood induction, the majority of the self-report measures (with the exception
of the ZRESDAS and ZRESRSARC) were not significantly correlated with HP, RSA, or PEP. For
formerly depressed participants exposed to the neutral mood induction, the majority of the selfreport measures (with the exception of the PANAS-X NPOST and PEPBL5, PANAS-X GPRE,
PANAS-X GPOST, and PEPRC5 and VASDS, ZRESVAS, RSADS5RA, and ZRESRSARA) were not
significantly correlated with HP, RSA, or PEP. For healthy control participants exposed to the
sad mood induction, the majority of the self-report measures (with the exception of the
ZRESDAS, ZRESVAS, and ZRESPEPRA, VASDS and PEPDS5RC, PANAS-X PDS, PANAS-X SDS, and
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HPDS5RA, PANAS-X SDS and HPDS5RC, ZRESPANAS-X P and ZRESHPRA, and ZRESPANAS-X G
and ZRESHPRC) were not significantly correlated with HP, RSA, or PEP. For healthy control
participants exposed to the neutral mood induction, the majority of the self-report measures (with
the exception of the PANAS-X NPOST, PANAS-X PPRE, and PEPBL5, PANAS-X PPRE and
PEPRC5, VASDS and HPDS5RA, PANAS-X SDS and PEPDS5RC, ZRESDAS and ZRESHPRC,
ZRESPANAS-X N, ZRESPANAS-X G, and ZRESPEPRC) were not significantly correlated with
HP, RSA, or PEP. Overall, these correlations show a similar pattern to those previously reported
for the entire sample with the exception of some measures.
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Table 23. Correlation Matrix for Cognitive, Mood, and Cardiovascular Pre- and Post-Mood Induction Scores for the Entire Sample
Measure
1. DAS I
2. DAS II
3. VASPRE
4. VASPOST
5. PANAS-X NPRE
6. PANAS-X NPOST
7. PANAS-X PPRE
8. PANAS-X PPOST
9. PANAS-X GPRE
10. PANAS-X GPOST
11. PANAS-X SPRE
12 PANAS-X SPOST
13. HPBL5
14. HPMI5
15. HPRC5
16. RSABL5
17. RSAMI5
18. RSARC5
19. PEPBL5
20. PEPMI5
21. PEPRC5

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

.73e
-.31e
-.17
-.47e
-.45e
.21c
.22c
-.47e
-.43e
-.44e
-.45e
-.03
-.04
-.12
.02
-.01
-.03
.06
-.04
.07

-.24d
-.26d
-.43e
-.40e
.12
.27d
-.44e
-.46e
-.42e
-.43e
-.02
.004
-.13
-.01
.003
-.03
.06
-.03
.03

.36e
.37e
.41e
-.06
-.13
.34e
.33e
.35e
.37e
.11
.12
.11
.07
.14
.11
-.16
-.09
-.15

.08
.22c
-.07
-.27d
.08
.17
.14
.39e
-.18
-.21
-.21
.07
.17
.08
-.29
-.21
-.26

.91e
.08
.08
.87e
.80e
.78e
.67e
.06
.13
.10
.09
.02
.13
-.13
-.04
-.03

.06
.02
.79e
.84e
.73e
.75e
.00
.03
.04
.01
-.01
.06
-.17
-.10
-.09

.85e
-.07
-.04
-.08
-.05
.02
.10
.09
.09
.15
.16
.25
.27
.38c

-.07
-.11
-.07
-.17
.09
.16
.14
.08
.11
.14
.34c
.33c
.44d

.90e
.70e
.60e
.04
.03
.01
.10
.05
.14
-.13
-.07
-.11

.67e
.70e
-.05
-.09
-.04
.04
-.003
.09
-.07
-.04
-.06

.84e
-.12
-.07
-.06
.08
-.01
.10
-.27
-.16
-.18

-.03
-.01
.02
.06
-.01
.06
-.27
-.16
-.15

.95e
.94e
-.02
.13
.02
.23c
.23c
.23c

.96e
.04
.14
.07
.22c
.23c
.25c

-.03
.08
.02
.20c
.21c
.25c

.75e
.90e
-.19
-.20
-.06

.80e
-.13
-.14
-.06

-.07
-.07
.03

.91e
.89e

.91e

Note. DAS I = Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional Attitudes Scale – Short Form II; VAS = Visual
Analogue Scale; PRE = pre mood induction; POST = post mood induction; PANAS-X = Positive and Negative Affect Scale – Expanded
Form; N = negative affect general dimension scale; P = positive affect general dimension scale; G = guilt basic negative emotional
scale; S = sadness basic negative emotional scale; HP = heart period at baseline; BL = baseline; 5 = average obtained during a fiveminute interval; MI = mood induction; RC = recovery; RSA = respiratory sinus arrhythmia; PEP = pre-ejection period; c = p < .05; d = p
< .01; e = p < .001.
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Table 24. Correlation Matrices for Cognitive, Mood, and Cardiovascular Pre- and Post-Mood Induction Scores by Group
Measure
1. DAS I
2. DAS II
3. VASPRE
4. VASPOST
5. PANAS-X NPRE
6. PANAS-X NPOST
7. PANAS-X PPRE
8. PANAS-X PPOST
9. PANAS-X GPRE
10. PANAS-X GPOST
11. PANAS-X SPRE
12 PANAS-X SPOST
13. HPBL5
14. HPMI5
15. HPRC5
16. RSABL5
17. RSAMI5
18. RSARC5
19. PEPBL5
20. PEPMI5
21. PEPRC5

1.

2.

3.

4.

5.

6.

7.

8.

.69e
-.03
.21
-.55e
-.49e
.03
-.05
-.53e
-.49e
-.48e
-.44d
.28
.18
.14
-.12
-.08
-.06
-.04
-.07
.04

.13
.04
-.50e
-.46d
-.02
-.01
-.54e
-.58e
-.35c
-.31c
.28
.21
.07
-.21
-.14
-.11
.03
.06
-.05

.14
.22
.16
-.10
-.04
.19
.15
.29
.15
-.06
.03
-.001
.13
.11
.08
-.26
-.21
-.22

-.12
.11
.07
-.23
-.13
.02
-.05
.19
-.56c
-.57c
-.57c
-.02
.08
-.02
-.24
-.21
-.15

.90e
.15
.28
.87e
.80e
.76e
.66e
.06
.19
.12
.23
.16
.28
-.24
-.14
-.12

.15
.17
.78e
.88e
.72e
.76e
-.08
.01
.02
.11
.07
.18
-.09
-.04
.04

.83e
-.02
.03
-.13
.10
.06
.09
.08
.08
.10
.11
.01
.04
.20

.13
.07
.02
.03
.10
.09
.04
.16
.20
.24
.09
.11
.17

Measure
1. DAS I
2. DAS II
3. VASPRE
4. VASPOST
5. PANAS-X NPRE
6. PANAS-X NPOST
7. PANAS-X PPRE
8. PANAS-X PPOST
9. PANAS-X GPRE
10. PANAS-X GPOST
11. PANAS-X SPRE
12 PANAS-X SPOST
13. HPBL5
14. HPMI5
15. HPRC5
16. RSABL5
17. RSAMI5
18. RSARC5

1.

2.

3.

4.

5.

6.

7.

8.

.72e
-.44e
-.28c
-.33d
-.34d
.20
.21
-.33d
-.29d
-.33d
-.38e
-.28
-.24
-.34
.07
.03
-.03

-.39e
-.31d
-.29c
-.25c
.06
.24c
-.27c
-.27c
-.40e
-.42e
-.21
-.16
-.29
.05
.06
-.01

.46e
.48e
.58e
.02
-.10
.46e
.46e
.35e
.52e
.30
.28
.28
.05
.15
.14

.14
.20
-.06
-.22c
.14
.15
.19
.48e
.09
.11
.07
.14
.21
.15

.91e
.19
.19
.82e
.72e
.74e
.62e
.02
.11
.12
-.001
-.09
.03

.16
.14
.76e
.75e
.67e
.68e
.08
.13
.14
-.02
-.07
.01

.85e
.04
.08
.08
-.01
-.01
.04
.04
.07
.18
.17

-.01
-.01
.04
-.14
.10
.15
.15
.01
.09
.09

FD
9.

.86e
.70e
.53e
.07
.12
.08
.19
.12
.23
-.22
-.12
-.13
HC
9.

.91e
.62e
.61e
.01
.01
-.01
.06
-.001
.10
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10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

.69e
.70e
-.06
-.05
-.001
.13
.04
.17
-.05
-.03
.03

.84e
-.35
-.23
-.23
.27
.16
.31
-.47
-.33
-.26

-.38
-.26
-.20
.16
.06
.18
-.36
-.25
-.13

.97e
.95e
-.45
-.36
-.33
.12
.12
.06

.96e
-.35
-.29
-.28
.02
.03
.004

-.40
-.30
-.34
-.02
-.08
.08

.89e
.93e
-.67d
-.64c
-.57c

.91e
-.65d
-.66d
-.57c

-.57c
-.56c
-.52

.96e
.92e

.94e

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

.56e
.62e
-.02
-.03
.01
.03
-.05
.08

.80e
.12
.17
.18
-.03
-.14
-.02

.31
.30
.28
.03
-.06
.01

.97e
.94e
.24
.37
.22

.95e
.24
.33
.23

.16
.24
.20

.69e
.88e

.76e

Table 24 Continued
19. PEPBL5
20. PEPMI5
21. PEPRC5

.12
-.03
.05

.05
-.12
-.004

-.02
.08
-.01

-.30
-.17
-.24

-.002
.08
.11

-.19
-.10
-.08

.36
.40c
.42c

.45c
.46c
.51d

.40
.09
.09

-.02
.04
.06

-.06
.08
.02

-.17
-.02
-.04

.27
.35
.35

.36
.43c
.44c

.29
.38
.38

.02
.03
.12

.07
.08
.10

.16
.19
.24

.97e
.96e

.96e

Note. FD = formerly depressed; HC = healthy control; DAS I = Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional
Attitudes Scale – Short Form II; VAS = Visual Analogue Scale; PRE = pre mood induction; POST = post mood induction; PANAS-X =
Positive and Negative Affect Scale – Expanded Form; N = negative affect general dimension scale; P = positive affect general
dimension scale; G = guilt basic negative emotional scale; S = sadness basic negative emotional scale; HP = heart period at baseline;
BL = baseline; 5 = average obtained during a five-minute interval; MI = mood induction; RC = recovery; RSA = respiratory sinus
arrhythmia; PEP = pre-ejection period; c = p < .05; d = p < .01; e = p < .001.

243

Table 25. Correlation Matrices for Cognitive, Mood, and Cardiovascular Pre- and Post-Mood Induction Scores by Group and Condition
8.

FD/SMI
9.

Measure
1. DAS I
2. DAS II
3. VASPRE
4. VASPOST
5. PANAS-X NPRE
6. PANAS-X NPOST
7. PANAS-X PPRE
8. PANAS-X PPOST
9. PANAS-X GPRE
10. PANAS-X GPOST
11. PANAS-X SPRE
12 PANAS-X SPOST
13. HPBL5
14. HPMI5
15. HPRC5
16 RSABL5
17. RSAMI5
18. RSARC5
19. PEPBL5
20. PEPMI5
21. PEPRC5

1.

2.

3.

4.

5.

6.

7.

.78e
-.17
.42
-.85e
-.76e
.17
.07
-.79e
-.78e
-.77e
-.67d
.29
.22
.16
-.18
-.09
-.17
-.03
-.09
.06

.01
.28
-.63d
-.60d
.06
-.03
-.68e
-.71e
-.54c
-.51c
.15
.06
-.003
-.15
.02
-.02
-.14
-.16
-.07

.16
.20
.09
-.05
-.07
.03
-.01
.09
-.03
-.47
-.42
-.35
.50
.49
.34
-.08
-.21
-.18

-.46
-.23
.06
-.31
-.49c
-.35
-.40
-.12
-.36
-.31
-.46
.19
.13
.07
-.14
-.06
-.18

.87e
.10
.35
.90e
.80e
.88e
.72e
.002
.12
.002
.32
.26
.41
.06
.22
.16

.04
.12
.77e
.89e
.82e
.84e
-.18
-.12
-.11
.27
.21
.37
.33
.37
.26

.77e
-.10
-.08
-.21
.04
.50
.56
.45
.23
.32
.27
.03
.06
.22

Measure
1. DAS I
2. DAS II
3. VASPRE
4. VASPOST
5. PANAS-X NPRE
6. PANAS-X NPOST
7. PANAS-X PPRE
8. PANAS-X PPOST
9. PANAS-X GPRE
10. PANAS-X GPOST
11. PANAS-X SPRE
12 PANAS-X SPOST
13. HPBL5
14. HPMI5
15. HPRC5
16. RSABL5
17. RSAMI5

1.

2.

3.

4.

5.

6.

7.

.13
.01
.87e
.01
.82e
-.07
.60d
.42
-.04
.45
-.01
.36
-.07
.26
.13
.39
-.02
.36
.15
.12
.12
.11
.22
.25
.07
FD/NMI
8.
9.

.63e
.15
-.17
-.24
-.26
-.17
-.15
-.27
-.21
-.14
-.25
.36
.25
.12
-.08
-.10

.14
-.07
-.41c
-.35
-.10
-.01
-.44c
-.46c
-.17
-.13
.20
.01
-.16
-.31
-.31

.37
.29
.30
-.10
-.03
.32
.38
.52d
.47c
-.49
-.52
-.44
.000
.000

.21
.31
-.05
-.11
.27
.32
.36
.43c
-.62
-.58
-.51
-.20
.10

.95e
.21
.24
.88e
.81e
.58d
.55d
-.15
-.07
-.08
.16
.08

.25
.26
.84e
.87e
.58d
.63e
-.23
-.16
-.16
-.02
-.04

.93e
.08
.14
-.05
.14
-.62
-.58
-.55
-.05
-.09

.12
.18
.04
.20
-.41
-.47
-.55
.06
.02

.91e
.57d
.49c
-.01
.002
-.01
.28
.28
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10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

.79e
.79e
-.14
-.12
-.06
.17
.02
.20
.39
.38
.25

.81e
-.31
-.20
-.29
.34
.25
.42
-.25
-.11
-.20

-.19
-.03
-.07
.33
.24
.39
-.17
-.06
-.10

.98e
.95e
-.76c
-.70c
-.74c
.08
.09
.25

.94e
-.67c
-.64
-.67c
-.01
.04
.20

-.74c
-.67c
-.74c
.12
.07
.27

.94e
.94e
-.51
-.49
-.51

.96e
-.52
-.55
-.53

-.46
-.46
-.48

.95e
.93e

.95e

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

.53d
.52d
.05
.04
.03
.15
.11

.94e
-.67
-.64
-.62
.22
.08

-.79
-.74
-.69
.01
-.12

.97e
.93e
-.21
-.08

.97e
-.15
-.02

-.13
.03

.85e

Table 25 Continued
18.
19.
20.
21.

RSARC5
PEPBL5
PEPMI5
PEPRC5

.04
-.07
-.01
-.06

-.20
.43
.53
.26

.02
-.48
-.39
-.54

-.12
-.73
-.65
-.54

.16
.72
-.70
-.80

-.01
-.81c
-.77
-.83

-.04
-.05
-.01
-.03

.12
.03
.12
-.39

.32
-.80
-.74
-.98d
HC/SMI
9.

Measure
1. DAS I
2. DAS II
3. VASPRE
4. VASPOST
5. PANAS-X NPRE
6. PANAS-X NPOST
7. PANAS-X PPRE
8. PANAS-X PPOST
9. PANAS-X GPRE
10. PANAS-X GPOST
11. PANAS-X SPRE
12 PANAS-X SPOST
13. HPBL5
14. HPMI5
15. HPRC5
16. RSABL5
17. RSAMI5
18. RSARC5
19. PEPBL5
20. PEPMI5
21. PEPRC5

1.

2.

3.

4.

5.

6.

7.

8.

.71e
-.55e
-.35c
-.30c
-.30c
.04
.02
-.34c
-.31c
-.31c
-.38c
-.24
-.22
-.36
.13
.04
-.07
-.08
-.30
-.13

-.46d
-.38c
-.26
-.25
.01
.17
-.35c
-.34c
-.45d
-.47e
-.16
-.11
-.25
.03
-.01
-.05
.09
-.13
.02

.41d
.54e
.69e
.06
-.05
.56e
.56e
.42d
.59e
.26
.23
.22
-.08
-.01
.07
.27
.38
.26

.13
.24
.01
-.13
.19
.18
.33c
.65e
.16
.09
.09
.10
.16
.14
-.13
.07
-.03

.92e
.36c
.33c
.73e
.63e
.74e
.48e
.11
.19
.22
-.05
-.03
.01
.24
.37
.31

.33c
.31c
.67e
.68e
.71e
.58e
.08
.14
.15
-.11
-.09
-.03
.12
.24
.16

.82e
.18
.23
.25
.08
-.05
-.02
.01
.14
.15
.24
.14
.29
.21

Measure
1. DAS I
2. DAS II
3. VASPRE
4. VASPOST
5. PANAS-X NPRE
6. PANAS-X NPOST
7. PANAS-X PPRE
8. PANAS-X PPOST
9. PANAS-X GPRE
10. PANAS-X GPOST
11. PANAS-X SPRE
12 PANAS-X SPOST
13. HPBL5
14. HPMI5

1.

2.

3.

4.

5.

6.

7.

.05
.08
.89e
.17
.51e
-.11
.45d
.07
.10
.16
.08
.16
.04
.002 .01
.03
.12
.11
.19
.38
.31
.45
.40
.43
.33
HC/NMI
8.
9.

.73e
-.30
-.22
-.37c
-.38c
.35c
.42d
-.33c
-.28
-.37c
-.38c
-.33
-.30

-.33c
-.42d
-.32
-.25
.13
.35c
-.20
-.20
-.36c
-.37c
-.32
-.35

.64e
.45d
.43d
-.01
-.15
.41d
.34c
.38c
.39c
.53
.43

.33c
.20
.03
-.21
.23
.22
.34c
.28
.16
.19

.90e
-.02
-.02
.91e
.84e
.76e
.82e
-.20
-.18

-.05
-.08
.86e
.84e
.68e
.80e
.11
.09

.88e
-.10
-.10
-.15
-.13
.03
.14

-.09
-.15
-.19
-.19
.11
.18

.94e
.73e
.81e
-.16
-.18
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.19
-.79
-.73
-.98e

.20
-.79
-.70
-.53

-.06
-.69
-.61
-.30

.08
.33
.24
-.31

.11
.23
.09
-.26

.08
.23
-.09
-.18

.93e
-.89c
-.85c
-.91c

.87e
-.83c
-.89c
-.95c

-.73
-.70
-.95c

.98e
.91e

.96e

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

.43d
.47e
.01
-.02
.02
-.05
-.02
.08
.20
.29
.18

.74e
.32
.34
.36
.01
.05
.03
.09
.30
.20

.45
.38
.36
.02
.04
-.01
-.04
.16
.06

.97e
.92e
.45
.47
.34
.55c
.58c
.55c

.95e
.36
.37
.28
.60c
.62c
.61c

.25
.27
.25
.61c
.65c
.61c

.92e
.85e
.38
.30
.37

.89e
.46
.40
.44

.58c
.54
.55

.96e
.98e

.98e

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

.70e
.83e
-.07
-.07

.92e
.29
-.29

.06
.08

.97e

Table 25 Continued
15.
16.
17.
18.
19.
20.
21.

HPRC5
RSABL5
RSAMI5
RSARC5
PEPBL5
PEPMI5
PEPRC5

-.33
.02
.04
.02
.50
.44
.42

-.42
.09
.16
.04
.22
.12
.18

.48
.17
.27
.20
-.35
-.29
-.34

.16
-.11
-.15
-.07
-.21
-.17
-.24

-.11
.07
-.16
.06
-.41
-.45
-.27

.13
.05
-.09
.04
-.56c
-.53
-.33

.08
.04
.28
.12
.59c
.53
.66d

.15
.10
.27
.14
.45
.39
.54

-.13
.01
-.11
-.004
-.35
-.40
-.27

-.01
.08
-.12
.05
-.32
-.33
-.08

-.17
-.05
-.27
-.06
-.25
-.22
-.25

.16
-.01
-.22
-.01
-.28
-.22
-.07

.96e
.11
.52
.19
-.17
-.02
.02

.95e
.15
.47
.23
-.02
.14
.18

.14
.37
.21
-.17
-.02
.03

.47d
.90e
-.11
-.01
.12

.63e
.15
.19
.20

-.06
.03
.15

.97e
.92e

.92e

Note. FD = formerly depressed; HC = healthy control; SMI = sad mood induction; NMI = neutral mood induction; DAS I =
Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional Attitudes Scale – Short Form II; VAS = Visual Analogue
Scale; PRE = pre mood induction; POST = post mood induction; PANAS-X = Positive and Negative Affect Scale – Expanded Form; N =
negative affect general dimension scale; P = positive affect general dimension scale; G = guilt basic negative emotional scale; S =
sadness basic negative emotional scale; HP = heart period at baseline; BL = baseline; 5 = average obtained during a five-minute
interval; MI = mood induction; RC = recovery; RSA = respiratory sinus arrhythmia; PEP = pre-ejection period; c = p < .05; d = p < .01; e
= p < .001.
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Table 26. Correlation Matrices for Cognitive, Mood, and Cardiovascular Change Scores for
Entire Sample
Measure
1.
DASDS
2.
VASDS
3.
PANAS-X NDS
4.
PANAS-X PDS
5.
PANAS-X GDS
6.
PANAS-X SDS
7.
HPDS5RA
8.
HPDS5RC
9.
RSADS5RA
10. RSADS5RC
11. PEPDS5RA
12. PEPDS5RC
Measure
1.
ZRESDAS
2.
ZRESVAS
3.
ZRESPANAS-X N
4.
ZRESPANAS-X P
5.
ZRESPANAS-X G
6.
ZRESPANAS-X S
7.
ZRES5HPRA
8.
ZRES5HPRC
9.
ZRES5RSARA
10. ZRES5RSARC
11. ZRES5PEPRA
12. ZRES5PEPRC

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

-.20c
.04
.26d
-.15
-.02
.18
.06
.05
.10
.01
.07
1.

.24d
-.36e
.28d
.48e
-.11
-.18
.15
-.10
.17
-.06
2.

-.05
.58e
.46e
-.24
.01
.12
.05
-.21
-.31
3.

-.17
-.38e
.08
.05
-.08
.04
-.14
.04
4.

.48e
-.24
.15
.05
.10
-.28
-.27
5.

-.18
-.08
.03
-.08
-.02
.15
6.

.59e
-.23
-.15
.13
.15
7.

-.02
.19
.08
.06
8.

.47e
-.12
-.28
9.

.04
-.16
10.

.37e
11.

-.23c
-.01
.29e
-.07
-.17
.18
-.03
.04
.07
-.12
.05

.29d
-.38e
.52e
.28d
-.12
-.28
.20c
-.04
.22
-.08

-.06
.53e
.64e
-.22
.05
.05
.01
-.14
-.24

-.40e
-.15
.11
.11
-.08
.04
-.16
.09

.52e
-.13
-.002
.004
-.09
.08
.18

-.27
.12
.01
.08
-.28
-.24

.59e
-.09
-.06
.12
.21c

-.16
.04
.08
.17

.46e
-.12
-.15

.16
-.04

.45e

Note. DAS = Dysfunctional Attitudes Scale; DS = difference score; VAS = Visual Analogue
Scale; PANAS-X = Positive and Negative Affect Scale – Expanded Form; N = negative affect
general dimension scale; P = positive affect general dimension scale; G = guilt basic negative
emotional scale; S = sadness basic negative emotional scale; HP = heart period at baseline; 5 =
average obtained during a five-minute interval; RSA = respiratory sinus arrhythmia; PEP = preejection period; ZRES = standardized residualized change scores; c = p < .05; d = p < .01; e = p <
.001.
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Table 27. Correlation Matrices for Cognitive, Mood, and Cardiovascular Change Scores by
Group
Measure
1. DASDS
2. VASDS
3. PANAS-X NDS
4. PANAS-X PDS
5. PANAS-X GDS
6. PANAS-X SDS
7. HPDS5RA
8. HPDS5RC
9. RSADS5RA
10. RSADS5RC
11. PEPDS5RA
12. PEPDS5RC
Measure
1. ZRESDAS
2. ZRESVAS
3. ZRESPANAS-X N
4. ZRESPANAS-X P
5. ZRESPANAS-X G
6. ZRESPANAS-X S
7. ZRES5HPRA
8. ZRES5HPRC
9. ZRES5RSARA
10. ZRES5RSARC
11. ZRES5PEPRA
12. ZRES5PEPRC

1.

2.

3.

4.

-.31
-.09
.24
-.20
-.06
.22
.40
.15
.12
.35
.02
1.

.47d
-.52e
.40c
.56e
-.18
-.36
.22
-.05
-.06
-.25
2.

-.18
.71e
.56e
-.34
.09
.16
.07
-.39
-.54c
3.

-.26
-.56e
-.36
-.15
.06
.18
-.02
-.23
4.

-.25
-.07
.22
-.02
-.22
.07
.11
.14
.19
.35
.07

.48d
-.52e
.53e
.40c
-.19
-.43
.25
-.04
-.04
-.22

-.17
.61e
.74e
-.31
.05
.05
-.03
-.39
-.47

-.49e
-.23
-.35
-.16
.14
.32
-.02
-.21

Measure
1. DASDS
2. VASDS
3. PANAS-X NDS
4. PANAS-X PDS
5. PANAS-X GDS
6. PANAS-X SDS
7. HPDS5RA
8. HPDS5RC
9. RSADS5RA
10. RSADS5RC
11. PEPDS5RA
12. PEPDS5RC
Measure
1. ZRESDAS
2. ZRESVAS
3. ZRESPANAS-X N
4. ZRESPANAS-X P
5. ZRESPANAS-X G
6. ZRESPANAS-X S
7. ZRES5HPRA
8. ZRES5HPRC
9. ZRES5RSARA
10. ZRES5RSARC
11. ZRES5PEPRA
12. ZRES5PEPRC

1.

2.

3.

4.

-.11
.13
.25c
-.12
.02
.07
-.15
.03
.10
-.26
.03
1.

.03
-.29d
-.01
.41e
.09
-.03
.08
-.13
.42c
.27
2.

-.02
.44e
.36e
-.19
-.10
.10
.04
.11
.09
3.

-.14
-.34d
.10
.09
-.11
.01
-.22
.10
4.

-.16
.06
.28c
-.07
-.08
.12
-.14
.03
.04
-.43c
-.07

.10
-.32d
.50e
.01
.09
-.16
.16
-.04
.48c
.20

.004
.43e
.48e
-.08
.07
.06
.04
.20
.11

-.37e
-.09
.14
.21
-.13
-.03
-.25
.17

FD
5.

6.

7.

8.

9.

10.

11.

-.01
.29
.11
.01
-.13
-.01
6.

.54c
-.38
-.72d
.02
.23
7.

.18
-.41
-.41
-.003
8.

.53d
-.41
-.06
9.

-.06
-.17
10.

.60c
11.

-.33
.10
-.003
.12
-.43
-.24

.55c
-.13
-.50
.05
.21

.12
-.50
-.43
.06

.48d
-.44
-.11

-.15
-.19

.59c

6.

7.

8.

9.

10.

11.

.30d
-.01
.45c
.003
.08
.04
-.03
5.

-.38
-.44c
-.04
-.14
.13
.39c
6.

.48c
-.08
.08
-.15
.06
7.

-.10
.36
.10
.08
8.

.46e
.05
-.43c
9.

.10
-.18
10.

.46c
11.

.29d
.30
-.35
.02
-.10
.26
.39c

-.06
.51d
-.05
.08
.04
-.14

.45c
-.07
.06
-.15
.16

-.29
.20
.16
.14

.46e
.05
-.20

.09
.01

.39c

.60e
-.31
.16
.03
.14
-.42
-.30
5.

.65e
.10
.33
-.03
-.09
-.07
.07
HC
5.
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Note. FD = formerly depressed; HC = healthy control; DAS = Dysfunctional Attitudes Scale; DS
= difference score; VAS = Visual Analogue Scale; PANAS-X = Positive and Negative Affect
Scale – Expanded Form; N = negative affect general dimension scale; P = positive affect general
dimension scale; G = guilt basic negative emotional scale; S = sadness basic negative emotional
scale; HP = heart period at baseline; 5 = average obtained during a five-minute interval; RSA =
respiratory sinus arrhythmia; PEP = pre-ejection period; ZRES = standardized residualized change
scores; c = p < .05; d = p < .01; e = p < .001.
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Table 28. Correlation Matrices for Cognitive, Mood, and Cardiovascular Change Scores by
Group and Condition
Measure
1. DASDS
2. VASDS
3. PANAS-X NDS
4. PANAS-X PDS
5. PANAS-X GDS
6. PANAS-X SDS
7. HPDS5RA
8. HPDS5RC
9. RSADS5RA
10. RSADS5RC
11. PEPDS5RA
12. PEPDS5RC
Measure
1. ZRESDAS
2. ZRESVAS
3. ZRESPANAS-X N
4. ZRESPANAS-X P
5. ZRESPANAS-X G
6. ZRESPANAS-X S
7. ZRES5HPRA
8. ZRES5HPRC
9. ZRES5RSARA
10. ZRES5RSARC
11. ZRES5PEPRA
12. ZRES5PEPRC

1.

2.

3.

4.

-.58c
-.20
.20
-.03
-.21
-.04
-.09
.25
.38
.29
-.25
1.

.57c
-.46
.22
.57c
.39
-.41
-.21
-.38
.28
-.10
2.

-.15
.73e
.52c
-.33
.30
.11
.09
-.48
-.62
3.

-.15
-.65d
-.47
-.10
.24
.34
-.28
-.40
4.

-.43
-.10
.13
-.10
-.11
-.35
-.40
.44
.58c
.21
-.17

.52c
-.49
.49c
.19
.37
-.45
-.08
-.29
.25
-.13

-.11
.56c
.78e
-.34
.24
.01
.06
-.46
-.56

-.57c
-.11
-.53
-.17
.32
.46
-.30
-.35

Measure
1. DASDS
2. VASDS
3. PANAS-X NDS
4. PANAS-X PD5
5. PANAS-X GDS
6. PANAS-X SDS
7. HPDS5RA
8. HPDS5RC
9. RSADS5RA
10. RSADS5RC
11. PEPDS5RA
12. PEPDS5RC
Measure
1. ZRESDAS
2. ZRESVAS
3. ZRESPANAS-X N
4. ZRESPANAS-X P
5. ZRESPANAS-X G
6. ZRESPANAS-X S
7. ZRES5HPRA
8. ZRES5HPRC
9. ZRES5RSARA
10. ZRES5RSARC
11. ZRES5PEPRA
12. ZRES5PEPRC

1.

2.

3.

4.

.14
.18
.19
-.29
.39
-.13
.85
.11
-.02
.38
.35
1.

.32
-.30
.10
.29
.79
.05
.57c
-.12
-.49
.16
2.

-.11
.72e
.62e
-.20
-.06
.24
-.05
.32
-.06
3.

-.07
-.26
-.78
-.38
-.01
.21
.51
.19
4.

.07
.06
.22
.36
-.26
-.47
.37
-.01
-.02
.55
.39

.35
-.28
.29
.14
.69
.15
.58c
-.15
-.19
.77

-.09
.69e
.62d
-.13
-.25
.09
-.28
.36
.25

-.17
-.07
-.77
-.36
.07
.37
.52
.13

FD/SMI
5.

6.

7.

8.

9.

10.

11.

.24
.45
.06
-.11
-.09
.13
6.

.16
-.56
-.87d
.28
.13
7.

.32
-.21
-.50
-.10
8.

.67d
-.42
.08
9.

-.05
.16
10.

.58
11.

-.01
.57
-.07
.04
-.46
-.14

.10
-.24
-.54
.32
.16

.26
-.44
-.49
.04

.65d
-.53
-.09

-.21
-.05

.56

6.

7.

8.

9.

10.

11.

.39
-.54
-.55
.21
.19
.15
-.45
5.

.07
.60
.16
.003
-.09
-.44
6.

.89c
-.17
-.63
-.70
-.03
7.

.16
-.46
-.46
-.06
8.

.47
-.35
-.38
9.

.03
-.63
10.

.77
11.

.34
.29
.71
-.10
-.44
-.06
.05

-.51
-.56
.12
.05
.15
-.39

.88c
.08
-.41
-.74
-.13

.10
-.34
-.64
-.22

.41
-.30
-.12

-.05
-.31

.79

.59d
.01
.61
-.10
-.01
-.44
-.19
5.

.65d
.40
.50
-.002
-.004
-.02
.15
FD/NMI
5.
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Table 28 Continued
Measure
1. DASDS
2. VASDS
3. PANAS-X NDS
4. PANAS-X PDS
5. PANAS-X GDS
6. PANAS-X SDS
7. HPDS5RA
8. HPDS5RC
9. RSADS5RA
10. RSADS5RC
11. PEPDS5RA
12. PEPDS5RC
Measure
1. ZRESDAS
2. ZRESVAS
3. ZRESPANAS-X N
4. ZRESPANAS-X P
5. ZRESPANAS-X G
6. ZRESPANAS-X S
7. ZRES5HPRA
8. ZRES5HPRC
9. ZRES5RSARA
10. ZRES5RSARC
11. ZRES5PEPRA
12. ZRES5PEPRC

1.

2.

3.

4.

-.19
-.01
.26
-.10
-.01
.26
-.03
.14
.30
-.48
-.31
1.

.03
-.26
-.09
.40d
-.22
-.15
.08
-.13
.53
.56c
2.

-.01
.53e
.42d
-.25
-.23
.01
.12
-.05
-.49
3.

-.09
-.40d
.55c
.18
.07
.12
-.27
.13
4.

-.22
-.06
.27
-.12
-.08
.21
.04
.04
.16
-.64c
-.28

.10
-.28
.51e
-.04
-.21
-.29
.17
-.02
.60c
.47

.02
.42d
.52e
-.13
-.05
-.05
.09
.08
-.40

-.41d
-.07
.55c
.32
-.01
.06
-.29
.27

Measure
1. DASDS
2. VASDS
3. PANAS-X NDS
4. PANAS-X PDS
5. PANAS-X GDS
6. PANAS-X SDS
7. HPDS5RA
8. HPDS5RC
9. RSADS5RA
10. RSADS5RC
11. PEPDS5RA
12. PEPDS5RC
Measure
1. ZRESDAS
2. ZRESVAS
3. ZRESPANAS-X N
4. ZRESPANAS-X P
5. ZRESPANAS-X G
6. ZRESPANAS-X S
7. ZRES5HPRA
8. ZRES5HPRC
9. ZRES5RSARA
10. ZRES5RSARC
11. ZRES5PEPRA
12. ZRES5PEPRC

1.

2.

3.

4.

-.20
.27
.29
-.16
.03
-.32
-.50
-.07
-.23
.02
.22
1.

-.30
-.30
.13
-.16
.58c
.18
-.34
.07
.06
-.08
2.

.01
.32
.25
-.51
.06
.17
-.04
.29
.52
3.

-.23
-.12
-.25
.04
-.27
-.28
-.06
.17
4.

-.27
.20
.36c
-.04
-.10
-.28
-.59c
.03
-.14
-.13
.10

-.31
-.27
-.002
.20
.38
.07
-.30
-.06
.15
-.08

.04
.39c
.40c
-.41
.27
.10
-.05
.29
.61c

-.17
-.16
-.21
.11
-.21
-.21
-.07
.17

HC/SMI
5.

6.

7.

8.

9.

10.

11.

-.65c
-.68d
-.05
-.16
.05
-.12
6.

.53
-.33
.15
-.14
.27
7.

-.22
.46
.08
.04
8.

.50d
.23
-.08
9.

.24
-.09
10.

.63c
11.

-.16
.52
-.07
.16
.10
-.53

.59d
-.31
.08
-.16
.38

-.50
.28
.10
.04

.49d
-.05
.10

.11
.06

.51

6.

7.

8.

9.

10.

11.

.15
.16
.49
-.04
-.13
-.13
.36
5.

-.18
-.08
-.14
-.02
.21
.72d
6.

.34
-.20
-.06
-.29
-.13
7.

-.15
.09
.09
.12
8.

.48d
-.22
-.66c
9.

-.21
-.32
10.

.39
11.

.13
-.12
.16
-.12
.01
.21
.74d

.18
.49
-.09
-.13
-.14
.46

.18
-.26
-.12
-.28
-.01

-.22
.03
.27
.26

.47d
-.08
-.48

-.06
-.07

.35

.34c
-.16
.44
-.004
.18
.10
-.50
5.

.34c
-.54
-.65c
-.02
-.14
.25
-.02
HC/NMI
5.
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Note. FD = formerly depressed; HC = healthy control; SMI = sad mood induction; NMI = neutral
mood induction; DAS = Dysfunctional Attitudes Scale; DS = difference score; VAS = Visual
Analogue Scale; PANAS-X = Positive and Negative Affect Scale – Expanded Form; N =
negative affect general dimension scale; P = positive affect general dimension scale; G = guilt
basic negative emotional scale; S = sadness basic negative emotional scale; HP = heart period at
baseline; 5 = average obtained during a five-minute interval; RSA = respiratory sinus arrhythmia;
PEP = pre-ejection period; ZRES = standardized residualized change scores; c = p < .05; d = p <
.01; e = p < .001.
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CHAPTER 8
DISCUSSION
Vulnerability to depressive relapse and recurrence is difficult to delineate as it likely
reflects a complex interaction of biological, psychological, and environmental factors. The
majority of research on vulnerability to depressive relapse and recurrence has identified stable,
unchangeable traits that are not amenable to modification (Burcusa & Iacono, 2007).
Consequently, it is currently challenging for medical and mental healthcare providers to prevent
or intervene during the depressogenic cycle. More research is needed to identify malleable
vulnerability factors that can be specifically targeted during treatment or following treatment for
relapse prevention to reduce the occurrence of future episodes of depression.
Four such factors that have been proposed as potential pathways of vulnerability to
relapse and recurrence for formerly depressed individuals include cognitive, mood, and
cardiovascular reactivity to and recovery from sadness. There is still disagreement in the
cognitive and mood reactivity literature whether dysfunctional thinking patterns or dysphoric
mood states characterize remitted MDD. While the literature has examined cardiovascular
functioning in formerly depressed individuals, there are significant concerns about the quality
and generalizability of studies focused on cardiovascular reactivity in response to sadness in
remitted MDD due to multiple methodological issues. There have been no studies conducted to
date that have focused on cardiovascular recovery from sadness in remitted MDD. The present
study aimed to characterize cognitive, mood, and cardiovascular reactivity to and recovery from
a sad mood induction in individuals with a history of depression compared to healthy, never
depressed individuals.
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The first aim of this study was to examine cognitive reactivity in response to an
experimentally-induced sad mood in remitted MDD. Theories of depression have proposed that
dysfunctional patterns of thinking represent a cognitive vulnerability that contributes to the
etiology, maintenance, and reoccurrence of depression (Beck, 1967; Lau, Segal, & Williams,
2004; Scher, Ingram, & Segal, 2005). While these dysfunctional patterns of thinking have been
observed in currently, but not formerly, depressed individuals (as reviewed by Teasdale, 1999),
formerly depressed individuals continue to be at increased risk for depressive relapse and
recurrence. Theoretical models, including the differential activation hypothesis by Teasdale
(1988) and mood state dependent hypothesis by Miranda and Persons (1988), have proposed that
cognitive vulnerabilities remain latent in formerly depressed individuals, are activated by
dysphoric mood, and perpetuate depressed mood. Cognitive reactivity has been proposed as a
predictor of relapse and recurrence.
A large body of literature has investigated cognitive reactivity in remitted MDD. Crosssectional studies have generally shown that formerly depressed individuals exhibit cognitive
reactivity in response to sadness compared to individuals without a history of depression (Gemar
et al., 2001; Lau et al., 2012; Miranda et al., 1990, 1998; Roberts & Kassel, 1996; Van der Does,
2002). In addition, longitudinal studies have shown that formerly depressed individuals who
exhibit cognitive reactivity while euthymic or dysphoric have higher rates of relapse and
recurrence over time (Jarrett et al., 2012; Kuyken et al., 2010; Segal et al., 1999, 2006).
However, there are inconsistencies in this literature base. More specifically, some studies have
failed to find cross-sectional differences in cognitive reactivity in response to sadness between
formerly depressed and never depressed participants (Brosse et al., 1999; Dykman, 1999; Fresco
et al., 2006; Pfeiffer et al., 2015; Van der Does, 2005). In addition, one study has failed to find
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that cognitive reactivity was predictive of relapse longitudinally (Lethbridge & Allen, 2008). The
current study sought to contribute to this investigation and clarify prior inconsistent results. It
was hypothesized that formerly depressed participants exposed to the sad mood induction would
report significantly higher levels of dysfunctional beliefs on the DAS-SF II post-mood induction
than formerly depressed participants exposed to the neutral mood induction and healthy control
participants exposed to the sad and neutral mood inductions.
The second aim of this study was to examine mood reactivity in response to an
experimentally-induced sad mood in remitted MDD. Theories of depression have proposed that
differential affective responding to emotionally-valenced stimuli represent an affective
vulnerability that contributes to the etiology and reoccurrence of depression (Rottenberg &
Gotlib, 2004). While depression is typically conceptualized as a condition marked by sad, low
mood, there do appear to be differences in the expression of both positive and negative emotions
among currently depressed individuals (Rottenberg et al., 2005b). Theoretical models, including
the positive attenuation hypothesis, the negative potentiation hypothesis, and the emotional
context insensitivity hypothesis by Rottenberg and Gotlib (2004), have proposed that depression
is marked by differential affective responding to emotionally-valenced stimuli that perpetuates
depressive symptoms or leads to recurrence of depression. Much like cognitive vulnerabilities, it
has been proposed that differential affective responding to emotionally-valenced stimuli may
remain latent in formerly depressed individuals, be activated by dysphoric mood, and perpetuate
depressed mood (Rottenberg et al., 2005b). Mood reactivity has been proposed as a predictor of
relapse and recurrence.
A smaller body of literature has investigated mood reactivity in remitted MDD. Crosssectional studies that principally focused on cognitive reactivity have failed to find differences in
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mood reactivity among formerly depressed and never depressed participants (Brosse et al., 1999;
Dykman, 1997; Fresco et al., 2006; Gemar et al., 2001; Lau et al., 2012; Miranda & Persons,
1988; Miranda et al., 1998; Solomon et al., 1998; Van der Does, 2002, 2005). Longitudinal
studies have generally shown that formerly depressed individuals who exhibit blunted (i.e.,
decrease happiness in response to a sad mood induction; Lethbridge & Allen, 2008) or
exaggerated (i.e., increased sadness in response to a sad mood induction; van Rijsbergen et al.,
2013) mood reactivity are more likely to experience another depressive episode. However, this is
a limited literature base that requires additional inquiry. More specifically, some studies have
failed to find cross-sectional differences in mood reactivity in response to sadness between
formerly depressed and never depressed participants (Brosse et al., 1999; Dykman, 1997; Fresco
et al., 2006; Gemar et al., 2001; Lau et al., 2012; Miranda & Persons, 1988; Miranda et al., 1998;
Solomon et al., 1998; Van der Does, 2002, 2005). In addition, only two longitudinal studies
evaluating whether mood reactivity is predictive of relapse and recurrence have been conducted.
While there is currently disagreement in the literature about whether cognitive or mood
reactivity are markers of vulnerability for relapse in remitted MDD, there is clear support for the
notion that such vulnerabilities are mood state dependent in remitted depression. The current
study sought to contribute to this investigation and clarify prior inconsistent results. It was
hypothesized that formerly depressed and healthy control participants exposed to a sad mood
induction would report significantly higher levels of dysphoric mood on the VAS post-mood
induction than formerly depressed and healthy control participants exposed to the neutral mood
inductions, with no significant differences in formerly depressed and healthy control participants
exposed to the sad mood induction.
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Psychological research has attempted to identify biological and physiological correlates
of psychological conditions, rather than relying solely on subjective self-report measures.
Individual differences in cardiovascular functioning have been observed in a variety of different
psychological conditions, including current MDD (Chang et al., 2012; Ehrenthal et al., 2010; Jin
et al., 2015; Kemp et al., 2010, 2012; Kikuchi et al., 2009; Liang et al., 2015; Nugent et al. 2011;
Panaite et al., 2016; Rottenberg, 2007b; Rottenberg et al., 2003, 2005a, 2007a; Salomon et al.,
2009; with the exception of Rottenberg et al., 2005b; Tsai et al., 2003). Theoretical models,
including the polyvagal theory by Porges (1995), biopsychosocial model of challenge and threat
by Blascovich and Tomaka (1996), and hawk-dove model by Smith (1982), have proposed that
there is an association between behavioral, psychological, and physiological responding. These
theories have been explored in currently depressed individuals but have not yet been adequately
assessed in formerly depressed individuals. While it appears that the cardiovascular functioning
of formerly depressed participants generally resembles that of healthy control participants at rest
or in response to stress (Ahrens et al., 2008; Bylsma et al., 2014; Chang et al., 2013; Salomon et
al., 2013; Vaccarino et al., 2008), it is plausible that the differences in cardiovascular functioning
observed in currently depressed individuals may be mood state dependent in formerly depressed
individuals.
The third aim of this study was to explore cardiovascular reactivity in response to an
experimentally-induced sad mood in remitted MDD. A small body of literature has investigated
cardiovascular reactivity in remitted MDD. While some cross-sectional studies have shown that
formerly depressed individuals exhibited an abnormal pattern of cardiovascular reactivity in
response to sadness compared to individuals without a history of depression (Yaroslavsky et al.,
2013, 2014 Study 2), others have failed to find a significant difference among formerly
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depressed and never depressed participants (Bylsma et al., 2015; Rottenberg et al., 2005b). As
previously reviewed, there are significant concerns about the quality and generalizability of these
due to multiple methodological issues (e.g., mixed sample of current and remitted depression,
lack of assessment of CVD, limited range of cardiovascular measures assessed, lack of control
group, limited investigation of adult-onset depression). The current study sought to advance this
area of inquiry and address these methodological issues. It was hypothesized that formerly
depressed individuals exposed to the sad mood induction would exhibit a maladaptive pattern of
cardiovascular reactivity (i.e., decreased HP and RSA and increased PEP) during the mood
induction compared to formerly depressed participants exposed to the neutral mood induction
and healthy control participants exposed to the sad and neutral mood inductions.
The fourth aim of this study was to explore cardiovascular recovery in response to an
experimentally-induced sad mood in remitted MDD. Cardiovascular recovery provides an
estimate of how long the physiological changes attributable to an emotionally-valenced stimulus
persist after the stimulus has been removed. Research has suggested that cardiovascular recovery
can result in the identification factors that contribute to the development of psychopathology and
physiological abnormalities (Linden, Earle, Gerin, & Christenfeld, 1997; Haynes, Gannon,
Orimoto, O’Brien, & Brandt, 1991). Unfortunately, none of the research on cardiovascular
reactivity in remitted MDD has assessed cardiovascular recovery (Bylsma et al., 2015;
Rottenberg et al., 2005b; Yaroslavsky et al., 2013, 2014 Study 2). The current study sought to
establish this area of inquiry in remitted MDD. It was hypothesized that formerly depressed
individuals exposed to the sad mood induction would exhibit reduced cardiovascular recovery
(i.e., decreased HP, RSA, and CO and increased PEP compared to baseline) during the recovery
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film compared to formerly depressed participants exposed to the neutral mood induction and
healthy control participants exposed to the sad and neutral mood inductions.
Self-Report Measures
Formerly depressed participants reported significantly higher levels of current depressive
symptoms on the BDI-II than healthy control participants. Formerly depressed participants
reported a mean score of 9.91 out of 63 on the BDI-II, which suggests the presence of mild
depressive symptoms. Healthy control participants reported a mean score of 3.32 out of 63 on the
BDI-II, which suggests the presence of minimal depressive symptoms. Despite the presence of
some residual depressive symptoms, none of the formerly depressed participants met diagnostic
criteria for a major depressive episode within the last month while none of the healthy control
participants met diagnostic criteria for a major depressive episode within their lifetime.
Formerly depressed and healthy control participants reported similar levels of state
anxiety symptoms on the STAI-I. Formerly depressed participants reported a mean score of
44.53 out of 80 on the STAI-I while healthy control participants obtained a mean score of 45.74
out of 80 on the STAI-I. The scores reported by this sample are slightly above the proposed cut
scores of 39 to 40 for clinically significant symptoms of state anxiety on the STAI-I (Addolorato
et al., 1999; Knight, Waal-Manning, & Spears, 1983). While no formal predictions were set, the
lack of significant difference between groups was surprising given the fact that state anxiety
symptoms have been shown to highly correlate with measures of depression (Julian, 2011).
Consequently, it would be reasonable to foresee that formerly depressed participants would have
reported greater state anxiety symptoms on the STAI-I than healthy control participants given the
fact that they reported significantly higher levels of depressive symptoms reported on the BDI-II.
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Cognitive and Mood Measures
As expected, measures of cognition and mood assessed at different time points during the
experimental paradigm were significantly correlated. More specifically, the DAS-SF I & II,
VAS, and PANAS-X N, P, G, and S were significantly and positively correlated respectively
when using pre- and post-mood induction measures. These findings suggested that while change
in dysfunctional thoughts, dysphoric mood, and affective states were observed across the
experimental paradigm for some measures, measures of cognition and mood continued to
correlate throughout the experimental paradigm.
In addition, measures of cognition and mood were significantly correlated when using
difference and residualized change scores. The DAS was positively correlated with the PANASX P and negatively correlated with the VAS. Of note, the valences of these correlations are in the
expected direction as lower scores on the DAS are indicative of increased dysfunctional beliefs.
The VAS was positively correlated with the PANAS-X N, G, and S and negatively correlated
with the PANAS-X P. The PANAS-X N was positively correlated with the PANAS-X G and S
while the PANAS-X P was negatively correlated with some measures of the PANAS-X G and S.
Finally, the PANAS-X G was positively correlated with the PANAS-X S. These findings
indicated an association between dysfunctional thoughts, dysphoric mood, and affective states
across the experimental paradigm.
Correlations observed in the formerly depressed and healthy control groups were similar
to those observed in the entire sample with one important exception; the pre- and post-mood
induction VAS measures were not significantly correlated in the formerly depressed group,
suggesting that there was a significant difference in dysphoric mood pre- and post-mood
induction for formerly depressed participants. While this was true for formerly depressed
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participants exposed to both the sad and neutral mood induction, the correlation for pre- and
post-mood induction VAS measures was stronger for formerly depressed participants exposed to
the neutral mood induction (r = .37, p > .05) compared to formerly depressed participants
exposed to the sad mood induction (r = .16, p > .05). These findings indicated that all formerly
depressed participants report a change in dysphoric mood pre- and post-mood induction, with a
greater change reported by formerly depressed participants exposed to the sad mood induction.
Cognitive Reactivity
Contrary to expectations, there were no significant differences in cognitive reactivity on
the DAS post-mood induction in formerly depressed participants exposed to the sad mood
induction when using difference scores, residualized change scores, and repeated measures (see
Figures 12 to 14). Post-hoc analyses revealed that the current study had a relatively low chance
(13-36%) of detecting an effect due to insufficient power while sensitivity analyses indicated that
at least a medium effect size was necessary to detect an effect if sufficient power had been
obtained.
Figure 12. Cognitive Reactivity – Difference Score Post-Mood Induction
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Figure 13. Cognitive Reactivity – Residualized Change Score Post-Mood Induction
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Figure 14. Cognitive Reactivity – Repeated Measures Pre- and Post-Mood Induction
36
30
24

DAS

18
12
6
0
Pre-Mood Induction

Group/Condition

■Formerly Depressed/Sad Mood Induction
■Healthy Control/Sad Mood Induction

Post-Mood Induction

■Formerly Depressed/Neutral Mood Induction
■Healthy Control/Neutral Mood Induction

However, there was one significant difference in cognitive reactivity that was identified
using multiple comparisons. Formerly depressed participants reported significantly higher levels
of dysfunctional beliefs on the DAS post-mood induction than healthy control participants when
using residualized change scores. Of note, this measure can be counterintuitive to interpret as
lower scores on the DAS are indicative of greater levels of the dysfunctional beliefs. This finding
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is in line with the majority of the cognitive reactivity literature, which has found that formerly
depressed participants report higher levels of dysfunctional beliefs in response to a transient sad
mood compared to healthy controls (Gemar et al., 2001; Lau et al., 2012; Miranda et al., 1990,
1998; Roberts & Kassel, 1996; Van der Does, 2002). Notably, much of this research has elected
to use residualized change scores rather than difference scores. In the current study, significant
differences in cognitive reactivity may have been found between groups when using residualized
change scores, but not difference scores, due to increased power with the former analysis.
Analyses conducted with residualized change scores have more power due to smaller standard
error and are therefore more likely to detect an effect (Castro-Schilo et al., 2018). In addition,
research has shown that results can differ when analyses are conducted using difference scores
and residualized change scores due to Lord’s paradox, which postulates that this difference
occurs when the pattern or lack of pattern of change differs between groups and when baseline
differences on the predictor are stable, change equally, or change unequally (as reviewed by
Castro-Schilo et al., 2018).
Contrast analyses indicated that formerly depressed participants exposed to the sad mood
induction reported significantly higher levels of dysfunctional beliefs on the DAS post-mood
induction compared to healthy control participants exposed to the sad mood induction and
formerly depressed and healthy control participants exposed to the neutral mood induction when
using residualized change scores. As previously mentioned, analyses conducted with residualized
change scores have more power due to smaller standard error (Castro-Schilo et al., 2018) and the
planned contrasts have the most power of all analyses as they only assess a circumscribed set of
comparisons (Field, 2009). Therefore, it is questionable if the significant planned contrast results
with residualized change scores but not difference scores and repeated measures is simply a
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reflection of inflated type I error. The lack of consistent finding was unexpected as a significant
proportion of the available research has found that formerly depressed individuals exhibit
cognitive reactivity in response to sadness compared to healthy controls (Gemar et al., 2001; Lau
et al., 2012; Miranda et al., 1990, 1998; Roberts & Kassel, 1996; Van der Does, 2002). However,
there has been disagreement in the literature, with a subset of studies failing to find differences in
cognitive reactivity in response to sadness based on depressive history (Brosse et al., 1999;
Dykman, 1999; Fresco et al., 2006; Pfeiffer et al., 2015; Van der Does, 2005).
One potential reason for the current study’s finding may be the measure that was
employed. The DAS-SF I & II, an abbreviated version of the original DAS, was used to measure
cognitive reactivity. The DAS-SF I & II was chosen over the DAS because it is significantly
shorter (9-items versus 40-items) and the two measures have been shown to have similar
psychometric properties. As previously noted, Beevers and colleagues (2007) found that there
were no significant differences in residualized change scores for the DAS-A, DAS I, and DAS II
(p = .79-.93, d = .00-.01) and the residualized change scores for the DAS-A, DAS I, and DAS II
were very strongly correlated (r = .84-.91), suggesting that the long and short forms of the DAS
perform similarly. The current study had the unique challenge of obtaining multiple self-report
measures while participants were connected to psychophysiological equipment. The DAS-SF I &
II was selected to minimize the amount of attentional demands, time, and movement needed to
answer self-report measures as all of these factors can adversely impact psychophysiological
recording. While none of the studies investigating cognitive reactivity have used the DAS-SF I &
II, this is not because the measure is viewed unfavorably by depression researchers but rather,
due to the fact that only four of these studies were conducted after the creation of the DAS in
2007. It is possible that different results may have been obtained using the DAS in the current
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study as there may have been more variability with the 40-item measure. Additional research is
needed to explore whether or not the DAS-SF I & II performs similarly to the DAS when
assessing cognitive reactivity in a sample of formerly depressed participants.
Manipulation Check
As expected, participants exposed to the sad mood induction reported significantly higher
levels of sadness on the VAS post-mood induction than participants exposed to the neutral mood
induction when using difference scores, residualized change scores, and repeated measures. This
change in pre- and post-mood induction measures (28.33%, increase of 28.33 points of 100-point
scale) far exceeded the requirement of greater than 10.00% change in mood state that has been
commonly used in the literature to indicate that a mood induction procedure has induced its
intended mood state (Martin, 1990). In addition, participants exposed to the neutral mood
induction did not exhibit a significant change in sadness (3.39%, increase of 3.39 points of 100point scale) when assessing pre- and post-mood induction measures. Overall, these results
suggest that the mood induction procedure successfully induced a transient sad mood in
participants exposed to the sad mood induction and did not induce a transient sad mood in
participants exposed to the neutral mood induction.
As expected, participants exposed to the sad mood induction reported significantly higher
levels of sadness on the PANAS-X post-mood induction than participants exposed to the neutral
mood induction when using difference scores and residualized change scores. While there were
no significant differences between conditions when using repeated measures, it is possible that
this is due to lower power in the between-subjects portion of this analysis (Guo, Logan, Glueck,
& Muller, 2013). This change in pre- and post-mood induction measures aligns with the
aforementioned changes in sadness on the VAS and corroborates the claim that the mood
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induction procedures successfully induced a transient sad mood in participants exposed to the
sad mood induction and did not induce a transient sad mood in participants exposed to the
neutral mood induction.
As expected, there were no significant differences in reporting of positive affect, fear, and
hostility on the PANAS-X between conditions when using difference scores, residualized change
scores, and using repeated measures. While not significant due to the adjusted p value used due
to violations of homogeneity of variance, participants exposed to the sad mood induction
reported significantly higher levels of negative affect on the PANAS-X post-mood induction
than participants exposed to the neutral mood induction when using residualized change scores
but not difference scores or repeated measures. The PANAS-X negative affect general dimension
scale contains the following affective states: afraid, scared, nervous, jittery, irritable, hostile,
guilty, ashamed, upset, and distressed. It is possible that this finding was due to the fact that
participants exposed to the sad mood induction reported elevations on the PANAS-X negative
affect general dimension scale and PANAS-X guilt basic negative emotions scale, which both
include some of the same affective states (i.e., guilty, ashamed). Overall, these results generally
suggest that the mood induction procedure did not induce unintended general or specific
affective status in participants exposed to both the sad and neutral mood inductions.
Contrary to expectations, participants exposed to the sad mood induction reported
significantly higher levels of guilt on the PANAS-X post-mood induction than participants
exposed to the neutral mood induction when using difference scores and residualized change
scores. While there were no significant differences between conditions when using repeated
measures, it is possible that this is due to lower power in the between-subjects portion of this
analysis (Guo, Logan, Glueck, & Muller, 2013). Examination of the data indicated that this
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pattern of responding was observed in formerly depressed participants exposed to the sad mood
induction rather than healthy control participants exposed to the sad mood induction (F(1,119) =
14.92, p < .001, η2 = .11). While it was not anticipated that emotions other than sadness would be
reported, the presence of guilt makes intuitive sense given its association with the construct of
depression. According to schema theory, which significantly influenced cognitive
conceptualizations of depression, the depressogenic schema is associated with “themes of
personal deficiency, worthlessness, self-blame, guilt, deprivation, and rejection” (Martin, 1990,
p. 687). Excessive or inappropriate guilt is commonly experienced during a major depressive
episode, insomuch as guilt is a symptom in the diagnostic criteria for MDD (APAA, 2013) and
included as a question in multiple clinician rating scales (e.g., Hamilton Rating Scale for
Depression (HAM-D)) and self-report measures (e.g., BDI-II, PHQ-9, Center for Epidemiologic
Studies of Depression Scale (CES-D), and Geriatric Depression Scale (GDS)) of depression.
Research has consistently found that the constructs of depression and guilt are associated
with each other (as reviewed by Orth, Berking, & Burkhardt, 2006). A study by Ghatavi,
Nicolson, MacDonald, Osher, and Levitt (2002) investigated whether guilt is state and/or trait
dependent in depression. Participants included individuals with current MDD (n = 34), remitted
MDD (n = 22), chronic cardiac illness (n = 20), and healthy control participants without a history
of Axis I disorders (n = 59). Of note, individuals with chronic cardiac illness were recruited as a
comparison group free from psychiatric conditions with “similar global functioning” (Ghatavi et
al., p. 308). Results indicated that participants with current MDD reported significantly higher
levels of state guilt than all other participants while participants with remitted MDD reported
significantly higher levels of state guilt than cardiac and healthy controls. In addition,
participants with current and remitted MDD reported similar levels of trait guilt, which were
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significantly higher than cardiac and healthy controls. This study suggested that formerly
depressed individuals experience elevated levels of state guilt compared to individuals without a
history of depression as well as levels of trait guilt that are comparable to currently depressed
individuals. In line with the differential activation and mood state dependent hypotheses, it is
possible that elevations in state guilt observed in currently depressed individuals may remain
latent in formerly depressed individuals until activated by a dysphoric mood. Additional research
is needed to investigate whether or not guilt is mood state dependent in remitted MDD.
Mood Reactivity
As expected, participants exposed to the sad mood induction reported significantly higher
levels of dysphoric mood on the VAS post-mood induction than participants exposed to the
neutral mood induction when using difference scores, residualized change scores, and repeated
measures. This finding was in line with the literature that used a combination of music and
autobiographical recall and observed mood reactivity in all participants who were subjected to
the sad mood induction condition (Fresco et al., 2006; Gemar et al., 2001; Jarrett et al., 2012;
Kuyken et al., 2010; Lau et al., 2012; Pfeiffer et al., 2015; Segal et al., 1999, 2006; Van der
Does, 2002, 2005). Additionally, this finding makes intuitive sense; engaging in an emotionallyvalenced auditory and cognitive task induced the intended affective response.
Contrary to expectations, formerly depressed participants reported significantly higher
levels of dysphoric mood on the VAS post-mood induction than healthy control participants
when using difference scores, residualized change scores, and repeated measures. While the
interaction between group and condition was not significant (see Figures 15-17), it is possible
that this is due to lack of power rather than lack of effect. Examination of the means and standard
deviations for the VAS pre- and post-mood induction measures, difference scores, and
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residualized change scores do suggest that there are significant discrepancies in the levels of
dysphoric mood reported by the different groups and conditions, with formerly depressed
participants exposed to the sad mood induction reporting elevated post-mood induction scores on
the VAS compared to all other groups. Examination of the p values (p = .08-.14) for difference
scores and residualized change scores indicate that these analyses were approaching significance
and may have been significant if sufficient power had been obtained. In addition, examination of
the effect sizes (η2 = .02-.03) for difference scores and residualized change scores indicate that
they were in the small to medium range. While this was not true when using repeated measures,
it is possible that this is due to lower power in the between-subjects portion of this analysis (Guo,
Logan, Glueck, & Muller, 2013). Post-hoc analyses revealed that the current study had a
relatively low chance (1-26%) of detecting an effect due to insufficient power while sensitivity
analyses indicated that at least a medium effect size was necessary to detect an effect if sufficient
power had been obtained.
Figure 15. Mood Reactivity – Difference Score Post-Mood Induction
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Figure 16. Mood Reactivity – Residualized Change Score Post-Mood Induction
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Figure 17. Mood Reactivity – Repeated Measures Pre- and Post-Mood Induction
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Contrast analyses indicated that formerly depressed participants exposed to the sad mood
induction reported significantly higher levels of dysphoric mood on the VAS post-mood
induction compared to healthy control participants exposed to the sad mood induction and
formerly depressed and healthy control participants exposed to the neutral mood induction when
using difference scores, residualized change scores, and repeated measures. Of all analyses, the
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planned contrasts have the most power as they only assess a circumscribed set of comparisons
(Field, 2009). Unfortunately, these findings are challenging to clearly interpret as they are
obfuscated by differing results obtained when disparate analytic techniques are employed and
marginally insignificant results that are likely attributable to insufficient power.
Taken together, results generally appear to suggest that formerly depressed participants
exposed to the sad mood induction exhibited elevated mood reactivity in response to sadness
compared to healthy control participants exposed to the sad mood induction and formerly
depressed and healthy control participants exposed to the neutral mood induction. This finding
runs contrary to all of the cross-sectional studies that have failed to find any group differences in
mood reactivity between formerly depressed and never depressed participants (Brosse et al.,
1999; Dykman, 1997; Fresco et al., 2006; Gemar et al., 2001; Lau et al., 2012; Miranda &
Persons, 1988; Miranda et al., 1998; Segal et al., 2006; Solomon et al., 1998; Van der Does,
2002, 2005).
There are a few potential reasons for the discrepant findings when comparing the current
study to the literature base. First, a subset of the studies employed a different measure to evaluate
mood reactivity (Multiple Affect Adjective Check List (MAACL); Dykman, 1997; Fresco et al.,
2006; Miranda & Persons, 1988; Solomon et al., 1998). Second, the studies that employed the
VAS or a similar Likert-scale mood rating measure (e.g., “not at all” for 0 to “extremely” for 10
rating of sadness without a visual representation of this rating system) have used a restricted
range of potential scores (Gemar et al., 2001; Lau et al., 2012; Miranda et al., 1998; Segal et al.,
2006; Van der Does, 2002, 2005). Only one study (Brosse et al., 1999) used the same version of
the VAS employed in the current study, which obtained a rating of participants’ current mood
state on a 100-millimeter line anchored by “not at all” at 0 and “extremely” at 100. It is possible
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that this version of the VAS captured a greater level of variability in participants’ mood state and
therefore, was more likely to identify differences than the other mood rating measures.
Cardiovascular Functioning
As expected, measures of cardiovascular functioning assessed at different time points
during the experimental paradigm were significantly correlated. More specifically, five-minute
HP, RSA, and PEP during baseline, mood induction, and recovery were significantly and
positively correlated when using pre- and post-mood induction measures while five-minute HP,
RSA, and PEP reactivity and recovery were significantly and positively correlated when using
difference and residualized change scores. These findings suggested that while change in
cardiovascular functioning was observed across the experimental paradigm for some measures,
measures of cardiovascular functioning continued to correlate throughout the experimental
paradigm.
Baseline Cardiovascular Functioning
As expected, there were no significant differences in baseline cardiovascular functioning
for HP, RSA, or PEP assessed with both two- and five-minute averages between groups when
using univariate analysis. The lack of significant differences in baseline cardiovascular
functioning between groups is consistent with previous studies that have failed to find significant
differences in cardiovascular functioning at rest among individuals with remitted MDD (Bylsma
et al., 2014, 2015; Chang et al., 2013; Rottenberg et al., 2005b; Salomon et al., 2013; Vaccarino
et al., 2008). In addition, this finding is in line with the differential activation and mood state
dependent hypotheses, which suggests that vulnerabilities to depression remain latent in formerly
depressed individuals and are only observable during a dysphoric mood state.
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Cardiovascular Reactivity
Contrary to expectations, the hypothesized pattern of cardiovascular reactivity (i.e.,
decreased HP and RSA and increased PEP) was not observed in formerly depressed participants
exposed to the sad mood induction when using difference scores, residualized change scores, and
repeated measures. The hypothesized pattern of cardiovascular reactivity was based on a
combination of theoretical models and previous empirical findings examining differences in
cardiovascular reactivity in the response to sadness in formerly depressed individuals. In the
current study sample, a different pattern of cardiovascular reactivity (i.e., increased HP and RSA
and blunted PEP) in response to the sad mood induction emerged among formerly depressed
participants, albeit without significant differences for the group by condition interaction.
Examination of the effect size values indicated that effect sizes ranged from non-existent (η2 = <
.001) to in the small to medium range (η2 = .03). Post-hoc analyses revealed that the current
study had a relatively low chance (7-20%) of detecting an effect due to insufficient power while
sensitivity analyses indicated that at least a medium effect size was necessary to detect an effect
if sufficient power had been obtained. Clearly, the current study was under powered to detect
such an effect across the different cardiovascular measures.
However, some significant differences in cardiovascular reactivity were identified using
multiple comparisons. These differences were mainly found in HP, which is defined as the
amount of time between heart beats measured in millisecond. HP was used in lieu of HR, which
is defined as the number of beats produced by the heart per minute. While HP and HR are
reciprocal measurements of cardiovascular functioning, they are not linearly related and can
generate discrepant results when there are significant differences across participants or changes
within participants. HP was selected because the current study hypothesized that changes in
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cardiovascular functioning would be attributable to autonomic effects and cardiovascular
differences were ascribed to the experimental task (condition: sad, neutral) and group
membership (group: formerly depressed, healthy control; Berntson et al., 2007).
Results revealed that formerly depressed participants exhibited significantly higher
levels of five-minute HP reactivity during the mood induction than healthy control participants
when using difference scores and residualized change scores (see Figures 21-23). Of note,
differences between groups were not observed when using two-minute HP reactivity (see Figures
18-20). While this was not true when using repeated measures for both two- and five-minute HP
reactivity, it is possible that this is due to lower power in the between-subjects portion of this
analysis (Guo, Logan, Glueck, & Muller, 2013).
Examination of the means and standard deviations for the two- and five-minute HP
baseline and mood induction measures suggest that this is due to differences in resulting
averages when using the two approaches to calculate reactivity. Both groups showed similar
cardiovascular functioning at baseline. In addition, both groups showed a cardiovascular reaction
in response to the mood induction. For the two-minute HP averages, formerly depressed
participants exhibited an increase in HP of 26.74 milliseconds compared to baseline
cardiovascular functioning during the mood induction while healthy control participants
exhibited an increase in HP of 13.48 milliseconds during the mood induction compared to
baseline cardiovascular functioning. For the five-minute HP averages, formerly depressed
participants exhibited an increase in HP of 14.00 milliseconds during the mood induction
compared to baseline cardiovascular functioning while healthy control participants exhibited a
decrease in HP of 1.69 milliseconds during the mood induction compared to baseline
cardiovascular functioning. Together, these findings suggest that the magnitude of cardiovascular
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reactivity differed when using two-minute HP averages and the extent to which cardiovascular
reactivity attenuated over time differed when using five-minute HP averages.
Figure 18. Two-Minute Heart Period – Difference Score during Mood Induction
90

HPDS2

70
50
30

10
-10
-30

Group/Condition
■Formerly Depressed/Sad Mood Induction
■Healthy Control/Sad Mood Induction

■Formerly Depressed/Neutral Mood Induction
■Healthy Control/Neutral Mood Induction

Figure 19. Two-Minute Heart Period – Residualized Change Score during Mood Induction
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Figure 20. Two-Minute Heart Period – Repeated Measures Pre- and during Mood Induction
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Figure 21. Five-Minute Heart Period- Difference Score during Mood Induction
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Figure 22. Five-Minute Heart Period – Residualized Change Score during Mood Induction
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Figure 23. Five-Minute Heart Period – Repeated Measures Pre- and during Mood Induction
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Multiple comparisons and contrast analyses were not significant for HP, RSA, or PEP.
While not statistically significant, examination of the p values (p = .06-.08) for the contrast
analyses for two-minute HP difference scores and residualized change scores and five-minute HP
residualized change scores indicate that these analyses were approaching significance and may
have been significant if sufficient power had been obtained. While this was not true when using
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repeated measures for both two- and five-minute HP reactivity contrast analyses, it is possible
that this is due to lower power in the between-subjects portion of this analysis (Guo, Logan,
Glueck, & Muller, 2013). Both of these findings are meaningful. The difference in magnitude of
cardiovascular reactivity for two-minute HP suggests that when observed over a short period of
time, formerly depressed individuals exposed to a sad mood induction may exhibit more
pronounced HP reaction compared to healthy control individuals exposed to a sad mood
induction as well as formerly depressed and healthy control individuals exposed to a neutral
mood induction (see Figure 24). The extent to which cardiovascular reactivity attenuated over
time significantly differed for five-minute HP, which suggests that when observed over a more
extended period of time, formerly depressed individuals exposed to a sad mood induction may
exhibit an elevated HP in response to an emotionally-valenced stimulus compared to healthy
control individuals exposed to a sad mood induction as well as formerly depressed and healthy
control individuals exposed to a neutral mood induction (see Figure 24). The latter finding points
to importance of the remitted MDD literature moving beyond its persistent focus on
cardiovascular reactivity to additionally investigate differences in cardiovascular recovery.
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Figure 24. Minute by Minute Heart Period during Mood Induction
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Cardiovascular Recovery
Contrary to expectations, the expected maladaptive patterns of cardiovascular recovery
(i.e., decreased HP and RSA and increased PEP compared to baseline) was not observed during
the recovery film in formerly depressed participants exposed to the sad mood induction when
using difference scores, residualized change scores, and repeated measures. The hypothesized
pattern of cardiovascular recovery was also based on a combination of theoretical models and
previous empirical findings examining differences in cardiovascular recovery in response to
stress among formerly depressed individuals given the lack of investigation of cardiovascular
recovery in the response to sadness in formerly depressed individuals. In the current study
sample, a different pattern of cardiovascular recovery (i.e., increased HP and RSA and blunted
PEP) during the recovery film emerged among formerly depressed participants, albeit without
significant differences the group by condition interaction for RSA and PEP. Examination of the
effect size values indicated that effect sizes ranged from non-existent (η2 = < .001) to small to
medium (η2 =.05). Post-hoc analyses revealed that the current study had a relatively low chance
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(6-28%) of detecting an effect due to insufficient power while sensitivity analyses indicated that
at least a medium effect size was necessary to detect an effect if sufficient power had been
obtained. The current study was under powered to detect such an effect in some of the
cardiovascular measures.
However, some significant differences in cardiovascular recovery were identified using
multiple comparisons. While not significant due to the adjusted p value used due to violations of
homogeneity of variance, formerly depressed participants exhibited significantly higher levels of
two-minute HP during the recovery film when using difference and residualized change scores as
well as five-minute HP during the recovery film when using residualized change scores than
healthy control participants. The difference in magnitude of cardiovascular recovery was not
large enough to reach statistical significance for five-minute HP recovery using difference
scores. Examination of the means and standard deviations for the baseline and recovery measures
and difference score do suggest that there are discrepancies in HP recovery exhibited by the
different groups. Examination of the p values (p = .02-.05) indicate that this analysis was
approaching significance and may have been significant if sufficient power had been obtained. In
addition, examination of the effect sizes (η2 = .04-.06) for the two-minute HP difference scores
and residualized change scores and five-minute HP residualized change scores indicate that they
were in the small to medium and medium range.
While not significant due to the adjusted p value used due to violations of homogeneity
of variance, formerly depressed participants exposed to the sad mood induction exhibited
significantly higher levels of two-minute HP during the recovery film when using difference and
residualized change scores than formerly depressed participants exposed to the neutral mood
induction and healthy control participants exposed to the sad and neutral mood inductions (see
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Figures 25-27). In addition, formerly depressed participants exposed to the sad mood induction
exhibited significantly higher levels of five-minute HP during the recovery film when using
residualized change scores than formerly depressed participants exposed to the neutral mood
induction and healthy control participants exposed to the sad and neutral mood inductions (see
Figures 28-30). While five-minute HP recovery using difference scores did not meet statistical
significance, examination of the p values (p = .06) indicated that these analyses were
approaching significance and may have been significant if sufficient power had been obtained. In
addition, examination of the effect size (η2 = .04) for the five-minute HP difference score
indicate that they were in the small to medium range. While there were no significant differences
between groups and conditions when using repeated measures, it is possible that this is due to
lower power in the between-subjects portion of this analysis (Guo, Logan, Glueck, & Muller,
2013).
Figure 25. Two-Minute Heart Period during Recovery Film
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Figure 26. Two-Minute Heart Period – Residualized Change Score during Recovery Film
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Figure 27. Two-Minute Heart Period – Repeated Measures Pre- and during Recovery Film
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Figure 28. Five-Minute Heart Period during Recovery Film
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Figure 29. Five-Minute Heart Period – Residualized Change Score during Recovery Film
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Figure 30. Five-Minute Heart Period – Repeated Measures Pre- and during Recovery Film
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Contrast analyses were not significant for RSA and PEP but were for some HP measures.
Contrast analyses indicated that formerly depressed participants exposed to the sad mood
induction exhibited significantly higher levels of two-minute HP when using residualized change
scores and five-minute HP when using difference scores and residualized change scores during
the recovery film compared to healthy control participants exposed to the sad mood induction
and formerly depressed and healthy control participants exposed to the neutral mood induction.
While this was not true when using repeated measures for both two- and five-minute HP
recovery, it is possible that this is due to lower power in the between-subjects portion of this
analysis (Guo, Logan, Glueck, & Muller, 2013).
Examination of the means and standard deviations for the two- and five-minute HP
baseline and recovery measures suggest that the two approaches to calculating recovery resulted
in slightly different findings. Both groups showed similar cardiovascular functioning at baseline.
However, there was a stark difference in cardiovascular recovery obtained during the recovery
film. For the two-minute HP averages, formerly depressed participants exposed to the sad mood
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induction exhibited an increase in HP of 29.11 milliseconds during the recovery film compared
to baseline cardiovascular functioning. While formerly depressed and healthy control
participants exposed to the neutral mood induction did not return to baseline cardiovascular
functioning levels, their HP during the recovery film was significantly lower than formerly
depressed participants exposed to the sad mood induction. Interestingly, healthy control
participants exposed to the sad mood induction actually exhibited HP levels that were lower than
their baseline cardiovascular functioning levels during the recovery film.
For the five-minute HP averages, formerly depressed participants exposed to the sad
mood induction exhibited an increase in HP of 25.00 milliseconds during the recovery film
compared to baseline cardiovascular functioning. Formerly depressed and healthy control
participants exposed to the neutral mood induction showed a decrease of HP compared to their
two-minute HP averages that was closer to their baseline cardiovascular functioning levels.
Healthy control participants exposed to the sad mood induction continued to exhibit HP levels
that were lower than their baseline cardiovascular functioning levels during the recovery film,
albeit to a lesser degree. Together, this suggests that the magnitude of cardiovascular recovery
differed when comparing two- and five-minute HP averages and the extent to which
cardiovascular recovery attenuated over time differed across groups and conditions when using
two- and five-minute HP averages.
Both of these findings are meaningful. The difference in attenuation of cardiovascular
recovery for two-minute HP suggests that when observed over a short period of time, formerly
depressed individuals exposed to a sad mood induction may exhibit less reduction in HP during
recovery compared to healthy control individuals exposed to a sad mood induction as well as
formerly depressed and healthy control individuals exposed to a neutral mood induction (see
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Figure 31). The difference in attenuation of cardiovascular recovery for five-minute HP suggests
that when observed over an extended period of time, formerly depressed individuals exposed to a
sad mood induction may continue to exhibit elevated HP during recovery compared to healthy
control individuals exposed to a sad mood induction as well as formerly depressed and healthy
control individuals exposed to a neutral mood induction (see Figure 31). Together, these findings
suggest that cardiovascular recovery following a transient sad mood is impaired among formerly
depressed individuals when examined using both two- and five-minute HP averages.
Figure 31. Minute by Minute Heart Period during Recovery Film
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Implications
Several important implications can be drawn from the current study. The finding that
generally, formerly depressed individual exposed to the sad mood induction experienced
elevated levels of mood, rather than cognitive, reactivity provides a meaningful data point in the
inconsistent literature base. Empirical evidence has found that compared to healthy control
participants, those with remitted MDD report significant increases in dysfunctional beliefs (i.e.,
cognitive reactivity; Kuyken et al., 2010; Segal et al., 1999, 2006) or dysphoric mood (i.e., mood
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reactivity; van Rijsbergen et al., 2013) in response to an experimentally-induced sad mood and
prospectively predict relapse of depression over time. There has been disagreement in the
literature whether dysfunctional thinking patterns or dysphoric mood states characterize remitted
MDD, with recent research advancing the idea that mood reactivity may be an important
construct of interest. While the current study sought to add clarity to the literature, results raise
questions about what may be driving the different findings between studies. Additional research
is needed to advance our understanding of these potentially malleable vulnerability factors
associated with a history of depression, whether it be identification of mediators, moderators, or
predictors of cognitive and mood reactivity.
In terms of treatment, the finding that formerly depressed individual exposed to the sad
mood induction experienced elevated levels of mood reactivity may have important implications
for psychotherapy. The evidence-based treatments for depression that are currently recognized
by Division 12 of the American Psychological Association (APAB, 2016a) include the following
13 treatment modalities: acceptance and commitment therapy (ACT), behavioral activation,
cognitive behavioral analysis system of psychotherapy, CBT, CT, emotion focused therapy,
interpersonal psychotherapy, problem-solving therapy, rational emotive behavioral therapy
(REBT), reminiscence/life review therapy, self-management/self-control therapy, self-system
therapy, and short-term psychodynamic therapy. Of note, the majority of the second and third
wave therapies listed above are theorized to impact emotions indirectly. More specifically, the
cognitive model that second wave psychotherapies (i.e., CBT, CT, REBT) are based on theorize
that an individual’s perception of an event results in automatic thoughts that spurs a cascade of
behavioral, emotion, and physiological responses (Beck, 1964). Consequently, the cognitive
model postulates that restructuring negative automatic thoughts, as well as intermediate and core
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beliefs further along during the course of therapy, changes behavioral and emotional reactions
(Beck, 2011). In other words, traditional cognitive-behavioral approaches to psychotherapy
result in alterations of emotional responses through indirect techniques.
Third wave psychotherapies (e.g., ACT, dialectical behavior therapy (DBT),
mindfulness-based cognitive therapy (MBCT)) are more closely connected by the techniques
utilized rather than theoretical underpinning. Third wave therapies typically employ mindfulness
strategies to increase awareness and acceptance of internal experiences including thoughts,
feelings, and physiological sensations (Brown, Gaudiano, & Miller, 2013). In addition, some of
these psychotherapies employ emotion-focused techniques. For example, DBT, an empiricallysupported treatment for borderline personality disorder (BPD; Division 12 of the APAB, 2016b)
that traditionally consists of individual psychotherapy, group-based skills training, phone
consultation, and team consultation (Linehan, 1993), focuses on building emotion regulation,
distress tolerance, mindfulness, and interpersonal effectiveness skills. The emotion regulation
module includes skills such as understanding and identifying emotions, changing undesirable
emotions, reducing vulnerability to emotions, and managing intense emotions. The distress
tolerance module includes skills such as crisis survival and radical acceptance of emotional
reactions (Linehan, 2015).
While individuals with MDD and BPD exhibit different deficits in emotion regulation, it
is possible that the emotion regulation and distress tolerance skills that are integral to DBT may
be beneficial to formerly depressed individuals. Theoretical and empirical evidence suggests that
vulnerability associated with depression remain latent in individuals who have recovered from a
depressive episode until activated by dysphoric mood. This dysphoric mood is hypothesized to
be exacerbated over time, to the point of resulting in a depressive relapse or recurrence. It is
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possible that providing individuals with remitted MDD emotion regulation and distress tolerance
skills at the final phase of treatment initially targeting current MDD or during booster sessions
for relapse prevention may increase their ability to recognize when a dysphoric mood occurs and
select the appropriate strategies (e.g., mindfulness, problem solving, opposite action, cognitive
restructuring; Linehan, 2005) to manage these emotions effectively and prevent the onset of a
prolonged depressed mood. Research is needed to empirically test whether or not teaching these
skills to at-risk remitted MDD populations could result in reductions in depressive relapse and
recurrence over time.
While there were no significant differences in cardiovascular reactivity when examining
the group by condition interaction, formerly depressed individuals generally exhibited a trend of
elevated levels of HP and reduced attenuation of HP during the sad mood induction when using
planned comparisons. As previously noted, HP has been used in the literature as an index of
arousal, task involvement, and mental load and effort (Jorna, 1992). This finding suggests that
formerly depressed individuals may experience elevated arousal during a sad mood and be more
engaged in and devote more cognitive resources to the mood induction task. While not examined
in the current investigation, one potential mechanism of action that may be explored to explain
increased task involvement and mental load and effort in formerly depressed individuals during a
sad mood induction is rumination given its prevalence in this population (Olatunji, NaragonGainey, & Wolitzky-Taylor, 2013). Importantly, this finding points to potential differences in
cardiovascular recovery in this population. The current study makes an important contribution to
the literature as it was the first to investigate cardiovascular recovery following a sad mood
induction in formerly depressed participants.
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The finding that generally, formerly depressed individual exposed to the sad mood
induction exhibited elevated levels of HP during the recovery film greatly extends the current
literature. A review of the remitted MDD literature indicates that only two studies have assessed
cardiovascular reactivity in formerly depressed individuals, albeit in response to stress rather
than sadness. Both of these studies suggested that formerly depressed individuals exhibited
cardiovascular recovery following a speech stress test that resembled healthy control, rather than
currently depressed, individuals (Bylsma et al., 2014; Salomon et al., 2009). Thus, this was the
first study to investigate multiple measures of cardiovascular recovery from a transient sad mood
in formerly depressed individuals. Using planned comparisons, the current study found that
individuals with a history of depression take significantly longer to return to baseline levels of
HP following a sad mood induction when using both two- and five-minute averages compared to
healthy, never depressed individuals. This finding is striking as the study’s sample consisted of
younger (M = 20.79, SD = 5.65), healthy individuals free from a variety of physical and mental
health conditions that could have confounded the results. It is possible that formerly depressed
individuals who are older, have experienced more depressive episodes over the course of their
lifetime, and have comorbid physical and mental health conditions would exhibit a more
pronounced cardiovascular response to a transient sad mood or experience more negative
repercussions due to impaired HP recovery.
Results suggest that formerly depressed individuals exposed to a sad mood induction
experience elevated arousal during recovery and have more difficulty disengaging from a task.
While not examined in the current investigation, one potential mechanism of action to explain
the lasting impact of a sad mood induction on formerly depressed individuals is continued
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rumination during the recovery period. Future research could investigate this possibility by
asking participants to complete a state measure of rumination following the recovery period.
The lasting impact of a transient sad mood on formerly depressed individuals may
explain the susceptibility to CVD in this population. Higher HP during experimental tasks that
involve attention is believed to be adaptive, as it is thought to represent arousal, task
involvement, and mental load and effort. However, elevated HP during recovery may not be
adaptive, especially if this persists for extended periods of time or occurs with regular frequency.
The closest clinical variable that could serve as a proxy for elevated HP during recovery is
resting HR, or the number of beats produced by the heart per minute while completely at rest.
Research has indicated that elevated resting HR is associated with an increased risk of negative
health outcomes, including cardiovascular events, CVD, and mortality, in individuals with and
without pre-existing cardiovascular problems (Ho et al., 2014). A recent meta-analysis by Zhang,
Shen, and Qi (2015) investigated the relationship between resting heart rate and all-cause and
cardiovascular mortality. 46 prospective cohort studies met the inclusion and exclusion criteria,
resulting in data from over 1,000,000 participants drawn from the general, rather than medically
compromised, population. Results indicated that with every incremental increase of 10 beats per
minute resting HR, there was an increase in the relative risk of all-cause (RR = 1.09, CI = 1.071.12) and cardiovascular mortality (RR = 1.08, CI = 1.06-1.12) when cardiovascular risk factors
were controlled for. Subgroup analyses were conducted to examine group differences in
mortality risk. Using 45 beats per minute resting HR as a reference group, the risk of all-cause
mortality increased linearly with resting HR while the risk of cardiovascular mortality
significantly increased at 90 beats per minute resting HR. This meta-analysis, along with a large
body of literature, has indicated that resting HR is an independent predictor of mortality in the
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general population (Zhang et al., 2015, p. E60). Therefore, elevated HP in response to a transient
sad mood and impaired HP recovery is likely maladaptive.
It is possible that the impaired HP recovery observed in formerly depressed individuals
exposed to the sad mood induction in the current study may increase vulnerability to depression
and contribute to the development of psychopathology and physiological abnormalities (Linden
et al., 1997; Haynes, Gannon, Orimoto, O’Brien, & Brandt, 1991). It is important to note that
two characterizations of cardiovascular functioning were not captured by the experimental
paradigm: the typical length of impaired HP recovery and occurrence of HP reactivity and
recovery. First, impaired HP recovery may extend longer than was captured by the current study,
which observed cardiovascular recovery over a 10-minute period. Given that HP continued to be
elevated in formerly depressed individuals exposed to the sad mood induction at the 10-minute
mark (see Figure 31), it is not currently known how long the elevation in HP would typically
persist. Second, HP reactivity and impaired HP recovery in response to a transient sad mood
likely occurs more often than was modeled in the experimental paradigm. Moreover, fluctuations
in mood are common during daily life; a dysphoric mood may arise when an individual is
reminded of a sad memory, reflects on a past failure, experiences a social slight, or engages in an
interpersonal conflict. Therefore, elevations in HP and the resulting impaired HP recovery likely
occurs at multiple times during the day and may last for extended amounts of time. There is a
distinct possibility that formerly depressed individuals may regularly exhibit a pattern of
repeated HP reactivity and impaired HP recovery in response to a transient sad mood, which
impacts their cardiovascular health and functioning in a clinically significant manner. Further
study of the duration of impaired HP recovery and incident of HP reactivity and recovery is
needed to experimentally and clinically validate this theory.
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In addition, it is plausible that impaired HP recovery following a transient sad mood in
formerly depressed individuals are implicated in the well-established relationship between
depression and CVD (Haigh & Bogucki, 2017; Haigh et al., 2018b). If formerly depressed
individuals exhibit a pattern of repeated HP reactivity and impaired HP recovery in response to a
transient sad mood, cardiovascular abnormalities may arise. While the current study did not
directly explore this connection, it is an important first step for investigating this hypothesis.
More research is needed to replicate these findings, extend these findings using longitudinal
methods and if longitudinal results identify an association between cardiovascular recovery and
physiological abnormalities, investigate biological mechanisms to determine the
pathophysiological process at play and the efficacy of interventions (e.g., respiratory feedback,
biofeedback, emotion regulation strategies) designed to facilitate cardiovascular recovery
(Sharpley, 2002).
Finally, the variable results obtained using different timing for (i.e., two- versus fiveminutes) and approaches (i.e., difference versus residualized change score) to calculate
cardiovascular reactivity and recovery illustrate the challenge of conducting psychophysiological
research. Unfortunately, there is little consistency across the literature as to how many minutes
should be averaged to calculate reactivity and recovery or which time segments of reactivity or
recovery should be selected. More research is needed to establish more formal guidelines as to
the appropriate amount of time and timing of segments that researchers should select depending
on their research question, experimental task, and population of interest, among other factors
(Linden et al., 1997). This knowledge may be helpful for moving psychophysiological research
forward as it would likely reduce some of the ambiguity associated with psychophysiological
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analyses and increase standardization across studies, increasing the ease of cross-study
comparisons.
Strengths
The current study has several strengths, which meaningfully extend the findings of
previous research. First, the current study addressed the multiple methodological issues present
in previous research. Prior literature has relied upon a mixed sample of participants who were
currently or formerly depressed (Bylsma et al., 2015; Yaroslavsky et al., 2013, 2014 Studies 1
and 2; with the exception of Rottenberg et al., 2005b) and examined a very limited range of
cardiovascular measures (i.e., HR or RSA only; Rottenberg et al., 2005b; Yaroslavsky et al.,
2013, 2014 Studies 1 and 2; with the exception of Bylsma et al., 2015). A large portion of the
literature has failed to compare cardiovascular reactivity in response to both sad and neutral
mood inductions (Yaroslavsky et al., 2013, 2014 Studies 1 and 2; with the exceptions of Bylsma
et al., 2015 and Rottenberg et al., 2005b) and was conducted in formerly depressed adolescents
(Bylsma et al., 2015; Yaroslavsky et al., 2014 Study 2; with the exceptions of Rottenberg et al.,
2005b and Yaroslavsky et al., 2013, 2014 Study 1) rather than adults. Finally, none of the
literature explicitly assessed for the presence of CVD or investigated cardiovascular recovery
(Bylsma et al., 2015; Rottenberg et al., 2005b; Yaroslavsky et al., 2013, 2014 Studies 1 and 2).
Accordingly, this is the first study to examine a broad range of cardiovascular measures
to assess cardiovascular reactivity to and recovery from sadness in an exclusively remitted MDD
adult sample free from CVD. The current study employed a quasi-experimental design, which
compared two groups (i.e., formerly depressed, healthy control) randomly assigned to two
experimental conditions (i.e., sad and neutral mood induction). Together, the quasi-experimental
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design, stringent inclusion and exclusion criteria, and control of potential confounding variables
allowed for competing explanations to be ruled out.
Second, the current study determined eligibility and group assignment using a structured
clinical interview, the SCID-IV-RV, that had been adapted in accordance with the DSM-5. The
SCID was developed in an effort to increase diagnostic reliability for DSM diagnoses through
the use of standardized questions that aligned with diagnostic criteria and consistent language to
enhance interrater agreement (Bergman & Fors, 2005). To be accurately determined, clinical
diagnoses must be evaluated using a structured or semi-structured clinical interview rather than
self-report measures due to the biases associated with these instruments (Paulhus & Vazire,
2007). The use of the SCID-IV-RV in the current study allowed for diagnostic accuracy across
the different experimenters evaluating whether or not participants met the inclusion and
exclusion criteria.
Third, the current study employed multiple reliable and standardized methods that are in
line with the recommendations of RDoC. Under the negative valence system, there are multiple
constructs including acute threat (“fear”), potential harm (“anxiety”), sustained threat, frustrative
non-reward, and loss. MDD aligns most closely with the construct of loss in the negative valence
system (National Institute of Mental Health, 2011). RDoC recommends the use of multiple levels
of analysis to assess a construct in an effort to obtain a more comprehensive understanding of the
pathological mechanisms underlying current diagnostic categories and eventually, create a
dimensional diagnostic system (Cuthbert, 2014). The RDoC negative valence systems
workgroup has identified multiple behavioral assessment methods for studying the construct of
loss including rumination, withdrawal, worry, crying, sadness, loss-relevant recall bias,
attentional bias to negative valenced information, guilt, morbid thoughts, psychomotor
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retardation, anhedonia, increased self-focus, deficits in executive functioning, loss of drive,
decreased libido, shame, amotivation, memory impairments, and intrusive thoughts (National
Institute of Mental Health, 2011). In this study, cognitive reactivity aligns most closely with
intrusive thoughts while mood reactivity aligns most closely with sadness. In addition, the RDoC
negative valence system has identified multiple physiological assessment methods for studying
the construct of loss including ANS, HPA, and neuroimmune dysregulation and prolonged
psychophysiological reactivity (National Institute of Mental Health, 2011). In this study,
cardiovascular reactivity aligns most closely with prolonged psychophysiological reactivity, and
could also be subsumed under cardiovascular recovery. While the current study did assign group
membership according to DSM diagnostic criteria, it did adopt a more dimensional approach in
line with the recommendations of RDoC.
Limitations and Future Directions
The current study has several limitations, which can be addressed by future research.
First, the study sample was recruited from the University of Maine psychology undergraduate
participant pool and the surrounding community. The study sample was predominantly younger,
female, Caucasian, never married college students despite significant efforts to recruit a more
diverse sample. Consequently, the study sample is not representative of the U.S. population.
While the reported rate of depression is higher women (Eaton et al., 2007; Grant et al., 2009;
Hasin et al., 2005; Kessler et al., 2003; Kuehner, 2003, Seedat et al., 2009), younger to middleaged adults (Eaton et al., 2007; Grant et al., 2009; Haigh et al., 2018a; Kessler et al., 2003, 2005,
2010), and Caucasian individuals (Alegría et al., 2008; Williams et al., 2007), more research is
needed on risk for recurrence of depression across the population. Future research should attempt
to recruit a more diverse and representative sample.
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Second, the sample size recruited for the current study was relatively small. Significant
efforts were made to recruit a sample size that was large enough to detect an effect should it be
present. Power analysis using G*Power 3.1.9.2 (Faul et al., 2007) indicated that a sample of 128
participants would result in an 80.00% chance of detecting a medium effect between two groups
(i.e., formerly depressed and healthy control participants) exposed to two versions of the
experimental paradigm (i.e., sad or neutral mood induction). While the recruitment target was
met (N = 132), even slightly exceeded, distribution of participants was uneven between groups
(nFD = 45, nHC = 87) and conditions (nSMI = 65, nNMI = 67). The main issue with unequal sample
sizes when conducting ANOVA analyses is that it can impact homogeneity of variance. ANOVA
is robust statistical test that can handle “moderate departures” from homogeneity of variance
(Grace-Martin, 2019b). In the current study, multiple steps were explored in an attempt to
remedy the violation of homogeneity of variance, including transforming the data to reduce
skewness, or decreasing the α level to reduce the likelihood of type II error (S. W. Ell, personal
communication, February 9, 2016).
There were a variety of reasons for uneven distribution between groups and conditions in
the current study. In regard to groups, it was challenging to recruit formerly depressed
participants that met the inclusion and exclusion criteria. This is likely multifactorial and may be
due to stigma associated with mental illness, elevated rates of comorbid medical and mental
health conditions in depressed populations, and the chronic, recurrent nature of depression that
may have resulted in eligible participants identified at screening who were subsequently
excluded when assessed using the SCID-IV-RV at a later timepoint. Contrariwise, it was
significantly easier to recruit healthy control participants. In regard to conditions, participants
were assigned to the conditions roughly evenly, with slight differences in the size of groups due
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to between-session attrition from sessions 1 and 2. Finally, the power analysis conducted a priori
may not have been precise as it was it was challenging to determine the anticipated effect size.
First, the current study drew from two distinct literature bases (i.e., cognitive and mood literature
and cardiovascular literature) that had different conventions and effect sizes of findings. Second,
the cardiovascular literature for remitted depression was limited and often neglected to report
effect sizes for findings. Future research that aims to replicate these findings should ensure that
an adequate sample size is recruited to detect small to medium effects. Both researchers and
editors should ensure that effect sizes are reported to allow for accurate power analyses when
replicating results. In addition, future research that obtains an adequate sample size could
consider dividing formerly depressed individuals into subgroups of variables that may mediate or
moderate the relationship between depression and cognitive, mood, and cardiovascular reactivity
and recovery in an effort to better predict recurrence of depression and advance precision
medicine (Monroe et al., in press).
Third, the inclusion and exclusion criteria used in the current study were stringent. The
inclusion and criteria omitted potential confounding variables that could have impacted
psychophysiological measures. All participants were excluded from the study if they did not
speak and read English fluently, were color blind, had been diagnosed with a learning disability
that interferes with their ability to read or process visual information, had experienced certain
physical conditions known to impact the recording of physiological responses, or underwent
brain or neural surgery or brain radiation treatment. In addition, the inclusion and criteria omitted
participants who met diagnostic criteria for certain psychiatric disorders. Formerly depressed
participants were excluded if they met diagnostic criteria for current MDD within the past
month, current substance abuse within the past 6 months, current or past substance dependence,
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bipolar disorder, psychotic disorder, acute suicidal ideation, or mood episodes secondary to
general medical conditions while healthy control participants were excluded if they met
diagnostic criteria for any current or past psychological disorder. Consequently, the entire sample
was exceptionally healthy, both physically and mentally. The rigor of the inclusion and exclusion
criteria may have had the unintended consequence of selecting for a sample that may not be
representative of depressed individuals seeking treatment in the community, which should be
considered to avoid inappropriately extrapolating results to community-samples. Future research
may consider using more lenient criteria, when possible, to obtain a more realistic sample of
treatment seeking patients. More specifically, formerly depressed participants with diverse
psychiatric presentations and healthy control participants with a history of non-depressive
disorders may be included or considered as a separate comparison group.
Fourth, CO, which was originally proposed as a cardiovascular measure, was dropped
from analyses due to concerns its accuracy. Typical values for resting CO range from 4 to 12
liters per minute (J. Schmidt, personal communication, April 16, 209). Average CO values
ranged from 1.62 to 365.73 during baseline, 1.49 to 390.58 during the mood induction, and 1.69
to 175.80 during recovery, indicating that this cardiovascular measure was not accurate. It was
determined that this issue was due to inaccurate SV values. SV is not used to calculate HP, RSA,
or PEP and therefore, these cardiovascular measures were not affected. Future research should
include CO as a cardiovascular measure to evaluate the efficiency of the heart in response to a
transient sad mood (Berntson et al, 2007). In addition, future research should expand beyond
cardiovascular measures to also include neuroendocrine and immunological measures in an
effort to understand their relationship and the pathopsychophysiological cascades that contribute
to dysfunction and disease (Linden et al., 1997).
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Fifth, treatment history (i.e., current and past CBT and antidepressant use), which was
originally proposed as a potential covariate, was not adequately captured in the study sample.
Treatment history data was not collected for 16 formerly depressed and 40 healthy control
participants. Due to the large amount of missing data, treatment history was removed from
further analyses. CBT use was originally proposed as a potential covariate because previous
research has suggested that engagement in CBT is associated with lower levels of cognitive
reactivity (Jarrett et al., 2012; Kuyken et al., 2010; Segal et al., 1999). None of the
cardiovascular studies conducted in remitted MDD participants reported participants’
engagement in CBT interventions or psychotherapy more broadly (Ahrens et al., 2008; Bylsma
et al., 2014, 2015; Chang et al., 2012; Rottenberg et al., 2005b; Salomon et al., 2013; Wilson et
al., 2016; Yaroslavsky et al., 2013, 2014a, 2014b). Antidepressant use was originally proposed as
a potential covariate because previous research has found an association between antidepressant
use and certain measures of cardiovascular functioning (e.g., RSA; Licht et al., 2008). While the
majority of the cardiovascular studies conducted in remitted MDD participants did not exclude
for the use of antidepressant medications (Ahrens et al., 2008; Bylsma et al., 2014, 2015;
Rottenberg et al., 2005; Salomon et al., 2013; Wilson et al., 2016; Yaroslavsky et al., 2013,
2014a, 2014b, with the exception of Chang et al., 2012), only a subset of these studies
considered antidepressant medication as a potential covariate (i.e., Rottenberg et al., 2005b;
Salomon et al., 2013; Vaccarino et al., 2008; Yaroslavsky et al., 2013, 2014a, 2014b). Of those
studies, there were no significant differences based on medication status. Future research may
consider including both CBT and antidepressant use as potential covariates to further expand
upon the research base.
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Sixth, potential mediators and moderators of cardiovascular reactivity and recovery were
not adequately captured in the current sample. As previously mentioned, one potential
mechanism of action that may be explored to explain elevated cardiovascular reactivity and
impaired cardiovascular recovery is rumination. This could be investigated by asking participants
to record the thoughts that they were having during the mood induction and recovery period. Of
note, it would be interesting to compare differences in cardiovascular recovery and rumination
among formerly depressed individuals using different recovery tasks: a film that consists of
potentially distracting visual and auditory stimuli, a piece of music that consists of potentially
distracting auditory stimuli, a meditative exercise that consists of potentially distracting spoken
words, and a silent recovery period without any distractions. Another potential mechanism of
action that may be explored to explain impaired cardiovascular recovery is impaired mood
recovery. This could be investigated by asking participants to complete the VAS after the
recovery period. Future research may consider including these and other potential mediators and
moderators to further expand upon the research base.
Conclusions
Increasing our understanding of vulnerability to depressive relapse and recurrence of
depression is necessary to reduce the burden of this often-debilitating disorder, with an exigency
to identify potentially malleable factors that can be targeted during treatment or following
treatment for relapse prevention. Four potentially malleable factors that may be implicated in
depressive relapse and recurrence include cognitive, mood, and cardiovascular reactivity to and
recovery from sadness. Results from the current study suggest that mood, rather than cognitive,
reactivity in response to a transient sad mood is observed in formerly depressed individuals. In
addition, results from the current study suggest that reduced HP recovery, rather than other
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measures of cardiovascular recovery or cardiovascular reactivity, following the induction of a
transient sad mood is observed in formerly depressed individuals. Additional research is needed
to replicate previous results indicating that mood reactivity is predictive of depressive relapse
and recurrence as well as assess if the differences in cardiovascular responding observed in
formerly depressed individuals persist over time and contribute to the development of MDD.
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APPENDICES
Appendix A. Recruitment Flyers

HAVE YOU NEVER
BEEN DEPRESSED?
Help the Maine Mood Disorders lab at UMaine in Orono learn more
about how changes in mood impact risk for depression by
participating in a paid research study.
Take our survey if you:
Have no history of depression, anxiety, or any other emotional
disorder
Do not suffer from alcohol abuse or dependence
Are between 18 and 60 years of age
If you qualify:
● Session 1 (Interview for about 1.5 hours in our lab; $20
compensation)
● Session 2 (Physiological recording while you complete a
computer task in the lab for about 1 hour; $15 compensation)
● Session 3 (Online questionnaires that will take about 30
minutes; entered in drawing with 1 in 10 chance to win a $25
VISA Card)

TAKE OUR ONLINE SURVEY
TO SEE IF YOU ARE ELIGIBLE!
Scan this QR code
or Visit: tinyurl.com/k3s2mrp
or Text: 207-518-8089
or Email: mainemooddisorderslab@gmail.com
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Appendix B. Screening Consent Forms
Welcome to the University of Maine Psychology Department Pre-screening Questionnaires!
You have chosen to participate in research studies to meet your research experience requirement.
One option to partially complete this requirement is to complete the prescreening questionnaires.
The purpose of this screening is to find individuals who score in certain ranges on questionnaires
for several different research projects. Dr. Fayeza Ahmed, Dr. Emily Haigh, Dr. Jordan LaBouff,
Dr. Rebecca Macaulay, Dr. Shannon McCoy, Dr. Doug Nangle, and Dr. Rebecca SchwartzMette, professors in the Psychology Department, are conducting this screening. Based on your
responses, you may be contacted to participate in one or more studies or you may not be
contacted at all.
What Will You Be Asked to Do?
If you decide to participate, you will be asked to complete a series of questions about yourself,
your attitudes, and your beliefs. This prescreening survey will take no longer than 60 minutes.
Risks
You may be asked questions like the following: Have you ever had a panic attack; have you ever
been depressed; how do you feel about your political party; do you experience any of the
following premenstrual symptoms (e.g., difficulty concentrating, depressed mood, breast
tenderness); do you think fat people tend to be fat pretty much through their own fault; would
you be upset if you learned that your son was gay; if I was hanging out with a homosexual
person, I would worry that other people would think I was a homosexual too; do you consider
yourself a Christian; have you lost interest in sex completely; are you feeling down, depressed,
or hopeless; do you think that you may be dirty or contaminated; do you think Male
homosexuality is a perversion; etc. You may become uncomfortable answering some of the
questions. If you have any concerns, please contact Melissa Jankowski (Graduate Student
Coordinator of the Psychology Subject Pool) on First Class. If any of the questions or content
raises concerns that you wish to discuss and debrief with a professional, you should contact the
University of Maine’s Counseling Services at Cutler Health Center (207-581-1392).
Compensation:
You will receive 1 hour of research credit for participating in this study. You must reach the
finishing page of the survey to receive credit.
Confidentiality
We need your name if you wish to be contacted for participation in one of the research projects.
This information will not be shared with anyone other than the individuals' research teams
named above, and identifying information will be kept separate in a different file (i.e., you will
be identified by an arbitrary number). The data file without identifying information will be kept
on password protected computers in locked laboratories indefinitely. The keyed file linking your
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name with your arbitrary identifier will be stored separately on a password protected drive in a
locked laboratory or office, using software that provides additional security. The prescreening
data and key linking names with ID numbers will be destroyed at the end of the semester.
Voluntary
Participation is voluntary. While skipping an occasional answer is acceptable, in order for the
data to be useful, most questions must be answered. You must reach the finishing page of the
survey to receive credit. If you decide at any point that you would rather not continue with the
prescreener, you can do the article reviews OR participate in those studies that do not involve the
prescreener (and there are plenty of these studies).
Contact Information
If you have questions about this screening, please contact Dr. Jordan LaBouff (207-581-2826),
352 Little Hall, or e-mail: sona.admin@umit.maine.edu). If you have questions about your rights
as a research participant, please contact Gayle Jones, Assistant to the University of Maine’s
Protection of Human Subjects Review Board, at 207-581-1498 (or e-mail
gayle.jones@umit.maine.edu).
By clicking "yes" below, I consent to participate in this study.
Yes – I consent to participate and I am over 18 years old
No – I do not consent

I am under 18 but I would like to participate
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Attention and Elaboration Study: Prescreen
The University of Maine at Orono
Prescreening Informed Consent Document (Community Participants)
You are invited to participate in a research project being conducted by Dr. Emily Haigh, in the
Department of Psychology at the University of Maine. The purpose of the research is to learn
about the emotional and physiological responses related to sad mood. You must be at least 18
years of age to participate.
What Will You Be Asked to Do?
Complete a set of online questionnaires to determine if you are eligible for the study.
As part of the online survey you will answer questions about how you’re feeling (e.g. “After I
overeat, occasionally I feel guilt or self-hate,” “I feel guilty all the time,” or “I am disgusted with
myself.”) and different types of thoughts that people sometimes have (e.g., “I worry about
making mistakes” or “I do not need the approval of other people in order to be happy”). This
portion of the study will take about 15-20-minutes total.
If you are eligible for the study, you will receive an email inviting you to sign up to complete
Session 1 in the lab. During Session 1, participants will complete questionnaires and an
interview, where they will be asked about their mood (e.g., “In the past month, have you been
feeling depressed or down?”) and different symptoms (e.g., “In the past month, have you had
trouble sleeping?”). After the interview, a graduate student will measure your height and weight.
Session 1 will take about 1.50 hours.
Based on information gathered during Session 1, some participants will be asked to take part in
Session 2. If you are eligible and decide to participate in the second part, you will be scheduled
for another session that will take place on a different day. For Session 2, you will be asked to
participate in physiological recording (sensors to detect electrical impulses will be attached to
your chest and back) while you complete the following: self-report questionnaires, a
computerized attention task, and listen to either a sad or neutral piece of music designed to
induce a short-lasting sad mood or no change in mood.
Participants that complete the second portion of the study will be invited to complete a third and
final portion of the study. For this part of the study, you will receive an email with a link to
some questions about your mood and whether you have experienced any recent stressful events.
Risks
It is possible that you may feel uncomfortable when answering questions about yourself. At any
point during the study, you have the right to skip questions you do not wish to answer, or stop
the session and choose not to participate in the remainder of the study. You will not need to
provide a reason for stopping the session. You will receive a list of referrals for counseling
services at the end of this questionnaire that can be downloaded. If you indicate that you wish to
harm yourself, Dr. Emily Haigh will contact you by email.
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Benefits
While this study will have no direct benefit to you, this research will help us learn more about
how experiencing brief sad mood relates to depression.
Compensation
While there is no direct compensation for filling out this prescreen, by answering these questions
you may qualify for Session 1 and Session 2 in our laboratory. These sessions include monetary
compensation for time and travel expenses.
Confidentiality
We need your name if you wish to be contacted for participation in this research project. This
information is not shared with anyone outside of the lab. Identifying information will be kept
separate in a different file. A code number will be used to protect your identity. The data file
without identifying information will be kept on a password protected computer in a locked
laboratory indefinitely. The keyed file linking your name and code number will be stored
separately on a password protected computer in the investigator’s locked office and will only be
accessible by Dr. Emily Haigh, Maine Mood Disorders Lab graduate students, and research
assistants who have been trained to deal with sensitive material. Your name or other identifying
information will not be reported in any publications. The key linking your name to the data will
be destroyed two years after data analysis is complete, which we anticipate will be in December,
2018. The key and the data files will be stored on separate computers. All data will be kept
indefinitely by the investigators. You may decide that you do not want your data used in this
research. If you would like your data removed from the study and permanently deleted, please
email your request to the Principal Investigator, Dr. Emily Haigh, at emily.a.haigh@maine.edu.
Voluntary
Participation is voluntary. If you choose to take part in this study, you may stop at any
time. You may also skip any questions you do not wish to answer.
Contact Information
If you have any questions about this study, please contact Emily Haigh at
Emily.a.haigh@maine.edu. If you have any questions about your rights as a research participant,
please contact Gayle Jones, Assistant to the University of Maine’s Protection of Human Subjects
Review Board, at 581-1498 or via e-mail gayle.jones@umit.maine.edu.
Future Studies
Would you be interested in being contacted for future studies conducted in the lab for
monetary compensation?
Yes

No
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By clicking “Yes” below, you indicate that you have read and understand the above
information and agree to participate.
If you are no longer interested, please click “No” to exit to questionnaire.
Yes

No
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Appendix C. Screening Self-Report Measures
Contact Information
Thank you for your interest in our study! Please provide your contact information below so we
can contact you if you are eligible.
Please provide your full name: _____
Please provide your email address: _____
Please provide your phone number (including area code): _____
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Demographic Information
To start with, we would like to get some background information from you.
1. What is your age? _____
2. What is your date of birth (MM/DD/YYYY)? _____
3. What is your gender?
○ Male
○ Female
4. What is your marital situation (please check one)?
○ Married
○ Separated
○ Never married/single
○ Common law marriage
○ Divorced
○ Widowed
5. Do you consider yourself to be Hispanic or Latino (i.e., a person of Mexican, Puerto
Rican, Cuban, South or Central American, or other Spanish culture of origin, regardless
of race)?
○ Yes
○ No
6. Do you consider yourself to be Franco-American?
○ Yes
○ No
7. What is your race?
○ Native American or Alaska Native (i.e. a person having origins in any of the original
peoples of North, Central, or South America)
○ Asian (i.e. a person having origins in any of the original peoples of the Far East,
Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China,
India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam)
○ Black or African American (i.e. a person having origins in any of the black racial
groups of Africa)
○ Native Hawaiian or Other Pacific Islander (i.e. a person having origins in any of the ..
original peoples of Hawaii, Guam, Samoa, or other Pacific Islands)
○ White (i.e. a person having origins in any of the peoples of Europe, the Middle East, or
North Africa)
○ Multiple races
○ None of the above

330

8. What is the highest grade in school you have completed (please check one)?
○ Less than High School
○ High School
○ 1 year of college or technical school
○ 2 or more years of college but did not graduate
○ 4 years of college with degree
○ Postgraduate, M.D., Ph.D.
○ A.A. or other degree that is not a B.A. or B.S.
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General Health Screen (GHS)
Please answer yes or no to the following questions:
1. Do you speak and read English fluently?
○ Yes
○ No
2. Are you color-blind?
○ Yes
○ No
3. Have you ever been diagnosed with any learning disabilities that interfere with your
ability to read or process visual information?
○ Yes
○ No
4. Have you lost consciousness for more than one hour ever?
○ Yes
○ No
5. Have you ever been diagnosed with any neurological disorder, such as Alzheimer’s
Disease, Parkinson’s Disease, Huntington’s Disease?
○ Yes
○ No
6. Have you ever had a stroke, hemorrhage, or brain tumor?
○ Yes
○ No
7. Have you ever had brain/neural surgery or brain radiation treatment (e.g. for brain
tumor)?
○ Yes
○ No
8. Do you have multiple seizures or Epilepsy?
○ Yes
○ No
9. Have you ever been diagnosed with cardiovascular disease? Heart disease?
Hypertension? Medication-dependent diabetes?
○ Yes
○ No
Comments: _____
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Beck Depression Inventory – Second Edition (BDI-II)
This questionnaire consists of 21 groups of statements. Please read each group of statements
carefully, and then pick out the ONE STATEMENT in each group that best describes the way
you have been feeling during the PAST TWO WEEKS, INCLUDING TODAY. Bubble in the
number beside the statement you have picked. If several statements in the group seem to apply
equally well, bubble in the highest number for that group. Be sure that you do not choose more
than one statement for any group, including Item 16 (Changes in Sleeping Pattern) or Item 18
(Changes in Appetite).
1. Sadness
 I do not feel sad.
 I feel sad much of the time.
 I am sad all the time.
 I am so sad or unhappy that I can't stand it.
2. Pessimism
 I am not discouraged about my future.
 I feel more discouraged about my future than I used to be.
 I do not expect things to work out for me.
 I feel my future is hopeless and will only get worse.
3. Past Failure
 I do not feel like a failure.
 I have failed more than I should have.
 As I look back, I see a lot of failures.
 I feel I am a total failure as a person.
4. Loss of Pleasure
 I get as much pleasure as I ever did from the things I enjoy.
 I don't enjoy things as much as I used to.
 I get very little pleasure from the things I used to enjoy.
 I can’t get any pleasure from the things I used to enjoy.
5. Guilty Feelings
 I don't feel particularly guilty.
 I feel guilty over many things I have done or should have done.
 I feel quite guilty most of the time.
 I feel guilty all of the time.
6. Punishment Feelings
 I don't feel I am being punished.
 I feel I may be punished.
 I expect to be punished.
 I feel I am being punished.
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7. Self-Dislike
 I feel the same about myself as ever.
 I have lost confidence in myself.
 I am disappointed with myself.
 I dislike myself.
8. Self-Criticalness
 I don't criticize or blame myself more than usual.
 I am more critical of myself than I used to be.
 I criticize myself for all of my faults.
 I blame myself for everything bad that happens.
9. Suicidal Thoughts or Wishes
 I don't have any thoughts of killing myself.
 I have thoughts of killing myself, but I would not carry them out.
 I would like to kill myself.
 I would kill myself if I had the chance.
10. Crying
 I don't cry any more than I used to.
 I cry more than I used to.
 I cry over every little thing.
 I feel like crying, but I can’t.
11. Agitation
 I am no more restless or wound up than usual.
 I feel more restless or wound up than usual.
 I am so restless or agitated that it’s hard to stay still.
 I am so restless or agitated that I have to keep moving or doing something.
12. Loss of Interest
 I have not lost interest in other people or activities.
 I am less interested in other people or things than before.
 I have lost most of my interest in other people or things.
 It’s hard to get interested in anything.
13. Indecisiveness
 I make decisions about as well as ever.
 I find it more difficult to make decisions than usual.
 I have much greater difficulty in making decisions than I used to.
 I have trouble making any decisions.
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14. Worthlessness
 I do not feel I am worthless.
 I don’t consider myself as worthwhile and useful as I used to.
 I feel more worthless as compared to other people.
 I feel utterly worthless.
15. Loss of Energy
 I have as much energy as ever.
 I have less energy than I used to have.
 I don’t have enough energy to do very much.
 I don’t have enough energy to do anything.
16. Changes in Sleeping Pattern
 I have not experienced any change in my sleeping pattern.
 I sleep somewhat more than usual.
 I sleep somewhat less than usual.
 I sleep a lot more than usual.
 I sleep a lot less than usual.
 I sleep most of the day.
 I wake up 1-2 hours early and can't get back to sleep.
17. Irritability
 I am no more irritable than usual.
 I am more irritable than usual.
 I am much more irritable than usual.
 I am irritable all the time.
18. Changes in Appetite
 I have not experienced any change in my sleeping appetite.
 My appetite is somewhat less than usual.
 My appetite is somewhat more than usual.
 My appetite is much less than usual.
 My appetite is much greater than usual.
 I have no appetite at all.
 I crave food all the time.
19. Concentration Difficulty
 I can concentrate as well as ever.
 I can't concentrate as well as usual.
 It's hard to keep my mind on anything for very long.
 I find I can't concentrate on anything.
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20. Tiredness or Fatigue
 I am no more tired or fatigued than usual.
 I get tired or fatigued more easily than usual.
 I am too tired or fatigued to do a lot of the things I used to do.
 I am too tired or fatigued to do most of the things I used to do.
21. Loss of Interest in Sex
 I have not noticed any recent change in my interest in sex.
 I am less interested in sex than I used to be.
 I am much less interested in sex now.
 I have lost interest in sex completely.
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Patient Health Questionnaire – 9 (PHQ-9)
For the two weeks in your life when you felt the most blue, sad, or depressed, how often were
you bothered by any of the following problems?
Rarely/
Not at all

Several
days

0
0

1
1

More than
half the
days
2
2

0

1

2

3

0
0

1
1

2
2

3
3

0

1

2

3

0

1

2

3

0

1

2

3

Not at all

Somewhat

Very

Extremely

0

1

2

3

1. Little pleasure or interest in doing things
2. Feeling down, depressed or hopeless
Trouble falling or staying asleep or
3.
sleeping too much
4. Feeling tired or having little energy
5. Poor appetite or overeating
Feeling bad about yourself – or that you
6. are a failure or you have let yourself or
your family down
Trouble concentrating on things, such as
7. reading the newspaper or watching
television
Moving or speaking slowly so that other
people could have noticed. Or the opposite
8.
– being so fidgety or restless that you have
been moving around a lot more than usual

How difficult did these problems make it
for you to do your work, take care of
9.
things at home, or get along with other
people?
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Nearly
every day
3
3

Beck Anxiety Inventory (BAI)
Below is a list of common symptoms of anxiety. Please carefully read each item in the list.
Indicate how much you have been bothered by that symptom during the past month, including
today, by circling the number in the corresponding space in the column next to each symptom.

Not at all
1. Numbness or tingling
2. Feeling hot
3. Wobbliness in legs
4. Unable to relax
5. Fear of worst happening
6. Dizzy or lightheaded
7. Heart pounding/racing
8. Unsteady
9. Terrified or afraid
10. Nervous
11. Feeling of choking
12. Hands trembling
13. Shaky/unsteady
14. Fear of losing control
15. Difficulty breathing
16. Fear of dying
17. Scared
18. Indigestion
19. Faint/lightheaded
20. Face flushed
21. Hot/cold sweats

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Mildly, but it Moderately – it Severely – it
didn’t bother me wasn’t pleasant bothered me a
much
at times
lot
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
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Appendix D. Counseling Resources
If you feel upset after having completed the study or find that some questions or aspects of the
study triggered distress, talking with a qualified clinician may help. The following represents a
list of resources that you may contact. These resources are options and in no way do they reflect
an endorsement by the University of Maine.
Counseling Services
ON-CAMPUS RESOURCES Available for UMaine Faculty, Staff, and Students
Counseling Center
207-581-1392
Weekdays 8:00 amCutler Health Building
http://www.umaine.edu/counseling/ 4:30 pm
(Gannet Hall side)
After business hours,
(FREE to UMaine students)
call UMaine Police,
581-4040 or
911amPsychological Services Center
207-581-2034
Weekdays
8:00
330 Corbett Hall
http://umaine.edu/clinicalpsychology/ 4:30 pm
(Sliding fee scale; costs are
psychological-services-center/
your responsibility)
COMMUNITY RESOURCES Available to Anyone
Community Health &
207-947-0366
Weekdays 8:00 amCounseling Services
http://www.chcs-me.org/
5:00 pm
42 Cedar Street
Bangor, ME 04401
(Any costs are your
responsibility)
Maine Warm Line
(Any costs are your
responsibility)

1-888-771-9276
7 days/week 5:00 pmhttp://www.thecommunityconnector. 8:00 am
org/directory/profile/maine-warm-line

Maine Suicide and Crisis
Hotline
(Any costs are your
responsibility)

1-888-568-1112
http://www.maine.gov/suicide/youth/
index.htm

7 days/week 24 hours

Psychological Services Center
207-581-2034
Weekdays 8:00 am330 Corbett Hall
http://umaine.edu/clinicalpsychology/ 4:30 pm
(sliding fee scale)
psychological-services-center/
Contact Your Primary Care
Provider
(Any costs are your
responsibility)
NATIONAL RESOURCES
Mental Health Services Locator http://store.samhsa.gov/mhlocator
National Suicide Prevention Lifeline, Toll-Free, 24-hour Hotline, 1-800-273-TALK
(1-800-273-8255)
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Appendix E. Recruitment Email
Hello,
Thank you very much for your interest in the research we are conducting at the Maine Mood
Disorders Lab. We appreciate you taking the time to contact us and complete the online survey.
Your responses to the survey indicate you qualify for the next step of our study, an in-person
interview in our lab. This will take approximately two hours. This session will involve the
completion of several online questionnaires about how you are feeling and different types of
thoughts people sometimes have. You will then participate in an interview that will ask you
about your mood and different symptoms related to disorders like depression and anxiety (e.g.,
In the past month, have you had trouble sleeping?). More details will be provided once you are
scheduled.
Using your name and email address, we created you a Sona Systems account. Sona is an online
resource we use for scheduling.
Please visit Sona here to schedule a time that works for you to come to the lab for approximately
1.50 to 2 hours, using the username and password below:
Username: FIRSTNAME.LASTNAME
Password: blackbear
You are only eligible to participate in “Attention and Elaboration Session 1.” Please click
on this study and enter the following password: blackbear.
Thank you again for your interest in the Maine Mood Disorders Lab. We look forward to seeing
you soon.
Best,
The Maine Mood Disorders Lab
MMDL Website
Visit us on Facebook
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Appendix F. Research Participation Credit Schedule
Credit will be awarded based on the amount of time that it takes for a participant to complete the
session. Allow participants who are distressed to end participation in the study (discuss this with
a graduate student) without loss of payment based on hours spent in the laboratory to the nearest
half hour, as indicated below.
Session 1:
Up to ½ hour
½ hour to 1 hour
1 hour to 1 ½ hours
1 ½ hours to 2 hours (or session completion)

.50 research participation credit
1 research participation credit
1.50 research participation credits
2 research participation credits

Session 2:
Up to ½ hour
.50 research participation credit
½ hour to 1 hour (or session completion) 1 research participation credit
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Appendix G. Payment Schedule
Regardless of time spent in lab, pay full amount if participant completes the session. Allow
participants who are distressed to end participation in the study (discuss this with a graduate
student) without loss of payment based on hours spent in the laboratory to the nearest half hour,
as indicated below.
Session 1:
Up to ½ hour
½ hour to 1 hour
1 hour to 1 ½ hours
1 ½ hours to 2 hours (or session completion)

$5.00
$10.00
$15.00
$20.00

Session 2:
Up to ½ hour
$8.00
½ hour to 1 hour (or session completion) $15.00
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Appendix H. Session 1 Consent Forms
Attention and Elaboration Study: Session 1
The University of Maine at Orono
Informed Consent Document (PSY 100, 212)
You are invited to participate in a research project being conducted by Dr. Emily Haigh, in the
Department of Psychology at the University of Maine. The purpose of the research is to learn
about the emotional and physiological responses related to sad mood. You must be at least 18
years of age to participate.
What Will You Be Asked to Do?
If you decide to participate, you will complete an online survey and an interview in the lab. As
part of the online survey you will answer questions about how you’re feeling (e.g. “After I
overeat, occasionally I feel guilt or self-hate.”) and different types of thoughts that people
sometimes have (e.g., “I worry about making mistakes” or “I do not need the approval of other
people in order to be happy”). This portion of the study will take about 30-minutes total.
Next, you will participate in an interview. During the interview, you will be asked about your
mood (e.g., “In the past month, have you been feeling depressed or down?”) and different
symptoms that are related to disorders like depression and anxiety (e.g., “In the past month, have
you had trouble sleeping?”) The interview will take about 1.50 hours. With your consent, we
will audio-record the interview. The audio-record will be used to confirm that the interview was
conducted properly by the researcher. Even if you agree to be audio-recorded, you may ask us to
stop or destroy the audio file at any time during or after the study is completed. After the
interview, a graduate student will measure your height and weight.
Based on information gathered during the interview and questionnaires, some participants will be
asked to take part in a second part of the study. If you are eligible and decide to participate in the
second part, you will be scheduled for another session that will take place on a different day.
During the second part of the study, you will be given a description of the study and asked to
give consent for the procedures involved. Briefly, you will be asked to participate in
physiological recording (sensors to detect electrical impulses will be attached to your chest and
back) while you complete the following: self-report questionnaires, a computerized attention task
and listen to either a sad or neutral piece of music designed to induce a short-lasting sad mood or
no change in mood.
Participants that complete the second portion of the study will be invited to complete a third and
final portion of the study. For this part of the study, you will receive an email with a link to some
questions about your mood and whether you have experienced any recent stressful events.
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Risks
It is possible that you may feel uncomfortable when answering questions about yourself. At any
point during the study, you have the right to skip questions you do not wish to answer, or stop
the session and choose not to participate in the remainder of the study. You will not need to
provide a reason for stopping the session. You will receive a list of referrals for counseling
services at the end of your session today.
Benefits
While this study will have no direct benefit to you, this research will help us learn more about
how experiencing brief sad mood relates to depression.
Compensation
You will receive 1 research credit for each hour of participation. Since the interview is expected
to take 1.50 hours and the survey is expected to take 30-minutes, it is likely that you will earn 2
credits today.
Confidentiality
Your name will not appear on any of the documents. A code number will be used to protect your
identity. This code is stored on a file with software designed to provide added security. Data will
be kept in the investigator’s locked office and will only be accessible by Dr. Emily Haigh, Maine
Mood Disorders Lab graduate students, and research assistants who have been trained to deal
with sensitive material. Your name or other identifying information will not be reported in any
publications. The key linking your name to the data will be destroyed two years after data
analysis is complete, which we anticipate will be in 2018. All data, including audio recordings,
will be kept indefinitely by the investigators. The key and the data files will be stored on separate
computers.
Voluntary
Participation is voluntary. If you choose to take part in this study, you may stop at any time. You
may also skip any questions you do not wish to answer. You will earn 1 credit for each hour of
participation with the possibility of earning 2 credits today.
Contact Information
If you have any questions about this study, please contact Emily Haigh at
Emily.a.haigh@maine.edu. If you have any questions about your rights as a research participant,
please contact Gayle Jones, Assistant to the University of Maine’s Protection of Human Subjects
Review Board, at 581-1498 or via e-mail gayle.jones@umit.maine.edu.
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Audiotaping
I agree to audio recording the interview.
Yes

No

Future Studies
Would you be interested in being contacted for future studies conducted in the lab for
monetary compensation?
Yes

No

Your signature below indicates that you have read and understand the above information
and agree to participate. You will receive a copy of this form.

____________________________________
Signature

________________
Date
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Attention and Elaboration Study: Session 1
The University of Maine at Orono
Informed Consent Document (Community Participants)
You are invited to participate in a research project being conducted by Dr. Emily Haigh, in the
Department of Psychology at the University of Maine. The purpose of the research is to learn
about the emotional and physiological responses related to sad mood. You must be at least 18
years of age to participate.
What Will You Be Asked to Do?
If you decide to participate, you will complete an online survey and an interview in the lab. As
part of the online survey you will answer questions about how you’re feeling (e.g. “After I
overeat, occasionally I feel guilt or self-hate.”) and different types of thoughts that people
sometimes have (e.g., “I worry about making mistakes” or “I do not need the approval of other
people in order to be happy”). This portion of the study will take about 30-minutes total.
Next, you will participate in an interview. During the interview, you will be asked about your
mood (e.g., “In the past month, have you been feeling depressed or down?”) and different
symptoms that are related to disorders like depression and anxiety (e.g., “In the past month, have
you had trouble sleeping?”). The interview will take about 1.50 to 2 hours. With your consent,
we will audio-record the interview. The audio-record will be used to confirm that the interview
was conducted properly by the researcher. Even if you agree to be audio-recorded, you may ask
us to stop or destroy the audio file at any time during or after the study is completed. After the
interview, a graduate student will measure your height and weight.
Based on information gathered during the interview and questionnaires, some participants will be
asked to take part in a second part of the study. If you are eligible and decide to participate in the
second part, you will be scheduled for another session that will take place on a different day.
During the second part of the study, you will be given a description of the study and asked to
give consent for the procedures involved. Briefly, you will be asked to participate in
physiological recording (sensors to detect electrical impulses will be attached to your chest and
back) while you complete the following: self-report questionnaires, a computerized attention task
and listen to either a sad or neutral piece of music designed to induce a short-lasting sad mood or
no change in mood.
Participants that complete the second portion of the study will be invited to complete a third and
final portion of the study. For this part of the study, you will receive an email with a link to some
questions about your mood and whether you have experienced any recent stressful events.
Risks
It is possible that you may feel uncomfortable when answering questions about yourself. At any
point during the study, you have the right to skip questions you do not wish to answer, or stop
the session and choose not to participate in the remainder of the study. You will not need to
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provide a reason for stopping the session. You will receive a list of referrals for counseling
services at the end of your session today.
Benefits
While this study will have no direct benefit to you, this research will help us learn more about
experiencing how brief sad mood relates to depression.
Compensation
You will receive $20 for participating in this research session to compensate you for your time
and travel expenses. If you do not complete the session you will receive compensation pro-rated
to the nearest half hour.
Confidentiality
Your name will not appear on any of the documents. A code number will be used to protect your
identity. This code is stored on a file with software designed to provide added security. Data will
be kept in the investigator’s locked office and will only be accessible by Dr. Emily Haigh, Maine
Mood Disorders Lab graduate students and research assistants who have been trained to deal
with sensitive material. Your name or other identifying information will not be reported in any
publications. The key linking your name to the data will be destroyed in about two years after
data analysis is complete, which we anticipate will be in 2018. All data, including audio
recordings, will be kept indefinitely by the investigators. The key and the data files will be stored
on separate computers.
Voluntary
Participation is voluntary. If you choose to take part in this study, you may stop at any time. You
may also skip any questions you do not wish to answer.
Contact Information
If you have any questions about this study, please contact Emily Haigh at
Emily.a.haigh@maine.edu. If you have any questions about your rights as a research participant,
please contact Gayle Jones, Assistant to the University of Maine’s Protection of Human Subjects
Review Board, at 581-1498 or via e-mail at gayle.jones@umit.maine.edu.
Audiotaping
I agree to audio recording the interview.
Yes

No
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Future Studies
Would you be interested in being contacted for future studies conducted in the lab for
monetary compensation?
Yes

No

Your signature below indicates that you have read and understand the above information
and agree to participate. You will receive a copy of this form.

____________________________________
Signature

________________
Date
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Appendix I. Session 1 Self-Report Measures
Demographic Information
To start with, we would like to get some background information from you.
1. What is your age? _____
2. What is your gender? _____
3. What is your date of birth (MM/DD/YYYY)? _____
4. What is your marital situation (please check one)?
○ Married
○ Separated
○ Never married/single
○ Common law marriage
○ Divorced
○ Widowed
5. Do you consider yourself to be Hispanic or Latino (i.e., a person of Mexican, Puerto
Rican, Cuban, South or Central American, or other Spanish culture of origin, regardless
of race)?
○ Yes
○ No
6. Do you consider yourself to be Franco-American?
○ Yes
○ No
7. What is your race?
○ Native American or Alaska Native (i.e. a person having origins in any of the original
peoples of North, Central, or South America)
○ Asian (i.e. a person having origins in any of the original peoples of the Far East,
Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China,
India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam)
○ Black or African American (i.e. a person having origins in any of the black racial
groups of Africa)
○ Native Hawaiian or Other Pacific Islander (i.e. a person having origins in any of the ..
original peoples of Hawaii, Guam, Samoa, or other Pacific Islands)
○ White (i.e. a person having origins in any of the peoples of Europe, the Middle East, or
North Africa)
○ Multiple races
○ None of the above
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8. What is the highest grade in school you have completed (please check one)?
○ Less than High School
○ High School
○ 1 year of college or technical school
○ 2 or more years of college but did not graduate
○ 4 years of college with degree
○ Postgraduate, M.D., Ph.D.
○ A.A. or other degree that is not a B.A. or B.S.
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Beck Depression Inventory – Second Edition (BDI-II)
This questionnaire consists of 21 groups of statements. Please read each group of statements
carefully, and then pick out the ONE STATEMENT in each group that best describes the way
you have been feeling during the PAST TWO WEEKS, INCLUDING TODAY. Bubble in the
number beside the statement you have picked. If several statements in the group seem to apply
equally well, bubble in the highest number for that group. Be sure that you do not choose more
than one statement for any group, including Item 16 (Changes in Sleeping Pattern) or Item 18
(Changes in Appetite).
1. Sadness
 I do not feel sad.
 I feel sad much of the time.
 I am sad all the time.
 I am so sad or unhappy that I can't stand it.
2. Pessimism
 I am not discouraged about my future.
 I feel more discouraged about my future than I used to be.
 I do not expect things to work out for me.
 I feel my future is hopeless and will only get worse.
3. Past Failure
 I do not feel like a failure.
 I have failed more than I should have.
 As I look back, I see a lot of failures.
 I feel I am a total failure as a person.
4. Loss of Pleasure
 I get as much pleasure as I ever did from the things I enjoy.
 I don't enjoy things as much as I used to.
 I get very little pleasure from the things I used to enjoy.
 I can’t get any pleasure from the things I used to enjoy.
5. Guilty Feelings
 I don't feel particularly guilty.
 I feel guilty over many things I have done or should have done.
 I feel quite guilty most of the time.
 I feel guilty all of the time.
6. Punishment Feelings
 I don't feel I am being punished.
 I feel I may be punished.
 I expect to be punished.
 I feel I am being punished.
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7. Self-Dislike
 I feel the same about myself as ever.
 I have lost confidence in myself.
 I am disappointed with myself.
 I dislike myself.
8. Self-Criticalness
 I don't criticize or blame myself more than usual.
 I am more critical of myself than I used to be.
 I criticize myself for all of my faults.
 I blame myself for everything bad that happens.
9. Suicidal Thoughts or Wishes
 I don't have any thoughts of killing myself.
 I have thoughts of killing myself, but I would not carry them out.
 I would like to kill myself.
 I would kill myself if I had the chance.
10. Crying
 I don't cry any more than I used to.
 I cry more than I used to.
 I cry over every little thing.
 I feel like crying, but I can’t.
11. Agitation
 I am no more restless or wound up than usual.
 I feel more restless or wound up than usual.
 I am so restless or agitated that it’s hard to stay still.
 I am so restless or agitated that I have to keep moving or doing something.
12. Loss of Interest
 I have not lost interest in other people or activities.
 I am less interested in other people or things than before.
 I have lost most of my interest in other people or things.
 It’s hard to get interested in anything.
13. Indecisiveness
 I make decisions about as well as ever.
 I find it more difficult to make decisions than usual.
 I have much greater difficulty in making decisions than I used to.
 I have trouble making any decisions.
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14. Worthlessness
 I do not feel I am worthless.
 I don’t consider myself as worthwhile and useful as I used to.
 I feel more worthless as compared to other people.
 I feel utterly worthless.
15. Loss of Energy
 I have as much energy as ever.
 I have less energy than I used to have.
 I don’t have enough energy to do very much.
 I don’t have enough energy to do anything.
16. Changes in Sleeping Pattern
 I have not experienced any change in my sleeping pattern.
 I sleep somewhat more than usual.
 I sleep somewhat less than usual.
 I sleep a lot more than usual.
 I sleep a lot less than usual.
 I sleep most of the day.
 I wake up 1-2 hours early and can't get back to sleep.
17. Irritability
 I am no more irritable than usual.
 I am more irritable than usual.
 I am much more irritable than usual.
 I am irritable all the time.
18. Changes in Appetite
 I have not experienced any change in my sleeping appetite.
 My appetite is somewhat less than usual.
 My appetite is somewhat more than usual.
 My appetite is much less than usual.
 My appetite is much greater than usual.
 I have no appetite at all.
 I crave food all the time.
19. Concentration Difficulty
 I can concentrate as well as ever.
 I can't concentrate as well as usual.
 It's hard to keep my mind on anything for very long.
 I find I can't concentrate on anything.
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20. Tiredness or Fatigue
 I am no more tired or fatigued than usual.
 I get tired or fatigued more easily than usual.
 I am too tired or fatigued to do a lot of the things I used to do.
 I am too tired or fatigued to do most of the things I used to do.
21. Loss of Interest in Sex
 I have not noticed any recent change in my interest in sex.
 I am less interested in sex than I used to be.
 I am much less interested in sex now.
 I have lost interest in sex completely.
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State-Trait Anxiety Inventory – I (STAI-I)
A number of statements which people have used to describe themselves are given below. Read
each statement and then circle the appropriate number to the right of the statement to indicate
how you feel right now, that is, at this moment. There are no right or wrong answers. Do not
spend too much time on any one statement but give the answer which seems to describe your
present feelings best.

Very Much So
Moderately so
Somewhat
Not at all

1.

I feel calm

1 2

3

4

2.

I feel secure

1 2

3

4

3.

I am tense

l

2

3

4

4.

I feel strained

1 2

3

4

5.

I feel at ease

1 2

3

4

6.

I feel upset

1 2

3

4

7.

I am presently worrying over possible misfortune

1 2

3

4

8.

I feel satisfied

1 2

3

4

9.

I feel frightened

1 2

3

4

10. I feel comfortable

1 2

3

4

11. I feel self-confident

1 2

3

4

12. I feel nervous

1 2

3

4

13. I am jittery

1 2

3

4

14. I feel indecisive

1 2

3

4

15. I am relaxed

1 2

3

4

16. I feel content

1 2

3

4

17. I am worried

1 2

3

4

18. I feel confused

1 2

3

4

19. I feel steady

1 2

3

4

20. I feel pleasant

1 2

3

4
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State-Trait Anxiety Inventory – II (STAI-II)

Very Much So
Moderately so
Somewhat
Not at all

A number of statements which people have used to describe themselves are given below. Read
each statement and then circle the appropriate number to the right of the statement to indicate
how you generally feel.

21. I feel pleasant

1

2 3

4

22. I feel nervous and restless

1

2 3

4

23. I feel satisfied with myself

1

2 3

4

24. I wish I could be as happy as others seem to be

1

2 3

4

25. I feel like a failure

1

2 3

4

26. I feel rested

1

2 3

4

27. I am "calm, cool, and collected"

1

2 3

4

28. l feel that d difficulties are piling up so that I cannot overcome them

1

2 3

4

29. l worry too much over something that really doesn't matter

1

2 3

4

30. l am happy

l

2 3

4

31. I have disturbing thoughts

1

2 3

4

32. I lack self-confidence

1

2 3

4

33. I feel secure

1

2 3

4

34. l make decisions easily

1

2 3

4

35. l feel inadequate

1

2 3

4

36. I am content

1

2 3

4

37. Some unimportant thought runs through my mind and bothers me

1

2 3

4

38. l take disappointments so keenly that l can 't put them out of my mind

1

2 3

4

39. I am a steady person

1

2 3

4

40. I get in a state of tension or turmoil as I think over my recent concerns and
interests

1

2 3

4
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Treatment History
Current Treatment
Are you currently seeing a therapist for emotional or behavioral problems?  
What type of therapy do you participate in (e.g., counseling, CBT, MBT, family, couples, group,
or interpersonal therapy)?
Notes:

Are you currently being prescribed medication for emotional or behavioral problems?  
What type of medication are you prescribed (i.e., name of and purpose of medication and
duration taken)?
Notes:

Past Treatment
Have you ever see a therapist for emotional or behavioral problems?  
What type of therapy did you participate in (e.g., counseling, CBT, MBT, family, couples, group,
or interpersonal therapy)?
Notes:

Have you ever been prescribed medication for emotional or behavioral problems?  
What type of medication were you prescribed (i.e., name of and purpose of medication and
duration taken)?
Notes:
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Appendix J. Session 1 Suicide Risk Assessment
Questions to ask if you think someone may be at risk for suicide:
Suicidal Ideation:
Are you currently suicidal?
Intent:
Do you think you would ever harm yourself or attempt suicide?
OR
Have you considered ways of killing yourself?
Plan/Preparations:
Do you have a suicide plan or have you made preparations for committing suicide?
Means:
Do you have means to kill yourself?
Suicide Attempt:
Have you ever attempted suicide?
IF YES, THEN
When was your last suicide attempt?
When Students will need to speak with a clinician:
If intent + suicide plan / intent + means / suicide plan + means / suicide attempt within last
2 weeks + suicide ideation = Student NEEDS to speak with a clinician.
*Use your judgment. If there is any question about whether a student (who has endorsed one or
more of the above items) should speak with a clinician, consult with the clinician. For example,
if a student endorses active suicidal ideation, but does not endorse intent or plan, you may still
want to touch base with a clinician.
*If Dr. Haigh is unavailable, contact Dr. O’Grady or Dr. Schwartz-Mette. (Contact information
on next page).
*If they are unavailable, walk student to the counseling center.
Checking in with students who endorse some of the questions, but DON’T NEED to speak
with a clinician (Can use script below but don’t have to say this verbatim):
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“I noticed that you endorsed (say what they endorsed). There are some very effective ways to
help with some of the concerns we spoke about during the interview today. I have a list of
referrals you may consider. I would strongly recommend these services to help with the way you
have been feeling.”
Regardless of whether the student is at risk for suicide or not, offer them the list of mental
health referrals.
Contact Information:
Emily Haigh:
207-581-2025 (office); 215-317-0133 (cell)
April O’Grady:
207-945-3935 (home); 207-478-9742 (cell)
Rebecca Schwartz-Mette:
207-581-2048 (office); 573-239-2202 (cell)
Counseling Services at UMaine:
207-581-1392
5721 Cutler Health Center, Room 125
Orono, Maine 04469
Campus Police:
207-581-4040
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Appendix K. Session 2 Consent Forms
Attention and Elaboration Study: Session 2
The University of Maine at Orono
Informed Consent Document (PSY 100, 212)
You are invited to participate in a research project being conducted by Dr. Emily Haigh in the
Department of Psychology at the University of Maine. The purpose of the research is to learn
about the emotional and physiological responses related to sad mood. You must be at least 18
years of age to participate.
What Will You Be Asked to Do?
A trained female research assistant will place sensors on your body in order to record electrical
activity of the heart, skin, and facial muscle groups. Once the sensors are placed on your body,
you will be asked to sit comfortably in front of a computer in a small room. You will then be
asked to complete the following tasks: watch a short video about Alaska’s Denali Mountain,
answer some questions about how you’re feeling (e.g. check a box to indicate whether you are
interested, upset, nervous), complete a short computer task and listen to either a sad or neutral
piece of music designed to induce a short-lasting sad mood or no change in mood. This portion
of the study will take approximately 1-hour total.
Risks
It is possible that you may feel uncomfortable when answering questions about yourself. At any
point during the study, you have the right to skip questions you do not wish to answer, or stop
the session and choose not to participate in the remainder of the study. You will not need to
provide a reason for stopping the session. You will receive a list of referrals for counseling
services at the end of your session today.
Benefits
This study will have no direct benefit to you, though it will help to better understand how
individuals process emotional information and how this relates to risk for depression.
Compensation
Students will earn 1 credit for their participation, unless they no longer require research points
for course credit (e.g., have already earned 5 research credits as required by PSY 100). In this
case, students will receive $15 for their participation. Monetary compensation is only available
to students who have met course research credit requirements.
Confidentiality
The code number you have been assigned during session 1 will again be used to protect your
identity. This code is stored on a file with software designed to provide additional security. All
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data will be kept in the investigator’s locked office and will only be accessible by Dr. Emily
Haigh and Maine Mood Disorders Lab graduate students and research assistants who have
completed training in order to deal with sensitive material. Your name or other identifying
information will not be reported in any publications. As previously described, the key linking
your name to the data will be destroyed in approximately two years after data analysis is
complete, which we anticipate will be in December, 2018. All data will be kept indefinitely by
the investigators. The key and the data files will be stored on separate computers. You may
decide that you do not want you data used in this research. If you would like you data removed
from the study and permanently deleted, please email your request to the Principal Investigator,
Dr. Emily Haigh, at emily.a.haigh@maine.edu.
Voluntary
Participation is voluntary. If you choose to take part in this study, you may stop at any time. You
may also skip any questions you do not wish to answer. If you are participating for monetary
compensation, you will receive $15 for participating in this research session to compensate you
for your time and travel expenses. If you do not complete the session, you will receive
compensation pro-rated to the nearest half hour.
Contact Information
If you have any questions about this study, please contact Emily Haigh at
Emily.a.haigh@maine.edu. If you have any questions about your rights as a research participant,
please contact Gayle Jones, Assistant to the University of Maine’s Protection of Human Subjects
Review Board, at 581-1498 (or e-mail gayle.jones@umit.maine.edu).
Your signature below indicates that you have read and understand the above information
and agree to participate. You will receive a copy of this form.

____________________________________
Signature

________________
Date
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Attention and Elaboration Study: Session 2
The University of Maine at Orono
Informed Consent Document (Community Participants)
You are invited to participate in a research project being conducted by Dr. Emily Haigh in the
Department of Psychology at the University of Maine. The purpose of the research is to learn
about the emotional and physiological responses related to sad mood. You must be at least 18
years of age to participate.
What Will You Be Asked to Do?
A trained female research assistant will place sensors on your body in order to record electrical
activity of the heart, skin, and facial muscle groups. Once the sensors are placed on your body,
you will be asked to sit comfortably in front of a computer in a small room. You will then be
asked to complete the following tasks: watch a short video about Alaska’s Denali Mountain,
answer some questions about how you’re feeling (e.g. check a box to indicate whether you are
interested, upset, nervous), complete a short computer task and listen to either a sad or neutral
piece of music designed to induce a short-lasting sad mood or no change in mood. This portion
of the study will take approximately 1-hour total.
Risks
It is possible that you may feel uncomfortable when answering questions about yourself. At any
point during the study, you have the right to skip questions you do not wish to answer, or stop
the session and choose not to participate in the remainder of the study. You will not need to
provide a reason for stopping the session. You will receive a list of referrals for counseling
services at the end of your session today.
Benefits
This study will have no direct benefit to you, though it will help to better understand how
individuals process emotional information and how this relates to risk for depression.
Compensation
You will receive $15 for your participation.
Confidentiality
The code number you have been assigned during session 1 will again be used to protect your
identity. This code is stored on a file with software designed to provide additional security. All
data will be kept in the investigator’s locked office and will only be accessible by Dr. Emily
Haigh and Maine Mood Disorders Lab graduate students and research assistants who have
completed training in order to deal with sensitive material. Your name or other identifying
information will not be reported in any publications. As previously described, the key linking
your name to the data will be destroyed in approximately two years after data analysis is
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complete, which we anticipate will be in 2018. All data will be kept indefinitely by the
investigators. The key and the data files will be stored on separate computers.
Voluntary
Participation is voluntary. If you choose to take part in this study, you may stop at any time. You
may also skip any questions you do not wish to answer. You will receive $15 for participating in
this research session to compensate you for your time and travel expenses. If you do not
complete the session you will receive compensation pro-rated to the nearest half hour.
Contact Information
If you have any questions about this study, please contact Emily Haigh at
Emily.a.haigh@maine.edu. If you have any questions about your rights as a research participant,
please contact Gayle Jones, Assistant to the University of Maine’s Protection of Human Subjects
Review Board, at 581-1498 (or e-mail gayle.jones@umit.maine.edu).
Your signature below indicates that you have read and understand the above information
and agree to participate. You will receive a copy of this form.

____________________________________
Signature

________________
Date
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Appendix L. Session 2 Self-Report Measures
Dysfunctional Attitudes Scale – Short Form (DAS-SF I)
The sentences below describe people’s attitudes. Circle the number which best describes
how much each sentence describes your attitude. Your answer should describe the way you
think most of the time.
Totally
Agree

Agree

Disagree

Totally
Disagree

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

If I don’t set the highest standards for
1. myself, I am likely to end up a second-rate
person.
My value as a person depends greatly on
2.
what others think of me.
People will probably think less of me if I
3. make a mistake.
I am nothing if a person I love doesn’t
4.
love me.
If other people know what you are really
5.
like, they will think less of you.
6.

If I fail at my work, then I am a failure as a
person.

1

2

3

4

7.

My happiness depends more on other
people than it does me.

1

2

3

4

I cannot be happy unless other people
8. admire me.

1

2

3

4

It is best to give up your own interests in
9. order to pleasure other people.

1

2

3

4
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Dysfunctional Attitudes Scale – Short Form (DAS-SF II)
The sentences below describe people’s attitudes. Circle the number which best describes
how much each sentence describes your attitude. Your answer should describe the way you
think most of the time.
Totally
Agree

Agree

Disagree

Totally
Disagree

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

If I do not do as well as other people, it
8. means I am an inferior human being.

1

2

3

4

If I fail partly, it is as bad as being a
9. complete failure.

1

2

3

4

If I am to be a worthwhile person, I must
1. be truly outstanding in at least one major
respect.
If you don’t have other people to lean on,
2.
you are bound to be sad.
I do not need the approval of other people
3. in order to be happy.
If you cannot do something well, there is
4.
little point in doing it at all.
If I do not do well all the time, people will
5.
not respect me.
6. If others dislike you, you cannot be happy.
People who have good ideas are more
7.
worthy than those who do not.
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Visual Analogue Scale (VAS)
We are interested in knowing about your current mood. Please mark an ‘X’ on the line below to
indicate how you feel right now. Use the labels above the line to help you in your judgment.

Sadness
extremely
not at all
-----------------------------------------------------+-----------------------------------------------------

Stressed
extremely
not at all
-----------------------------------------------------+-----------------------------------------------------

Happy
not at all
extremely
-----------------------------------------------------+-----------------------------------------------------
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PANAS-X
This scale consists of a number of words and phrases that describe different feelings and
emotions. Read each item and then mark the appropriate answer in the space next to that word.
Indicate to what extent you feel this way. Use the following scale to record your answers:
1
Very Slightly
or not at all
______ cheerful
______ disgusted
______ attentive
______ bashful
______ sluggish
______ daring
______ surprised
______ strong
______ scornful
______ relaxed
______ irritable
______ delighted
______ inspired
______ fearless
______ disgusted

2
A Little

______ sad
______ calm
______ afraid
______ tired
______ amazed
______ shaky
______ happy
______ timid
______ alone
______ alert
______ upset
______ angry
______ bold
______ blue
______ shy

3
Moderately

4
Quite of Bit

______ active
______ guilty
______ joyful
______ nervous
______ lonely
______ sleepy
______ excited
______ hostile
______ proud
______ jittery
______ lively
______ ashamed
______ at ease
______ scared
______ drowsy
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5
Extremely

______ angry at self
______ enthusiastic
______ downhearted
______ sheepish
______ distressed
______ blameworthy
______ determined
______ frightened
______ astonished
______ interested
______ loathing
______ confident
______ energetic
______ concentrating
______ dissatisfied
with self with self

Appendix M. Debriefing Form
Debriefing Form for Participation in a Research Study
University of Maine
Thank you for your participation in our study. Your participation is greatly appreciated.
Purpose of the Study:
The purpose of this study is to examine how the way you think and the way your body
physiologically responds (e.g. heart rate) to emotional stimuli relates to depression. This study is
important because it may help us understand how short periods of sad mood lead some
individuals to develop lasting depressed mood.
In this study you completed an interview and several questionnaires about how you think and
feel. You also completed an attention task (e.g. computer task) and using sensors to detect
electrical impulses we measured physiological arousal (e.g. heart rate) as you listened to music
designed to either make you feel sad or no change in your mood.
We expect to find that participants with a history of depression who completed an attention task
with negative words and listened to the sad music will report more sad mood and have a stronger
physiological response than individuals without a history of depression. Previous research has
shown that individuals with depression have difficulty turning their attention away from negative
stimuli and have negative repetitive thoughts in response to sad mood; however, little research
has examined how these factors relate to physiological functioning.
Do you have any questions about the study? When you were doing the study what did you think
the study was about? Was there any part of the study that was difficult? How is your mood now?
We realize that some of the questions asked may have provoked an emotional reaction. As
researchers, we do not provide mental health services and we will not be following up with you
after the study. However, we want to provide every participant in this study with a
comprehensive and accurate list of clinical resources that are available, should you decide you
need assistance at any time. Please see information pertaining to local resources at the end of
this form.
Confidentiality:
You may decide that you do not want your data used in this research. If you would like your
data removed from the study and permanently deleted please email your request to Principal
Investigator, Dr. Emily Haigh @ Emily.a.haigh@maine.edu.
Whether you agree or do not agree to have your data used for this study, you will still receive
compensation for your participation.
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Final Report:
If you would like to learn about the results of the study, let the researcher know and we will
email you a summary of the results at the end of the study.
Further Reading(s):
If you would like to learn more about cognitive vulnerability to depression please see the
following references:
Farb, N. A. S., Irving, J. A., Anderson, A. K., & Segal, Z. V. (2015). A two-factor model of
relapse/recurrence vulnerability in unipolar depression. Journal of Abnormal Psychology, 124(1),
38–53. http://doi.org/10.1037/abn0000031
Key, B. L., Campbell, T. S., Bacon, S. L., & Gerin, W. (2008). The influence of trait and state
rumination on cardiovascular recovery from a negative emotional stressor. Journal of Behavioral
Medicine, 31(3), 237–248. http://doi.org/10.1007/s10865-008-9152-9
Lethbridge, R., & Allen, N. B. (2008). Mood induced cognitive and emotional reactivity, life
stress, and the prediction of depressive relapse. Behaviour Research and Therapy, 46(10), 1142–
1150. http://doi.org/10.1016/j.brat.2008.06.011
Useful Contact Information:
If you have any questions or concerns regarding this study, its purpose or procedures, or if you
have a research-related problem, please feel free to contact the Principal Investigator, Dr. Emily
Haigh at 207-581-2053. If you have other concerns about this study or would like to speak with
someone not directly involved in the research study, you may contact the Chair of the
Department of Psychology (Dr. Michael Robbins, Michael_Robbins@umit.maine.edu)
If you have any questions concerning your rights as a research subject, you may contact Gayle
Jones at the University of Maine Institutional Review Board for the Protection of Human
Subjects at (207) 581-1498 or gayle.jones@umit.maine.edu.

(Counseling Resource List Attached – see Appendix D)
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